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ABSTRACT
BACKGROUND : This thesis examines the issue of unplanned pregnancy in 
women with diabetes mellitus (DM) in order to understand what factors promote 
or discourage effective preconception care. DM is a common disorder 
complicating pregnancy and unplanned pregnancy can present major health risks 
to both a woman with diabetes and her fetus (CEMACH 2005a ). In spite of the 
risks, less than half of women with diabetes are reported to plan their 
pregnancies (CEMACH 2007).
METHOD: Extended case method (Burawoy 1998) was applied to a case study: 
‘the prevention of unplanned pregnancy in women with type 1 or type 2 DM’. An 
ethnographic approach and feminist focus explored the macro and micro 
perspectives of the case. The study used mixed methods with three sequential 
phases; a database study reviewed the general practice records of 1683 women 
with diabetes and a comparison group. Questionnaires from 107 women followed 
by 32 semi structured interviews were then used to examine the experiences, 
attitudes and knowledge of women with diabetes and the health care 
professionals who provide their diabetes care. The first two phases were 
analysed using SPSS and the qualitative data by NVIVO 7.
FINDINGS: Incongruence in views between the health professionals and women 
with DM were found. This included the meaning of a ‘planned pregnancy, 
knowledge of preconception issues, and in use of contraception where 
differences in prescribing and less use of hormonal methods were seen. Women 
were found to experience a medicalised approach to care.
CONCLUSIONS: I argue that the approach to preconception care for women 
with DM requires reconceptualisation with a shift away from a medicalised model 
of care and a dynamic holistic bio-psychosocial model is proposed. My findings 
suggest that important factors appear to include the strength of relationships with 
health professionals, congruence of views between women with DM and their 
health carers, the belief systems of the women with diabetes in relation to 
planning for pregnancy, receptiveness to preconception information and care and 
the use of contraception.
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CHAPTER ONE
Introduction
1.0 Introduction and Statement of the Research Problem
This thesis concerns the prevention of unplanned pregnancy for women with type 
1 and type 2 Diabetes Mellitus (DM). DM is a metabolic disorder of multiple 
aetiology, characterised by hyperglycaemia (WHO 1999). 2.35 million people 
have diagnosed diabetes in the UK (NHS IC 2007), there is a rising incidence of 
diabetes worldwide (IDF 2007,) and it is predicted that by the year 2010, the 
number of people with diabetes in the UK will reach 3 million (WeMeRec 2005).
DM is a common disorder complicating pregnancy and affects 1 in 250 women in 
the UK (CEMACH 2007). Unplanned pregnancy can present major health risks 
to both a woman with diabetes and her fetus (CEMACH 2005a). Poor glycaemic 
control at conception and throughout pregnancy can accelerate the complications 
of diabetes and lead to severe obstetric complications. Macintosh et al (2006) 
found a fivefold increased risk of stillbirth, a threefold increased risk of perinatal 
mortality and a twofold increased risk of fetal congenital anomaly. In spite of the 
risks, less than half of women with DM are reported to plan their pregnancies 
(Holing et al 1998, CEMACH 2007).
The National Service Framework for Diabetes (NSF) (DH 2001a) highlights the 
need to look at standards of care in relation to DM and pregnancy and Standard
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Nine (Appendix One) addresses the particular needs of women at increased risk 
of unplanned pregnancy. In addition recent government policy (DH 2000, 2005b, 
2007a) advocates new ways of working to improve patient care, with patient 
involvement and self-management, being seen as paramount in achieving 
reduction in complications (DH 2007b). The NSF (DH 2001a) suggests that 
liaison should occur between providers of general contraception and 
professionals providing diabetes care, and that there should be integrated patient 
care pathways.
Recently the need for research in this area has been highlighted by the 
Confidential Enquiry into Maternal and Child Health (CEMACH 2007) which has 
published a national enquiry of care in pregnancy for women with DM 
establishing the need to identify barriers to women accessing preconception care 
and to identify strategies to support self care and pregnancy planning by women 
with DM. This report is considered further in the literature review (Chapter Three 
Section 3.2.2.4.) which shows that currently there is little research in this area 
and in addition my discussion with diabetes practitioners revealed little apparent 
promotion of contraceptive issues or of preconception care for women with DM.
This thesis therefore aims to address this gap in the evidence base pertaining to 
prevention of unplanned pregnancy in women with DM.
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1.1 Aims and objectives of the study
This thesis aims to examine the issue of unplanned pregnancy in women with 
DM and to understand which factors promote or discourage effective 
preconception care. A case study following Burawoy (1998) is undertaken with 
the following objectives:
e To elicit and understand the experiences, attitudes and knowledge of 
women with DM in relation to planning for pregnancy. (Micro perspective).
• To identify knowledge, skills and attitudes of health professionals involved 
in diabetes care, and compare these to the core competences required in 
relation to promotion of preconception care. (Micro perspective)
• To identify the systems, strategies and governance arrangements required 
to ensure that all relevant health care providers are able to effectively 
support self care and pregnancy planning for women with DM. (Macro 
perspective).
1.2 Research Questions
Following a review of the literature (Chapter Three), research questions were 
formulated, as outlined below and these are evaluated at the end of the thesis in 
Chapter Twelve, Key Findings and Conclusions:
• What factors are associated with prevention of unplanned pregnancy in 
women with DM?
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• What are the experiences, attitudes & knowledge in relation to planning for 
pregnancy for women with type 1 or type 2 DM?
• What factors promote or discourage effective preconception care in 
women with DM?
• What health care and advice is currently provided by health professionals 
in order to encourage positive pregnancy outcomes for women with DM?
• To what extent is there congruence between the women's & professional's 
perspectives in relation to reproductive health issues?
• How can health professionals encourage positive pregnancy outcomes for 
women with DM?
• What recommendations for practice can be generated?
1.3 Structure of the thesis
This section discusses and explains the reasons for the chosen structure of the 
thesis.
This current chapter introduces the reasons for undertaking the study and 
presents the research aims, objectives and questions. Chapter Two gives 
background information to support general understanding of the condition of 
diabetes mellitus (DM). This is important as women may have different 
experiences of health and care issues dependent on their type of DM and this 
background knowledge will allow judgments to be made in relation to differences
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within the research findings. Chapter Three reviews literature relating to the topic 
from a bio-psychosocial perspective, including policy in relation to pregnancy, 
planning pregnancy, preconception care, and contraception and health promotion 
for women with DM. Gaps in the literature are highlighted from which the 
research questions are formulated.
Chapter Four identifies the research approach, methodology, methods and tools 
for the study. Evidence for the case study was gathered during three phases. 
Firstly a database study reviewed the general practice records of women with 
DM and a comparison group. This information provided baseline evidence of 
reproductive health care issues amongst women with DM and the comparison 
group. Secondly a survey questionnaire was given to women with type 1 or type 
2 DM asking questions about reproductive health and planning for pregnancy. 
Thirdly a qualitative study examined the experiences, attitudes and knowledge of 
women with DM and health care professionals providing their diabetes care, in 
relation to planning for pregnancy. Please see Chapter Four, Section 4.0, Figure 
One for a diagrammatic representation.
The use of mixed methodology within this case study led to discussion as to the 
presentation of findings. The findings of quantitative studies are normally 
presented as results without interpretation (Polit et al 2001), whereas qualitative 
studies often combine presentation of findings with interpretation and discussion 
(Wolcott 2001). I have decided to present the findings independently for each of
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the three phases with Chapter Five giving results of statistical analysis of the 
database study, Chapter Six the statistical results of the questionnaire study and 
Chapters Seven to Nine the findings of the semi structured interviews in three 
themes; Diabetes, Diabetes and Pregnancy and Contraception. The findings of 
all three phases are then integrated and interpreted within the ‘Discussion’ in 
Chapter Ten before I return to the research questions in Chapter Eleven with 
discussion of the key findings of the study and make recommendations in relation 
to prevention of unplanned pregnancy for women with DM and for future 
research in this area. A dynamic holistic model of care is proposed, using 
evidence from the findings of my study and which addresses the factors that 
emerged as important in the prevention of unplanned pregnancy and promotion 
of preconception care for women with DM.
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CHAPTER TWO
Background Information
2.0 Introduction
Prior to a review of the literature in Chapter Three, this chapter gives background 
information to support general understanding in relation to the topic of prevention 
of unplanned pregnancy for women with DM. Women may have different 
experiences of health and care issues dependent on their type of DM and 
background knowledge of the condition of DM, the complications that can arise 
and the service provision and care for women with DM, will allow judgments to be 
made in relation to differences within the research findings from the database 
and from narrative from the women and health professionals.
2.1 Diabetes Mellitus
The aetiology, progression and complications of the different types of DM have 
bearing on the findings of my research in that women with type 1 DM had 
different experiences to women with type 2 DM. In addition the demography of 
the condition within the UK population means that increasing numbers of women 
will be affected with DM in the future as outlined below.
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The name ‘Diabetes Mellitus’ stems from the Greek words for siphon and sugar, 
describing the symptoms of polyurea and glycosuria (Clark 2004). DM is a 
chronic and progressive condition and can affect all ages (Nair 2007). It is 
characterised by chronic hypergycaemia caused by disturbances in 
carbohydrate, fat and protein metabolism as a result of defects in insulin 
secretion, insulin action, or both and is associated with significant morbidity and 
mortality (WHO 2006).
In the coming decades the number of people with DM is expected to increase 
significantly (IDF 2007). In 1985 an estimated 30 million people worldwide had 
diabetes, and this rose in 2000 to over 150 million. It is expected by 2025 that 
this figure may be 380 million (IDF 2007).
In the UK 2.35 million people have diagnosed DM (MHS IC 2007) and it is 
predicted that by the year 2010, this number will reach 3 million (WeMeRec
2005). The majority of cases will be of type 2 DM which has an increased 
prevalence with age and contributory factors such as an unhealthy diet, obesity, 
and a sedentary lifestyle (BMA 2004). In the UK the prevalence of diabetes in 
women aged 15-49 years is approximately 6 per 1000 (ONS 2000).
Classifications of DM are defined by aetiology. These include type 1, type 2, 
Gestational, Impaired Glucose Tolerance/Impaired Fasting Glucose and other 
rarer forms including maturity onset diabetes of the young (MODY), pancreatic
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disease, DM due to side-effects of steroid therapy, Cystic fibrosis-related DM 
and Cushing’s syndrome (Nair 2007, BMA 2004). For the purpose of my study 
subjects were women who had pre existing type 1 and type 2 DM and these 
conditions are outlined below along with Gestational Diabetes as some of the 
women had developed this condition prior to developing type 2 DM.
2.1.1 Type 1 Diabetes Mellitus
Type 1 DM accounts for between 5 to 10 per cent of all patients diagnosed with 
DM (Kumar & Clark 2005). It has a sudden onset usually before or during 
adolescence (Nair 2007). The aetiology is recognised to have two main forms 
resulting in destruction of pancreatic islet beta-cells with a consequential 
absolute deficiency of insulin (BMA 2004). It is considered to be attributable to 
an autoimmune process in which T lymphocytes infiltrate the islets of langerhans 
in the pancreas and destroy beta cells which produce insulin (BMA 2004). 
Genetic factors such as a predisposition to inherit DM (Chelala et al 2007, Rich 
et al 2006) and environmental agents such as exposure to Infection including 
rubella and enteroviruses have been identified (Taylor 2005, Davendra et al 
2004). Other theories involve exposure to chemicals and proteins such as cow’s 
milk at an early age (Akerblom 1999).
Symptoms of type 1 DM at onset include polyuria, polydipsia, fatigue, hunger, 
weight loss and ketoacidosis. Treatment is by replacement insulin (BMA and 
RPSGB 2007) and women with type 1 DM will be self administering regular
28
injections of insulin which may have a psychological and sociological impact on 
their daily lives (Snoek & Skinner 2000). Failure to administer insulin will lead to 
weight loss and complications as outlined in Section 2.1.5.
2.1.2 Type 2 Diabetes Mellitus
Type 2 DM accounts for more than 90% cent of all patients diagnosed with DM 
(BMA 2004), and despite previously being considered a disease of adults it is 
increasingly diagnosed in children and adolescents, (Fagot-Campagna et al 
2001, Diabetes UK 2006). It is estimated that one million people in the UK with 
type 2 DM are not yet diagnosed (MeReC 2004).
Type 2 DM is a complex metabolic disorder characterized by insulin resistance in 
peripheral tissue and an insulin secretory defect of the beta cells in the pancreas 
(Mayfield 1998, WHO 2006). In insulin resistance normal amounts of insulin are 
inadequate to trigger a response resulting in hyperinsulinaemia. In addition 
transportation of glucose into the cells for production of energy and the 
conversion of excess glucose into glycogen or fat for storage is impaired causing 
hyperglycaemia (Nair 2007). The onset is generally slow and the condition has a 
significant sub-clinical phase that may last several years (BMA 2004).
The aetiology of type 2 DM is multifactorial, it has a genetic base (Barroso 2005, 
Janssens et al 2006), but also strong behavioural and lifestyle elements. Risk 
factors include having a first-degree relative with DM, being from an ethnic group
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with higher incidence of type 2 DM (Black, Hispanic, Native American, Asian), 
obesity, women with a history of gestational diabetes or delivering a baby 
weighing over 9lbs , a sedentary life and lack of exercise 
(Diabetes UK 2007, Nair 2007). Intrauterine factors also appear to have 
importance in that there is a relationship between birth weight and the risk of type 
2 DM in later life. A recent meta-analysis of 14 studies by Harder et al (2007) 
found a clear statistical relationship between birth weight and risk of type 2 DM. 
High or low birth weight was equally found to be associated with increased risk of 
type 2 diabetes in later life.
Symptoms of type 2 DM are similar to those in type 1 DM but milder and no 
ketoacidosis is present (BMJ 2004). Treatment involves a combination of 
physical activity, dietary review and use of medication including a range of oral 
hypoglycaemics and / or insulin (BMA RPSGB 2007). Such regimens require 
daily intervention for women with diabetes which may impact on their 
psychological and sociological wellbeing (Snoek & Skinner 2000).
Despite the large population with possible covert type 2 DM, the National 
Screening Committee do not currently advocate screening for the condition (NSC
2006), and this may mean women potentially becoming pregnant with the risks 
associated with undiagnosed diabetes as discussed in Chapter Three.
30
2.1.3 Gestational Diabetes Mellitus (GDM)
Gestational diabetes (GDM) is defined as “a carbohydrate intolerance resulting in 
hyperglycemia of variable severity with onset and first recognition during 
pregnancy” (WHO 1999:19). The definition is criticised by many as being too 
broad as it includes women who may have had undiagnosed type 1 or type 2 DM 
prior to pregnancy and those with impaired glucose tolerance (Hollander et al 
2007, Simmons et al 2006). The definition ignores the fact that following delivery 
GDM resolves in 90% of women (Kim et al 2007, BMA 2004).
The incidence of GDM appears to be increasing (Hunt & Schuller 2007, Dabelea 
et al 2005). Estimates of prevalence vary widely in differing populations of 
between 1.8% and 17% (Hunt & Schuller 2007, Kim et al 2007, Janghorbani et al 
2006). It is more common in women who are obese (Jensen et al 2003), those 
with a history of large for gestational age babies and those with a family history of 
diabetes (BMA 2004). Certain ethnic groups have an increased risk including 
African American, Hispanic/Latino American and Asian populations (Hunt & 
Schuller 2007, Dabelea et al 2005).
The aetiology is believed to be as a result of an insufficient production of insulin 
which is normally produced to counteract the insulin resistance that occurs in the 
second and third trimesters of pregnancy (Buchanan 2001). GDM is also 
considered to be a pre diabetic state (BMA 2004) as women who have had GDM 
are at increased risk of developing diabetes later on in life (Agarwal et al 2007).
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Those with a previous history of GDM have a 5-10% risk of developing type 1 
DM and a 30% risk of type 2 DM (Diabetes UK 2007). It is known that such risk, 
especially in relation to type 2 DM, can be reduced by healthy diet, exercise and 
glucose monitoring (DH 2001a, Diabetes UK 2007) and therefore if prevention 
strategies are to be implemented it is important that GDM be identified.
Despite the increasing rates of GDM in pregnancy there is still no consensus on 
screening or the management and treatment of the condition (Hollander et al 
2007, Hyer & Shehata 2005, WHO 2006). In respect of screening, debate 
continues on an international, national and local level as to who and when to 
screen and the methods to use (WHO 1999, WHO 2006, IDF 2007, NICE 2003, 
Diabetes UK 2007). There is no consensus on which test is the most effective 
and a variety are used including simple urinalysis for glycosuria, to the use of 
random and fasting plasma glucose testing and glucose tolerance testing.
Clinically there are many variations in types of screening undertaken in the UK 
(Scott et al 2002), these include Universal screening, selective screening and no 
screening (Kadir et al 2007). WHO (1999) consider that it may be appropriate to 
screen pregnant women from high-risk populations during the first trimester of 
pregnancy. This would detect previously undiagnosed DM as formal systematic 
testing is usually done between 24 and 28 weeks of gestation. The National 
Institute for Clinical Evidence (NICE) has recognised the lack of guidance for 
screening and is currently producing UK guidelines for publication in March 2008 
(NICE 2005a).
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Treatment of GDM is again a contentious issue (Mitchell 2001) but includes 
dietary intervention, blood glucose monitoring and insulin therapy. Following 
delivery, insulin can be stopped immediately and an oral glucose tolerance test is 
carried out six weeks later to see if the condition has resolved or if type 2 DM is 
present (BMA 2004). My study included women who had pre existing type 1DM 
or type 2 DM but some of the women had developed Gestational Diabetes in 
their pregnancies prior to developing type 2 DM.
2.1.4 Diagnosis of Diabetes Mellitus
An understanding of normal blood glucose levels and those relating to a 
diagnosis of DM are important in relation to the desirable levels prior to 
pregnancy as mentioned in the literature, by health professionals and by women 
within my research. Diagnosis of DM is confirmed by presenting symptoms such 
as polydipsia, polyuria, unexplained weight loss and a fasting blood glucose level 
of more than Z.Ommol/litre and a two hour post-prandial glucose level of more 
than 11.1 mmol/I (WHO 2006) (Appendix Two). The blood test for Haemoglobin 
A1c, Glycated haemoglobin (HbA1c) shows average glycaemic levels over a 
period of two to three months and should be below 7% if DM is well controlled 
(Diabetes UK 2007).
2.1.5 Complications of Diabetes Mellitus
Women taking part in my research had experienced complications of DM and this 
impacted on the findings from my research in that many of the complications are
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significant for women using hormonal contraception and during pregnancy.
There are both physiological and psychological complications of DM cited in the 
literature which will be outlined below.
2.1.5.1 Physiological complications.
Women with DM are at risk of both macrovascular and microvascular 
complications (Laing et al 1999, Swerdlow & Jones 1996). Development of such 
complications can affect choices of contraception and outcome of pregnancy.
2.1.5.1.1 Macrovascular complications
The macrovascular complications include myocardial ischaemia leading to 
angina and myocardial infarction. Women with DM are at increased risk of 
stroke, both ischaemic and haemorrhagic. They are also more likely to develop 
peripheral vascular disease. There has been little evidence to suggest that 
women of childbearing age with DM are at increased risk of venous 
thromboembolism (VTE) (Keenan et al 2007), although a study by Petrauskiene 
et al (2005) found a two fold risk in VTE for patients with diabetes of all ages. 
Having such complications can affect a woman’s choices of contraception and 
can affect pregnancy outcome as discussed in Chapter Three.
2.1.5.1.ii. Microvascular complications
The microvascular risks include nephropathy, neuropathy and diabetic 
retinopathy (Nair 2007). Renal disease in people with diabetes has long been
34
recognised as a major complication (WHO 1999). Fortunately with better 
management of DM and better care for people with renal disease it is now a rare 
cause of death. However diabetic nephropathy and the presence of elevated 
urinary protein is an important marker of an increased risk of cardiovascular 
disease (CVD).
Neuropathy is a common complaint in patients with type 1 and type 2 diabetes. 
No universally agreed definition of diabetic neuropathy exists and the most 
sensitive tests, such as measurement of nerve conduction velocity, may find 
neuropathic abnormalities in a very large proportion of the diabetic population. 
This is particularly true in patients with long standing disease. However the 
presence of frank sensory loss in the feet or symptoms and signs due to 
autonomic neuropathy should be considered as signs of a high risk patient with a 
history of poorly controlled DM of long standing (Nair 2007). Such women could 
be advised against pregnancy as discussed in Chapter Three.
Three stages of diabetic retinopathy are commonly recognised: background, 
preproliterative and proliferative retinopathy. Most evidence on the natural 
history of diabetic retinopathy comes from the Wisconsin Epidemiological Study 
of Diabetic Retinopathy, a large scale study of a Caucasian population. There is a 
marked increase in the prevalence of preproliterative and proliferative retinopathy 
in people with type 1 DM after about fifteen years of disease (Fontbonne et al 
1987) which may be partly attributed to a protective effect that is lost after
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puberty (Kimmerle et al 1994). Retinopathy is more likely in patients who have 
poor glycaemic control or in those with poorly controlled blood pressure and 
there is some evidence that it is accelerated during pregnancy (Klein et al 1999) 
as discussed in Chapter Three Section 3.2.4.1. In my research women gave 
accounts of screening for retinopathy during pregnancy.
2.1.5.2. Psychological complications
Although DM is known to have a physical cause, Clark (2004) suggests there are 
complex intertwined psychological issues which can affect management of the 
condition. In relation to my research study these complications can affect 
behaviour which can result in unplanned pregnancy and in poor control of blood 
glucose levels. As a chronic illness, diabetes is unique in that patient behaviour 
can influence the outcome of the condition (Brooks and Roxburgh 1999) and this 
can be behaviourally and psychologically demanding for those with diabetes 
(DeLamater 2001). Psychosocial issues have been recognised as an important 
factor in the care and management of diabetes (Snoek 2000) and the NSF for 
Diabetes, Standard 3 (DH 2001a) and the Delivery Strategy (DH 2003) include 
provision of psychosocial support and patient centred psychosocial care. These 
policies are discussed further in Chapter Three in specific relation to pregnancy 
and are explored in relation to my research questions in Chapters Ten and 
Eleven.
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In relation to management of DM and to propose strategies for diabetes care, 
social cognition models such as the Health Belief Model (Becker and Janz 1985), 
the Theory of Reasoned Action (Fishbein & Ajzen 1975), Locus of Control (Rotter 
1966) and the Self-efficacy Theory (Bandura 1977) have been used to 
conceptualise the beliefs, cognitions and attitudes of those with diabetes (Snoek 
& Skinner 2000). Predictions of patients’ concordance or adherence with 
treatment and motivation for self care have been used within diabetes education 
models such as the Patient Empowerment Approach (Wilson 2004). Structured 
education programmes are used to promote diabetes self care and good 
glycaemic control such as The Dose Adjustment Programme for Normal Eating’ 
(DAPNE) for those with type 1 DM and The Diabetes Education and Self- 
Management for Ongoing and Newly Diagnosed’ (DESMOND) programme for 
those with type 2 DM. These programmes are discussed in relation to prevention 
of unplanned pregnancy in Chapter Ten and Eleven.
To effectively manage their DM, patients need to adhere to an ongoing and 
complex regime and frequently non adherence to treatment is seen (Clark 2004). 
Wilson (2004) discusses how behaviour such as following dietary and medication 
regimes, blood glucose monitoring and taking exercise are not strongly related to 
each other and some aspects may be adhered to better than others. In addition 
some patients may decide that they will have a better quality of life by being non 
concordant.
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Non adherence could be viewed as a psychological problem particularly as 
psychological treatments are used to improve adherence, but Lustman & Harris 
(1998) discuss how non-adherence is more likely to be the norm for many 
patients with DM. However non adherence may be a sign of other underlying 
psychological complications such as depression, anxiety and eating disorders 
and these are now described as they relate to issues that arose from my 
research findings.
2.1.5.2.i Depression
Depressive illness is twice as common for those with DM than in the general 
population (Anderson et al 2001). It is estimated to affect one in three people 
with DM and is more common in women than men (Diabetes UK 2007). Egede 
et al (2002) discuss how depression is associated with non adherence to 
treatment and poor glycaemic control resulting in increased health complications 
and therefore cost of health care.
Diabetes UK (2005) reported that depression may go unrecognised by health 
professionals and by patients with DM and that there was a lack of psychological 
support for the condition. Wilson (2004) highlights the importance of depression 
being identified and treatment offered in order to improve the quality of life for 
people with DM.
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2.1.5.2.ii Eating disorders
A growing area of concern is that of eating disorders being twice as evident 
amongst young women with type 1 DM as in the general population (Jones 2000, 
Diabetes, UK 2007). More recently the term ‘diabulimia’ has evolved to 
represent the condition where insulin doses are withheld in order to facilitate 
weight loss and Diabetes UK (2007) report that up to 1 in 3 teenagers may be 
abusing their insulin because of fear of gaining weight. This behaviour causes 
poor glycaemic control resulting in an increased risk of complications such as 
diabetic keto-acidosis and in the longer term, retinopathy and nephropathy.
2.1.5.2.iM Adolescence
Young people may find difficulty in general in coping with their diabetes. 
Adolescence is associated with a period of change, adjustment, rebellion against 
convention and a desire to be normal (Lustman & Harris 1998, Snoek 2000).
This can pose challenges when they are also learning to manage and live with 
DM and Hanna & Guthrie (2000) found that just one fifth of teenagers with DM 
felt that they fully complied with expected diabetes management. They often 
tended to ignore vulnerability to the consequences of poor blood glucose control 
and take risks in relation to their diabetes management. Guthrie et al (2003) 
discuss the importance of family, peers and health professionals in supporting 
adolescents through this transitional phase.
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2.1.6 Care for Women with Diabetes and Service Provision
My research highlights issues relating to current care provision made by women
with DM and the health professionals involved in their care and in order to 
facilitate understanding of this topic and that future proposed models can be 
evaluated. Current service provision is described below.
Traditionally, women with type 1 DM have been cared for within diabetes clinics / 
centre at acute NHS Trust services and women with type 2 DM have more often 
been cared for by General Practitioners and Practice nurses in primary care. 
However it is now increasingly accepted in policy initiatives such as the National 
Service Framework for Diabetes (DH 2001a) and the new General Medical 
Services (GMS) (DH 2006) contract for primary care that the majority of routine 
clinical care for all women with DM will be provided in primary care. As part of 
the GMS contract, the Quality and Outcomes Framework (OOF) system gives 
incentives to GP practices in return for collection of data against selected criteria 
in the management of long term and chronic conditions including DM (DH 2006). 
The purpose is to encourage high quality delivery of DM care (IC 2006) and most 
GP practices have developed a service to review and monitor people with DM 
within their practice.
This raises issues of continuity of care and partnership working between primary 
and secondary care (Alazri et al 2007) and has seen the development of roles for 
Diabetes Specialist Nurses and GPs with a special interest in DM. Diabetes UK 
(2007) has published recommendations for primary care and currently there is
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major reorganization of diabetes services within the Acute and Primary Care 
Trusts.
2.1.7 Conclusion
This Chapter gives background information about the condition of DM, the 
complications that can arise and the service provision and care of people with 
DM. It can be seen that for women with DM, that as well as the long term 
physical condition that diagnosis brings there are specific psychological and 
sociological issues that may impact on their lives. This information is relevant to 
understanding issues that arise within my research study in order to be able to 
make judgments from the women’s and health professionals accounts of 
experiences.
The following chapter reviews literature specifically relating to the case of “The 
prevention of unplanned pregnancy in women with type 1 or type 2 diabetes 
mellitus” from which gaps in evidence will be identified and explored within the 
research study.
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CHAPTER THREE 
Review Of The Literature
3.0 Introduction
Chapter Two introduces and gives background to the topic of diabetes mellitus 
(DM) including the complications that may occur and the care and service 
provision that women with DM may experience. This chapter takes a bio­
psychosocial approach to examine current and past literature and relevant policy 
in relation to pregnancy, planning pregnancy, preconception care, and 
contraception and health promotion for women with DM. Literature is analysed 
from a general perspective including the macro aspects of relevant policy and 
epidemiology before narrowing to the specific focus of the study. Conclusions 
regarding the literature are made in relation to prevention of unplanned 
pregnancy in women with DM, gaps in the literature are highlighted and from 
these research questions are identified for my own research study which seeks 
to further knowledge in this field. The chapter is divided into three main sections: 
Diabetes and Pregnancy (Section 3.2), Preconception Care for Women with DM 
(Section 3.3) and Contraception for Women with DM (Section 3.4).
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3.1 Search Parameters
A search for literature was carried out using the on line databases listed below 
and a manual search of the University of Surrey Library was also carried out for 
relevant text books and journal articles in relation to diabetes and pregnancy. 
Biomed 
CINAHL
MIDIRS (Midwives Information & Resource Service)
British Nursing Index 
Medline
Athens website via OVID 
Entrez PubMed 
Web of Science 
Diabetes Care 
Google 
EBSCOhost
3.1.1 Key search words
Diabetes Mellitus : Type 1, Type 2 and chronic illness, pregnancy, contraception, 
unplanned pregnancy, preconception care, preconception counseling, planning 
pregnancy, fatalism, médicalisation, health promotion.
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3.2 Diabetes & Pregnancy
3.2.1 Introduction
Diabetes Mellitus (DM) is a common disorder complicating pregnancy and affects 
1 in 250 women in the UK (CEMACH 2007). Before the discovery of insulin in 
1921, women with DM rarely reached childbearing age or survived through 
pregnancy. Termination of pregnancy was routinely recommended because of 
high maternal mortality rates (Potter & Kicklighter 2007). In the 1980’s research 
showed that control of blood glucose levels prior to and after conception can 
reduce these poor outcomes (Mills et al 1988). Today, despite improved health 
and care for women with DM, adverse pregnancy outcomes continue with 
perinatal mortality being nearly four times higher and the incidence of fetal 
congenital abnormalities being double that of the general population (Macintosh 
et al 2006, CEMACH 2007). It has been found that less than half of women with 
DM are reported to plan their pregnancies (Holing et al 1998, CEMACH 2007).
DM can present in pregnancy as gestational diabetes mellitus (GDM), however 
as has been discussed in Chapter Two, there is currently much contention about 
the diagnosis and treatment of GDM and for the purpose of this study and 
literature review, only established type 1 or type 2 DM will be included. In the 
main, women of child bearing age have traditionally had type 1 DM, but due to 
levels of obesity and later childbearing practices, there are now increasing 
numbers of women with type 2 DM in this age bracket (Clausen et al 2005) and 
the consequences of this are discussed in Section 3.2.4.2.
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This section of the review will look at literature pertaining to type 1 and type 2 DM 
and pregnancy including relevant policy, the pathophysiology of glucose control, 
maternal and fetal complications, psychological aspects and experiences of 
pregnancy, and adolescents with DM in relation to pregnancy.
3.2.2 United Kingdom (UK) Policy Relating to Diabetes and Pregnancy
Over the last two decades, UK governments, National Diabetes Organisations
and Professional Organisations have reviewed and reported on issues relating to 
diabetes care and pregnancy. Policies and recommendations for care have been 
developed with specific standards to be achieved in the National Service 
Framework for Diabetes (DH 2001a). Joint working with the World Health 
Organisation and International Diabetes Federation in Europe (WHO & IDF 1990) 
has also been a focus for improving care and outcomes in pregnancy. The 
literature sets the framework for care and guidelines that should be used by 
health professionals and that women can expect prior to, during and after 
pregnancy and aspects of this will be explored in later sections of this literature 
review.
3.2.2.1 The St Vincent Declaration
In 1989 following a meeting at St Vincent, Italy, organized by the World Health 
Organisation (WHO) and the International Diabetes Federation (IDF) in Europe, a 
joint statement was issued by European governments termed The St Vincent 
Declaration’ (WHO & IDF 1990). This set out aims for a model for prevention
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and self care and set a target to achieve outcomes for pregnancy for women with 
DM approximating those for women without DM by 1994 (WHO & IDF 1990). 
Unfortunately these targets were not achieved in the UK (Platt et al 2003,
Casson et al 1997) and the recent CEMACH report (2007) demonstrates that the 
vision of the declaration is still a goal to be achieved in the UK.
3.2.2 2 National Service Framework (NSF).
In 2001 The Department of Health published the National Service Framework 
(NSF) for Diabetes (DH 2001a) which set out a ten-year programme of change to 
deliver world class care and support for people with DM. Standard Nine focused 
on diabetes and pregnancy and included key interventions to ‘develop, 
implement and monitor policies that seek to empower and support women with 
pre-existing DM and those that develop DM during pregnancy to optimize the 
outcomes of their pregnancy’ (DH 2001:5). The interventions (see Appendix 
One) range from preconception to post natal care and will be discussed at 
relevant points later on in this literature review.
In 2002 the NSF Delivery Strategy was published (DH 2002) which set out 
national targets against which local NHS performance on the standards in the 
NSF for Diabetes can be judged. Subsequently the Department of Health has 
published reviews of progress of the standards including The way ahead: The 
Local Challenge’ published in 2007 (DH 2007c). This incorporated research by 
the Confidential enquiry into maternal and child health (CEMACH 2007) and 
showed that there was still a long way to go before the aspiration of the St
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Vincent Declaration is reached. The reports include examples of good practice to 
encourage and disseminate models of care such as a multi-disciplinary team 
approach and pre pregnancy care. However there appears to be a paucity of 
literature discussing use of these policies or of Standard Nine of the NSF in 
practice settings and further research could be suggested for this area.
3 2.2.3 The Quality and Outcomes Framework (QOF).
The General Medical Services (GMS) contract for general practitioners (GPs) in
the UK, encourages use of evidence-based interventions within primary care 
services. The Quality and Outcomes Framework (QOF) system forms part of the 
contract, and incentives are given in return for collection of data against selected 
criteria in the management of long term and chronic conditions including DM (DH
2006). The purpose is to encourage high quality delivery of DM care (IC 2007). 
The QOF has four main domains which include a set of indicators which are the 
criteria to measure achievement. The domains are clinical, organisational, 
patient care and additional services. In DM care for example, GPs are able to 
gain points and then payment for ensuring the practice has a register of patients 
by type of DM and for recording blood pressure and results of a variety of 
biochemical tests and interventions. Points can also be gained if patients are 
able to speak to GPs and nurses on the telephone and/or email them during the 
working day.
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The development of QOF has led to an increase of DM care within the GP 
surgery (Kenny 2005) especially for women with type 2 DM who are often 
managed by lifestyle change and oral medication. This is increasingly including 
the general care of women who are pregnant although women are often referred 
for more specialist care at a diabetes centre or for joint care with the obstetric 
services.
Diabetes UK (2007c) suggests that this framework is biomedically focused and 
does not encourage individual holistic care and I could find no literature relating 
to experiences of women with diabetes or health professionals views of the QOF 
in relation to pregnancy care. It would seem that data collection via QOF returns 
has allowed useful demographic and epidemiologic information to be published 
(QMAS 2006) in relation to the picture of DM in the UK which may highlight areas 
for improvement of care and services within primary health care.
3.2.2.4 The Confidential Enquiry into Maternal and Child Health (CEMACH)
A recent national enquiry by The Confidential Enquiry into Maternal and Child
Health (CEMACH 2007) of the quality of maternity care for women with DM in 
England, Wales and Northern Ireland has identified key recommendations for 
improving care in pregnancy to women with DM. The report was highlighted by 
the media nationally and by medical journals and described standards of 
diabetes and maternal care and the outcomes of 3808 pregnancies. It highlights 
a growing number of women with DM and shows that too many women are
48
poorly prepared for pregnancy. The report underlines a need for improved 
preconception care services and education in relation to glycaemic control and 
folic acid supplementation. Recommendations for clinical practice, audit and 
research are made (Appendix Three) and a leaflet with care guidelines has been 
produced for and distributed to GPs and the primary health care team. There 
appears to be a gap in the literature in that there is no evident or proposed 
evaluation of the effect of such recommendations on the knowledge or behaviour 
of health professionals and women with DM.
Recently CEMACH (2007) has commissioned a further study to investigate 
factors affecting uptake of preconception care by women with type 1 and type 2 
DM from different ethnic groups in London.
3.2.2.5 Diabetes UK
The UK Charity Diabetes UK undertakes many reviews and makes specific 
recommendations in relation to DM care in the UK. With regard to DM in 
pregnancy they have produced evidence based care recommendations including: 
The management of pregnant women with DM, Preconception care and Folic 
acid supplementation’ (Diabetes UK 2007). These guidelines have provided a 
framework for health professionals who choose to use them until the Department 
of Health guidelines from the National Institute for Clinical Excellence are 
published in 2008.
49
In practice there appears to be a diversity of care by individual health 
professionals and subsequent outcomes as shown by the CEMACH report 
(2007). Women with DM can access Diabetes UK information sheets via the 
web, including one on Pregnancy (Diabetes UK 2007) and can also belong to the 
organisation receiving ajournai which has articles about pregnancy for the laity 
from time to time.
3.2.2.6 National Institute of Clinical Excellence (NICE)
The National Institute for Clinical Excellence is responsible for providing national
guidance on the promotion of good health and the prevention and treatment of ill 
health in the UK (NICE 2007). In relation to DM, there are a number of clinical 
guidelines published and currently NICE has commissioned the National 
Collaborating Centre for Women’s and Children’s Health to develop a clinical 
guideline on DM in pregnancy for use in the NHS in England and Wales and due 
for publication in March 20081. The scope for this review raises many questions 
relating to prevention of unplanned pregnancy for women with DM and states 
that the guidance should include ‘pre-conceptional information’ including ‘what 
pre-conceptional information should be offered to women with diabetes?’ (NICE 
2005a:4) and ‘specific information of the importance of contraception in planning 
a pregnancy’. However it also states that advice about contraceptive methods 
for women with DM will not be included and this appears to be a missed 
opportunity in the guidance for health professionals.
1 now published see addendum Chapter Twelve
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3.2.3 Glycaemic control in pregnancy
This section will examine literature relating to the pathophysiology of glucose 
control and maternal glycaemic control in pregnancy in order to understand the 
complications that can occur in pregnancy with a woman with DM.
3.2.3.1 Pathophysiology of Glycaemic control in pregnancy
In pregnancy there are extensive hormonal changes which maintain the maternal
metabolic state and increase nutrient availability for the growing fetus by affecting 
carbohydrate metabolism. Weissgerber & Wolfe (2006) describe the hormones 
associated with these changes which include Oestrogen, Progesterone, Human 
Placental Lactogen (HPL), Insulin, Free Cortisol, and Prolactin.
Buchanan & Dornhorst (1996a) examined the metabolic stress of pregnancy and 
note that in the first trimester the increase in levels of oestrogen and 
progesterone affect glucose homeostasis and as a result there is a two to three 
fold rise in beta islet cell activity in the pancreas, with increased release of 
insulin, which is essential for normal glucose tolerance in pregnancy.
This rise in insulin causes the liver to deliver glycogen and stop glucose 
production and in addition there is decreased amino acid and increased fatty acid 
and ketone production. Human placental lactogen is released leading to
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maternal lypolysis and reduced use of glucose and aminoacids which are 
subsequently preserved for the fetus. (Potter & Kicklighter 2007)
Studies of infants whose mothers have DM, show that glucose and amino acids 
are able to cross the placental membrane into the fetal blood circulation (Potter & 
Kicklighter 2007). However insulin is unable to do this and fetal glucose levels in 
women with out DM are lower than those of the mother. When there is maternal 
hyperglycaemia the fetus is subjected to high glucose levels and responds by 
increased pancreatic beta cell activity and insulin levels. This ‘pro insulin’ in the 
presence of fetal amino acids acts as a growth factor which results in fetal 
macrosomia.
3.2.3.2 Maternal Glycaemic Control
As has been discussed previously several studies have shown the importance of 
optimal glycaemic control throughout the pregnancy in order to minimise the risk 
of complications (Jensen et al 2004, Evers et al 2004, Damm &, Molsted- 
Pedersen 1989, Mills et al 1988, Miller et al 1981). Taylor & Davison (2007) 
identify that congenital abnormality is related to poor glycaemic control with 
hyperglycaemia at or around the period of organogenesis, i.e. the first 42 days 
following conception. This can best be achieved through a planned pregnancy, 
with careful attention being placed on good glucose control from conception 
however unfortunately many pregnancies in women with diabetes seem to be 
unplanned and are rarely discussed with their health professionals (Janz et al
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1995, Mestman & Schmidt Sarosi 1993, Holing et al 1998). It has been 
suggested that many women with DM are insufficiently aware or advised of the 
importance of pre-pregnancy care (CEMACH 2005a, CEMACH 2007,Kjaer et al 
1992) and this is discussed in Section 3.3.3.
Pregnancy can affect a woman’s eating pattern and consequently her DM which 
is controlled by matching food intake to the body’s changing need for insulin. 
Walkinshaw (2003) in a Cochrane review discusses blood glucose monitoring 
between four and seven times a day. The insulin dose should be adjusted to 
achieve near normal pre- and postprandial capillary plasma glucose levels of: pre 
prandial 4.4 -  6.1 mmol/l, postprandial less than 8.6 mmol/l. Women who are 
pregnant may be highly motivated to ensure tight blood glucose control as they 
may be concerned about the effect of poor control on the fetus (Heller 2001).
Women with type 2 DM may need to be changed from use of oral hypoglycaemic 
agents to insulin to gain good glycaemic control prior to conception (Diabetes UK
2007). There has been concern in the past over oral hypoglycemics prescribed 
for type 2 DM causing congenital abnormalities. Recent research has been 
reassuring and no differences in outcome for abnormalities were noted between 
women on dietary control, insulin or oral hypoglycemic agents during the first 
eight weeks of pregnancy (Langer 2002, Feig & Palda 2002). There is increasing 
use of oral hypoglycemic agents to regulate blood glucose levels in pregnancy
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for women with type 2 DM and gestational diabetes (Tran et al 2004, Homko et al 
2004, Langer 2002).
In early pregnancy emesis gravidarum can disrupt normal eating and there may 
be a need for increase in insulin dose requirements due to the rise in insulin 
resistance that occurs. Taylor et al (2002) suggest that the increased need for 
insulin can occur from week eighteen to week twenty eight gestation and can be 
up to 40%.
The recommended tight control of blood glucose levels can mean that 
asymptomatic hypoglycaemia can occur more frequently and lead to increased 
risk of unexpected severe hypoglycaemia (Pearson 2008). Women need 
counselling about such risks and the importance of ensuring blood glucose levels 
are satisfactory before driving vehicles (Taylor and Davison 2007). Glucagon, a 
hormone secreted by the pancreas converts glycogen to glucose and can be 
injected and used in treatment of severe hypoglycaemia. A glucagon kit should 
be provided and as appropriate partners, family and friends may need training to 
use this (Pearson 2008).
3.2.4 Complications of pregnancy
Women with type 1 and type 2 DM have both higher maternal and fetal risk in 
pregnancy than the general maternity population. A recent population based 
study by Macintosh et al (2006) found a fivefold increased risk of stillbirth, a
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threefold increased risk of perinatal mortality and a twofold increased risk of fetal 
congenital anomaly.
In the past, women with DM who were pregnant invariably had type 1 DM as type 
2 DM was mainly seen in women above childbearing age. However the 
increasing prevalence of type 2 DM in the younger population has meant that 
pregnancy is becoming more common in women with type 2 DM (Clausen et al 
2005). The rising rates of type 2 DM could equal significant risk of maternal and 
perinatal complications in pregnancy as several studies show no difference 
between risks for type 1 or type 2 DM (CEMACH 2005a, Clausen et al 2005, 
Mactintosh et al 2006).
3.2.4.1 Maternal complications
Maternal complications in pregnancy for women with DM include severe 
episodes of hypo and hyperglycaemia, rapid progression of retinopathy, renal 
failure, pre-eclampsia, and possible mortality (CEMACH 2007, ACOG 2001, 
Betschart 1996, Girling & de Swiet 1997). However in the absence of obstetric 
complications the maternal mortality rate is no greater than the general 
population (Bewley 2002).
Pregnancy combined with DM brings a particular risk of deterioration of 
microvascular disease including retinopathy and nephropathy. There is evidence 
that retinopathy can worsen rapidly in pregnancy if it is present before pregnancy
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(Klein et al 1999) and randomised controlled studies have shown significant 
deterioration in retinopathy when blood glucose control is suddenly tightened as 
advised in pregnancy (Taylor & Davison 2007). Retinal screening is therefore 
advised (CEMACH 2007) and schedules include screening at booking, at sixteen 
to twenty weeks and at twenty eight weeks gestation (Taylor & Davison 2007).
Nephropathy (microalbuminuria, albuminuria) is also of great concern in women 
with diabetes. There can be a rapid increase in hypertension and protein urea 
with risk to the fetus and there can be permanent loss of maternal renal function 
(SIGN 2005, Heller 2001). CEMACH (2007) advises renal screening and results 
showing protein urea greater than 3.0g/24hr and serum creatinine greater than 
130mmol/L are associated with poor perinatal outcome (Djelmis et al 1999).
3.2.4.2 Fetal and neonatal complications
Perinatal morbidity and mortality is increased up to five fold compared with the 
general population for women with type 1 and type 2 DM (CEMACH 2005b) and 
so there are substantial risks for the fetus and baby. Several studies (Macintosh 
et al 2006, CEMACH 2005, Jensen 2004, Diabetes & Pregnancy Group France 
2003) identify poor outcomes including miscarriage, preterm delivery and still 
birth and potential congenital malformations including neural tube defects and 
cardiac and bone abnormalities. The large size of babies with macrosomia can 
increase the risk associated with caeasarian section and also birth injuries.
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Shoulder dystocia with the risk of Erb’s palsy, occurs in about 8% of births to 
women with diabetes (Taylor & Davison 2007).
In their study of perinatal mortality and congenital abnormality outcomes for 
women with typel and type 2 DM, Macintosh et al (2006) found equivalent rates 
in offspring of women with type 2 DM to those of type 1 DM. With increasing 
numbers of women with type 2 DM being diagnosed this raises the importance of 
promoting good periconceptional glycaemic control to this group in order to 
prevent increasing rates of abnormalities. Some studies have suggested that 
perinatal mortality could be even higher for women with type 2 DM than for 
women with type 1 DM ((Dundy et al 2000, Clausen et al 2005, Feig & Palda 
2002) due to the women being diagnosed later and having higher obstetric risk 
factors such as smoking and obesity and increased age. Obesity is associated 
with obstetric risks including late fetal death, macrosomia and preterm delivery.
Feig & Palda (2002:1692) discuss that some clinicians tend to be ‘laid back’ 
about the care of women with type 2 DM with the notion of it being ‘mild 
diabetes’ and that clinicians need educating as to the risks of anomalies. In 
order to avoid maternal and perinatal complications, women with type 2 DM who 
are pregnant require specific preconception and antenatal care similar to women 
with type 1 DM (Macfarlane & Tuffnell 2006) and with Primary Care Practitioners 
providing more of the care of women with diabetes is discussed in Chapter Two, 
Section 2.1.6 this may mean specific education and training is required.
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3.2.5 Psychological aspects of diabetes and pregnancy
DM can have the potential to cause significant psychological issues at all stages
of pregnancy including the planning stage. Women with DM may be told by 
health professionals that they should not become pregnant because of 
complications of DM or until they have good blood glucose control (Holings et al
1998). Thomas (2003) found that being told to wait until blood glucose results 
were normal to try to get pregnant was extremely stressful for women and likens 
the process to ‘arduous patienthood’ as described by Jobling (1977: 73). Holings 
et al (1998) found that 59% of women in their study did not plan pregnancy and 
one factor was the discouraging advice from health professionals concerning DM 
and pregnancy.
The literature refers to many concerns for women with DM in relation to 
pregnancy. Women may be worried about possible congenital abnormality which 
is associated with high blood glucose levels at conception and in early pregnancy 
(Taylor and Davidson 2007). Women may also worry about the genetic heredity 
issues of passing on DM. The risk of a women with DM passing on type 1 DM is 
between 1 and 3%. This rises to 6.1% if the father also has type 1 DM and 20% 
if both parents have type 1 DM (Djelmis et al 1999). Genetic risk for type 2 DM is 
currently being researched and recent studies have identified 3 genes that 
predispose to type 2 DM (Zeggini et al. 2007).
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It is apparent that women with DM may have very different experiences of 
pregnancy to that of women in general and this can raise significant 
psychological issues (Snoek 2000). During pregnancy a woman may have to 
cope with the uncertainty of hypoglycaemic episodes which may prevent her from 
driving and therefore restrict her mobility. Women with type 2 DM may have to 
adjust to treatment with injected insulin instead of oral hypoglycaemics. 
Pregnancy is an emotionally stressful time, and the demands of self 
management of glucose control are great for women with DM (Snoek 2000).
They have the added pressure of the knowledge that poor glycaemic control 
could potentially damage the fetus (Hofmanova 2006). In addition Holings et al 
(1998) found that women felt their partners did not understand the risks or the 
effort required to achieve good control and were not always able to support them 
psychologically.
During pregnancy, women with DM will have many hospital appointments and 
scans and Snoek (2000: 64) states that this may lead to the feeling that their 
pregnancy is being ‘taken over’ by health professionals. Thomas (2003) 
discusses how much attention may be given to the growth and development of 
the baby rather than to the well being of the mother. Many obstetricians prefer 
to deliver the baby early at thirty eight weeks (CEMACH 2005a) and often this 
requires induction of labour or delivery by caesarean section which is an 
intervention that may be concerning to the woman. CEMACH (2007) found high 
numbers of babies delivered to women in their study were admitted to neonatal
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units, often because of routine policy which could be a cause of stress to women 
with DM as they are maybe separated from their babies and may affect the 
establishment of breast feeding and of maternal bonding processes.
It would appear from the literature that women with DM have a very medically 
focused pregnancy and this concept of the médicalisation of pregnancy is 
discussed in the literature by many sociologists and feminists (Oakley 1981, Kent 
2000, Ehrenreich & English 2005,) who argue that it is a paternalistic model of 
social control with over emphasis on disease and the physiological aspects of 
pregnancy. They maintain that the medical and often male obstetric domination 
of childbirth, has denied women the right to make their own decisions and be in 
control of their bodies. Literature was not found relating to the views of women 
with DM in relation to the medical experience of pregnancy care and further 
research could examine whether such a model has any effect on planning for 
pregnancy for women with diabetes.
Women with DM may also be aware of the Department of Health research (DH 
2001a) that established reduced life expectancy for people with DM on average 
by twenty years for those with type 1 and 10 years for those with type 2 DM and 
this could invoke fears of not living long enough to raise a child (Hofmanova 
2006) thus adding to concerns over pregnancy.
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3.2.6. Adolescence, DM and unplanned pregnancy
The case study of prevention of unplanned pregnancy will include women aged
sixteen to nineteen to years who can be said to be going through the period 
termed ‘adolescence’ (Snoek 2000). During this time young people go through a 
major period of change and development and for the adolescent with DM this can 
be a critical time of adjustment (Snoek 2000).
In relation to preventing unplanned pregnancy, Charron-Prochownik & Michel 
(2006) discuss how adolescents do not think about the consequences of 
becoming sexually active and will engage in sexual activity without planning to do 
so. They are influenced by peer groups and may not have decision making skills 
to abstain from sexual intercourse. Falsetti et al (2003) studied condom use, 
pregnancy and sexually transmitted infection in adolescent females with and 
without type 1 DM and found that risky sexual activity was common and that 
having a chronic illness did not preclude risk taking sexual behaviour. In fact 
having DM in adolescence may compound risk factors due to the stressors of 
living with an chronic condition and the psychosocial issues of adolescence such 
as seeking independence, rebelliousness, peer influences, and expressing 
independence (Charron-Prochownik & Michel 2006).
Studies have found that adolescents are not always instructed on contraception 
or sexual issues (Janz et al 1995, Kjaer 1992) and that they were not aware of 
emergency contraception (Charron-Prochownik et al 2006b). With ‘diabulimia’ 
and unreliable blood glucose control being evident in the teenage population,
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(Diabetes UK 2007, Hanna & Guthrie 2000), there may be an increased risk of 
complications and congenital abnormality should pregnancy occur. Adolescents 
should therefore be targeted through reproductive health education and 
preconception counseling prior to sexual activity in order to empower them to 
prevent unplanned pregnancy (Charron-Prochownik et al 2006b).
3.2.7 Summary of literature -  DM and Pregnancy.
This section has looked at literature pertaining to type 1 and type 2 DM and
pregnancy including relevant policy, the pathophysiology of glucose control, 
maternal and fetal complications, psychological aspects and experiences of 
pregnancy, women with type 2 DM and adolescents with DM in relation to 
pregnancy. It can be seen that despite policies aimed at promoting equitable 
pregnancy outcomes for women with DM, they often experience higher rates of 
interventions and complications compared to the general population. Women 
with DM may therefore have very different experiences of pregnancy to that of 
women in general and this can raise significant psychological issues. Questions 
are raised from the literature as to how women with DM perceive pregnancy and 
the effect of current policy and services in relation to a woman planning a 
pregnancy.
The literature highlights that the risks of complications in pregnancy can be 
reduced by preconception care strategies and tight glycaemic control and the
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Section 3.3 looks at literature pertaining to preconception care for women with 
DM.
3.3 Preconception Care for Women with DM. 
3.3.0 Introduction
The importance for preconception care for women with DM is highlighted by the 
significant improvements in outcome of pregnancy seen in studies comparing 
women who have undergone preconception care with those who did not (Temple 
et al 2006, Diabetes & Pregnancy Group France 2003, McEIvy et al 2000, 
DCCTRG 1996). Literature relating to preconception care and planning for 
pregnancy will be discussed including planned versus unplanned pregnancy, 
medication issues, current dietary and lifestyle recommendations, preconception 
care services and what is currently known about knowledge of preconception 
issues by health professionals and women with DM.
3.3.1 The concept of preconception care
Arguments for preconception care stem from the fact that following conception, 
before a woman is aware of the pregnancy, the embryo may be susceptible to 
tetrogenic effects as it rapidly develops and organogenesis occurs. The 
developing embryo grows quickly so that by six weeks gestation (two weeks after 
a missed period), major organ and limb buds are formed. It is during this period 
of rapid growth that hyperglycaemia affects the embryo in women with DM and
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congenital malformations occur (Kendrick 2004). Hypoglycaemia however, does 
not appear to have any affect on the developing embryo (Gregory & Tattersall 
1992).
Over the last twenty years the promotion of preconception care has been 
highlighted in the government’s quest to reduce perinatal morbidity and mortality 
(DH 1992a, DH 2004) with emphasis on folic acid supplementation to prevent 
neural tube defects as discussed in Section 3.3.5.1 In order to take advantage 
of preconception care a woman has to plan to become pregnant and the concept 
of planning for pregnancy will now be examined in Section 3.3.2.
3.3.2 Planning for pregnancy: Planned versus unplanned
The literature is clear about the importance of women with DM planning for
pregnancy (CEMACH 2007, DH 2001a, Diabetes UK 2007), but studies have 
found that in reality there is a poor level of preparation for pregnancy by women 
with DM. Holings et al (1998) found 41% of a population based sample of 85 
women with DM had planned pregnancies and CEMACH (2007) in their enquiry 
of 384 women with DM also found that 41 % had planned their pregnancies. Dex 
& Joshi (2004), in an analysis of the Millennium Cohort Study, found the planned 
pregnancy rate for the general population in the UK was between 46 and 58%, 
which compares to similar figures in the USA (ADA 2002) and in Australia where 
Walters & Senaratne (2005) state that preparation for pregnancy is unusual.
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The concept of unplanned versus planned pregnancy has been explored in the 
general population by Earle (2004). Interview data were used to develop four 
categories of pregnancy intention including; ‘planned pregnancy’ as adopted by 
health professionals; ‘laissez-faire pregnancy’ for women who had stopped using 
contraception but were relaxed about planning for pregnancy; ‘recalcitrant 
pregnancy’ for those who wanted to be pregnant but for whom it would not be 
‘socially acceptable’ to plan a pregnancy and finally; the accidental pregnancy’ 
arising from contraceptive failure or those that were unexpected. There appears 
to be little literature in relation to women with DM or women with chronic illness in 
respect of this model although Thomas (2003:404) discusses how women with a 
pre-existing chronic illness have acquired ‘the status of patienthood’ prior to 
pregnancy and with this may come medical advice and expectations in planning 
a pregnancy.
With regard to use of contraception, CEMACH (2005a) found that there was less 
use of contraception prior to conception in women with type 2 DM than type 1 
DM and Holings et al (1998) found that of those women with unplanned 
pregnancy 70% used contraception less than half of the time.
Holings et al (1998) considers the psychological issues associated with 
unplanned pregnancy and found that those women with a locus of control 
attributed to ‘powerful others’ were more likely to have an unplanned pregnancy. 
This differs from other studies (Schlenk & Hart 1984, St James et al 1992) which
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have shown that those who deem that doctors are responsible for their health are 
more compliant with diabetes regimens. Holing et al (1998) also suggest that 
women who felt that their medical carers discouraged pregnancy were more 
likely to get pregnant either consciously or subconsciously. Snoek (2000) cites 
Coustan (1998) discussing the importance of the doctor- patient relationship in 
diabetes care and Janz et al (1995) also found that women who had previous 
discussions about preconception care with their health care provider were more 
likely to plan their pregnancies.
Janz et al (1995) found that women who sought preconception care were more 
likely to be married, employed and have higher levels of income and education. 
This concurs with Holings et al (1998) findings that women with unplanned 
pregnancies were poorer, less educated and more likely to belong to an ethnic 
minority group. Both these studies also discuss the importance of social support 
for women planning pregnancy with those women who are happy in their 
relationship and who have support from their partner in relation to their DM care 
being more likely to plan their pregnancies.
3.3.3 Women’s knowledge of preconception care
There appears to be little literature relating to women’s knowledge and behaviour 
in relation to preconception care. In 1992 my MSc study ‘Women’s knowledge of 
preconception care and the implications for family planning clinics’ (Shawe 1992)
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demonstrated a low level of knowledge of preconceptual issues in general and 
amongst well educated women.
The Diabetes & Pregnancy group in France (2005) assessed knowledge about 
preconception care in women with type 1 DM of childbearing age. They used a 
questionnaire to identify factors that could be associated with the absence of 
preconception care. They found that 48% of the sample were unaware of the 
risks associated with raised blood glucose levels. Use of contraception was 
associated with a higher knowledge of preconception care. Charron-Prochownik 
et al (2006a) also found that adolescent women with type 1 DM lacked 
awareness of preconception issues and the importance of contraception, but that 
they knew where to seek out information if required. This raises questions 
regarding the level of knowledge of preconception care amongst women with 
type 1 and type 2 DM and the impact on planning pregnancy for these women.
3.3.4 Preconception medication issues for women with diabetes
Insulin is currently unlicenced for use in pregnancy but is routinely used outside
the licence as studies have deemed most types of insulin safe for use in 
pregnancy (Jovanovic & Pettitt 2007, Diabetes UK 2007); Further studies into the 
safety of insulin analogues in pregnancy are currently being undertaken (Taylor & 
Davidson 2007, Jovanovic & Pettitt 2007). Women on oral hypoglycaemics, such 
as metformin or acarbose, may be transfered to insulin treatment because these 
drugs are known to cross the placenta and data are currently unavailable
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regarding safety during pregnancy. However studies are currently evaluating the 
use of metformin in pregnancy and as yet data are reassuring (Hughes & Rowan 
2006, Simmons et al 2004).
Women with diabetes may be prescribed medication for medical conditions which 
have presented as a result of complications of DM. These commonly include 
anti-hypertensives and statins. Women with hypertention are usually prescribed 
calcium channel blocking agents (Diabetes UK 2007) as angiotensin-converting 
enzyme inhibitors are contraindicated in pregnancy due to possible fetal 
anomalies and neonatal renal failure (Cooper et al 2006). Beta-adrenergic 
blocking drugs are linked to a lessening of awareness of hypoglycaemia. Statins 
for hyperlipidaemia are contraindicated in pregnancy due to teratogenicity found 
in animal studies (Murphy et al 2007) and women are advised to stop taking 
them before conception. No studies were found relating to knowledge and 
prescribing by health professionals regarding medication for women planning 
pregnancy and this could be investigated in future research.
3.3.5 Dietary and Lifestyle Advice
3.3.5.1 Folic Acid Supplementation
It has long been suspected that dietary factors had a role in neural tube closure 
and in 1964 BM Hibbard proposed that folic acid might be involved. Since then 
two randomized control trials (Laurence et al 1981 and MRC 1991) and two 
nonrandomized intervention trials (Smithells et al 1983 and Vergel 1992) showed
that a multivitamin or folic acid supplementation amongst women who had 
children with neural tube defects, reduced the recurrence in subsequent 
pregnancies.
The Medical Research Council (MRC) Vitamin trial in 1991 showed that a high 
dose of 4mg of folic acid prevented recurrence of neural tube defects in 72% of 
women with a previous history of such pregnancies. A Cochrane systematic 
review confirmed these findings (Lumley et al 1991) and an expert advisory 
group then made recommendations (DH 1992b). They firstly advised folic acid 
supplementation for all women planning pregnancy of 400mcg for twelve weeks 
prior to conception and for twelve weeks afterwards and secondly that women 
with a previous neural tube defect or at higher risk of such defects as in women 
with diabetes take 5mgs a day for the same period (Diabetes UK 2008, CEMACH 
2007, BMA 2004,RCOG 2003b). In the CEMACH study (2005a) only 39% of 
3808 pregnancies studied had documented that folic acid was taken prior to 
conception and this was even less for women with type 2 DM. This raises 
questions over the awareness of women with DM to take folic acid or of the 
health professionals awareness to prescribe the higher dose to women with DM, 
planning pregnancy.
3.3.5.2 Specific Preconception Advice
Women who are planning pregnancy are advised to eat a healthy diet with plenty 
of fresh fruit and vegetables. The Food Standards Agency (2008) have made
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some recommendations regarding specific foodstuffs including caffeine intake, 
liver, fish, unpasteurised cheeses, undercooked poultry and eggs and cook chill 
meals. More detail on these topics is included in Appendix Four. Other advice is 
highlighted in reports from the BMA RPSBG (2007), RCOG ( 2006) and the DH 
(2007d) in relation to the importance of not smoking and on alcohol consumption 
during pregnancy and screening in the preconception period for genetic risk and 
infections. In addition there are concerns around environmental and 
occupational hazards such as heavy metals, organic solvents, pesticides and 
herbicides, anaesthetic gases and anti cancer drugs used in health care. 
(McDiarmid & Gehle 2006).
There appears to be little literature specifically relating to women with DM in 
relation to the above. The National Service Framework for diabetes (DH 2001a) 
suggests an annual discussion with women of childbearing age, including advice 
on smoking cessation, dietary advice & folic acid, exercise & rubella status. 
Guidelines by Diabetes UK (2007) mention counseling for risk factors but studies 
in women with DM were only found in relation to screening for retinal assessment 
(Vijan et al 2000) and renal function (Kramer & Mol itch 2005) which are 
recommended as a baseline prior to conception. CEMACH (2007:46) note that 
‘just over half of women in their study had a retinal assessment or renal function 
test in the twelve months before pregnancy’.
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3.3.6 Preconception care services and counseling
The National Service Framework (DH 2001a) Standard Nine states that every
year a woman should be given information about the risks associated with 
pregnancy and the benefits of good glycaemic control but there is no 
recommendation for specific preconception services. CEMACH (2005b) found 
that just 17% of maternity units in England Wales and Northern Ireland reported 
that they provided a multidisciplinary DM preconception service. In the same 
study only 35% of women had been offered preconception counseling by their 
health professionals, although 53% had had a discussion about glycaemic 
control. Other studies concur and Kim et al (2005) found low rates of counseling 
in a study of women with diabetes aged 18 - 45years especially in the lower age 
ranges
Several studies have indicated the need for increased patient education about 
the risks of pregnancy and DM, use of contraception and genetic counseling 
(Kjaer et al 1992, Janz et al 1995, Gibb et al 1994, CEMACH 2007). Studies of 
adult women with DM have shown that those who had a greater awareness of 
preconception care were more likely to seek care preconceptually and to use 
contraception more consistently (Janz et al 1995, Charron-Prochownik 2006b).
In the literature there appears to be a debate concerning the best way to provide 
counseling or preconception services for women with DM in order to encourage 
preconception care. In 1976 Dr Judith Steel started a pre pregnancy clinic in 
Edinburgh based on a medical model. Women aged fourteen to forty years
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attending diabetes services, were invited by letter to a consultation with the aim 
of assessing their suitability for pregnancy by detecting serious or potentially life- 
threatening complications of DM. An evaluation of seven years of the service 
was positive and 126 patients were seen, however it was acknowledged that the 
patients were self selected and motivated. Results of the study showed that 12 
of the women participating were considered to be medically unfit and were 
advised against becoming pregnant and another 4 women decided not to take 
the risks associated with pregnancy. There was a high incidence of women 
presenting with infertility (26 out of 126 women) but many of these came forward 
when the clinic started, after years of them failing to conceive (Steel 1985).
Janz et al (1995) found that only one third of women in their study attended for 
preconception care and recommend that health professionals must regard every 
consultation with women with DM as a preconception visit. In addition the 
support of family and friends should be elicited to encourage motivation.
Health care providers should start discussing positive aspects of preconception 
care with patients at puberty as this can influence the outcome of pregnancies in 
women with DM (Charron-Prochownik & Michel 2006)
Varughese et al (2007) evaluated preconception advice given in an adult DM 
clinic against the National Service Framework (DH 2001a) guidelines by 
reviewing the case notes of 70 women. Results showed that many adults were 
not given advice at their annual review and only 24% had a documented
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discussion of preconception issues. 29 of the patients were receiving treatment 
with potentially teratogenic drugs which should have been stopped prior to 
pregnancy.
The French Diabetes & Pregnancy Group (2003) discusses that diabetes care 
providers should be aware of the failure of preconception care in women with 
DM, however they are unsure of the way to enhance preconception attendance. 
Media involvement and announcements have been found to encourage 
preconception attendance in a study by McEIvy et al (2000) and Berstein & 
Sanghvi (1999) suggest a model of care of inserting a ‘preconception’ form in the 
medical notes of attendees at clinics to raise awareness during consultations.
Gregory & Tattersall (1992) reviewed available studies to evaluate whether 
Diabetic Pre pregnancy Clinics are worthwhile. They concluded that they are of 
benefit to the women who attend them but that overall such clinics do not reduce 
the rate of congenital abnormalities in the population of women with DM. More 
recently Temple et al (2006) studied a cohort of women with type 1 DM and 
found that attendance at clinics was associated with improved glycaemic control 
in early pregnancy and significant reduction in adverse fetal and neonatal 
outcomes, however it made no difference to the control in later pregnancy or to 
rates of macrosomia or preeclampsia which, they suggest, merits further study.
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Kim et al (2005) found that preconception counseling rates for women with DM 
are low and could be vastly improved. The study concluded that more family 
planning and contraceptive services should be advertised to women with DM.
From the evidence above it appears therefore that models of care encouraging 
preconception counseling, education and possible attendance at services need 
to be developed and evaluated.
3.3.7 Preconception care - Health professionals involved
Moos (2004) discusses that no profession has become a champion for
preconception health promotion in the USA where there is poor appreciation of 
incidence of unintended pregnancy, with the belief that women will seek the care 
appropriate to their need. Similarly in the UK the CEMACH report (2007) found 
there was little multidisciplinary preconception care and identified that the main 
underlying factor to suboptimal care was failure by health professionals to 
provide it. The report makes recommendations for educational updating of all 
primary and secondary care professionals likely to be involved in a local area.
Willhoite et al (1993) discuss the implementation of a state wide program to 
educate health care providers and women with pregestational DM in Maine New 
England. Three patient care guidelines were produced and delivered on 
preconception counseling, prenatal care and contraception for women with
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established DM. The project showed a success in relation to improved 
pregnancy outcomes.
Klinke & Toth (2003) conclude that preconception care to women with DM should 
be provided by GPs in primary care, who have regular and early contact with 
women of childbearing age. Other studies have looked at clinics held by 
secondary care staff with joint preconception clinics with maternity and adult 
diabetes services (Gregory & Tattersall 1992) but no studies were found 
evaluating attendance of women at different providers. Diabetes care teams 
often include dieticians but there appears little literature into their role within 
preconception care. Currently Murphy et al (2007) a multi-professional DM group 
in East Anglia UK are implementing a programme aimed at ensuring that women 
are provided with the appropriate information to make an informed choice 
regarding preconception attendance. They are sending a guided patient 
information leaflet directly to all women with type 1 or type 2 DM and to all GP 
practices.
The attitudes and practices of health professionals can be an important factor in 
encouraging women to plan their pregnancies if they establish positive ongoing 
relationships with women with diabetes. Holing et al (1998) found that women 
who reported such relationships with diabetes care professionals, were more 
likely to plan their pregnancies and Scott (2005) argues that diabetes nurse
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specialists have a key role in preconception care as they are more likely to know 
the women at risk and have a relationship with them.
Several studies conclude that many health professionals have not had training in 
preconception care and that practice policies and procedures need developing 
along with effective education strategies for the future (Heyes et al 2004, 
Charron-Prochownik & Michel 2006, CEMACH 2007).
3.3.8 Summary of literature - Preconception Care for women with diabetes
This section has looked at the literature pertaining to preconception care for
women with DM including planned versus unplanned pregnancy, medication 
issues, current dietary and lifestyle recommendations, preconception care 
services and knowledge of such issues by health professionals. There are gaps 
within the literature that raise questions which will be explored by my research 
study and these include knowledge by women and health professionals in 
relation to preconception care and the best way to encourage promotion of 
planning for pregnancy and preconception care by women with DM. In addition 
the literature relating to unplanned pregnancy highlighted variations in the use of 
contraception by women with DM and the next section goes on to explore the 
literature specifically relating to this topic.
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3.4. Contraception for Women with Diabetes Mellitus
3.4.0 Introduction
Guillebaud (2004) suggests that a woman’s choice of contraception will depend 
on several factors including personal preferences, plans for future pregnancies, 
her medical health, and the effectiveness, risks and side effects of the 
contraceptive method. Despite contraception being freely available in the UK 
(Appendix F ive), Glasier & Winikoff (2005) propose that many unplanned 
pregnancies are due to failure to use any method at all or a failure in using a 
method correctly.
Contraception is an important issue for women with DM as the risks to the 
mother and fetus in pregnancy are high when blood glucose levels are raised or 
uncontrolled in early pregnancy (Mactintosh et al 2006, CEMACH 2007).
Women are therefore advised to continue with a reliable method of contraception 
until their HbA1c is stable at recommended levels (CEMACH 2007). This section 
aims to review literature relating to choices of contraception and the use and 
outcomes of types of contraception for women with DM. The review has been 
published and can be seen in Appendix Six: Shawe J, Lawrenson R (2003) 
Hormonal Contraception in women with Diabetes Mellitus: Special considerations 
Treatments in Endocrinology 2 (5) 321-330.
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Table One - Contraceptive Methods
METHOD EFFECTIVENESS
Barrier Methods of Contraception
Male Condom 98% effective (fpa 2007a)
Female Condom 95% effective (fpa 2007a)
Diaphragms 92-96% effective (Cook et al 2003)
Spermacides 70-94% effective (Glasier & Winikoff 2005)
Hormonal Methods of Contraception
Combined oral contraceptive pill Over 99% effective (fpa 2007a)
Progesterone only preparations 99% effective (fpa 2007a)
Sub dermal Inplants 99% effective (fpa 2007a)
Transdermal Patch 99% effective (fpa 2007a)
Injectable Contraception 99% effective (fpa 2007a)
Intrauterine System Over 99% effective (fpa 2007a)
Other Methods
Intrauterine Device 99% effective (fpa 2007a)
Natural methods 80 -  98% effective (fpa 2007a)
Male Sterilisation - Vasectomy 1in 2000 failure (fpa 2007a)
Female Sterilisation 1 in 200 failure (fpa 2007a)
Emergency contraceptive pill 5% - 42% failure depending on time of 
administration (FFPRHC 2006)
Emergency Intrauterine Device 98-99% effective fpa 2007a)
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3.4.1 Choice of Contraceptive Method
There are fourteen methods of regular contraception and emergency 
contraception as listed in Table One and detailed in Appendix Seven. The 
effectiveness listed refers to typical use for all cycles including factors such as 
compliance (Steiner et al 1996).
Women with DM are at increased risk of complications such as cardio-vascular 
disease which may influence the risk-benefit equation when the choice of 
contraception is being made (Shawe & Lawrenson 2003). Contraceptive choice 
may also differ depending on the type of diabetes. Women with type 1 DM are 
likely to have had DM before they become sexually active and to use 
contraception to delay or prevent pregnancy. They will usually therefore require 
effective and reversible methods of contraception. For adolescents who often 
have unstable diabetes due to their erratic lifestyles and who are likely to be 
starting sexual relationships, reliable contraception is essential in order to 
prevent unplanned high-risk pregnancies (Charron-Prochownik & Michel 2006).
Women with type 2 DM, which has an increased prevalence with age (BMA 
2004) are more likely to have completed their family and so permanent methods 
such as sterilisation are likely to also be an option. However with the increasing 
problem of obesity and the associated high prevalence of type 2 DM in this 
group, many more women with type 2 DM of childbearing age may be seen.
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CEMACH (2007) found less use of contraception in women with type 2 DM 
compared to those with type 1 DM in the twelve months prior to their pregnancy.
Women who have developed gestational DM are faced with the problem that DM 
is likely to re-occur and develop as type 2 DM (Agarwal & Dhatt 2007). They 
may be at increased risk of macrovascular problems and this will influence 
contraceptive choice.
For women with DM who require contraception, the requirement is for a reliable 
method balanced against the risk of side effects and complications of DM. With 
the rise in cases of DM, increasing evidence is appearing that further thought 
needs to be given to the contraceptive options for these women (Shawe & 
Lawrenson 2003) and the following sections will examine literature in relation to 
specific methods of contraception and use in women with DM.
3.4.2 Hormonal methods of contraception
3.4.2.1 Combined oral contraception
The most frequently chosen method of hormonal contraception for young women 
with DM is a combined oral contraceptive (COC) containing oestrogen and a 
progestogen (see Appendix Seven). The newer products (second and third 
generation COCs ) are less androgenic and exhibit differences in their effects on 
lipids (Crook 1997) which is of potential importance in women at higher risk of 
cardiovascular complications such as women with DM. This is discussed in
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Section 3.4.5.5 which examines contraception on the lipid profile of women with 
DM.
The newest COC contains 30mcg of ethinylestradiol and 3 mg of drospirenone 
(BMA & RPSGB 2007). It does not significantly influence weight, blood pressure 
or lipids in women without DM (BMA & RPSGB 2007)and it has an 
antimineralocorticoid effect which might suggest that it is unlikely to adversely 
affect glucose control (Porcile & Gallardo 1991). However I could not find data on 
its use in women with DM and from clinical experience, women with DM are 
prescribed a range of COCs.
3.4.2.2 Cyproterone acetate and ethinylestradiol.
This product combines the anti-androgen cyproterone acetate with 35meg of
ethinylestradiol and is used to treat women with acne who also require 
contraception. It has also been used in women with polycystic ovarian syndrome 
(POOS) particularly to reduce the problem of hirsutism. There is a well 
recognised association between PCOS and type 2 DM (Parsey & Pong 2000) 
and so women with type 2 DM who have PCOS may be prescribed this product 
jointly for contraception and to control symptoms of PCOS.
3.4.2.S Progestogen only oral preparations
The progestogen only preparations (POPs) (Appendix Seven) are seen as 
suitable for women with DM who have, or who are at risk of complications of
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diabetes, or who smoke or are breast-feeding (Guilebaud 2004). POPs are 
slightly less effective than combined preparations and can lead to more 
menstrual irregularities. The older type of POP needs to be taken regularly at the 
same time each day and for some women with DM this is no problem if taken 
with a regular dose of insulin or OHA (Shawe & Lawrenson 2003). However the 
newest POP containing Desogestrel can be taken in a twelve hour time window 
and works by preventing ovulation as its primary method of operation (Guillebaud 
2004). It is therefore more reliable and could be very suitable for women with 
DM.
5.4.2.4 Parenteral progestogen only preparations.
There are a number of parenteral progestogen only preparations, available as an 
injectable preparation or as an implant. They are effective in preventing 
pregnancy and are useful for women requiring long-term contraception but who 
do not want to consider sterilisation (Guillebaud 2004). They too have the 
problem of menstrual irregularities. There is little information on the use of these 
products in women with DM (Shawe & Lawrenson 2003) although Edelman & 
Isley (2007) in their recent up date and review of the single rod implant, consider 
it a safe option for women with DM and for those with medical complications.
3.4.2.5 Intrauterine system
The intrauterine system is an intrauterine device that also contains progestogen. 
The local action of the progestogen within the uterus and cervical canal is
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thought to negate risks of pelvic infection associated with the device (Guillebaud 
2004). This means that this may be an option for women with DM who can be at 
greater risk from infection (Clark 2004). There is some concern however that the 
progestogen may slightly influence carbohydrate and lipid metabolism (WHO 
2000) but Kayikcioglu et al (2006) studied 48 women over the period of a year 
and found no significant changes.
3.4.3 Risks of developing diabetes from hormonal contraception.
There has been concern that use of hormonal contraception may increase the
risk of developing DM for certain populations (BNF 2007, Wing rave et al 1979, 
Kjos et al 1998). The low dose COC does not appear to increase the risk of 
developing type 1 or 2 DM for women without DM (Wingrave et al 1979, Kim et al 
2001, Chasen-Taber et al 1997). Studies of populations at higher risk of 
developing type 2 DM however, found an increase risk with Depot 
Medroxyprogesterone contraception (DMPA) (Wingrave et al 1979) and POP’s 
taken when breast feeding.(Kjos et al 1998).
3.4.4 Use of hormonal contraception by women with diabetes.
There is limited information on the use of hormonal contraception by women with
DM. Almost all the studies have been in women with typel DM. There have 
been some descriptive studies on patterns of contraceptive practice in women 
with DM from a number of other countries particularly Europe (Kjaer et al 1992, 
Kimmerle et al 1994, Fontbounne et al 1987, Kim et al 2002, Lawrenson et al
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1999) and New Zealand (Gibb et al 1994). Mostly these studies recruited 
women from specialist DM clinics and only two were comparative studies (Parsey 
& Pong 2000, Kim et al 2002). The principal methods of contraception used by 
women with DM are COCs, POPs, injectable progestogen, intrauterine 
contraceptive devices (IUD), barrier methods and sterilisation. However 
significant differences have been identified in prescribing patterns for women with 
type 1 DM compared with women without DM (Lawrenson et al 1999). Women 
with type 1 DM were more likely to be prescribed a COC than a POP, but were 
more likely to be prescribed a POP than women in the general population. To 
further examine patterns of contraception and use of contraception, phase one of 
my study will look at women with type 1 or type 2 DM.
Some women with DM appear to be concerned about the risks of taking the COC 
and may avoid this method of contraception because of feared metabolic and 
cardiovascular side effects (Kim 2002, Gibb et al 1994) and literature relating to 
such outcomes with use of hormonal contraception is examined below in Section 
3.4.5.
3.4.5 Outcomes of hormonal use in women with diabetes.
This section considers literature relating to the outcome of use of hormonal
contraception by women with DM in relation to glycaemic control and the 
complications that can arise with DM. Macrovascular and microvascular disease, 
hypertension, lipid profile and body weight are discussed and studies show the
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complexities that must be considered in the prescribing and choices of hormonal 
contraception for women with DM.
3.4.5.1 Glycaemic control
One of the concerns in prescribing hormonal steroids to women with DM is that 
they adversely affect glycaemic control and thus increase their risk of 
complications. The evidence that sex hormones can affect glycaemic control 
comes from a number of sources. The increased levels of sex steroids that 
occur with puberty have been shown to cause increased insulin resistance but 
confined to peripheral sites (Polderman et al 1994). The administration of 
testosterone and oestrogen to transsexuals has also been shown to reduce 
peripheral glucose uptake (Anderson et al 1997). However oestrogen 
replacement therapy improves glycaemic control in postmenopausal women with 
DM (Anderson et al 1997, Darko et al 2001). Thus the level of oestrogen 
appears to be important in determining whether the action on insulin sensitivity is 
beneficial or detrimental (Livingstone & Collinson 2002). Studies of COCs in 
young non-diabetic women have also shown changes in insulin sensitivity and 
glycaemic control (Peterson et al 1994, Skouby et al 1991, Blum et al 1983) 
whilst the arm of one of these studies who were taking a POP (ethinodiol 
diacetate O.Smcg) increased their mean HbA1c from 5.8% to 8.7% (Blum et al 
1983). However the clinical impact of these changes is hard to assess.
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Prospective studies in the United States (Chasen-Taber et al 1997) have shown 
no increased risk of developing type 2 DM in women taking COCs, and this was 
also found to be true in a prospective study of Latin American women with a 
history of gestational diabetes. However patients in this second study taking 
POPs did have a significantly increased risk (Kjos et al 1998).
When oral contraceptives were first introduced there were some case reports of 
increased insulin requirements and ketoacidosis in diabetic women taking oral 
contraceptives. A study of 88 women with insulin dependent diabetes treated 
with oral contraceptives, had 17% who required a small increase in insulin and 
two patients needed more than a 20 unit increase in insulin. This study had no 
comparison group and the significance of these findings was not tested (Steel & 
Duncan 1980). Radberg et al (1982) showed in their study a 7% increase in the 
insulin requirements of patients taking a COC containing 50mcg of ethinyl 
oestradiol and 250mcg of lynoestranol. More recent studies on women taking 
third generation COC s have shown less of a problem. One study showed a 
significant increase in fasting blood sugar in a group of diabetic women 
randomised to SOmcg ethinyloestradiol/gestodene (Diab et al 2000) whilst two 
other studies (Skouby et al 1982, Peterson et al 1994) showed no change in 
glycaemic control, insulin requirement or HbA1c in the groups randomised to low 
dose COCs. It would seem that although there are some theoretical reasons to 
worry about the changes in glycaemic control for women with DM taking COCs, 
with the newer low dose products there seems to be little evidence that these
changes are of any clinical relevance. Godsland (1996) has shown that by 
encouraging exercise any negative affects of COCs on insulin resistance can be 
abolished. There is a suggestion that the use of progestogen only preparations, 
whether oral or injectable are more likely to disturb the glycaemic control of 
patients with DM, but there maybe other more important considerations which will 
outweigh this concern when considering which contraceptive to prescribe.
There are theoretical interactions between oral hypoglycaemics used by women 
with type 2 DM and oral contraceptives due to the effects on liver metabolism. 
However there is little evidence to suggest that this is a problem in clinical 
practice and no adjustments in dose or alternative prescription is required (Steel 
1985). No interactions between COCs and exogenous insulin were found in the 
literature.
3 4.5.2 Macrovascular disease
The most important concern about the use of hormonal contraception in women 
with DM relates to the risk of macrovascular complications. The original work in 
the 1970s from the RCGP study, RCOG 1977, supported by the Oxford family 
planning study Vessey et al (1977) suggested an increased risk of myocardial 
infarction (Ml) in women taking oral contraceptives. These studies were based 
on women taking products containing high doses of oestrogen (SOmcg or more) 
and showed the risks were principally increased in women who smoked and 
were over 35 years of age. In women younger than 30 years of age the absolute
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risk of Ml is less than 1:100,000 years. Studies of low dose COC pills in this age 
group have been unable to show an increased risk of ischaemic heart disease 
(Jensen et al 1991, Sidney et al 1998). The risks of CVD in women taking 
COCs have more recently been reviewed and confirmed using international data 
for women over 35 years who smoke (Farley et al 1998). The increased risk of 
CVD in women with DM means that the additional risk of using a COC has 
always been viewed with caution.
There are two well recognised risk factors associated with an increased risk of 
stroke in young women; the use of COCs and diabetes. Although stroke is an 
extremely rare occurrence in young women, the increased relative risk in women 
using COCs has meant again combined products have been used with caution.
In a large Danish retrospective case-control study, (Lidegard 1995) pregnant 
women and women with chronic conditions were assessed for risk of cerebral 
thromboembolic attacks and the interaction of these risk factors with oral 
contraceptive use was investigated. The study based on 497 cases concluded 
that a woman with DM taking a low dose COC has a tenfold increase in risk of a 
cerebral thromboembolic attack.
Any increase in CVD risk may result from changes within the blood clotting 
system. COCs decrease antithrombin and increase factor X, factor 11, 
plasminogen, and platelet aggregation by reducing the production of prostacyclin 
(Mammen 1982). Peterson et al (1994) suggests that there is increased
susceptibility of the coagulation system in women with DM. Although prothrombin 
time measurements were decreased in COC users this was not found to be 
clinically significant (Diab & Zaki 2000). Thus there are some interesting 
theoretical reasons why COCs in women with DM might be associated with 
increased thrombogenesis but few clinical studies in diabetic patients on COCs 
demonstrate an increased risk of adverse outcomes.
No increased risk of macrovascular disease has been demonstrated in women 
taking POPs whether they had DM or not. There has been a recent paper 
showing that women taking DMPA had significantly reduced vasodilation in their 
brachial arteries. It was suggested that this might indicate an increased risk of 
CVD but again there are no outcome data to support this (Sorenson et al 2002).
3.4.5.3 Microvascular disease 
3.4.5.3.Î Nephropathy
A study by Monster et al (2001) showed an association with the appearance of 
microalbuminuria and the use of COCs in women without DM. This study is 
worrying in that if women with DM had been included then the combined risk may 
have been a cause for concern. Nevertheless there is no evidence that the use 
of oral contraceptives in women with DM precipitates renal failure (Garg et al 
1994) and with modern treatment this is now a rare complication in women of this 
age with type 1 or type 2 DM.
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3.4.5.3.Ü Neuropathy
Neuropathy is a common complication of DM, occurring in 20-25% of cases and 
increasing with age. I could not find any studies to suggest that oral 
contraceptives worsen the development of neuropathy in women with DM.
3.4.5.3.iii Retinopathy
It is recognised that retinopathy is a chronic complication of DM and that this can 
worsen rapidly during pregnancy (Klein et al 1999). This has led to concern as to 
whether women using COCs or POPs are at an increased risk of retinopathy. 
Studies of retinopathy in diabetic women (Garg et al 1994, Klein et al 1999) are 
reassuring in that they have shown no increase in risk. However Kirwan et al
(1997) studied patients sustaining another cause of blindness, retinal vein 
occlusion and noted that of nine patients under the age of 35 years with retinal 
vein occlusion, six were taking COCs. This highlights the importance of regular 
retinal screening for women with DM.
3.4.S.4 Hypertension
COCs have been reported to slightly raise diastolic and systolic blood pressure 
(Girling & de Swiet 1997). Studies in women with DM using a COC have not 
established any significant hypertensive effects (Diab & Zaki 2000, Klein et al 
1990). In fact in a study using a gestodene formulation, a decrease in diastolic 
blood pressure was noted and attributed to the antialdosterone effect of 
gestodene (Diab & Zaki 2000). For women with established hypertension, COC
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use increases cardiovascular mortality and smoking further increases this risk 
(Farley et al 1998). The risk-benefit equation must be assessed for women with 
DM who have hypertension but a COC is unlikely to be a good contraceptive 
choice. (See Table Two below WHO 2000).
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TABLE TWO: WHO MEDICAL ELIGIBILITY CRITERIA FOR 
CONTRACEPTIVE USE
(Improving access to quality care in Family Planning WHO 2000)
Category 1 A condition for which there is no restriction for the use of the contraceptive method.
Category 2 A condition where the advantages of the method generally outweigh the risks.
Category 3 A condition where the theoretical or proven risks usually outweigh the advantages of using the method. 
Category 4 A condition that represents an unacceptable health risk if the contraceptive method is used.__________
Type of 
Diabetes COC POP DMPA IMPLANTS IUS IUD BARRIER STERILISATION
Type 1 
No History 
of Vascular 
Disease
2 2 2 2 2 1 1
Caution - Sterilisation 
can be conducted in 
a routine setting with 
extra precautions
Type 1 
Vascular 
Disease 
present
3/4 2 3 2 2 1 1
Special - The 
procedure should be 
undertaken by 
experienced surgical 
and anaesthetic staff
Type 2 
No History 
of Vascular 
Disease
2 2 2 2 2 1 1
Caution - Sterilisation 
can be conducted in 
a routine setting with 
extra precautions
Type 2 
Vascular 
Disease 
present
3/4 2 3 2 2 1 1
Special - The 
procedure should be 
undertaken by 
experienced surgical 
and anaesthetic staff
3.4.5.5 Lipid Profile
Concern regarding the relationship between the COC, the development of 
cardiovascular disease and the role of lipids has led to studies examining the 
effect of the COC on lipid profiles. It has been found that whilst the estrogen 
component of the COC appears to increase the antiatherogenic High Density 
Lipoprotein Cholesterol (HDL-C), the progestogen content may either increase or 
reduce levels depending on the chosen formulation (Crook 1997, Porcile & 
Gallardo 1991). In addition triphasic COC formulations may cause a rise in
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plasma triglyceride concentrations (Peterson et al 1995). Women with DM may 
be predisposed to dyslipidaemia and thus to an increased risk of atherosclerosis 
The lipid metabolism of women with typel DM is thought to be more sensitive to 
the influence of 19-norprogestogens than to alkyloid oestrogens (Betschart
1996). Peterson et al (1995) studied type 1 DM over twelve months and found 
no evidence of changes in serum levels of lipoproteins known to be associated 
with atherosclerosis. However a recent comparative study showed changes in 
lipoprotein metabolism (Sorenson 2002). The metabolic profiles in women with 
uncomplicated DM using a variety of contraceptive methods was examined over 
a nine month period. Women chose to use either Norplant, DMPA, the COC 
(gestodene formulation) or an Intrauterine Device (IUD), (the control group). In 
respect of lipids, the results showed an increase in total cholesterol (TC) for the 
controls, a decrease in TC and HDL with use of Norplant, an increase in TC and 
Low Density Lipoprotein (LDL) and decrease in HDL with DMPA. With the COC 
a decrease was seen in LDL and an increase in HDL. The progestogen 
component of the COC was gestodene which is oestrogen dominent and 
therefore the HDL increase persists unlike with levonorgestrel or norethisterone 
formulations which have been shown to curb this effect (Crook 1997). The study 
recommended that the use of DMPA in women with DM should be avoided 
because of the potential unfavourable affect on lipid profiles. In agreement with 
other literature, (Geurts 1993) Norplant and low dose oral contraceptives 
appeared to cause minimal lipid change and any effects were thought unlikely to 
be of any clinical significance. However any hormonal method is only
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recommended after careful baseline monitoring of lipid profiles in order that any 
future alterations can be assessed.
In summary the use of POPs tend to alter the lipid profile, whilst third generation 
products such as gestodene have been shown to decrease LDL and increase 
HDL’s. Thus third generation COCs might be preferred, particularly in women 
with DM who have associated dyslipidaemia.
3.4.6 Body Weight.
Weight gain should be avoided, particularly in women with DM because of the 
association with worsening glycaemic control. A prospective study following 
diabetic users of COC, DMPA and Norplant for nine months showed no 
significant differences in body weight (Geurts 1993). This may have been 
influenced by the close medical supervision & dietary control of subjects. 
However it is reassuring in that weight control did not appear to be a significant 
factor that would affect prescribing decisions.
3.4.7 Non Hormonal methods
Use of non hormonal methods of contraception in women with DM are poorly 
reported in the literature and little evidence was found. St James et al (1992) 
found in a longitudinal five year study of 203 women that women with DM tended 
to use condoms more frequently. No studies were found relating to use of 
diaphragms, caps, natural methods or lUDs by women with DM.
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3.4.8 Summary of literature - Contraception for women with diabetes
This final section of the literature review has looked at literature relating to
choices of contraception and the use and outcomes of types of contraception for 
women with DM. Contraception is an important issue for women with DM to 
prevent unplanned pregnancy and subsequent complications. They are advised 
to use a reliable method of contraception and not conceive until blood glucose 
levels are below 7mmols/l. However the literature highlights possible differences 
in prescribing and use of contraception in women with DM that may put them at 
risk of unplanned pregnancy. The literature indicates that there are specific 
factors that need consideration for women with DM in relation to contraception in 
view of the complexity and potential complications of this long term condition.
The risk-benefit equation needs evaluating for each individual woman and health 
professionals need a depth of understanding of such factors and these will be 
investigated as part of my case study.
3.5 Conclusion of Literature Review
The review of the literature has established that despite advances in diabetes 
care, adverse pregnancy outcomes continue for women with DM (Macintosh et al 
2006, CEMACH 2007). Research has shown that optimum glycaemic control at 
conception and throughout pregnancy can prevent poor outcomes but less than 
50% of women with DM plan their pregnancies (CEMACH 2007) and they often
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conceive with poor control. This led to enquiry concerning the topic of prevention 
of unplanned pregnancy for women with DM.
The literature reveals that although national policy highlights the importance and 
provides guidelines for planning pregnancy for women with DM, in reality there 
appears to be a poor level of preparation by women with DM. The concept of 
unplanned versus planned pregnancy was explored and psychological issues 
highlighted but there was little literature found in relation to women with DM or 
those with a chronic illness and this needs further exploration to elicit and 
understand the experiences, attitudes and knowledge of women with DM in 
relation to planning for pregnancy.
The literature in relation to provision of preconception care services highlighted 
that there is debate concerning the best way to provide counseling or 
preconception services for women with DM in order to encourage preconception 
care. It appears therefore that there is a need to identify the knowledge, skills 
and attitudes of health professionals in relation to promotion of preconception 
care. In addition there appears to be a gap in the literature which needs 
exploring, concerning the congruence between women with DM and health 
professional views in relation to reproductive health issues and particularly in 
relation to advice and use of contraception.
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The issues and gaps highlighted within the review of the literature form the basis 
of the research questions formulated within my case study as recorded in 
Chapter One, Section 1.2. The next chapter of the thesis explains the research 
approach and methodology used to carry out the case study of prevention of 
unplanned pregnancy for women with type 1 or type 2 DM.
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CHAPTER FOUR 
Research Approach, Mixed Methodology & Methods
4.0 Introduction
This chapter identifies the research approach, methodology, methods and tools 
for my study which uses the extended case method (Burawoy 1998). The case 
under study is: The prevention of unplanned pregnancy in women with type 1 or 
type 2 diabetes mellitus (DM). The reason for using an ethnographic approach 
and feminist focus for the study is explained and is discussed and justified. The 
rationale for use of a mixed methodological design following Burke Johnson et al 
(2007) is given to show why a three phase study design was chosen so as to 
compound understanding of the case and answer the research questions posed 
in Chapter One, Section 1.2.
In this chapter I demonstrate how firstly a quantitative retrospective cohort study 
using a database was developed. This study sought to establish baseline 
evidence of reproductive health care issues amongst women with type 1 and 
type 2 DM and a comparison group of women without DM. The resulting 
analysis then informed Phase Two, a questionnaire survey and Phase Three, a 
qualitative semi structured interview study. These subsequent phases examined 
the experiences, attitudes and knowledge of women with diabetes and the health 
care professionals who provide their diabetes care in relation to planning
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pregnancy and preconception care. Figure One shows a diagrammatic 
representation of the studies. The methodology used in each phase of these 
studies is presented and limitations discussed. I also discuss authenticity and 
ethical considerations in relation to the case and conclude with an overall 
summary of the study design and methods.
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Figure One
Diagrammatic representation of the three phases of the case study : The 
prevention of unplanned pregnancy in women with type 1 or type 2
diabetes mellitus (DM).
Case study:
The prevention of unplanned pregnancy 
in women with type 1 
or type 2 diabetes mellitus (DM).
Phase Three 
Semi structured Interviews 
Sixteen Health Professionals and Sixteen Women with DM
Phase Two 
Questionnaires 
107 Women with DM
Phase One 
General Practice Research Database Study 
1060 Women with type 1 DM and 6360 controls 
442 Women with type 2 DM with 2652 controls
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4.1 Theoretical Framework
This section will discuss the theoretical framework for my study. The rationale for 
the ethnographic approach, feminist focus, use of extended case method and the 
mixed method three phase study will be explained.
4.1.1 Ethnographic approach
My study was based on an ethnographic approach in that it aimed to understand 
the reproductive choices of a group of women who lived with DM. The study is 
influenced by the principles of ethnography and these principles were used to 
explore the case from both the perspective of the group of women with DM and 
that of the health professionals involved in their care. Ethnography has a 
background in cultural anthropology and includes descriptive studies of people 
and cultures (Hancock 1998), seeking to understand the perspectives of others 
(Hammersley in Hubermann et al 2002). Boyle (1994) interprets the cultural 
perspective as studies of groups that have something in common or a shared 
experience and in this case this would consist of women living with DM or being 
a health professional caring for women with DM.
Purists may argue that ethnography is a methodology which to be valid has 
specific procedures, techniques and methods of analysis that should be followed 
(Bazely 2004). However as a researcher using ethnographic principles such as 
reflexivity, participant observation and analysis of data from an emic perspective I
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would argue that whilst recognising limitations, this approach draws on strategies 
which allow a holistic insight and understanding of the case in question.
Reflexivity incorporates the concept that the researcher is part of the world being 
studied and within this recognises the use of ones own experience and 
subjectivity (Hammersley and Atkinson 1983, Morse 1994). It is a continuous 
process of reflection by the researcher (Parahoo 2006) on the influences of the 
dynamics between the researcher and the research field. This enables an 
understanding of the context of the research problem, which for myself, is both 
from the perspective of a woman and as a nurse working in the field of 
reproductive health with contact in the diabetes centres where the participants 
were recruited.
Participant observation combines participation in the lives of people under study 
whilst maintaining some professional distance (Boyle 1994) thus allowing for 
observation and recording of data. Burawoy (1991) sees that the challenge for 
participant observation is for researchers to recognise their own inherent biases 
and to integrate this knowledge within their analyses.
This ethnographic principle was ostensibly incorporated within the study in two 
respects. Firstly whilst handing out questionnaires to relevant patients, I spent 
many hours in the diabetes centres and clinics observing women with DM and 
the different processes and procedures that they have to undergo for treatment,
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monitoring and follow up for their condition. Secondly, during the process of 
interviewing I spent time in the homes of the women with DM and in the work 
environments of the health professionals.
Ethnography incorporates the anthropologic distinction between data analysis 
from an emic (insider’s perspective) or etic (outsider’s interpretation) (Savage 
1995, Silverman 1993). Using such principles, this study sought to interpret 
questionnaire and interview data from an emic perspective of the population 
under study i.e. health professionals and women with DM. Terminology used 
and views of both groups were examined for content and congruence.
In addition my field notes of general observations within the clinic setting, for 
example clinic routine, guidelines for care and waiting times were analysed from 
an etic perspective. This study uses the extended case method after Burawoy 
(1998) (see Section 4.1.4) and in relation to this model, the emic perspective 
could be seen as an interpretation at the micro level and the etic, as analysis 
from a macro perspective.
4.1.2 Feminist Focus
The study has a feminist focus, apposite in respect that the participants studied 
were women, i.e. women with DM and mainly female health professionals, the 
researcher is a woman and the research questions were focused on female 
reproductive health and pregnancy. There are several definitions of feminism, 
these differ in their emphasis and it has become common to talk of ‘feminisims’
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(Harper & Hartman 1997). Hall and Stevens (1991) identify three basic 
principles of feminisms; Valuing of women and their experiences, ideas and 
needs; Recognition of the ideological, structural and interpersonal conditions that 
oppress women; Desire to bring about change.
Feminisims thus embody the concept that women’s experiences are central 
(Oakley 1981, Harding & Nicholson 1990) and the approach recognises that the 
outcome of the research should highlight any awareness or deficit discovered, 
seeking redress with goals of empowerment and social transformation (Harper & 
Hartman 1997). Feminism as a political movement has political assumptions 
such as emancipation and the demise of patriarchy (Travers 2001). Male 
domination within the field of medicine has been evident (Ehrenreich & English
2005) and in this study the Consultant Diabetologist at each of the four diabetes 
centres were all men. Reproduction and pregnancy which were once seen to be 
natural events, have also gradually been taken under the jurisdiction of the 
medical profession (Oakley 1981,1986, Ehrenreich & English 2005), which has 
led to a higher incidence of interventions and use of technology during childbirth 
(Oakley 1986). For women with DM this is of particular relevance as they are 
more likely to experience a medically focused pregnancy (Snoek & Skinner 
2000). A feminist focus to my research will seek to highlight and provide 
reflection in the light of the influence of medicalised care.
In a feminist approach to research there is a preference for use of qualitative 
methods and an emphasis on intersubjectivity and reflexivity (Harper & Hartman
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1997). This idea of establishing a dialogue with respondents rather than treating 
them as sources of data was important during the semi structured interviews in 
allowing their perspectives to be discussed and Voices to be heard’ (Lugones & 
Spelman 1983 in Harper & Hartman 1997:37). I was aware that there can be 
seen to be a hierarchical position to interviewing (Fontana & Frey 1994) and as a 
woman interviewing women, I attempted to minimise any such status differences 
and develop a rapport to allow expression of feelings & thoughts as discussed by 
Oakley (1993) in the chapter ‘Interviewing Women, A Contradiction in Terms?’. 
This felt especially important as the women with DM disclosed stories of their 
distress at miscarriage or complications due to their DM.
Smith (1987), developed feminist methodology starting with the lived experiences 
of women, she showed how these experiences are shaped by outside influences 
such as extra local social organisations. Smith (1999) states use of the 
extended case method to enable exploration of the divergence between 
everyday life and administrative accounts of it. My study also uses the extended 
case method to examine the experiences, attitudes and knowledge of women 
with DM in relation to reproductive health issues. In addition the knowledge and 
attitudes of the health professionals that care for them will be explored and the 
congruence between the women's and professional's perspectives analysed.
This is discussed later Section 4.1.4 where the extended case method (Burawoy
1998) is modeled in relation to my study.
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4.1.3 Case study method
The use of case study method arises out of a desire to study real life events in 
their natural settings with the aim of understanding complex social phenomena 
(Yin 2003). It is seen as an important method in health care research with the 
participant’s perspective being central to the process (Zucker 2001), as in order 
to understand an individual’s behaviour, it is necessary to consider the situation 
‘from the actor’s point of view’ (Becker 1970 in Hamel et al 1993:17).
Case studies typically combine data collection methods and the research can 
range in complexity using both or either quantitative or qualitative methodology 
(Yin 1984). The objective is to produce an ‘in depth’ study of the case or cases 
under consideration (Hamel et al 1993) and the method can be used to 
accomplish various aims. These include description of the case in detail 
(Hancock 1998), to generate theory (Yin 1984), and to understand the dynamics 
present in a situation (Eisenhardt 2002). There can be several different levels of 
analysis and the purpose is not necessary to generalise as Case Study Method 
is both ‘particularistic and contexual’ (Hancock 1998:7).
In relation to health care, case studies are particularly valuable for the “subjective 
richness of patients recounting their experience and the meanings implicit in 
them to help guide practice” (Zucker 2001: 1) and this was an important reason 
for choosing case study method to study reproductive choices of women with DM 
and health care professionals involved in their care. However rather than use the 
traditional case study method it was seen important to embrace a wider holistic
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context including external influences by use of the extended case method 
following Burawoy (1998).
4.1.4 Extended Case Method
The extended case method ‘applies reflexive science to ethnography in order to 
extract the general from the unique, to move the ‘micro’ to the ‘macro’ and to 
connect the present to the past in anticipation of the future, all by building on pre­
existing theory’ (Burawoy 1998:5). Participant observation is used to situate 
observations of everyday life within the larger scale extra local context.
The term ‘Extended Case Method’ is believed to have been coined by the 
Manchester School of Social Anthropology in their studies of African culture 
(Gluckman 1958, 1964 and Garbett 1970 in Burawoy 1998). At that time the 
studies highlighted discrepancies between normative prescriptions and everyday 
practices and linked them to wider issues of colonialism.
Burawoy’s research studied populations and corporations both from a top to 
bottom and bottom to top approach. Immersing himself in the environment and 
life world of his subject, he extended out from the local micro world to look at the 
wider (macro) influences allowing discovery of “multiple processes, interests, and 
identities” (Burawoy 1998:6). Interview and observational transcripts were 
enhanced by analysis of policy and guidelines. In my study the impact of 
national policy on health, local policy and clinical guidance for health
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professionals and service delivery were some of the ‘macro’ influences 
considered to be important influences to study.
Burawoy (1998) was also clear about the limitations and dangers inherent in this 
style of research in relation to abuses of power. He alerts the researcher to the 
need for constant vigilance and self-monitoring against the risks of ‘domination’, 
silencing’, ‘objectification’ and ‘normalising’ (Burawoy 1998:22). As a researcher 
who is a nurse I am in the privileged position of having contacts within the field 
that I am researching and this could have influenced recruitment of health 
professionals and subjects. Some subjects may have been influenced by the 
fact that I was a nurse and it was important to acknowledge any influence that 
this may have had on the interviews or of analysis within the study. Burawoy
(1998) describes the concept of the ‘insider outsider’ status and as a nurse 
researcher I may have been seen as an ‘insider’ by the professionals who may 
have felt threatened by the interviews as I was examining their practice and 
policies in relation to preconception care and this may have affected their 
responses. To the women with DM, as a sexual health nurse, I was an ‘outsider’ 
allowing them to talk openly about their diabetes care.
Burawoy (1998) developed a codification to guide the extended method including 
the concepts of Intervention, Processes, Structuration and Reconstruction, and 
this framework has been used in my research to study the case in question as 
illustrated in Figure Two below.
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Interventions included the General Practice Research Data base analysis, clinic 
observations, questionnaires and semi structured interviews with women with 
DM and the health professionals involved in their care. Observation of 
influences of my role as a researcher on the process and my personal 
philosophical viewpoint were also considered as an intervention.
The concept of process was evident during the semi structured interviews which 
allowed probing and exploring of discourse in order to contextualise the narrative 
of the women with DM and health professionals. In addition the observations 
made whilst attending the clinics were followed up with investigation into 
normative practices.
The principle of structuration is up held by the reflexive philosophical basis of 
this study whereby the research environment is seen as dynamic and there is 
awareness and reflection on the external influences and settings of the research 
including feminism. During analysis, the effects of external forces such as 
service delivery, national and local policy and the concept of médicalisation was 
examined and cases compared and connected. This integrating approach was 
also used in the analysis of congruence between health professionals and 
women’s views to provide a ‘macro’ perspective on the case.
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The discussion and conclusion chapters of my study support the element of 
reconstruction within the model. These chapters link ‘the case’ to the wider 
context and result in the generation of theory, recommendations for practice and 
development of care pathways.
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Figure Two 
Model of Extended Case Method
(Burawoy 1998)
The prevention of unplanned pregnancy in women with type 1 or type 2
diabetes
A
Structuration
• Integration of case
and w ider context 
Influences of:
• Service Delivery
• National & Local 
Policy
• Médicalisation
• Feminism
Intervention L#
•  Database study 1
• Future • Questionnaires Awareness of
Research •  Semi structured 1 domination,
•  Possible silencing,
Changes in interviews objectification &
Clinical normalisation
Practice • Clinic ■
observations B  / V
Reconstruction ^ The Case
• Generation of theory 1
• Recommendations “The prevention of
fo r practice
unplanned pregnancy in
women with type 1 and
• Development o f Care 1 type 2 DM.”
• Feedback to
participants
Processes
Further investigation 
& follow  up on 
observations. 
Probing and 
discussion during 
semi structured 
interviews
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4.1.5 The Case
The 'case' in question is ‘the prevention of unplanned pregnancy for women with 
type one and type 2 diabetes Mellitus’. Yin (2003) suggests that cases can relate 
to a variety of subject matter including individuals, groups, decisions, 
programmes, processes or organisational changes. A case study can relate to 
one case or a number of cases, which when analysed by the researcher may 
explain specific phenomena. In this instance the case relates to the process of 
reproductive choices of a group of women who have type 1 or type 2 DM but is 
‘extended’ (Burawoy 1998) by considering issues relating to the impact of bio 
psychosocial influences such as médicalisation, feminism, medical condition, 
health professional influences such as knowledge and experience, national & 
local policy (DH 2001a, CEMACH 2007, NICE 2005b) and delivery of services.
4.1.6 Mixed methodology
In order to explore and gain understanding of the case in respect of my research 
questions, my study uses mixed methodology. This has been formally defined by 
Burke Johnson & Onwuegbuzie (2004:17) as ‘research where the researcher 
mixes or combines quantitative and qualitative research techniques, methods, 
approaches, concepts or language into a single study. It makes use of pragmatic 
method and system of philosophy’. Polit et al (2001: 217), see use of combined 
methods to be an ‘emerging trend’ and there is recognition that by focusing on 
just quantitative or qualitative methods that researchers may ‘miss important 
parts of the story’ (National Science Foundation 1997:1).
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Traditionally research has been labelled as using either quantitative or qualitative 
methodology. Both stem from opposing paradigms with quantitative methods 
being from a traditional scientific positivist viewpoint and qualitative methods 
being from a naturalistic paradigm (Polit et al 2001). For some purists the 
dichotomy between the two are seen as incompatible and should not be mixed 
(Polit & Beck 2004) and the term ‘paradigm wars’ has even developed (Leech 
and Onwuegbuzie 2005). Others including myself, take a pragmatic view that 
there is an opportunity for using both in a third methodology of mixed research 
(Burke Johnson et al 2007) and in my study I would argue that the research 
questions could not have been fully answered by use of one methodology alone.
The use of mixed-methodology can combine the complementary strengths of 
quantitative and qualitative research to help overcome the weakness of using a 
single methodological approach (Johnson & Turner 2003, Polit & Beck 2004). 
Parahoo (2006) considers that, due to the nature of nursing phenomena, both 
methodologies have valuable and distinct contributions to make within the field of 
nursing research. Provided that the most appropriate methodology for the inquiry 
is selected then both approaches can be of benefit within a study. In this study 
qualitative methodology was used to establish meaning from the epidemiological 
data generated by the quantitative phase.
Quantitative research can provide hard’ scientific evidence, measuring variables 
and examining them by numerical and statistical procedures. This can be
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particularly useful when identifying trends and patterns and for comparative 
purposes (Parahoo 2006, Polit et al 2001, Bowling 2002). In my study the 
General Practice Research Database was used to select variables and compare 
trends which could be analysed for statistical significance. The strengths of 
quantitative research are commented on by many and include objectivity, 
generalisability, ease of replication, ease of interpretation, validity and control 
over extraneous variables (Polit & Beck 2004, Sarantakos 1998). Limitations of 
this methodology cannot be ignored including limited, narrow, data (Cluett & Bluff
2006), possible inability to understand human phenomena (Parahoo 2006) and 
loss of the situational context (Polit & Beck 2004). The qualitative phase of the 
study therefore allowed the meaning of such quantitative data to be explored.
Qualitative research employs a subjective approach, involving naturalistic inquiry 
within a diverse theoretical framework (Sarantakos 1998, Silverman 1994 
Parahoo 2006). A wide range of data collection methods are used and it is 
interpretative and reflective (Silverman 2002). Strengths of this approach include 
the ability to describe complex phenomena, generation of theory and the ability to 
be responsive to local situations and stakeholder requirements (Sarantakos
1998). There is interpretive analysis of data coded as text, exploring how and 
why phenomena occur (Axinn & Pearce 2007). My study used questionnaires 
and interviews to generate a wealth of rich textual data in relation to women with 
diabetes and their reproductive health which contributed to give meaning to and
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an understanding of the case that could not have been gained by quantitative 
methods which only give numerical or statistical information.
Previously it has been suggested that using mixed-methodology can overcome 
some of the limitations of quantitative and qualitative research, but it too can 
have challenges. Researchers may not have training in both paradigms and this 
may pose an obstacle to using mixed-methodology appropriately (Polit & Beck 
2004). Leech and Onwuegbuzie (2005) argue that students should learn to 
include both paradigms in their research within health services and from a 
personal perspective, having had previous training in quantitative research I 
wanted to ensure that during this study I gained skills in understanding qualitative 
methodology to help me in supervising nursing students who often choose this 
methodology for their degree studies.
A range of mixed method typologies are described in the literature (Greene & 
Caracelli 1997, Burke Johnson & Onwuegbuzie 2004, Polit & Beck 2004, Polit et 
al 2001) and the variety of ways in which methods are integrated are ‘almost 
limitless’ (Polit et al 2001:220). Bazeley (2004:142) states that it is important to 
clarify ‘ just what is being mixed and how it is being mixed’. Designs include; 
‘mixed model’ where qualitative and quantitative phases are mixed within or 
across the stages of the research and mixed-methodology’ where distinct 
quantitative and qualitative phases are included in the overall study. Such 
designs can be further classified according to emphasis on paradigm (ie. equal
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status versus dominant status) and by time order (ie. concurrent versus 
sequential). As will be discussed later, this study uses a qualitatively dominant, 
mixed methodology, sequential model within its case study design.
Greene & Caracelli (1997) cluster designs into two broad categories of 
component designs and integrated designs. Component designs use 
quantitative and qualitative methodology as discrete components within the 
study, only combining the two during interpretation and reporting.
Polit & Beck (2004) suggest that integrated designs have greater integration of 
the methods throughout all phases of the research and are suited to theory 
building and testing. Four types are described including iterative design, as in my 
study, where findings from one method are used as a basis for the progression of 
the research. My study used the extended case method (Burawoy 1998) with a 
sequential component design with a distinct initial quantitative phase using a 
database which was used to inform the dominant qualitative phase. The 
qualitative phase utilised a mixed model of integrated iterative design with a 
questionnaire which was used to select subjects for further study by in depth 
interview.
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4.1.7 Authenticity and Rigour
In order to meet the basic principles of research I needed to demonstrate rigour 
throughout all of the three phases of the study. Issues relating to rigour have 
been discussed previously in this chapter within the extended case method 
(Section 4.1.4) and mixed method research (Section 4.1.6). The issues of 
validity, reliability and bias were specifically addressed within each study in order 
that the methods used can be seen to be relevant and the conclusions made can 
be seen to be an accurate account of the phenomena studied (Hammersley 
1990, Silverman 2002). Parahoo (2006) considers bias to be the greatest threat 
to validity and reliability of the data. Sources of bias are many and include the 
researcher, as discussed earlier in Section 4.1.4, the environment and methods 
of data collection.
In the database study, the data used have been used extensively for cohort and 
case-control studies and has in the past been found to be valid and of high 
quality (Wood & Martinez 2004, Jick et al 2003, Lawrenson et al 1999, Walley & 
Mantgani 1997, Hollowell 1997). The age and sex distribution of the patient 
population on the database matched that estimated by the Office for National 
Statistics (ONS) for the total population of England & Wales in 1998 (ONS 2000). 
Further comment on the validity and reliability of the database can be seen in 
Section 4.3.1.2 .
To enhance validity within my questionnaire study a pilot study was undertaken. 
Oppenheim (1992: 47) discusses the importance of pilot work to ensure all
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aspects of the questionnaire are tested to ‘make sure it works as intended’. Five 
women with DM were asked to complete questionnaires and the results were 
reviewed. Parahoo (2006) discusses how the validity of a questionnaire is linked 
to extent that the research questions are addressed by the results and reliability 
to the consistency by which respondents answer the questions. Following the 
pilot study some changes were made to enhance validity and reliability such as 
rewording of questions to provide uniformity of meaning as discussed further in 
Section 4.3.2.3.Î of this chapter.
The semi structured interviews involved systematic collection of data and a topic 
guide was used to structure the interviews and provide some consistency of 
questioning. The Interviews were taped and then transcribed verbatim and 
speech emphasis highlighted by use of italics or bold script within the text. In the 
stage of analysis the degree of consistency with which instances are assigned to 
the same category for coding on different occasions was examined by re 
listening and recoding the tapes and comparing the assigned coding categories.
Koch (1994) discusses criteria for ‘trustworthiness’ within qualitative paradigms 
and applies the criteria of credibility, transferability and dependability to data.
The importance of an audit trail is highlighted using a ‘journal’ to enable a visible 
decision trail of the methodological and analytical selection within the research.
In my study, field notes made during the interviews and my reflections written in
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my research diary were used during the analysis to demonstrate the process 
followed.
Silverman (2002:177) warns of ‘anecdotalism’ whereby the researcher only 
includes the results that illustrate the issue whilst ignoring other cases. He 
suggests ways to prevent this including using the ‘constant comparative method’ 
of comparing the emerging themes within different groupings. Using NVIVO 7 as 
a tool for analysis provided me with the ability to review, code and list themes 
from the narrative which could be tested across groups and to this aim part of 
this study involved comparison for congruence of interviews with both women 
with diabetes and the health professionals looking after them.
In using mixed methods, my study may have increased validity by comparing 
results by triangulation of the data (Denzin & Lincoln 2004). Yin (2003) 
discusses that the strength of case study data are the opportunity to include 
different sources of data which can be subjected to data triangulation leading to 
the findings of the case study being supported by more than one source of data. 
Huberman et al (2002:14) describe this as being ‘highly synergistic’ with the 
potential for theory building. Polit et al (2001 ) argue that methodology using multi 
methods can enhance validity as there is the opportunity for examining the data 
and offering more alternative interpretations which may give more confidence in 
the results. In my study, data from three phases, the database, questionnaire
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study and interviews were integrated and interpreted to examine the case; 
‘Prevention of unplanned pregnancy in women with type 1 or type 2 DM’.
4.2 Ethical Considerations
Ethical consideration is required at every stage of the research process in order 
to protect the rights of participants (Polit & Beck 2004). In this study they were a 
significant factor throughout the entire research process from the first choice of 
the topic through to the design, implementation and writing up of the research. 
Polit et al (2001) consider that ethics in research relates to the quality of the 
research procedures with respect to their adherence to professional, legal and 
social obligations to the participants.
The International Council of Nurses (ICN 1996) discusses six ethical principles to 
guard patients from harm and these have been amalgamated into The four rights 
of subjects who are considering participation in research’ (Parahoo 1997:79). 
These are now discussed in Section 4.2.1 below.
4.2.1 The right not to be harmed
It is the obligation of a researcher that no participants within the research should 
experience any harm as a result of the research (Rees 2003). It is therefore 
necessary to do an assessment of benefits and risks within the study including 
physical, psychological, emotional, social & economic factors (Burns & Grove
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2001 ). In my study there was no risk seen with regard to physical involvement 
for participants but psychological and emotional aspects were highlighted in 
relation to possible distress caused by the potential to arouse strong emotion in 
discussion of previous experiences such as complications of pregnancy, 
miscarriage or abortion. This risk was drawn to their attention in the information 
sheet for participants (Appendix Eight) and access to counselling services was 
discussed with the health professionals at the four sites in the event of the need 
for referral. To leave a participant in emotional distress with no support or 
safeguard in place after the data have been gathered would be considered 
morally wrong (Smith 1992).
The behaviour of the researcher is also an ethical issue which has the potential 
of harming the participant (Parahoo 2006) and during the collection of data it was 
seen as vital to be insightful to respect the participants’ feelings, values and 
personal beliefs. Attention was given to the sensitive phrasing of questions and 
to subsequent probing and discussion of issues raised.
4.2.2 The right of full disclosure
Full disclosure means that the researcher has comprehensively informed 
participants about the study including the risks and benefits ensuring informed 
consent (Polit & Beck 2004). Potential participants received an information sheet 
(Appendix Eight) and contact details to enable further discussion before 
consenting to participate in this study. Indirect consent was implied by the
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women with DM completing the questionnaires but Bell (2005) argues that this 
could be an unfair assumption. As a researcher I was aware of this issue and 
the obligation to protect people from coercion and I ensured that completion of 
the questionnaires was entirely voluntary and anonymous unless the women 
completed contact details consenting to be interviewed. In this case a separate 
form was signed to confirm consent (Appendix Nine).
4.2.3 The right of self-determination
The participants had the right to decide whether to take part in the study (Waltz 
et al 1991) and there was emphasis in the consent form on the right to withdraw 
at any time for any or no reason. Time was spent with each potential participant 
answering questions that arose from the information sheet or consent form. 
Freedom from coercion was ensured as described above and all participants 
were assured that the study had been carefully reviewed and approved by ethical 
committees and management from host NHS Trusts.
4.2.4 The right of privacy, anonymity and confidentiality
Individuals have the right to privacy which can be invaded during the research
process. Privacy includes maintaining confidentiality and anonymity of data 
(Hutchinson & Wilson 1994:311) and in this study all participants were assured of 
confidence in these matters. Subjects were allocated a code number which was 
used to protect participant identity and anonymity and there was omission of 
personal characteristics and area of work. Data were only handled by myself as
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the Chief Investigator and my supervisors and was kept securely and processed 
in accordance with the Data Protection Act (1998).
4.2.5 Ethical Approval
In the UK an ethics review is one of a series of safeguards intended to protect 
individuals, ensuring that studies protect the rights, dignity and welfare of people 
participating in research within the NHS (DH 2005a). My study, having three 
phases and being based on four sites, required several different applications for 
ethical review.
The General Practice Research Data base study sought and gained approval 
from the Scientific & Ethical Advisory Group (SEAG) (Appendix Ten) and as the 
questionnaire and qualitative study involved recruitment of both health service 
staff and patients ethical approval was needed from the NHS Central Office 
Research Ethics Committee (COREC) and the local Research Ethics committee 
(REC) for each site (Appendix Eleven). In addition as a student of the University 
of Surrey, the University ethics committee approval was also gained (Appendix 
Twelve).
4.3 The Three Phases Of The Study
In this section the methodology and justification for undertaking each of the three 
phases of the case study are discussed and methods used in data collection and
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analysis detailed. As has been previously described the study uses a sequential 
component design with a distinct initial quantitative phase using a database 
which was used to inform the dominant qualitative phase. The qualitative phase 
utilised a mixed model of integrated iterative design with a questionnaire which 
was used to select subjects for further study by in-depth interview.
4.3.1 Phase One Of The Case Study -  A Quantitative Study Using The 
General Practice Research Database
4.3.1.1 Introduction
The General Practice Database (GPRD) is used by the University of Surrey 
Postgraduate Medical School for research purposes and provides anonymised 
patient data from General Practices across the UK that is assessed to be of 
research quality. In designing the case study of the prevention of unplanned 
pregnancy in women with type 1 and type 2 DM, a search of the literature 
revealed that there was little epidemiological or demographic information relating 
to reproductive health issues for women with DM. I therefore decided to use the 
GPRD to obtain an overview of the reproductive issues for women with DM and a 
statistical review of contraception prescribed by General Practice. These data 
would then inform the design of the questionnaire study from which women 
would be selected for interview.
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A retrospective cohort study was planned where current phenomena are studied 
using data from the past (Parahoo 2006), with the aim of explaining current 
phenomena by examining factors that are associated with it (Polit & Beck 2004). 
In this case the medical and prescribing records of a cohort of women with DM 
were analysed and compared to a cohort of women without DM. Relying on 
existing data which may be incomplete or difficult to decipher can be a draw back 
of this method (Parahoo 2006, Polit & Beck 2004), however the GPRD has 
previously been assessed as having reliable data of high quality and validity 
(Wood & Martinez 2004, Jick et al 2003, Lawrenson et al 2000, Walley & 
Mantagani 1997, Hollowell 1997).
4.3.1.2 The General Practice Research Database (GPRD)
The GPRD is a longitudinal database that was set up in 1987. It is used in
primary care to record patient consultation and prescription records. It therefore 
has excellent prescribing data linked to diagnosis and outcomes (Mulnier 2006). 
The population on the database is dynamic as patients register and deregister 
with practices contributing to the data. Unbiased rates of patient events found in 
the general community can be estimated, as opposed to those predicted by 
clinical trials, where subjects are selected and usually motivated volunteers. An 
age and sex matched comparison group of women without DM can be selected 
allowing a more reliable comparison of differences between those with and 
without DM. The selected comparison group may however contain some 
patients with undiagnosed DM as it is estimated that there are one million people 
in this position in the UK (Diabetes UK 2007).
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The database consists of four relational tables which form the medical records of 
patients. The “PATIENT” table contains demographic data, the “MEDREC” table 
the disease diagnoses, symptoms and outcomes, the “PREVENTION” table has 
records of vaccinations, anthropometric measurements, physiological 
measurements, smoking and alcohol consumption data and the “THERAPY” 
table contains prescribing data. Each patient has a unique identification number 
(PATID) that links together information in the four tables (Mulnier 2006).
Medical diagnoses and symptoms are recorded on the database using Oxford 
Medical Information System (OXMIS) codes or Read codes (the coding system 
adopted by the Department of Health for use in General Practice). Prescriptions 
are recorded using the Prescription Pricing Authority (PPA) codes. The age and 
sex distribution of the patient population on the database matches that estimated 
by the Office for National Statistics (ONS) for the total population of England & 
Wales in 1998 (ONS 2000).
4.3.1.3 The GRPD Study - Cohort Design
The term cohort is used to describe a group of respondents who are followed up 
over a period of time (Parahoo 2006). This cohort study uses four cohorts 
followed for twelve months, one with type 1 DM and a second matched for age 
with cohort one but without type 1 DM. The third cohort were women with type 2 
DM and the fourth matched for age without type 2 DM.
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Women with type 1 or type 2 DM who were on the database for the year 2001 
were sampled for a range of variables including diabetes, medical and obstetric 
history, contraception use and smoking. Thus in my study, the database was 
used to measure retrospectively over a twelve month period, the number of 
cases for a variety of variables relating to a group of women with type 1 or type 2 
DM and matched control groups of women without DM.
The study population included women with diabetes aged 15 to 44 years 
inclusive and a comparison group without diabetes matched for age. This age 
range was chosen as the most relevant for study of woman with diabetes of 
childbearing age (Briese & Muller (1995), Kimmerle et al (1994), Gibb et al 1994). 
As has been discussed earlier, ethical approval was obtained from the Scientific 
& Ethical Advisory Group (SEAG) (Appendix Ten).
All subjects present on the database from 1st January 2001 until 31st December 
2001, with an OXMIS and or READ code for DM prior to this date were identified. 
All those with a first code for DM after this date or with only a history of 
gestational diabetes were excluded from the patient and reference groups.
Patients with type 1 DM were identified using an algorithm based on age at 
diagnosis, type of treatment and age at treatment. (Figure Three) Thus those 
treated with insulin only and aged less than 35 years at diagnosis of diabetes
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were deemed to have Type 1 diabetes. Patients with type 2 DM were those who 
had a diagnosis of diabetes and were treated with diet alone with monitoring for 
diabetes or were treated with an oral hypoglycaemic agent or were aged 35 
years or older at diagnosis if treated with insulin. (Figure Three) This definition 
has been used by Eurodiab studies and has been agreed internationally 
(Piwernetz et al 1993). Further modifications have been agreed locally and those 
patients who are diagnosed before the age of 35 years and treated with an oral 
hypoglycaemic agent but are switched to insulin in less than 6 months and 
continue on insulin can also be considered as type 1. Where the age of 
diagnosis was unknown or where there was uncertainty about the differentiation 
of type of DM then these were considered as an intermediate category and 
excluded from analysis. Therefore patients had to have a diagnosis of diabetes 
and supporting information such as a prescription or notes record indicative of 
diabetes to be considered. The control group of patients had no record of 
diabetes or prescription for a diabetes drug or record of diabetes monitoring to be 
included as a comparison.
Figure Three: Algorithm to show identification of type of DM
Type 2 
DMType 1 DM
Treatment by 
Insulin alone
Age at 
diagnosis 
under 35
Age at 
diagnosis 
over 35
Treatment 
by Insulin 
alone
Treatment 
by OHA
Treatment 
by diet 
alone
(Piwernetz et al 1993)
128
In order to establish the optimum number of participants for the control group, 
statistician support was used to undertake a power calculation. The main goal of 
statistical power analysis and sample size estimation is to judge the size of 
sample required in order to ensure accurate and reliable statistical conclusions 
(Statistica 2005). Using the assumption of 2-sided values of P<0.05 and the 
observed number of cases or non cases, the odds ratios that could be detected in 
our studies at 95% power were calculated. Comparison groups were randomly 
selected from the GPRD of six women per patient with diabetes matched by year 
of birth. Comparison subjects had no record of or treatment for diabetes at any 
time in their medical record.
The available data included demographic factors, medical diagnoses, symptoms, 
prescriptions and hospital admissions. Following a review of the literature 
variables of interest were identified and codes developed (Table Three). These 
included the type of diabetes, age, record of pregnancy, abortion or miscarriage 
during 2001 and any record of hysterectomy or sterilisation. Codes for medical 
and medication history, smoking status and use of contraception were also 
developed.
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Table Three: Literature Base for Choice of Variables
Age Groups Type 1 under 35 at 
diagnosis -  Treated by 
insulin
Lawrenson et al 1999., 
Nair 2007.,
BMA RPSGB 2007.
Type 2 over 35 at 
diagnosis -  Oral 
treatment or insulin or 
dietary control.
BMA RPSGB 2007., 
Fagot-Campagna et al 
2001.,
Diabetes UK 2006.
Age related to 
pregnancy
Type 1 -  younger age Lawrenson et al 1999., 
Clausen et al 2005.
Risks associated 
with age Maternal Nephropathy SIGN 2005., Girling & 
de Sweit 1997.
Maternal Neuropathy Heller 2001.
Maternal Retinopathy Klein et al 1999.
Fetal risk Macintosh et al 2006., 
Clausen et al 2005., 
CEMACH 2005a., 
Jensen 2004., Diabetes 
& Pregnancy Group 
France 2003.
Perception of risk 
with age
Greater for type 2 Cundy et al 2000., 
Clausen et al 2005., 
Feig & Palda 2002.
Health Professional 
Advice with age
General NSFDH 2001a., 
Diabetes UK 2007., 
CEMACH 2005a., 
CEMACH 2007.,Kjaer et 
al 1992.
Adolescents Diabetes UK 2007., 
Hanna & Guthrie 2000.
Ethnicity Increased risk factor for 
type 2 diabetes
Diabetes UK 2007., Nair 
2007.
130
Contraception Use of contraceptive 
methods.
Kjaer et al 1992 
Kimmerle et al 1994, 
Fontbonne et al 1987., 
Kim et al 2002., 
Lawrenson et al 1999., 
Gibb et al 1994.
Type 1 DM Manolopoulos et al 
2001.
Type 2 DM Guilebaud 2004. 
Parsey & Pong 2000.
Hormonal contraception S h awe & Lawrenson 
2003.
Adolescents Charron-Prochownik & 
Michel 2006
Method of contraception was identified using prescription codes for the year 
2001. Oral hormonal contraceptives (OC) were identified using PPA codes 
according to classification in the British National Formulary (BNF 2006).
Combined oral contraceptives (COC) were defined as either 2nd generation if 
they contained less than 50 microgrammes of oestrogen and a progestogen 
other than desogestrel or gestodene, or 3rd generation if oestrogen was 
combined with desogestrel or gestodene as the progestogen. Progestogen only 
products included oral products (POP) or injectable progestogen products. 
Codes for Cyproterone acetate combined with 35 microgrammes ethinyl
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oestradiol (Dianette), Emergency contraception (Shering PC4) and intrauterine 
devices were identified separately.
All patients with a code for previous hysterectomy or sterilisation were identified 
and removed before analysis of contraceptive methods.
4.3.1.4 Statistical analysis
Data were analysed using the statistical software package for social science 
(Argyrous 2001). Descriptive data analysis was performed such as frequencies 
and cross tabulations. A 2-sided value of P<0.05 was considered statistically 
significant. In order to make comparisons between women with DM and the 
general population, prescribing rates to women with type 1 DM and their matched 
comparison group were compared for the year 2001 and then similarly repeated 
for subjects with type 2 DM and their matched group. Odds ratios were 
calculated at 95% confidence levels and the Pearson Chi squared test used to 
identify statistical significance for categorical variables and the Mann-Whitney U 
test for continuous variables and general linear models where there was a 
combination.
Confounding variables which may affect the research outcome by accident 
(Cluett & Bluff 2000) were identified and examined during the analysis. Variables 
included the age of subjects and co-morbidities such as obesity, smoking and 
coronary vascular disease.
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To explore the relationship between diabetic status and pregnancy among older 
women logistic regression was used. Diabetes type and age were included as 
independent variables in order to adjust for any age related preference. This 
analysis used only data on women over 30 years of age in 2001 and therefore 
excluded the lower age groups where there were few women with type 2 DM or 
their matched comparisons.
4.3.1.5 Summary
The findings of the GPRD database study highlighted statistical data in relation to 
use of contraception by women with DM and provided an overview of 
demographic and epidemiological factors which are reviewed in Chapter Five; 
Findings of the Database study. Data such as that highlighting the significant 
difference in the prescribing of contraception and pregnancy outcomes for 
women with type 1 DM or type 2 DM were used in the design of questions for the 
next phase of my research, the questionnaire study. This aimed to elicit more 
specific detail and meaning as to why there are differences for women with DM 
and the possible effects on planning for pregnancy.
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4.3.2 Phase Two Of The Case Study -  A Questionnaire Survey Study
4.3.2.1 Introduction
The previous section of my thesis has discussed the initial quantitative Phase 
One of the case study using the GRPD database as part of the sequential 
component design. These data from Phase One are now used along with 
relevant literature to inform the dominant qualitative phase of my research and 
this section discusses the design and development of Phase Two, the 
questionnaire and its use as a data collection tool in four NHS Trust Diabetes 
centres thought to be broadly representative of women with diabetes in Southern 
England.
4.3.2. 2 Ethical Approval
An overview of ethical issues has been described earlier in Section 4.2. This 
phase of the study involved National Health Service (NHS) patient and staff 
participation and thus required several levels of ethical approval. Ethical approval 
was gained to carry out the study at four diabetes centres at NHS Trust sites in 
Southern England. Overall approval was sought and gained from the NHS 
Central Office Research Ethics Committee (COREC) (Appendix Eleven), then for 
each of the four diabetes centre sites Local Research Ethics Committee consent 
was applied for and gained. The ethics committee requested I change the lowest 
age of participants from fifteen years to sixteen years of age. To ensure consent 
by participants, letters of introduction, information sheets for patients and 
information sheets for staff and written consent forms were prepared (Appendix
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Nine). The women with DM were given a copy of the information sheet to keep 
when I handed out the questionnaires in the diabetes clinics.
4.3.2.3 Questionnaire Tool
The study used self administered questionnaires with the purpose of 
investigating in ‘the field’ some of the issues arising from the database study 
such as use of contraception and decisions about pregnancy by women with DM, 
and then to select a cohort of women with DM for interview. The self 
administered questionnaire has benefits of accurate sampling, a high response 
rate and minimum of interviewer bias (Oppenheim 1992). The researcher has 
some personal contact and can give necessary explanation but not interpretation 
of the questions. The questionnaire was developed in light of the research 
questions (See Chapter One, Section 1.2), following review of both the literature 
and the results of the database study. An example question is seen below and 
the questionnaire is provided in Appendix Thirteen.
Figure Four: Example of Question from questionnaire 
2. Pregnancies
2a. Have you ever been pregnant? Yes No
If no please go to question 2j
2b. I am currently pregnant Yes No
2c. How many children do you have?
2d. How old were you when you had your first child? —
2e. Did you have diabetes before your first pregnancy?
2f Did you plan your pregnancies?
Yes No 
Yes No
135
2g. Were you given information about your diabetes and planning for pregnancy / pre
conception care? Yes No
2h. If Yes who gave you information?
Please state below:
2i. Were there any complications with your pregnancies? Yes No
If yes please can you explain below.
2j- Are you seeking to become pregnant in the future? Yes No
Question topics aimed to elicit information in relation to the case and included 
medical and diabetic history, reproductive and contraceptive history and advice 
given by health professionals. The questionnaire contained twelve questions 
which were coded numerically to aid data analysis and a mix of closed and open 
questions were included. Closed questions give respondents a choice of 
answers and ask them to select the ones that apply (Parahoo 2006). Open 
questions offer no choice but space for free writing, allowing respondents the 
freedom to write their views (Oppenheim 1992). It was seen as important to 
have a mix of questions with the closed questions giving specific focus to topics 
relevant to the research questions and the open questions enabling participants 
to expand and explain answers given.
At the end of the questionnaire there was space for further comment and then an 
optional section inviting the participant to add contact details of telephone 
number and e-mail address in order that they could be contacted for interview at 
a later stage.
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4.3.2.3.i .Pilot study
The questionnaire was reviewed by a Consultant Diabetologist and a Diabetes 
Nurse Specialist and small changes made by the addition of questions on the 
management of diabetes. In order to review the questionnaire for understanding 
and ease of completion a pilot study was undertaken at one of the Diabetes 
Centres using five women with DM. Following this, several questions were 
reworded to provide uniformity of meaning and the order of questions was altered 
to facilitate understanding and flow.
4.3.2.3.ii Data collection
Senior staff from the diabetes centres were visited and their cooperation gained 
for the centre to take part in the study. Written information sheets (Appendix 
Eight) were given to staff members and dates arranged for me to attend diabetes 
clinics to hand out questionnaires to appropriate women. On registering at the 
clinic, women with DM who were aged between 16 and 44 years inclusive were 
identified by the nurses or clinic clerk and then approached by the researcher or 
nurse with an information sheet and asked if they would participate and complete 
a questionnaire. One centre had changed service delivery to mainly Primary 
Care clinics in GP surgeries and so the nurses agreed to hand out 
questionnaires themselves in these clinics and the questionnaires were posted 
back to me in stamped addressed envelopes that I provided.
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4.3.2.3.iii Data analysis
Data from the closed questions were analysed using the Statistical Package for 
Social Science (SPSS). Text from the open questions were coded by assigning 
data to categories and then labeling the categories numerically. Results can be 
seen in Chapter Six; Findings of the Questionnaire Study. In addition the free 
text comments were analysed separately and allocated to categories used within 
the semi structured interview analysis and results can be seen in Chapter Eight; 
Findings of semi structured interviews -  Diabetes and Pregnancy.
4.3.2.4 Field Notes
I recorded observational notes during my time spent in the diabetes clinics and 
these included notes relating to clinic routines, environment and waiting times 
and the professionals that the women saw. I reflected on situations that occurred 
and the process of my contact with the participants. Where possible I was able 
to access the local NHS Trust guidelines for care and clinic protocols in order to 
be able to use them during analysis to examine and relate the ‘macro’ influences 
on the findings. The observations also allowed comparison and exploration of 
different models of service delivery.
4.3.2.5. Summary
This section has looked at the development, data collection and methods of 
analysis of the questionnaire study, the findings of which can be seen in Chapter 
Six; Findings of the Questionnaire Study. As part of the sequential design of this
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case study, the questionnaires were then used to select those women with DM 
who had agreed to participate further by being interviewed. Questionnaires from 
women who had completed their contact details were identified, collated and then 
the answers to specific variables were examined such as type of diabetes, age 
group, obstetric history, ethnicity, whether preconception care advice had been 
given and comments written by the participant. This allowed nonprobability 
purposive sampling as described by Miles & Huberman (1994) to be undertaken 
to select women for interview as part of the final phase three of the study as 
described in the next section.
4.3.3 Phase Three Of The Case Study -  A Qualitative Study Using Semi 
Structured Interviews
4.3.3.1. Introduction
This qualitative phase of my study is rooted in the interpretive paradigm of 
naturalistic inquiry. This places emphasis on understanding the complexity of 
human experience as it is lived (Polit & Beck 2004), actively seeking to discover 
meaning (Denzin 1989). Building on data from Phase One the database study 
and Phase two the questionnaire study, this section will describe the methods 
used to select subjects and undertake semi structured interviews with sixteen 
women with type 1 or type 2 DM, (four from each NHS Trust site) and sixteen 
health professionals involved in their care. Interviews are an important source of 
case study information (Yin 2003) and were a key component of this study.
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4.3.3.2 Ethical approval
Section 4.3.2.2 described methods used to achieve ethical approval for Phase 
Two of the study and for this Phase Three, additional forms for written consent 
were required (Appendix Nine). The consent forms were signed before interview 
and stated that subjects had received and read the information sheet and were 
willing to be interviewed.
4.3.3.3 Semi structured interviews
Semi structured, focused interviews with four women with DM and four health 
professionals providing their care from each of the four NHS Trust sites took 
place during 2006. A total number of thirty two interviews were chosen by 
purposeful sampling which is discussed later in this chapter.
The semi structured style of interview was selected as the best means of 
achieving answers to the research questions for the study within the given time 
frame. This method of interviewing can provide some control over the process 
for the researcher, as there is flexibility to “adjust the interview to meet the goals 
of the study” (Sarantakos 1998:256). In this study initial questions were 
standardised using a topic guide as seen in Appendix Fourteen and discussed 
further in Section 4.3.3.3.vi. This ensured that specific areas were covered but it 
was also possible to probe into and clarify emerging information within the one 
hour interview. The Topic Guide (Appendix Fourteen) was developed from a
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review of relevant literature and from data gained during Phase One and Two of 
my study.
Semi structured interviews are useful in researching sensitive topics (Parahoo 
2006) and for them to be successful it is essential to gain the trust of the 
participant (Denzin & Lincoln 1994). This was especially important in 
interviewing women about what could be seen as ‘personal’ topics of 
contraception and pregnancy and was helped by previously meeting the women 
in the diabetes clinics when handing out the questionnaires and in their 
knowledge that I was a nurse and midwife.
Having previously met the women helped with establishing rapport which was 
important in being able to understand and attempt to see the situation from their 
perspective (Oppenheim 1992). Oakley (1981) describes interviewing as a 
masculine paradigm excluding traits such as emotion and sensitivity, but 
interviewing with a feminist focus as was undertaken in this study, recognises the 
interviewer as a human being with emotions and feelings, thereby avoiding 
hierarchical pitfalls and giving greater insight into the process.
The interviewing style was aimed to maintain rapport and personal questions 
were asked so that participants felt like they were participating in a discussion as 
recommended by Hancock (1998). If there was difficulty answering certain
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questions then prompts were sensitively used to encourage further dialogue and 
elaboration of the topic.
4.3.3.3.i Recording interview data
All participants consented to my audio-taping the interviews for transcription later. 
This was seen as important in order to obtain an accurate record of the interview 
that could be played and replayed to allow detailed recording of the conversation. 
Polit et al (2001) discuss how participants may be self conscious and concerned 
about the recording equipment at the beginning of the interview but within a few 
minutes they rapidly forget it is present.
In addition during the interview contemporaneous notes were made recording 
key topic headings and responses and any other factors of interest such as body 
language of the participant, interruptions and notes on the setting and 
impressions of the process. Silverman (2002:126) suggests recording what you 
see and hear and also how you are behaving and being treated.
Following the interview further post debriefing notes were made with impressions 
of the overall process, anecdotes any other relevant issues. Huberman et al 
(2002) suggest field notes are a running commentary to the researcher and can 
start the process of data analysis during data collection.
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4.3.3.3.Ü Sampling Frame
The design of this study reflected the need for nonprobability purposive sampling 
as described by Miles & Huberman (1994). In this type of sampling, cases are 
selected deliberately (Punch 2005) with a specific purpose in mind (Neuman 
2006). Particular types of cases from a unique or specific population (Neuman 
2006) can be selected with a clear focus for in-depth investigation (Devine & 
Heath 1999). The representativeness of the sample is unimportant in 
comparison to the ability of the chosen sample to achieve deeper understanding 
of the topic (Neuman 2006). The sampling strategy should be systematic and 
robust in order to justify inclusion of cases and give credibility to any claims that 
can be made about the data (Devine & Heath 1999).
The sampling frame for the women with DM, reflected the selection of cases in 
relation to specific variables linking to the research questions for the study. 
Variables included the type of DM, age group, obstetric history, ethnicity, whether 
preconception care advice had been given and comments written by the 
participant. The aim was to achieve an overall selection of four women from 
each of the four sites with the characteristics seen in Table Four This was to 
enable a variety of views to be sought in respect of answering the research 
questions of the study (Chapter One Section 1.2) and to allow comparison 
between sites. An algorithm was therefore developed and applied to the data 
as shown below in Figure Five:
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Figure Five 
Algorithm for Sampling Frame
1. Take all cases SPSS file Diabetes data
2. Sort into Four Age groups 16-19, 20-29, 30-39, 40+
Use - Transform -  recode - into different variable -  age into ‘agegroup’ 
where 1= 16-19, 2= 20-29, 3= 30-39 and 4= 40 -44
3. Use Analyse / descriptive statistics / frequencies to sort variables
4. Sort by Marital Status
5. sort by Ethnicity -  many not recorded
6. Sort by treatment with Insulin and tablets
7. Sort by previous pregnancy or no previous pregnancy
8. Sort those with previous pregnancy with complications
9. Sort by those wanting a pregnancy in the future
10. Sort by those given information on pre conception care
11. Sort by choice of contraception
12. Sort by comments - interest
13. Sort all cases that agree to participate in interviews ( data - select cases -  
if agree =1)
14. Sort to 4 sites - Centre one to Centre four and repeat steps 1-11 
Sort each site data by age group steps 1-11
15. CROSS TABULATION and split file by age groups to analyse -  age 
groups versus previous pregnancy versus patient number to get specific 
patient related variables.
16. Select patients from above using criteria in Table Four below:
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Table Four
Selection of four women from each of the four sites for interview
Aim to Achieve
One woman from each age group
16-19 years
20-29 years
30-39 years
40-44 years
A variety of ethnic groups.
Two women with treatment for insulin and two without insulin using 
dietary or oral hypoglycemic treatments.
Two with previous pregnancies 
One planned pregnancy 
One unplanned
One with complications of pregnancy and one without complications 
in pregnancy
One woman who is currently pregnant
Two who were given advice and two were not given advice on pre 
conception care
Choice of contraception -  four different methods if possible 
Women who had made comments of interest
4.3.3.3.iii Recruitment of women with DM for interview - Making contact.
The selected women were initially contacted by e-mail or text using the concept
of pre-notification to increase positive response rates. E-mail & text have 
become a quick and useful method for contacting potential participants (Haller et 
al 2006) as the message can be answered at a convenient time, which may be
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important in gaining a positive response from those with busy lives. The study 
followed guidelines developed by The Royal College of Nursing (RCN) for use of 
text messaging services within health care in recognition of the increasing use of 
Text (RCN 2006).
A text or e-mail message was left for the women explaining the purpose of the 
contact as a follow up from the questionnaire and asking for a convenient time to 
telephone. Women were then telephoned to make an appointment for the 
interview.
4.3.3.3.iv Recruitment of Health Professionals for interview.
Diabetes health professionals involved in the care of women selected for
interview were contacted and asked to participate in the study. All health 
professionals who were contacted agreed to an interview. Four diabetes health 
professionals from each diabetes centre were selected including dieticians, 
nurses and doctors. In order to promote anonymity the health professionals have 
not generally been identified by profession within the study findings but are 
referred to as health professionals (HP).
4.3.3.3.V Interview venue
The setting for interview should be non-threatening and in an environment where 
the participant feels comfortable (Oppenheim 1992). The women with DM were 
telephoned and asked where they would prefer to be interviewed, and for their
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convenience most interviews took place in their homes, and two were completed 
in the clinic setting. Two of the youngest women who were students and one 
other participant were interviewed by telephone as they were unable to meet face 
to face but agreed to a telephone conversation. The interviews with health 
professionals took place in the diabetes centres or workplace of the health 
professionals.
4.3.3.3.vi Interview schedules/ topic guide
The Interview schedules/ topic guide was developed from a review of relevant 
literature and from data gained earlier in my research. During Phase One the 
General Practice Database study, demographic and epidemiological data 
highlighted relevant issues and topics in relation to women with diabetes that 
could be further explored at interview. In Phase Two the questionnaire study, 
women completed closed and open questions which on analysis established a 
range of topics and themes for future examination.
These themes and topics with pre established questions were used to guide the 
structure of the conversations with the women with DM and health professionals 
(Appendix Fourteen). The structure complied with characteristics of the 
nonscheduled standardised interview (Denzin & Lincoln 1994). In development 
of the schedule I ensured that questions were open ended, in a logical sequence 
and that probes designed to elicit more detailed information were included.
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4.3.3.S.vii Pilot study
One health professional and one woman with DM were interviewed and used as 
pilot data. The benefit of pilot work has been discussed previously in Chapter 
Four (Section 4.1.7). Following this, adjustments were made to flow of the 
interview schedule and the theme of ‘emergency contraception’ emerged and 
was therefore included in the topic guide.
4.3.3.3.viii Data analysis and coding
Interview data were transcribed using Microsoft Word and then prepared for 
coding and analysis by use of the computer soft ware package NVIVO 7 as 
discussed in Section 4.3.3.3.x below.
4.3.3.3.ix Transcripts
Data were transcribed verbatim as soon as possible after the interviews. Since 
the interviews had been audiotaped it was possible to listen to the tape recording 
repeatedly in order to ensure that the transcripts were a reliable record. Most of 
the transcripts were transcribed by the researcher herself by firstly listening to the 
entire interview to grasp the overall content and then by listening and transcribing 
each question and answer using a transcribing machine. Transcripts that had 
been transcribed by a secretary were checked by reading and listening at least 
three times to ensure accurate transcription. Silverman (2002) notes that 
repeated listening to the tape can reveal previously unnoted features. During 
transcription notes were made of use of language, inflection and emphasis during
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the interviews. The comments /field notes that were made during the interviews 
were then added if thought to add context to the transcription.
4.3.3.3.x NVIVO 7
The software package NVIVO 7 was used as a data handling management 
system for data collected from the semi-structured interviews and field notes. 
Seale (2002) discusses the rise in use of computer-assisted analysis of 
qualitative data (CAQDAS) due to advantages in allowing large volumes of data 
to be handled with speed. The package also has the ability to support 
presentation of data for publication including production of diagrams and flow 
charts.
The thirty two interviews generated a large amount of text which were imported 
into the package as ‘sources’ of data and then the process of ‘open coding’ 
followed as discussed by Polit et al (2001 ). The transcripts of interviews with the 
health professionals and women with DM were coded separately and the huge 
amount of data felt quite overwhelming. The data were analysed by reading the 
narrative and assigning labels based on the meaning elicited from the narrative. 
This led to many initial topics being identified using a system of nodes (codes) 
and I kept notes of decisions I made. Following initial coding the transcripts were 
re read and listened to for specific emphasis and meaning that was incorporated 
into the transcribed text. The aim was to find all possible data related to final 
themes and sub themes (Neuman 2006). Main categories and themes were
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highlighted for the health professionals and women with DM as can be seen in 
Figures Six and Seven.
There were eleven categories for the Health Professionals: Glycaemic Control; 
Pregnancy; Contraception; Structure of Services; General Diabetes Care; 
Training; Policy and Guidance; Médicalisation; Hard Work; Teenagers & Young 
People and Type of Diabetes. For the women with DM there were eight 
categories: Glycaemic Control; Pregnancy; Contraception; Structure of Services; 
General Diabetes Care; Teenagers & Young People; Health Professionals and 
General Diabetes Care. These were then refined and sub categories developed 
as they emerged by creating free nodes and an example in relation to the 
category ‘Pregnancy’ for the women with DM is shown in Figure Eight and further 
examples in Appendix Fifteen.
Figure Six: Main Categories -  Health Professionals
GLYCAEMIC "N (  PREGNANCY 'N  ( CONTRACEPTIo'\ f STRUCTURE 0 " A  (  GENERAL '  
CONTROL N SERVICES DIABETES CARE
J  V. y x_ y v.
HARD WORK
y v
MED1CALISAT10
y v_
TYPEOF ^  
DIABETES
y v.
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Figure Seven: Main themes Women with DM
WOMEN
WITH
DIABETES
C GLYCAEMIC 
CONTROL
n. CONTRACEPTIONA rSTRUCTURE 
OF SERVICES
r
j  v_ J v. J v v  v_
Figure Nine contains an exert from a coded transcript which can be seen in more 
detail in Appendix Sixteen.
Three overarching topics emerged as Living with Diabetes, Diabetes and 
Pregnancy and Contraception and the findings are presented in Chapters Seven 
to Nine using these headings.
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Figure Eight
Coding example for the theme of pregnancy from transcripts from Women 
with DM
CODING EXAMPLE 
PREGNANCY
PREG NANCY
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Figure Nine: Coded exert from interview with a health professional
Q:Thinking about planning for pregnancy and contraception, do you recommend 
any particular contraceptive method?
A:No, I don’t I don't get involved to be honest.
Q:What do you do if someone asks?
A:lf someone asks I usually send them off to the family planning clinic for advice. 
In the olden days, when I was first a diabetes nurse there was issues about the 
contraceptive pill and diabetes, but I think that’s, I don’t think that’s a problem 
now -  she says (laughs), but I don’t feel qualified to advise people on family 
planning issues.
NARRATIVE CODING
Q:Thinking about planning for 
pregnancy and contraception, do you 
recommend any particular contraceptive 
method?
A:No, 1 don’t 1 don't get involved to be 
honest.
Tree NodesNCONTRACEPTION
Tree Nodes\CONTRACEPTION\ 
ADVICE
Q: What do you do if someone asks?
A: If someone asks 1 usually send them 
off to the family planning clinic for 
advice.
Tree Nodes\CONTRACEPTION\ 
REFERRAL
In the olden days, when 1 was first a 
diabetes nurse there was issues about 
the contraceptive pill and diabetes, but 1 
think that’s, 1 don’t think that’s a problem 
now- she says (Laughs),
Tree Nodes\CONTRACEPTION\ 
COMPLICATIONS & SIDE 
EFFECTS
, but 1 don’t feel qualified to advise 
people on family planning issues.
Tree Nodes\CONTRACEPTION\ 
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4.3.5 Conclusion
In conclusion this chapter has identified the methodological approach used for 
the case study after Burawoy (1998). The three phase study uses ethnographic 
principles and a feminist focus to explore the case: The prevention of unplanned 
pregnancy in women with type 1 or type 2 DM.
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The philosophical rationale for the study includes both positivist and interpretative 
methodology with both being seen as important and the use of mixed 
methodology being inherent in the study design; I have argued that this 
pragmatic approach created synergy within the study with the different 
methodology reflecting different aspects of reality and aiding understanding of 
complex multidimensional real life events in exploration of the research 
questions.
The study uses a sequential component design with a distinct initial quantitative 
phase which was used to inform the dominant qualitative phase. The qualitative 
phase used a mixed model of integrated iterative design with a questionnaire 
which was used to select subjects for further study by in depth interview. The 
methods and tools used in each phase of the study are described and issues of 
authenticity and rigour explored. Consideration is given to ethical issues and 
principles and evidence of approval from ethical review bodies is included.
The complementary strengths of quantitative and qualitative methods allowed 
meaning to be established from epidemiological data generated by the database 
and questionnaire study and the triangulation of the data may enhance validity of 
the findings. This case study also considers the effects of the wider ‘macro’ 
external influences such as policy on the data with the overall aim of examining 
the issue of unplanned pregnancy in women with DM and to understand what 
factors promote or discourage effective preconception care.
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The next five chapters present the case study findings in the following format 
Chapter Five: Findings-Database study; Chapter Six:Findings-Questionnaire 
Study; Chapter SevemFindings-Living with Diabetes; Chapter EightFindings- 
Pregnancy; Chapter Nine:Findings -Contraception. As has been discussed 
earlier the interpretation of the findings are mainly discussed within Chapters Ten 
(Discussion) and Eleven (Key Findings and Conclusions).
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CHAPTER FIVE 
Findings: General Practice Database Study
5.00 Introduction
This Chapter presents the findings for Phase One of the case study which used 
the General Practice Database (GPRD) to obtain an overview of the reproductive 
issues for women with DM and a statistical review of contraception prescribed by 
General Practice. The GPRD is described in Chapter Four Section 4.3.1.2.
5.1 Study Population
There were 136 general practices contributing research quality data on the 
GPRD on January 1st 2001. From these practices 1683 women aged 15 to 44 
years of age inclusive, with codes for diabetes were identified.
Using the algorithms described in the methodology (Chapter Four Section
4.3.1.3), 1060 patients were identified as having type 1 DM and 442 as type 2 
DM. The remaining 181 women were deemed of indeterminate diabetes type 
and excluded from the study. For controls 6360 and 2652 women respectively, 
were randomly selected matched by age for the type 1 DM and type 2 DM 
comparison groups. In order to analyse contraceptive method use, women who
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had been sterilised or had had a hysterectomy prior to 2001, were also excluded 
from the study, leaving 947 patients with type 1 DM and 5898 in their comparison 
group and 365 with type 2 DM and 2252 in their comparison group.
5.1.1 Age and Type of DM
Table Five shows the distribution of age and type of DM for the cohort and figure 
1 makes a graphical comparison.
Table Five Age group and Type of diabetes
AGE GROUP TYPE 1 DM TYPE 2 DM
15-19 yrs n= 102 9.6% n = 0 0%
20-24 yrs n =105 9.9% n = 7 1.6%
25-29 yrs n = 153 14.4% n = 11 2.5%
30-34 yrs n = 263 24.8% n = 30 6.8%
35-39 yrs n = 258 24.3% n = 120 27.1%
40-44 yrs n = 179 16.9% n = 274 62.0%
n n= 1060 n =442
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Figure Ten Age distribution and Type of DM
QTYPE 1 
■  TYPE 2
15-19yrs 20-24yrs 25-29yrs 30-34yrs 35-39yrs 40-44yrs
Age
The mean age was 31.7 years for women with type 1 DM and 39.5 years for 
women with type 2 DM. These results are consistent with national data for 
diabetes (Diabetes UK 2007) and also reflect the gradual onset and significant 
sub-clinical phase with type 2 DM that may last several years before diagnosis 
(BMA 2004).
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5.1.2 Pregnancy
There was no difference between women with type 1 DM and their comparison 
group with regard to having had a pregnancy or delivery during 2001. However 
women with type 2 DM were significantly less likely to have had a pregnancy or 
delivery than women matched from the comparison group. P<0.05 (OR 0.49 
95% Cl 0.25- 0.94). See Table Six
Table six: Pregnancy or delivery in 2001
TYPE 1 TYPE1 OR & SIG TYPE2 TYPE2 OR & SIG
CONTROL 95% Cl n=365 CONTROL 95% Cl
n=947 n=5898 n=2252
10.8%
n=102
10.0% 
n= 587
1.09
0.88-1.36
n/s 2.7% 
n= 10
5.5%
n=133
0.49
0.25-0.94
P<0.05
Similar findings regarding pregnancy or delivery were found for women over 30 
years of age (Table Seven a).
Table Seven a: Delivery in 2001 women aged over 30 years
TYPE 1 
N=588
TYPE1
CONTROL
n=3755
OR & 
95% Cl
SIG TYPE2
n=348
TYPE2
CONTROL
n=2144
OR & 
95% Cl
SIG
10.4% 9.6% 1.10 n/s 2.3% 4.8% 0.47 P<0.05
N=61 n= 360 0.86 — 
1.41
00IIc n=103 0.23-0.93
This indicated that women with type 1 DM were significantly more likely to have a 
pregnancy over the age of 30 years compared with those women with type 2 DM. 
See Table Seven b. OR 2.33 (95% Cl 1.91-2.84) P<0.01. However this did not
159
account for age which is associated with likelihood of pregnancy. The age 
structure of the population of women with typel DM when compared with those 
with type 2DM, even when restricted to women aged over SOyears is very 
different. When adjusted for age there was no difference in the rate of pregnancy 
in women aged over 30 with typel DM compared to women with type 2 DM. OR 
1.22 (95% Cl 0.97-1.52)
Table Seven b: PREGNANCY OR DELIVERY IN 2001 WOMEN AGED OVER 
30 YEARS - type 1 DM compared with type 2 DM
TYPE 1 TYPE 2 OR & 95% SIG
DM DM Cl
n=588 n=348
10.4%
n=61
2.3% 
n= 8
2.33
(1.91-2.84)
P<0.01
5.1.4. Sterilisation
There is no significant difference in records of sterilisation in the year 2001 for 
women with type 1 DM and the comparison group or for women with type 2 DM 
and the comparison group. See Table Eight.
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Table Eight: Sterilisation in year 2001
TYPE 1 
n=947
TYPE1
COMPARISON 
n= 5898
OR & 
95% Cl
SIG
TYPE 2 
n=365
TYPE2
COMPARISON
n=2252
OR & 
95%CI
SIG
STERILISATION
IN 0.5% 0.6% 0.86 n/s 0.5% 0.8% 0.68 n/s
2001
n=5 n=35 0.33-2.21 n=2 n=18 0.15-2.94
5.1.5 Hysterectomy
There is no significant difference in records of hysterectomy for women with type 
1 DM and the comparison group or for women with type 2 DM and the 
comparison group. See Table Nine.
Table Nine: Hysterectomy in 2001
TYPE 1 
n=947
TYPE1
COMPARISON 
n= 5898
OR &
95% Cl
SIG
TYPE 2 
n=365
TYPE2
COMPARISON
n=2252
OR & 
95% Cl
SIG
HYSTERECTOMY 
IN 2001 0% 0.2% 0 n/s 1.1% 0.5% 2.07
n=12 n=4 n=11
0.66-6.25 n/s
5.1.6 Comparison of Contraceptive methods
Comparisons were made for utilisation of contraceptive methods between 
women with diabetes and their controls and for type of DM. Data for use of non 
hormonal methods such as diaphragms, caps and condoms were seen to be 
unreliable and poorly recorded, possibly because these are often not prescribed
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or fitted by GPs. Therefore this study analysed use of the intrauterine device and 
hormonal methods which appeared to be well recorded reliable data.
5.1.6.1 Intrauterine device
There is no significant difference in records of intrauterine device use for women 
with type 1 DM and the comparison group or for women with type 2 DM and the 
comparison group. See Table Ten.
Table Ten: Records of use of IUD.
TYPE 1
DM
n=947
TYPE1
COMPARISON 
n= 5898
OR & 
95% Cl
SIG
TYPE 2 
n=365
TYPE 2 DM
COMPARISON
n=2252
OR &
95% Cl
SIG
INTRAUTERINE
DEVICE 1.1% 0.8% 0.77 n/s 1.1% 1.0% 0.89
n=10 n=47
0.39-1.53
n=4 n=23
0.32-2.6 n/s
Hormonal Contraception
Hormonal contraception was prescribed to 238, (25.1%) of 947 women with type 
1 DM and 1739, (29.5%) of 5898 women in the comparison group and to 42, 
(11.5%) of 365 women with type 2 DM compared with 400 (17.8%) of the 2252 
women without diabetes. Women with type 1 DM or type 2 DM were significantly 
less likely to use hormonal contraception p<0.01. (Type 1 DM. OR 0.83 95% Cl 
0.69-0.93. Type 2 DM. OR 0.60 95% Cl 0.42-0.83).
Table Eleven shows the utilisation of hormonal contraceptive methods for the 
year 2001 for type 1 DM and comparisons and type 2 DM and comparisons.
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Table Eleven: Utilisation of hormonal contraceptive methods for the year 
2001 for type 1 DM and comparisons and type 2 DM and comparisons.
Type 
1 DM
n=947
Type 1 
comparison 
n= 5898
OR and
(95%
Cl)
Type 
2 DM 
n=365
Type 2
compariso
n
n=2252
OR and 
(95% Cl)
Combined 
oral pill
18.0% 24.3% 0.68
(0.57-
5.5% 12.8% 0.39
(0.24-
n=170 n=1433 .80) n=20 n=288 0.62)
Progestogen
6.8% 4.2% 1.65
(1.26-
6.3% 4.9% 1.31
(0.82-
only pill n=64 n=248 2.13) n=23 n=110 2.00)
4.6% 3.0% 1.56 5.5% 1.6% 3.57
Injectable 
Depo Provera
n=44 n=177 (1.12-
2.11)
n=20 n=36 (2.15-
5.60)
3.4% 2.3% 1.5 1.1% 1.5% 0.72
Emergency
contraception
n=32 n=136 (1.02-
2.14)
n=4 n=34 (0.20-
1.87)
1.4% 2.4% 0.58 0.5% 0.7% 0.77
Dianette n=i3 n=142 (0.30-
0.99)
n=2 n=16 (0.09-
2.80)
ALL ORAL 25.1% 29.5% 0.83 11.5% 17.8% 0.60
HORMONAL n=238 n=1740 (0.69-
0.93)
n=42 n=401 (0.42-
0.83)
5.1.6.2. Combined oral contraceptive pills
Overall women with DM were more likely to be prescribed a 2nd generation 
than a 3rd generation combined pill2 and there was no significant difference 
between subjects with type 1 DM and the comparison group. However women 
with type 2 DM were significantly less likely to be prescribed a 3rd generation
2 these products are described in Chapter Three Section 3.4.2.1
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COC, (only one individual out of 365 cases) p<0.01 (OR 7.42 95% Cl 1.02 - 
54.01). Table Twelve compares type of diabetes and use of 2nd or 3rd generation 
combined pills.
Table Twelve: Type of DM and use of 2nd or 3rd generation combined pills.
TYPE 1
DM
n=947
TYPE1
COMPARISON 
n= 5898
OR & 
95% Cl
SIG
TYPE 2 
DM
n=365
TYPE2
COMPARISON
n=2252
OR & 
95% Cl
SIG
COC
2nd
GENERATION
15.2%
n=144
20.7%
n=1221
1.46
1.21-
1.76
P<
0.01
5.2%
n=19
11%
n=248
2.24
1.39-
3.63
P<0.
01
COC
3rd
GENERATION
3.5%
n=33
4.3%
n=254
1.25
0.86-
1.81
n/s 0.3%
n=1
2.0%
n=45
7.42
1.02-
54.01
P<0.
01
ALL COC 18.7%
n=177
25%
n=1475
0.68
0.57-8.0
P<0.0
1
5.5%
n=20
13%
n=293
0.39
0.24-
0.62
P<0.
01
5.1.6.3 Progestogen only pills
Women with type 1 DM were more likely to be prescribed a combined pill (18%) 
than a progestogen only pill (6.8%) but were significantly more likely to be 
prescribed the POP than the comparison group (4.2%) p<0.01. OR 1.65 (95% Cl 
1.26-2.13). Women with type 2 DM were less likely to be prescribed the COC 
p<0.01 (OR 0.39 95% Cl 0.24-0.62) See Table Eleven.
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5.1.6.4 Injectable Depo Provera
The injectable contraceptive Depo Provera was significantly more likely to be 
given to women with DM than the comparison group. (Type 1 DM. OR 1.56 95% 
Cl 1.12-2.11, Type 2 DM. OR 3.57 95% Cl 2.15-5.60). See Table Thirteen
Table Thirteen: Use of Injectable Contraceptive Depo Provera
TYPE 1
DM
n=947
TYPE1
COMPARISON 
n= 5898
OR & 
95%CI
SIG
TYPE 2
DM
n=365
TYPE2
COMPARISON
n=2252
OR & 
95%CI
SIG
4.6% 3.0% 1.56 P<0. 5.5% 1.6% 3.57 P<
INJECTABLE n=44 n=177 05 n=20 n=36 0.0
DEPO 1.12- 2.15-5.60 1
PROVERA 2.11
5.1.6.5.Dianette
Diannette, (Ethinylestradiol / cyproterone acetate) was less likely to be 
prescribed to women with type 1 DM (OR 0.58 95%CI 0.30-0.99). There was no 
significant difference between women with type 2 DM and their comparison 
group for prescriptions of Diannette. See Table Fourteen
Table Fourteen: Use of Diannette
TYPE 1 DM 
n=947
TYPE1
COMPARISON 
n= 5898
OR & 
95%CI
SIG
TYPE 2 DM 
n=365
TYPE2
COMPARISON
n=2252
OR & 
95%CI
SIG
DIANETTE
1.4%
n=13.26
2.4%
n=141.55
0.58
0.31-
0.99
P<0.05 0.5%
n=1.83
0.7%
n=15.76
0.77
0.09-
2.80
n/s
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5.1.6.6 Emergency Contraception
Women with type 1 DM were more likely to be prescribed Emergency 
Contraception (OR 1.50 95% Cl 1.02-2.14) than the comparison group. There 
was no significant difference between women with type 2 DM and their 
comparison group for prescriptions of emergency contraception. See Table 
Fifteen
Table Fifteen: Use of Emergency Contraception
TYPE 1
DM
n=947
TYPE1
COMPARISON 
n= 5898
OR & 
95%CI
SIG
TYPE 2
DM
n=365
TYPE2
COMPARISON
n=2252
OR &
95%CI
SIG
EMERGENCY
CONTRACEPTION
3.4%
n=32
2.3%
n=136
1.50
1.02-
2.14
P<0.05 1.1%
n=4
1.5%
n=34
0.72
0.20-1.87
n/s
5.1.7 Conclusion
The findings of the database study show significant differences in the ages of 
women in relation to their type of DM consistent with national data for DM 
(Diabetes UK 2007) and the epidemiology of DM. There was no difference 
between women with type 1 DM and their comparison group with regard to 
having had a pregnancy or delivery during 2001. However women with type 2 
DM were significantly less likely to have had a pregnancy or delivery than women 
matched from the comparison group (P<0.05). For women over 30 years, there
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was no difference in the rate of pregnancy for women with typel DM compared 
to women with type 2 DM when adjusted for age.
In relation to contraception, hormonal methods appear well recorded on the 
GPRD, figures agreeing with UK statistics on use (Dawe & Rainford 2003).
There is however, an apparent low recording on the database of non-hormonal 
methods such diaphragms, caps, condoms and intra uterine devices. This may 
be related to the fact that women often attend community family planning clinics 
rather than the GP for these methods.
There was a significant difference in prescribing of contraception to women with 
diabetes in comparison to a group matched for age with no history of DM and 
women with type 1 DM or type 2 DM were significantly less likely to use 
hormonal contraception p<0.01. It is now recognised that hormonal 
contraception is a safe and effective option for women with uncomplicated 
diabetes. My study indicates that possibly there are significant numbers of young 
women with poorly controlled diabetes or other risk factors for cardiovascular 
disease that have influenced clinicians in avoiding the use of hormonal 
contraception. Paradoxically it is these women who are at most risk from 
unplanned pregnancy.
Further analysis and interpretation of these data will be considered in Chapter 
Ten in the integrated discussion. These data informed the design of the
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questionnaire for the second phase of the study and the next chapter will present 
the findings from analysis of the questionnaire study.
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CHAPTER SIX
Findings: Questionnaire Study
6.0 Introduction
This chapter presents the findings of 107 questionnaires completed by women 
with DM across the four diabetes centres. The questionnaire can be seen in 
Appendix Thirteen. As has been described in the methodology (Chapter Four) 
the rationale for the questionnaire was to ultimately select women for interview 
and at the end of the questionnaire women were asked to give their contact 
details if they agreed to be interviewed. Selected variables were used to create a 
sampling frame to select the women for semi structured interview as discussed in 
Chapter 4.3.3.3.ii. Figure Five. A description of those women interviewed is 
included at the end of this chapter.
The questionnaire data were analysed using the statistical package for social 
science (SPSS) and are presented as descriptive and summary statistics with 
cross tabulations and logistic regression being performed where possible. An 
initial descriptive overview of the women will be followed by examination of 
variables in relation to the case ‘prevention of unplanned pregnancy in women 
with type 1 or type 2 DM.
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The questionnaire contained space for free text comments which were 
thematically coded by hand and analysed separately to the quantitative data and 
this narrative has been included within the findings of the semi structured 
interviews.
6.1 Description of the Centres
Women were recruited from four diabetes centres in the South of England and 
there was an even spread across the Centres with twenty nine women recruited 
from Centre One, twenty five from Centre Two, twenty seven from Centre Three 
and twenty six from Centre Four.
All of the centres were based within NHS Hospital Sites but one of the centres 
was undergoing a change of service provision to work within the Primary Care 
Trust with diabetes professionals seeing patients at GP surgeries rather than in 
the hospital clinic setting.
6.2 Demographic Information
This section will present demographic information including age of the women 
completing the questionnaires, their marital status, ethnic origin and occupation.
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6.2.1 Age
Of the 107 women who completed the questionnaire; the youngest woman was 
17 years old and the oldest 44years old. The age profile across the centres 
varied and Centres Three and Four did not recruit any women under the age of 
20 years.
The mean age for all the women completing the questionnaires was 31 years. 
Data were grouped into ranges of 16-19 years, 20-29 years, 30-39 years and 40- 
44years to facilitate analysis. Table Sixteen shows the age grouping of the 
cohort and for each centre.
Table Sixteen: Age Groups at Centres
CENTRE 1 
n= 29
CENTRE 2 
n=25
CENTRE 3 
n=27
CENTRE 4 
n=26
ALL CENTRES 
n=107
Age Group 
16-19 yrs 5(17.2%) 4(16%) 0 0 9 (8.4%)
20-29 yrs 10(34.5%) 6 (24%) 6 (22.2%) 14(53.8%) 36 (33.6%)
30-39yrs 9(31%) 13(52%) 17(63%) 7 (26.9%) 46 (43%)
40-49yrs 5(17.2%) 2(8%) 4(14.8%) 5(19.2%) 16(15%)
6.2.2 Marital Status
70 (65.4%) of the women were married or in a partnership. 32 (29.9%) were 
single and 5 (4.7%) divorced.
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6.2.3 Ethnie Origin
17 of women did not complete this question and data were recorded as missing. 
81 (90%) of the women were of White Caucasian origin. 5 (5.5%) were Black 
and 4 (4.4%) Asian.
The study recruited few ethnic patients and although when planned it was hoped 
that two of the Centres would provide a more mixed ethnic grouping, in practice 
there were few such patients and in addition, some of these did not wish to 
complete questionnaires or be interviewed. There are specific ethnic groups who 
have a propensity to type 2 DM and their views would have been interesting in 
relation to preconception care and planning pregnancy.
6.2.4 Occupation
Only 18 women (16.8%) completed this question. 8 of the women were students 
and 6 stated housewife or mother as their occupation. The 4 other women were 
working in occupations including retail, law, at the Borough Council, and as a 
secretary. The questions on ethnicity and occupation were placed at the end of 
the questionnaire as they were felt to be of a sensitive nature, however they had 
a poor response causing data to be recorded as missing. In hindsight it may 
have been better to have placed these questions with other demographic 
information nearer the beginning of the questionnaire.
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6.2.5 Summary
The demographic data shows a range women age 17 to 44 years completed the 
questionnaire with a majority being married and of White Caucasian origin. The 
following section will go on to present data in relation to the medical history of the 
women.
6.3 Information on Medical History
This section will present data relating to the medical history of the women 
including their DM, medical conditions and whether they smoked.
6.3.1 Type of DM
Type of DM was determined using an algorithm (see Chapter Four, Section
4.3.1.3). The women were asked the year that they were diagnosed with DM, 
their age currently and how their DM was managed. 91 (85%) of the women 
were determined type 1 DM and 16 (15%) type 2 DM. The results may have 
been influenced by the use of Diabetes Centres for the recruitment which care for 
a higher number of women with type 1 DM whilst women with type 2 DM are 
often cared for by General Practitioners.
6.3.2 Medical Conditions
The women were asked if they had raised blood pressure and if they had any 
other medical conditions. Twenty one (19.6% of the women completing a
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questionnaire) were being treated for hypertension. 44 (41.1% of the women 
completing a questionnaire) had at least one medical condition in addition to their 
DM, 15 of these women had at least two medical conditions and 8 of the women 
had three medical conditions in addition to their DM. Please see Table 
Seventeen for a list of the common conditions and number of women reporting a 
condition.
Table Seventeen: Medical conditions of the women completing the 
questionnaire (n=44).
Medical Condition Number of women with the 
condition
Hypertension (with treatment) 21
Asthma 14
Thyroid Disease 12
Cardiac disease 8
Rheumatoid Arthritis 7
Polycystic ovary syndrome 5
Renal disease 4
Retinopathy 3
Other 13
The category ‘other’ included; Bowel disorders; Allergies; Mental Health 
problems; Epilepsy; Breast disorders and Endometriosis.
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6.3.3 Smoking
Women were asked if they smoked and 18 of the women (16.8%) were smokers.
6.3.4 Summary
The data relating to the medical history shows that a high proportion (85%) of the 
women had type 1 DM. In addition to their DM 44.1% of the women had at least 
one other medical condition. Despite the increase risk with DM of coronary heart 
disease, the data showed that 16.8% of the women were smokers. The next 
section will go on to present data in relation to pregnancy issues for the women 
completing the questionnaire.
6.4 Description of Women in relation to Pregnancy Issues
This section will present data in relation to pregnancy, complications of 
pregnancy and planning for pregnancy.
6.4.1 Pregnancies
Of the women who completed the questionnaire, 61 (57%) had had a previous 
pregnancy or were currently pregnant. 16 (15%) were currently pregnant. 21 
(19.6%) had one child, 21 (19.6%) had two children and 8 (7.5%) had three 
children. The mean age to have the first child was 27 years of age.
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6.4.2 Planning for pregnancy
6.4.2.1 Was Pregnancy Planned?
The Questionnaire asked the women who had had a previous pregnancy or were 
pregnant (n=61) whether they had had planned their pregnancies. 30 (49%) had 
planned their pregnancy and 31 (51%) had not planned the pregnancy. Section
6.6 will present data comparing women who had planned and those who had not 
planned their pregnancies.
6.4.2.2 Future Pregnancy Desired?
Women were also asked if they were seeking to become pregnant in the future 
(n=107). 54 (50.5%) were planning to become pregnant at some time in the 
future, 38 (35.5%) were not and 15 (14%) were unsure.
6.4.2.3 Information about Planning for Pregnancy.
Of the women that had had a previous pregnancy or were pregnant, 28 (48.3%) 
indicated that they had been given some information about planning pregnancy. 
30 (51.7%) answered that they had not had information. 3 women did not answer 
the question and data were recorded as missing. Table Eighteen shows which 
Health professionals gave information.
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Table Eighteen: Source of Information on Planning Pregnancy (n=28 but 11 
of the women ticked 2 professionals)
Health Professional Frequency
Diabetes Nurse 18
Doctor at Diabetes Clinic 15
GP or nurse at Surgery 6
6.4.3 Complications of Pregnancy
The women were asked about complications of pregnancy and 34 (56%) had had 
complications during pregnancy. 15 had at least two complications and 6 
reported three complications. The complications are listed in Table Nineteen 
below.
Table Nineteen: Complications of Pregnancy (n=34)
Complication Number of women 
reporting complication
Pre elampsia 22
Miscarriage 7
Macrosomia 7
Premature delivery 6
Poor control 4
Other 4
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The category ‘other’ included: Fetal cardiac complications; Twins; Pelvis symphis 
dysfunction and Infection.
6.4.4 Summary
The data shows that over half (57%) of the women had had a previous 
pregnancy or were currently pregnant. Of those pregnancies 56% of the women 
had had some sort of complication. With respect to planning pregnancy, over 
half (51%) of the pregnancies were unplanned and over half (51%) had not 
received any information about planning for pregnancy or pregnancy and DM.
The next section will present data on the use of contraception by women with 
DM.
6.5 Description of Contraceptive Methods Use by the women.
This section will present the findings in relation to use of contraception by the 
women who were asked about contraceptive methods that they had used in the 
past year.
6.5.1 Methods of Contraception used.
36 (33.6%) had not used any contraception at all, but 71 women had used a 
variety of methods which will now be described. 4 women (5.6%) had been 
sterilised and 1 woman (1.4%) had a partner who had had a vasectomy. 17
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women (23.9%) used condoms for contraception and 6 women (8.5%) stated that 
they used ‘natural methods’ of contraception.
Contraceptive pills were used by 34 women overall with 26 women (38.6%), 
taking the combined contraceptive pill and 8 (11.3%) the progesterone only pill. 
Other hormonal methods of contraception were used including the intrauterine 
system by 3 women (4.2%), Depo provera Injection (1 woman 1.4%) and the 
implant Implanon by 1 woman (1.4%). 4 women used an intrauterine device 
(5.6%).
Table Twenty & Table Twenty One show Frequency of use of Hormonal and Non 
Hormonal methods of contraception by women with diabetes answering the 
questionnaire.
Table Twenty: Frequency of Use of Hormonal Methods of Contraception
Method Frequency and % use of those using 
contraception
Combined Oral 
Contraception
26(36.6%)
Progestogen Only Pill 8(11.3%)
Intrauterine System 3 (4.2%)
Depo provera Injection 1 (1.4%)
Implant 1 (1.4%)
..
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Table Twenty One: Frequency of Use of Non Hormonal Methods of 
Contraception
Non Hormonal Methods Frequency and % use of those using 
contraception
Condom 17(23.9%)
Natural Methods 6 (8.5%)
Intrauterine Device 4 (5.6%)
6.5.2 Reason for choice of Method
The women were asked to explain why the method they were using was best for 
them. Reasons given were coded as seen in Table Twenty Two below. 58 
women of the 71 using contraception answered the question (missing data n=13)
Table Twenty Two: Why Women Believed Contraceptive Method was best 
for them.
Women’s Comment Frequency
N=71
Effective and Reliable 26
Medical Condition 
prevents other methods
14
Side effects on other 
methods
6
Regulates Menstruation 7
Doctor advised method 4
Breast Feeding 1
Total 58
Missing data 13
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6.5.3 Contraception advice received within the last year.
All 107 women were asked which Health Professionals had given them family
planning advice or a prescription for contraception in the past year. 38 (35.5%) 
of the women indicated that they had not received any advice on contraception 
during the past year. Of the women receiving advice, 20 women ticked two 
responses. Over half of the women had received advice from their GP (56 
women), 9 had received advice from the GP Practice nurse, 9 from the Nurse 
and 4 from the Doctor at the Diabetes Centre. 8 women had attended a family 
planning clinic and received advice.
6.5.4 Use of Emergency Contraception
Emergency Contraception had been used by 40 (37.4%) of the women 
responding to the questionnaire. Of the women that had used Emergency 
contraception, 39 replied to the question asking where they had obtained it and 
21 (54%), had obtained it from the GP, 8 (20.5%) from the chemist, 7 (18%) from 
the Family Planning clinic and 3 (8%) from Walk in Centres.
6.5.5 Summary
This section has presented results in relation to use of contraception by women 
with DM who completed the questionnaires. A variety of methods were used but 
over a third of women were not using any form of contraception (33.6%).
Reasons for their choice of method included, the effectiveness and reliability of 
the method and because their medical conditions prevented use of other
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methods. Over a third of women (35.5%) had not received any contraceptive 
advice within the past year and over a third (37.4%) had used emergency 
contraception. The following section will look further at data comparing women 
who had planned and those who had not planned their pregnancies.
6.6. Comparison of women who planned and women who had not planned 
their pregnancies.
In particular consideration of the research question ‘what factors are associated 
with prevention of unplanned pregnancy in women with DM, the following section 
presents data comparing findings between women who had planned and those 
who had not planned their pregnancies. Data includes demographic information, 
data relating to pregnancy and planning pregnancy and data relating to use of 
contraception.
6.6.1 Comparison of variables for those women who had planned and those 
women who had not planned their pregnancies.
Tables Twenty Three to Twenty Seven shows a comparison of variables for a 
cohort of sixty one women who had had a previous pregnancy or were currently 
pregnant, spit by whether they stated that their pregnancy was planned or 
unplanned. No statistical significant differences were found between the two 
groups for any of the variables.
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Table Twenty Three: Demographic Information
Planned
pregnancy
n=30
Unplanned
pregnancy
n=31
Test/Significance P value
Age group
20-29yrs
30-39yrs
40-44yrs
8 (26.7%) 
16(53.3%) 
6(20%)
10(32.3%)
12(38.7%)
9(29%)
Pearson Chi-Square 
n/s
P = 0.502
Marital
Status
Married
Divorced
Single
Partner
20 (66.7%) 
2 (6.7%)
2 (6.7%)
6 (20%)
15 (48.4%) 
1 (3.2%)
5 (16.1%) 
10 (32.3%)
Pearson Chi-Square 
n/s
P= 0.345
Type of 
Diabetes
Type 1
Type 2
24 (80%) 
6 (20%)
27 (87.1%) 
4 (12.9%)
Pearson Chi-Square 
Fisher’s Exact test 
n/s
P= 0.344
Smoker
Yes
No
7 (23.3%)
23 (76.7%)
5 (16.1%) 
26 (83.9%)
Pearson Chi-Square 
Fisher’s Exact test 
n/s
P= 0.350
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Table Twenty Four: Pregnancy
Planned
pregnancy
n=30
Unplanned
pregnancy
n=31
Test/Significance P value
Age of first 
pregnancy
16-
19yrs
20-
29yrs
30-
39yrs
40-
44yrs
0 (0%) 
19(63.3%) 
7 (23.3%) 
1 (3.3%)
7 (22.6%)
14 (45.2%) 
5 (16.1%) 
0 (0%)
Pearson Chi- 
Square
n/s
P= 0.28
Complications of 
Pregnancy
Yes
No
17(56.7%)
13(43.4%)
17(54.8%) 
12 (38.7%)
Pearson Chi-
Square
Fisher’s Exact
test
n/s
P=0.544
Missing 0 (0%) 2 (6.45%)
Table Twenty Five: Information given re planning for pregnancy?
Planned
pregnancy
n=30
Unplanned
pregnancy
n=31
Test/Significance P value
Yes
No
Missing
17(56.7%) 
11 (36.7%)
2 (6.7%)
11 (35.5%) 
19 (61.3%)
1 (3.2%)
Pearson Chi- 
Square 
Fisher’s Exact 
test 
n/s
P=0.58
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Table Twenty Six: Use of Contraception
Planned
pregnancy
n=30
Unplanned
pregnancy
n=31
Test/Significance P value
None
Natural
Condoms
COC
POP
IUD
IUS
Implant
Sterilisation
10(33.3%) 
3 (10%) 
4 (13.3%) 
7 (23.3%)
1 (3.3%)
2 (6.7%) 
2 (6.7%)
0 (0%)
1 (3.3%)
10(32.2%) 
2 (6.4%)
4 (12.9%)
5 (16.1%) 
2 (6.5%) 
2 (6.5%)
1 (3.3%)
1 (3.2%)
4 (12.9%)
Pearson Chi- 
Square 
n/s
P=0.911
Table Twenty Seven: Use of Emergency Contraception
Planned
pregnancy
n=30
Unplanned
pregnancy
n=31
Test/Significance P value
Yes
No
Missing
9(30%)
20 (66.7%)
1 (3.3%)
13(41.9%)
18(58.1%)
0(0%)
Pearson Chi-
Square
Fisher’s Exact
test
n/s
P=0.272
6.6.2 Logistic regression
Subsequent to the above statistical tests, logistic regression was performed to 
examine whether certain variables could predict the outcome of planned or 
unplanned pregnancy. The dependent variable used was ‘planned/unplanned 
pregnancy’ and the variables used for regression were: ‘Marital Status’, ‘Age’, 
Information given on planning pregnancy’ and ‘Smoking status’. These were
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chosen due to association with socio economic status and reference to increased 
likelihood of planning if women are aware of preconception issues (Janz et al 
1995, Charron-Prochownik 2006b). The results showed that no predictions could 
be made from these data as no statistically significant differences were evident 
as is reported in table Twenty Eight below.
Table Twenty Eight Summary of Model
Measure Significance
Cox & Snell R Square 0.113
Nagelkerke R Square 0.151
Hosmer & Lemeshow 
Test
0.661
Table Twenty Nine: Summary of Variables
Variable Wald
Chi
Squared
Significance Exp (B) 95.0% Cl 
for Exp (B) 
Lower
95.0% Cl 
for Exp (B) 
Upper
Information 
given re 
pregnancy
3.999 0.46 0.316 0.102 0.977
Age 0.266 0.606 1.023 0.939 1.113
Marital
Status
2.378 0.123 0.411 0.132 1.273
Smoking
Status
1.309 0.253 0.413 0.091 1.881
Constant 0.137 0.711 1.705 - -
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6.6.3 Summary
The results show that no differences could be established between those women 
who had planned and those who had not planned their pregnancies in respect of 
demographic variables, pregnancy issues or use of contraception. No 
predictions could be made from logistic regression using the chosen variables, 
Information given re pregnancy; Age of the woman; Smoking status and Marital 
status and this will be discussed further in Chapter Ten.
6.7 Description of the sixteen women who were interviewed
16 women were selected for interview and Chapter Four, Section 4.3.3.3.Ü 
describes the sampling frame and specific variables used to select these women 
from the women who had completed questionnaires and had agreed to be 
interviewed. This section gives an overview of characteristics of this group 
considering their demographic profile, description in relation to pregnancy issues 
and their use of contraception.
6.7.1 Demographic overview
6.7.1.1 Age
The youngest subject to be interviewed was 17 years old and the oldest 44 years 
of age. Table Thirty below shows the distribution of ages grouped for 
convenience.
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Table Thirty: Distribution of ages
Age Group Frequency Percent
16-19
3 18.8
years
20-29
4 25.0
years
30-39
5 31.3
years
40-44
4 25.0
years
Total 16 100.0
6.7.1.2 Marital Status
6 (37.5%) of the subjects were married, 4 (25%) were in a partnership and 6 ( 
37.5%) were single.
6.7.1.3 Ethnicity
15 (93.8%) of the subjects interviewed were white and 1 (6.3%) was of Asian 
ethicity.
6.7.1.4 Type of Diabetes
13 (81.3%) of the subjects had type 1 DM and 3 (18.8%) type 2 DM.
6.7.1.5 Smoking Status
Only 1 subject smoked with 93.8% therefore being non smokers
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6.7.1.5 Medical conditions
7 of the subjects had a medical condition in addition to their diabetes. These 
included having had a myocardial Infarction, retinopathy, hypothyroidism, 
osteoporosis, high cholesterol and poly cystic ovary syndrome.
6.7.2 Description of women interviewed in relation to pregnancy Issues
6.7.2.1 Previous Pregnancy
Of the 16 women 10 (62.5%) had had a previous pregnancy or were currently 
pregnant.
6 7.2.2 Previous pregnancy with complications
8 of the 10 women who had had a previous pregnancy had had complications. 
These included pre eclampsia, premature birth and poor control of their diabetes.
6.7.2.3 Current Pregnancy
1 woman was pregnant when she completed the questionnaire.
6.7.2.4 Age (group) of first pregnancy
Table Thirty One shows the age by group of first pregnancy for women selected 
for interview.
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Table Thirty One: Age ( Group) of First Pregnancy
Age of First Pregnancy Frequency Percentage
16-19 years 1 10%
20-29 years 4 40%
30-39 years 3 30%
Missing data 2 20%
Total 10 100%
6.7.2.5 Planned Pregnancy
Of the 10 women who had had a pregnancy 4 (40%) were planned and 6 (60%) 
were not planned.
6.7.2.6 Information given regarding planning pregnancy
Of the 10 women who had had a previous pregnancy or were pregnant, 2 (20%)
stated that they had been given information relating to planning a pregnancy and 8 
(80%) said that they had not had information.
6.7.3 Description of Contraceptive Methods Use by the women
The women were asked about contraception used during the past year and the 
results are described below. 5 (31 %) of the women said that they did not use any 
contraception.
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6.7.3.1 Methods of Contraception
11 (69%) of the women selected for interview had used a variety of methods 
contraception but use of hormonal methods were limited to use of the combined 
and progestogen only pills as shown in Table Thirty Two below.
Table Thirty Two: Summary of Methods of Contraception
Method Frequency Percentage of all methods
Non Hormonal
Condom 2 18.2%
Natural
Method
1 9.1%
Sterilisation 3 27.3%
Hormonal
Combined
Contraceptive
Pill
4 36.3%
Progestogen 
Only Pill
1 9.1%
6 7.3.2 Use of emergency contraception.
4 (25%) of the women had used emergency contraception in the past whilst 12 
(75%) had not.
6.7.3.3 Summary
This section presents an overview of results from the questionnaires completed 
by the sixteen women selected to be interviewed for the final phase of the case 
study. The results included a demographic description of the women, data 
relating to pregnancy issues and their use of contraception. As stated in Section
6.0 the questionnaire contained space for free text comments which were
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thematically coded by hand and analysed separately to the quantitative data and 
this narrative has been included within the findings of the semi structured 
interviews.
6.8 Conclusion
This chapter presents data from questionnaires completed by 107 women with 
diabetes from four diabetes centres in the South of England. The women ranged 
in age from 17 to 44 years and a majority were married and of white Caucasian 
origin.
The women had type 1 DM (85%) or type 2 DM (15%) and in addition to their DM
44.1 % of the women had at least one other medical condition. Over half (57%) 
of the women had had a previous pregnancy or were currently pregnant and of 
those pregnancies, 56% of the women had had some sort of complication. With 
respect to planning pregnancy, over half (51%) of the pregnancies were 
unplanned and over half (51%) had not received any information about planning 
for pregnancy or pregnancy and DM. No statistical difference could be 
established between those women who had planned and those who had not 
planned their pregnancies, in respect of demographic variables, pregnancy 
issues or use of contraception.
With respect to use of contraception, the women were using a variety of 
hormonal and non hormonal methods but over a third of the women (33.6%) had
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not used any form of contraception during the past year. Reasons for their 
choice of method included, the effectiveness and reliability of the method and 
because their medical conditions prevented use of other methods. Over a third 
of women (35.5%) had not received any contraceptive advice within the past year 
and over a third (37.4%) had used emergency contraception.
The Chapter gives a description of questionnaire data of the 16 women selected 
by algorithm from the 107 women for interview for Phase Three of the study. 
These women were aged 17 to 44 years with thirteen women having type 1 DM 
and three women type 2 DM. 10 of the women had had a previous pregnancy 
and of these 8 had experienced complications. Only 4 of the pregnancies had 
been planned pregnancies and 80% of the women said that they had not 
received information about planning for pregnancy. With regard to use of 
contraception, 31% of the women had not used any method in the last year and 3 
women had been sterilised. The others had used the combined and progestogen 
only contraceptive pill, condoms and natural methods.
As discussed in Chapter One, Section 1.3; the structure of the study, the 
interpretation of these data are included in Chapter Ten, Discussion and Chapter 
Eleven, Key findings and Conclusions. The following chapter will present data 
from the semi structured interviews with the sixteen women and sixteen diabetes 
health professionals that care for them.
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CHAPTER SEVEN 
Findings Of Semi Structured Interviews: Living With Diabetes
7.0 Introduction
This chapter is the first of three chapters presenting findings from Phase Three of 
the case study, the semi structured interviews. In Chapter One, I discussed how 
the use of mixed methodology had presented me with challenges regarding the 
presentation of the findings and Chapters Seven to Nine present data from the 
semi structured interviews in three themes; Living with Diabetes; Diabetes and 
Pregnancy and; Contraception. These data are then interpreted and integrated 
with data from Phase One and Phase Two within Chapter Ten ‘Discussion’.
The theme of ‘Living with Diabetes’ emerged from the interviews where women 
frequently talked about having diabetes’ in relation to their everyday life and this 
section includes the findings from analysis of narrative in two major themes; 
Coping with diabetes and Diabetes Care. Within the first theme, findings in 
relation to diagnosis; family history and; blood glucose control will be included 
and within Diabetes Care, models of service delivery and co ordination of care 
with the role of Health Professionals will be presented. In relation to my research 
questions, these findings put into context issues that women with DM have to 
cope with over and above the general population when planning for pregnancy.
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7.1 Coping with Diabetes
7.1.1 Diagnosis
In the questionnaire I had asked the women when they had been diagnosed with 
DM and during the interview several women then talked about how they were 
diagnosed and the meaning of this to them. Some of the women had had 
symptoms that had worried them and had visited the GP:
One Asian woman had been undergoing treatment for POOS after having been 
trying to become pregnant for four years.
‘I started to get pins and needles and numbness and they did a test then.’ T1 6
The GP would have been concerned about her symptoms being due to 
neuropathy which can occur with DM, due to high blood glucose levels damaging 
the fine capillaries of the extremities (Clark 2004). To have such symptoms may 
mean the DM was well established and it can be seen how DM can remain a 
hidden disease for many years. As highlighted in the Chapter Two, it is 
estimated that one million people in the UK with type 2 DM are not yet diagnosed 
(MeReC 2004). This woman was of Asian origin and had a family history of 
diabetes which would also increase her risk of type 2 DM.
Two women with type 1 DM had visited the GP with symptoms but had not been 
diagnosed with DM readily: One self diagnosed during a college course:
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‘I hadn’t got as far as the weight loss but I sort of had the excessive thirst 
and all of the other symptoms and actually at the time I was studying a 
HSC in biology and we’ve done a whole series of experiments about 
diabetes so I kind of spotted it, went to my doctor and said ‘I think I’m 
diabetic’, and he said ‘don’t talk rubbish’ (laughs) ‘come back another 
time.’ (T1 10)
No explanation was given for this doctor not testing for DM in this young woman. 
Type 1 DM is not a common illness seen in a General Practice population with 
the prevalence being 3.55% of the general population (QMAS 2006). An 
average practice will therefore have one or two patients with type 1 DM. Perhaps 
the GP felt the woman was a hypochondriac as she was studying about the 
disease.
Another, a teenager, had been to the GP on four occasions before she was 
diagnosed with DM:
‘I was doing my AS levels and it was just a really awkward time and it was 
probably the worst time it could have happened that I’d just started at my 
new college and I got a viral infection so it happened within the first few 
weeks and then for the whole of the 7 months I didn’t know, I was just 
feeling ill, I went to the doctors about 4 times but without putting them 
together you can’t really see what it is.’ (T1 14)
She had felt unwell for several months after having had a viral infection and had 
visited the GP with individual symptoms including weight loss, fatigue and 
Candida infection and was told she had post viral syndrome. She did not appear 
to blame the GP for the missed diagnosis but accepted that the whole picture 
needed piecing together like a jig-saw before DM was confirmed. It can be seen 
how the diagnosis of DM could be missed initially if patients present to the GP
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with ‘individual’ symptoms especially if they have a history of previous illness and 
life events which could be seen to be the cause.
One woman with type 2 DM was diagnosed preoperatively:
‘I was due to go in for an operation and it got found when you know, 
when you have the pre op thing done, my level was about 13.3 
when I found out, so it was really high and straightaway they put 
me on tablets.’ (T2 12)
Again this woman may have had type 2 DM for some time and only because she
was tested prior to having an operation was the diagnosis made. This diagnosis
by chance or opportunistic screening can also happen when women attend for
antenatal care and two women were diagnosed during or after pregnancy.
‘I remember I went into the midwife and she took a urine sample and said 
to me that I had quite high sugar but they said to me ‘have you eaten 
anything sugary? And I said Yes I’ve had a whole packet of fizzy sweets’ 
and it was ‘Oh! that will be why’, and it probably wasn’t why but they said 
‘Perhaps you should get called in on one of those fasting ones’. (T2 16)
The midwife had tried to ‘normalise’ the urine test result by saying that it was 
probably high because she had eaten a lot of fizzy sweets and this may have 
been to try to prevent the woman from worrying before she had further tests. 
However as discussed in Chapter Two, there is some ambiguity and much 
discussion about the diagnosis of gestational diabetes mellitus (GDM) in 
pregnancy and there is still no consensus on screening or the management and 
treatment of the condition (Hollander et al 2007, Hyer & Shehata 2005, WHO 
2006).
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It is however known that women who have had GDM are at increased risk of 
developing DM later on in life (Agarwal et al 2007). With 5 -10% having a risk of 
developing type 1 DM and a 30% having a risk of type 2 DM(Diabetes UK 2007). 
The second woman was diagnosed with GDM in her second pregnancy and then 
went on to develop type 1 DM.
‘I think after I'd had the baby and I was still in hospital they were taking 
blood samples to check it out and they said it was OK and then a year 
later they called me back to have a check-up and I had diabetes.’ (T1 4)
The increasing incidence of GDM is concurrent with increasing rates of type 1
and type 2 DM and can be seen in National Statistics for all age groups
(Diabetes UK 2007). Type 2 DM is now being seen in a younger age group and
diabetes health professionals have noticed an increase in women being
diagnosed with DM in the childbearing years.
‘Yes, definitely the age range has changed, I've been doing this particular 
job since 1999 and I’m seeing the goalpost change, yeah, its quite scary 
that actually. People who aren’t much older than me now, whereas before 
it was people who would have had children, not quite my age but yes, its 
very different dynamic now so then I have started to sort of see more 
patients who would be thinking of child bearing. (HP 9)
This health professional was in her late 20’s and was comparing her age to that
of women being diagnosed with diabetes. Her feelings that it was ‘quite scary’
related to the high numbers of younger women she was now seeing with DM in
comparison to a few years earlier. The rise in type 2 DM has been attributed to
rising levels of obesity and another health professional felt strongly about the
connection.
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‘I think the other thing that is clearly a problem is the type 2’s. We’ve got 
fat kids everywhere. They become fat adults and we’re going to have lots 
of type 2 diabetes.’ (HP 4)
7.1.2 Feelings on diagnosis
Whilst talking about how they had been diagnosed with DM, two of the women
spontaneously spoke about their feelings at diagnosis. One a teenager felt up
and down in relation to coping with DM:
Tm still not, I wouldn’t say I was completely accepted of it, I kind of went 
through a stage when I was first diagnosed its was like ‘yeah, I can deal 
with this’, ‘this is fine’, and then 6 months down the line I found I got really 
depressed and was like ‘do I really have this for the rest of my life’, sort of 
the world had ended’. (T1 14).
Another woman who had been trying to become pregnant for four years was very
despondent at diagnosis.
‘When I found out I had diabetes I got very upset thinking that things were 
going from bad to worse -  as I was trying to get pregnant and then that on 
top!’ (T1 6)
The initial positive attitude followed by depression links to experiences of illness 
(Morse & Johnson 1991), and highlights the importance of support mechanisms. 
In Chapter Two there is discussion that diagnosis of a chronic illness such as 
diabetes is associated with feelings of despair and depression (Anderson et al 
2001) and women with infertility may also experience such feelings (Raphael-Leff 
1994). At the time of her diagnosis, this woman was concerned that she may 
never become pregnant as she had a chronic disease.
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7.1.3 Diagnosis and Family History
Several women mentioned that they had a strong family history of DM and 
discussed the extent of morbidity this had caused for those family members.
One woman, who had type 2 DM herself, related the history of DM within her 
family in a very matter of fact way:
There’s a history of it in my family -  my paternal grandfather who was one 
of 11, and I think we knew that 7 or 8 of them had it. A few of them died in 
the second world war at a young age so we wouldn’t have known whether 
they would have had it or not, and a couple of them have died of it, 
because they refused to take medication. So a couple of the women, one 
went blind and then died and one just lay down and died and brothers took 
medication for it. I know an uncle of my father had it and my father and 
his brother are glucose intolerant often when they get checked but they’re 
not quite diabetic and my sister’s glucose intolerant. They believe she 
may have had gestational diabetes. She had problem pregnancies.’ (T2 
16).
For this woman, so many of her family had DM or were being monitored for 
glucose intolerance that it was almost seen as more surprising not to have DM. 
The extensive mortality and morbidity as a result of DM appeared to be 
measured in relation to compliance with treatment, with those not taking 
medication ultimately dying.
This almost ‘expectation’ to develop DM because of a family history was shown
by other women who also seemed resigned to the fact that they had DM because
of a genetic disposition in their family:
‘I have a very strong family history -  one brother and one sister both with 
insulin dependant diabetes and my mother is insulin dependant.’ (T1 6)
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‘My father had thrombosis and he’s diabetic, and he’s a double amputee 
and his mother was a diabetic. She died at his birth and then a few years 
ago my mother became diabetic and she had to have an amputation and 
she died the following morning, and my step-brother, he’s a diabetic. So, I 
got close checks regularly.’ ( T1 15)
The morbidity associated with DM was experienced first hand by these women
but due to the focus of the study was not explored further during the interviews.
It may however be a factor affecting the attitudes and behaviour of the women in
relation to care and treatment of their own diabetes and how they perceive
themselves in relation to women who do not have diabetes. One Health
Professional felt that women diagnosed with diabetes considered that they were
‘different’ to the general population:
‘I think that they see themselves as less fit than the normal population, I 
think that although we try to get over that diabetes, although it’s a chronic 
condition, it is something that they can control and they could control well, 
but a lot of them don’t, but they still see themselves as being different in 
terms of how their body functions, and I think that may affect other things. 
Its not grounded on anything but I think that they just think that.’ (HP 15)
This health professional appeared to be of the view that women with DM should
be able to control their DM and control it to such an extent that they could remain
as healthy as the ‘normal population’. This in itself implies that women with DM
are different to a population without DM, but contradictory she then appears
surprised that that the women with DM should see themselves as ‘less fit’ or
‘different in terms of body function’.
201
7.1.4 Blood Glucose control
Women talked about coping with having DM particularly in relation to controlling
and testing their blood glucose levels and the negative impact of this on daily life:
One teenager referred to testing as a ‘chore’.
‘At first I felt quite positive about it and I thought yeah, I can do my sugar 
levels four times a day, that’s fine’, and now its like ‘I don’t want to’, so it’s 
a chore, it is an absolute chore but I know it’s not the end of the world 
now.’ (T1 14)
Although she had initially felt positive about being able to test her blood glucose 
regularly, this soon became a laborious task with negative associations. This 
lead to her not always testing regularly even though she knew it could cause 
problems.
‘I think maybe I’m choosing not to know it because I know I am naughty 
with it, with it sometimes, because I don’t always test my sugar levels and 
things like that, but I do know it can cause problems’ (T1 14)
One women said that she knew what she should be doing to control her glucose 
levels but did not always comply with this and did not need to be told or 
reminded:
‘It’s really hard to say because you know you should be doing it 
[controlling blood glucose levels] anyway, you don’t need anybody to tell 
you to take your insulin and to make sure your sugars are OK and you eat 
the right things. You know exactly what to do.’ (T1 13)
This concurs with the views of one health professional who suggested that
generally patients may have less than optimal blood glucose levels on a day to
day basis.
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‘Quite often, sad to say, quite often either patients or staff have accepted 
less than optimal control.’ (HP 10)
Some women also appeared to resent being asked about their DM and 
controlling their blood glucose levels:
‘If you have diabetes - it can get annoying people telling you all the time -  
you just want to be left alone’ (T1 4).
This woman appeared to have a desire not to be reminded that she had DM and 
just wanted to get on with her life and be ‘normal’. This was also seen in another 
young woman who felt that her family were ‘nagging’ her:
‘I get it from the family every day. ‘How are you feeling? Are your sugars 
OK?’ Most of the family, nag me quite a lot. I get that quite a lot. I don’t 
think there’s anything anyone can say. It’s up to someone to want to take 
care of themselves’. (T1 15)
This woman aged twenty two years felt that her family and others who were
concerned about her diabetes care were interfering and she clearly felt angry and
wanted to be left to cope with it herself, as if becoming rebellious in her attitude.
She knew that it was up to her to care for her diabetes, although hinting that she
might not always do this well. She also was resentful of ‘advice’ which made her
more rebellious in her approach to her diabetes care:
‘I’ve found I’ve got a lot of people who use scare tactics with me, saying 
‘Oh, this will happen. ‘You’ll go blind’. ‘You’ll die at like 50’. ‘You’ll get all 
these different diseases.’ Trying to scare me into taking it [insulin], but it 
was more just upsetting me than making me want to take it. It was more 
thinking ‘Well, what’s the point of taking it because I’m going to die at 50 
anyway.’ I may as well enjoy myself. That’s what I thought then 
obviously.’ (T1 13)
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Several health professionals were concerned that there were increasing numbers
of young women not taking their insulin and therefore having uncontrolled DM
because of body image and wanting to remain thin.
‘With teenagers we have a lot of psychological problems and eating 
disorders with the girls, because they learn that if they don’t give their 
insulin they’ll lose weight and that sort of thing.’ (HP 15)
‘Young girls can eat what the hell they want and don’t take their insulin. 
They don’t put on weight. So therefore they screw their eyes and screw 
their kidneys but they stay slim, OK, and we know of the mentality and of 
the image of being slim.’ (HP 4)
Teenagers and young women may be highly influenced by current ‘fashion’
trends and also by their peers to be slim and may therefore take risks with their
diabetes. This regard for body image was evident in one teenager who was
concerned that her friends thought she had developed diabetes because she
was overweight (in fact she had type 1 diabetes following a viral infection).
‘I’m never going to be a skinny minny -  never- and I wasn’t at the time 
and I kind of, before all the weight started coming off - Yeah, I didn’t want 
people to think it was because I was fat basically and then I lost all the 
weight then it all kind of goes back on straightaway because you’re 
obviously taking the insulin and stuff, so that was really hard to deal with 
because I was like ‘yes, I’m losing weight’, and then it all goes back on.’ 
(Tl 14)
This teenager was very happy that she was losing weight before her treatment 
with insulin and then was despondent that when she started treatment she 
gained weight again. It could therefore be tempting for teenagers to take a risk 
with their health and not take insulin.
One health professional spoke about how teenagers who had not controlled their 
DM went on in later life to have regrets when they developed complications:
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The last one we saw up on the ward she’d got a far amount of eye 
damage from her diabetes and she didn’t control it well as a teenager and 
now she really regrets it and that all seems to be the story, they all regret 
what they’ve done.’ (HP 15)
The resulting high blood glucose levels from lack of insulin can lead to
complications such as retinopathy, neuropathy and nephropathy and cardiac
disease (Taylor & Davidson 2007).
Professionals were unsure what could be done as they felt teenagers naturally 
take risks:
They don’t do it because they want to be normal. They absolutely want to 
be normal.’ (HP 4)
I don’t know if you can do (anything), its part of normal development isn’t 
it really. I think that’s just what they do and then they get out of it, you just 
have to try to look after them around it don’t you.’ (HP 15)
Risk taking behaviour is more common in teenage years (DHSS 2000) and this
was accepted by these health professionals as a natural phenomenon with the
teenagers just wanting to be ‘normal’ like their peers. It was seen that during this
phase, health professionals would need to adapt care given until the young
people matured and came out of this phase of their life.
Encouraging and maintaining good blood glucose control in general was seen as 
a difficult task by some Health Professionals:
‘It’s an ongoing battle really.’ (HP 16)
This health professional found she was constantly seeing women in the clinic 
with less than well controlled blood glucose levels and felt that she always had to 
encourage them to try to improve their blood levels to prevent complications in
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the future. To this aim it was seen to be important for care and advice to be
individualised to women’s lifestyles:
‘I can think of one lady who was a hairdresser, who, she just didn’t eat, 
she didn’t have regular mealtimes at all and sort of grabbing stuff and 
trying to get her to get into a routine, which is difficult because that wasn’t 
her life, that’s not what she was about, she was about up and about doing 
people’s hair.’ (HP 9)
The health professional recognised that DM care and advice needed to be 
tailored to suit patient’s lifestyles as in the case of this woman who was on her 
feet all day as a Hairdresser with no time for regular meals. The professional 
was trying to establish good blood glucose control but regular routines required 
adapting to this woman’s lifestyle.
7.2 Summary
In summary women with DM may have complex issues to deal with when 
coping with the condition. Their experiences appear to be mainly negative and 
they may suffer psychological morbidity such as depression. Some of the 
women had a strong family history of diabetes and type 2 DM was being 
diagnosed at a younger age. Blood glucose monitoring and glycaemic control 
was seen as a chore and often the women were not well controlled and were 
sometimes reluctant to comply with advice. This was particularly true of 
teenagers who tended to take risks and not always take their insulin as 
prescribed.
206
7.3 Diabetes Care
7.3.1 Models of Care
Recent modernisation within the NHS (DH 2000) has seen the delivery of DM
services change from being very secondary care focused to more of a primary
care model of care. Traditionally diabetes health professionals and diabetes
nurse specialists have been employed by the Hospital Trusts and seen patients
at hospital but this has evolved to patients being cared for by their GPs and
practice nurses with Primary Care Trusts (PCTs) also employing specialist
nurses to support DM care in the community.
‘Our GPs historically have tended to refer everybody into the hospital 
services however, that is going to change in the future because of GP 
enhanced service, which is the POT.' (HP10)
‘Some of them, the GPs surgeries are looking after type 1, people with 
type 1 diabetes and certainly doing their annual reviews.’ (HP 16)
Models of care vary and one hospital based DM service has recently transferred
into the PCT from the Hospital Trust to work with GP practices:
‘A lot of the practices have got their diabetes clinics going on but of 
course, things have changed since we’ve gone out so now if 
they’ve got problems, hopefully we get to see them, yeah. We’re 
sort of working co-jointly with the practices.’ (HP 13)
‘We run most of our clinics out in primary care now so we see 
patients with either type 1 or type 2 diabetes in the community and 
in their surgeries, so patients don’t have to come up here (to 
hospital clinic) any more. (HP 12)
DM care in the patients’ homes or GP surgery is in line with Government policy to 
provide access to services locally for people (DH 2000) and in other areas
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hospital based diabetes nurse specialists visit local GP practices to run a joint 
clinic:
‘In some practices we run a joint clinic so it will be a diabetes 
specialist nurse and a practice nurse or it will be a diabetes 
specialist nurse in a GPs running a diabetes clinic together and 
usually these clinics are complex, so patients who are perhaps on 
insulin, either with type 1 or type 2. There are also clinics where I 
might do my own complex clinic, specialist in practice in surgeries 
and yeah, so I might be running one and the practice nurse might 
be running one alongside and then we sort of liaise in between 
about any problems.’ (HP12)
Other professionals were still hospital based but share the care of women with 
diabetes with the GP surgery. The patients will be seen in both sectors with ‘joint 
care':
‘Some of them will be seen jointly by us once a year maybe and by 
their general practice once a year.’ (HP 11)
There was uncertainty by some health professionals about the benefits of the
changes and the rapid discharge of patients who had been admitted to hospital.
‘And they’re out so quick. This girl I’m seeing now. She’s 24 -  DKA. As 
soon as I go back to talk to her now she’ll be discharged.’ (HP 2)
The hospital based Nurse Specialist was concerned about the quick discharge of
this girl who had been admitted with diabetic ketoacidosis (DKA) implying that
she would not have time to re-establish good blood glucose control before she
was discharged to prevent reoccurrence.
Other health professionals were concerned that the care would depend on the 
GP Practice:
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The GP, it depends on the GP, some GPs are very good and up and 
running with diabetes and others have a more sketchy knowledge. '(HP 
15)
This professional was concerned that some GP s knowledge of DM care may not 
be up to date, as traditionally they have referred women with DM to the hospital 
services for care.
Another professional hoped that the change would encourage a more holistic
care for the patient:
‘Historically, in this area, the GPs have sort of separated themselves from 
diabetes and I feel that they, it hasn’t been very holistic really in this area, 
so hopefully that will change.’ (HP 14)
However she also felt that most of the services would remain similar with the 
specialist still seeing most patients with type 1 DM:
‘I think realistically that what will happen is that the service will actually tick 
along very much as it is now. When we’ve spoken to our GPs and our 
practice nurses, they all have sorted hinted, even the one’s that are very 
keen on the enhanced service, that things won’t change will they, you 
know, they’ll still be referring in the same sorts of people.’ (HP 14)
Women with DM experienced different models of care depending on where they 
lived:
One woman had experienced and was in favour of DM care solely given in 
General Practice:
‘My original GP, he actually wanted diabetes care to be handled properly 
so he set up a diabetic clinic within his medical centre, that ran really really 
well and I think that if you could get the level of care that you get at the 
hospital at your GP its much better, the hospital is so overloaded, if they 
could take it out into the community medical centres. (T1 10)
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This woman was keen to be looked after by the GP if the level of care was seen
to be as good as at the hospital. She inferred that care by the hospital was of a
better level than at the GP but that the hospital had too many patients to see. In
my observations of the clinics, women often had to wait two to three hours to be
seen by health professionals in the hospital clinics. However this did not always
mean that they had a long appointment time:
‘I think the difficulty is just that these places are so overworked, I mean 
you sit in the waiting room for an hour and a half to get five minutes with 
the doctor and actually when you’re only seeing him once a year you have 
more questions than that.’ (T1 10)
This woman would have liked a longer appointment time with the diabetes
specialists for her annual review of her diabetes. This review is recommended
as part of the NSF for diabetes (DH 2001) and has increased work loads for
diabetes health professionals who are monitored on targets associated with the
NSF.
Another woman agreed that it was preferential to be seen at the local GP 
surgery:
Tm trying to think if going up to the hospital did anything for me. I don’t 
think it did really. I mean, the consultant did give me those antibiotics and 
she did a lot of reassuring which is quite nice.’ (T2 16)
Reflecting on her visits to the hospital whilst pregnant, the woman could not see
benefits from attending there in comparison to her usual check ups her GP. She
liked being seen locally at the GP surgery and thought the service had improved:
‘It’s improved in our surgery on the whole because they’ve delegated a lot 
of things to the nurse and they’ve put up signs saying that if you’ve got 
any of the following see the nurse, not the doctor. But then the nurse is 
sometimes harder to see than the actual doctor.’ (T2 16)
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Practice Nurses and Nurse Specialists had taken over some of the specialist 
work such as DM care, from the GPs but ironically this often meant that it was 
more difficult to get an appointment as the nurses were so busy.
Some women only ever attended the Hospital services for their diabetes care:
The hospital clinic -  I am seen in the diabetes clinic every 12 
weeks or so by the doctor and nurse and dietician - it's quite a long 
appointment.’ (T1 7)
‘I normally go to the Diabetes Centre.’ (T1 13)
‘I am always seen at the hospital -  no I don’t go to the GP at all.’
(T1 1)
‘I go to the hospital clinic only now. I don’t really see the GP.’ (T1
4)
One teenager found the hospital ‘scary’ and was going to transfer to GP care:
‘I just go to the clinic (hospital), I’m thinking of going to my doctors though 
because its probably easier to get to things but I’ll see how it goes and its 
not quite so scary. ( T1 14)
The fact that the surgery was easier to access than the hospital and that the 
teenager knew her GP and found her less intimidating were positive reasons to 
transfer her diabetes care to the Primary Care Service.
Other women had joint care from both the hospital clinic and at the GP surgery:
‘For my diabetes I tend to come here [hospital clinic]. I do see my GP also 
because she does a clinic every couple of weeks - In the surgery, so I like 
to make an appointment to see her, just to let her know how things are 
going, and if I’ve got any worries to catch them sooner rather than later 
(T1 15)
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This woman found this joint care reassuring and was happy to attend both 
services; however another woman found this joint care to be too many 
appointments:
They [GP] do invite me, but I ring them and say Tm happy. I’m doing 
twice a year at the hospital and it seems overkill to be going up there as 
well.’ (T2 16)
Her approach was that she was being seen by a specialist service at the hospital 
and therefore she did not require the GP to monitor her DM as well. However the 
GP may have contacted her as part of a holistic care service or because DM care 
is part of the Quality Outcomes Framework where GP practices can gain points 
and payment for care. Two students’, who were living away from home at 
University, also stated that their GPs were keen to monitor their diabetes care.
‘As I am at university, the GP here kind of insists on looking after my 
diabetes but at home I go to the hospital not my GP. So I have two lots of 
annual checks and am seen in between as well but I am OK.’ (T1 2)
‘I am seen in the diabetes clinic or by the GP at University and both 
sometimes - they all like to see me! Sometimes it seems crazy going 
again and having the same review.’ (T1 8)
It seems that these women did not resist having the ‘extra’ check ups and even
though one found it ‘crazy’ they complied and attended for care.
With the various models of care and services providing care it appeared to be
possible that some women may slip through the net and not receive DM care.
‘I didn’t actually see anybody for nearly 2 or 3 years at one point, I actually 
had had enough, so I kind of went into a bit of rebellion mode, so I was 
very happy not even to be reminded, so its not, nothing is ever anybody’s
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fault is it, we all have to take responsibility and I just took a holiday 
(laughs), like you can.’ (T1 10)
This woman with type 1 DM had been seen annually by the GP but moved house
and got ‘missed off the list’ for annual review reminders from her new GP. At this
point she felt happy not to be chased up and just took a break from having
regular care. She recognised that it was her responsibility and not that of the GP
surgery to register her for care and inferred that although she took a holiday’ this
break from care was not good for someone with diabetes.
7.3.2 Co ordination of care
With the different models of service provision some women felt that it was
important that their care was holistic and coordinated:
‘Here Dr x actually looks at my diabetes, he looks at the thyroid, he looks 
at the anemia, he looks at the connection that could be going on between 
all of them.’ (T1 10)
It was seen as important by this woman for her other health concerns to be
assessed in context of her DM which had not happened when she had attended
for a recent appointment.
One woman noted differences in the co ordination of care from Children’s 
services to that of adult DM care:
‘At the children’s clinic I saw the same person for years -  now I am at the 
main clinic I see a different person each time who doesn’t know me or my 
history and it is very impersonal -  and I find it quite pointless really -  It is 
completely different to seeing the consultant who would know you. They 
flick through your book and do the HbA1C but I don’t know.’ (T1 2)
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This woman had built up a relationship with the health professionals caring for 
her DM during her child and teenage years. The transfer to the adult services 
had seemed impersonal and the care uncoordinated.
Another woman was frustrated that the hospital and GP did not always agree on 
care required:
‘So for instance when I went to the hospital in March they said my 
cholesterol was slightly high and that they’d clock it six months later and if 
it was still high they’d put me on tablets, but when my doctor got that 
report he didn’t like it and wanted me on the tablets straight away and 
made me have a blood test and put me on the tablets.’ (T2 16)
This GP disagreed with the DM clinic decision to monitor the patient’s cholesterol 
in another 6 months and felt that his patient should be treated for the condition 
immediately. The woman complied with being ‘made’ to have a blood test and 
then take medication for high cholesterol but was frustrated at the lack of 
congruence of her DM care. This compliance with medical advice and testing by 
patients’ and relationships with health professionals is discussed in Chapter Ten.
The focus on more localised care in the Primary Care Trust (PCT) was felt by
some health professionals to have led to challenges in liaison and team work:,
‘Being employed by the PCT as opposed to the Hospital Trust does cause 
slight differences and I’ve never felt we’ve had perhaps had a team 
approach that we wish for, to be quite honest.’ (HP 9)
This health professional felt that there needed to be more of a team work
approach to DM care. The services being delivered in different ways and in
Primary Care may mean a new team and different ways of working with GPs and
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Practice Nurses. Another health professional fe lt that the health service worked
in such a way that ‘teams’ were in fact often professionals working individually
within a specialty with links of association:
‘Just because you work in the same specialty but different department, it 
doesn’t mean to say that you’re a team. I would say that we’re more 
associates, because we associate with each other. But I think that’s the 
way the health service is.’ (HP 2)
This health professional worked in the hospital Trust seeing patients’ with DM 
who were admitted with acute exacerbation of their condition or as an emergency 
and in essence she then had a liaison role with the other diabetes health 
professionals who she felt she associated with. This concept ties in with the idea 
of liaison that another professional mentioned:
‘I feel that we work closely together but normally just with certain patients 
really and I think our liaison is sort of one of our strengths and things.’ (HP 
1)
The communication between health professionals about certain patients was 
seen to be strength of the service. The health professionals appeared to have 
individual roles and case loads and then referred patients to each other as 
necessary. A patient may be referred to the dietician for specialist dietary advice, 
or a pregnant woman to the diabetes nurse specialising in antenatal care.
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7.3 Other support mechanisms
As well as contacting Health Professionals some of the women spoke about and
using other mediums for advice and information. One woman felt that she would
have liked a ‘helpline’ to ask questions and although she had tried NHS Direct
she felt that they were not able to answer specialised queries.
‘I have used NHS Direct but they’re kind of very standard questions; I feel 
like I wouldn’t need to go and see the GP or even come here [hospital] as 
often if there was somewhere you could go to ask some of those 
questions.’ ( T1 10)
This woman felt that a telephone or internet help line for clinical questions 
relating to her DM would prevent her from taking up appointments with health 
professionals. Many GP surgeries are now offering telephone appointments 
which may have been relevant for this woman.
Another found support from the charity Diabetes UK;
‘I was always logging onto Diabetes UK and everything, so, I’m a member 
and get the magazine and stuff now which I find, its really interesting to 
see that there are other people that think like you and have similar 
problems to you, so that’s really nice’ (T1 14)
Diabetes UK provides advice and support to its members and this teenager 
found the organization helpful in supporting her in coping with DM.
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7.4 Summary
Recent policy has seen DM care moving towards a Primary Care focus with the 
GP surgery providing more diabetes care either autonomously or with support 
from diabetes specialist services. There appears a need to ensure co-ordination 
of care including the transfer from children’s services into adult services and for 
pregnant women into antenatal services. Health professionals had some 
concerns about team working in new structure but felt that they were good at 
liaison.
7.5 Conclusion
This Chapter includes the findings from analysis of narrative in two major 
themes; Coping with diabetes and Diabetes Care. These data have highlighted 
complex issues that women with DM have to cope with in everyday life over and 
above the general population whilst ‘living with diabetes’. These include coming 
to terms with and coping with a chronic condition that needs constant vigilance in 
regards to diet, blood glucose testing and medication. Glycaemic control was 
seen as a chore and often the women and particularly teenagers were not well 
controlled and were sometimes reluctant to comply with advice. It is 
unsurprising that women with DM may have negative experiences and that they 
may suffer psychological morbidity such as depression.
217
Organisation of services varied in each local area but was becoming more 
Primary Care focused. This had meant challenges for liaison between DM and 
primary care services and this impacted on the care women received.
The above issues are important when considering prevention of unplanned 
pregnancy for women with DM as they may affect the behaviour and attitudes of 
women with DM and the health professionals caring for them and these will be 
discussed in Chapter Ten. The next chapter looks at findings from semi 
structured interviews in relation to DM and Pregnancy.
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CHAPTER EIGHT
Findings Of Semi Structured Interviews:
Diabetes and Pregnancy
8.00 Introduction
This chapter presents findings from the narrative relating to the main focus of my 
study; issues around pregnancy and planning for pregnancy and includes the 
following categories: Knowledge and expectations of pregnancy and DM; 
Glycaemic control in pregnancy; preconception care and; care in pregnancy. 
These topics were of particular interest in relation to the case; prevention of 
unplanned pregnancy in women with type 1 or type 2 DM and so the chapter is 
substantial in comparison with previous chapters presenting findings. As 
discussed in the structure of the thesis in Chapter One Section 1.3 the 
interpretation of findings from this chapter will be mainly be discussed in Chapter 
Ten which integrates findings from all three phases of the study.
8.1 Knowledge of pregnancy issues for women with DM
The following section includes narrative and responses from the women in reply 
to being asked what they had heard about DM and pregnancy in general and 
what specific advice they had been given in relation to DM and pregnancy before 
they became pregnant.
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8.1.1 Expectations of pregnancy for women with DM
Prior to first pregnancy, some women had negative perceptions in regard to DM
causing complications during pregnancy or with the baby. Some of these
perceptions stemmed from information or experiences from the past:
‘I was told (by doctor) when I was 15 that I should not have children and I 
remember thinking that it didn’t have any relevance at the time -  I was 
only a kid and when I got pregnant I have memories of worrying that they 
would be distorted (sic) and diabetic.’ (T1 1)
This woman now in her 40’s had been told when she was a teenager with DM 
that she should not have children. In the past before improved DM care and 
medication, pregnancy for women with DM often resulted in high morbidity and 
mortality. When this woman did become pregnant she was therefore worried 
about the baby having abnormalities and DM.
Another woman reflected on her childhood experience of having a neighbour with 
DM:
There was a woman who lived on the estate that I lived at when I was a 
child, she’d got diabetes and she used to inject with this great big 
contraption, used to shoot the syringe into her arm, absolutely terrifying 
and she did have two children but I remember my Mum saying how hard it 
was and it was unusual she’d been able to get pregnant and there was 
just this whole kind of horror kind of associated with the whole thing. (T1 
10)
This woman was left with frightening memories from her childhood of DM. This 
was due to a neighbour with the condition using a huge syringe to inject insulin 
and stories of the problems and difficulties in respect of pregnancy for the 
neighbour. This had lead to an overall pessimism and negativity associated with
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pregnancy for someone with DM. This negative association in relation to 
pregnancy was also borne out by another woman:
‘I was told that the baby would be big and I would be more likely to
lose it due to high blood sugars.’ (T1 3)
This woman had been warned that she may have a large baby and that she may 
miscarry due to poor glycaemic control. As has been discussed in the literature, 
Macintosh et al (2006) found a fivefold increased risk of stillbirth, a threefold 
increased risk of perinatal mortality and a twofold increased risk of fetal 
congenital anomaly in women with DM. Women with DM may have large babies 
with macrosomia due to poor blood glucose control and this increases the risk of 
caeasarian section and also birth injuries such as shoulder dystocia with the risk 
of Erb’s palsy (Taylor & Davison 2007).
These negative experiences in relation to pregnancy for women with DM may 
have profound psychological affects for these women with DM which are 
discussed in the literature by Snoek (2005). It has been shown that by 
preconception care with tight glycaemic control from conception, it is possible 
that such morbidity could be prevented or minimised (Taylor & Davison 2007). 
However as will be discussed in the next section many women are still unaware 
or do not manage their glycaemic control prior to conception.
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8.1.2 Pre conception knowledge and advice
The women were asked at interview about any specific advice about pregnancy 
that they had received from health professionals. Most comments were in 
relation to the tight control of blood glucose:
The advice I had was not to get pregnant until my sugars were under 
control.” (T1 13)
‘I can remember once someone I was talking to said to keep your blood 
sugars between 4 and 7 if you were pregnant so that was sort of stricter. 
But, no apart from that, no nothing.’ (T1 2)
The health professionals had given advice about the importance of having good
glycaemic control before conception and during pregnancy and as seen in
Chapter Three Section 3.2.4.2 this has been discussed in the literature in
respect of preventing fetal anomalies and complications in pregnancy. This will
be discussed further in Section 8.7 (blood glucose control) as a specific topic
within the findings in pregnancy. The health professionals also mentioned that
they would advise about retinopathy checks:
‘I usually discuss that with them, that they need to have their eyes 
checked and that it would be more frequent throughout their 
pregnancy.’ (HP 1)
However none of the women interviewed mentioned any reference to receiving 
information about eye checks in relation to preconception or pregnancy care.
One woman had been given advice by her doctor that it was a good time for her 
to conceive:
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‘In fact on one occasion I saw the doctor and he said ‘Look, your control is 
very good, so if you’re thinking about having kids then now is an 
appropriate time.’
I was really quite impressed ... That must be a very difficult thing for a 
doctor to say to someone. Obviously he knows my background. He knew 
we’d been married for a few years and that must have been possibly a 
year before x was conceived. So we kind of sat and had a discussion and 
talked it through.(T1 11)
The woman appeared very complimentary about her doctor, discussing the topic
of her ‘having children’, which she felt would be a difficult thing for him to discuss.
She felt that he was able to raise the topic because he knew her marital situation
and he had made the assumption that the couple would be planning to have
children in the future. The doctor had noted that her glycaemic control was
stable which meant that there would be less risk to the fetus and mother if
conception occurred. The woman was receptive to the information and a
discussion had taken place.
Other women were not so receptive and although the topic had been broached
by health professionals at consultation they did not want to discuss it:
‘well they ask you if you are thinking of getting pregnant - but I am not - 
well not yet - 1 am getting married this summer and we do want children 
but I was thinking of waiting a while yet - we have only just bought a 
house’ (T2 9)
‘No, they just, when I was first diagnosed they just said that its very 
important that if you are thinking about getting pregnant to talk to a doctor 
before you start trying to, I just said no, thank you’. (T1 14)
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Neither of these young woman felt that pregnancy was currently relevant to their 
situation and therefore did not want to discuss the topic with the health 
professional.
Other women could also remember they should seek advice from a health 
professional if they were thinking of becoming pregnant:
Oh - 1 think they might have said come back if you ever decide that is 
what you want to do sort of thing [get pregnant]’.
Q: Was that at the diabetes clinic?
‘Yes I think when I was diagnosed.(T1 8)
‘Well nothing much -  x,- when I told her I was getting married, did say to 
talk to her if I wanted to get pregnant as there could be complications but 
that’s all really.(T2 9)
Another woman had gained information from written media and health
professionals:
‘Maybe the doctor, GP ... it’s just something.. I’d already had lots of 
information with the British Diabetic Association, their magazines. I’d see 
a leaflet and I’d picked it up.’ (T1 15)
Although some women recalled being given information or had read or sought
advice themselves, many women when asked about knowledge of pregnancy
issues for women with DM or of advice that they had been given, had no
recollection of any connections between DM and pregnancy or having being
given any advice and many comments were along the lines of:
‘No, nothing at all.’ (T2 16)
‘No nothing really that I can think of.’ (T1 3)
‘Well nothing really -  how do you mean?’ ( T1 7)
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Other women when diagnosed as being pregnant were surprised by the reaction
of the health professionals caring for them:
‘I had no knowledge of affects on getting pregnant at all - when I 
conceived my first son diabetes to me was just something I had and I 
didn’t think that it had any affect on pregnancy and I went to see my 
doctor and then at my next diabetic clinic when I told them - they went 
into panic mode.’ (T1 5)
When this woman conceived she had no knowledge of the complications that her
DM could cause to the pregnancy. DM was a condition she ‘lived with’ and it
appears that the GP did not recommend any specialist pregnancy care as the
woman waited until the next appointment with the DM clinic to be seen. The
diabetes professionals were obviously concerned knowing that the pregnancy
was well established and the risks involved and as she saw it ‘went into panic
mode’. She went on to say that despite planning her pregnancy she could not
explain why she did not think about her DM.
‘I wasn’t young and naive and I did read books about getting pregnant -  
come off the pill 3 months before -  take folic acid etc but I did not link the 
two -  diabetes and pregnancy -  I cannot explain why that happened.’ ( T1
5)
Another woman had routinely gone to see the midwife when she found out she
was pregnant and was urgently referred for specialist care at the diabetes centre.
‘No I hadn’t [any knowledge] actually, I didn’t have a clue. I found I was 
pregnant and saw the midwife and she advised me straightaway - get in 
touch with the diabetic centre.’ (T2 12)
Some of the women felt that health professionals should give more advice about 
pregnancy to women with DM. One woman had not realised that there may be 
differences in her pregnancy care due to her DM:
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‘Well-1 feel that they could be a bit more on the ball -  I didn’t know the 
questions to ask so you don’t ask them -  I thought everyone went to the 
hospital that often and having all these tests I just blindly went along with it 
-  all of this stuff that is more likely to happen to you because you have 
diabetes - it should be outlined more so you are more aware of it. There 
were lots of appointments. It was only at the antenatal group when the 
others were talking about GTT [Glucose Tolerance Test] - I thought oh 
well they’d got what I’ve got -  I shudder now when I think about it - i t  was 
all a bit of a mess.’ (T1 3)
This woman felt that the diabetes health professionals had not made her aware 
of how DM could affect her pregnancy. She was concerned that her lack of 
knowledge could have caused complications. She had thought all the many 
appointments and scans were normal care in pregnancy and it was only when 
DM was discussed by women at her antenatal class who had been referred for 
glucose tolerance test (for gestational diabetes) that she began to realise what 
complications could have occurred.
It appeared that a majority of the women had not asked health care professionals
for advice about planning pregnancy and I asked if there were any reasons for
this. Some women said that they just didn’t think about asking for advice at the
time and some now felt ‘lucky’ that all had turned out well.
I think it is difficult -  you don’t ask or take things in until it happens do 
you? It wasn’t something I had even thought about at the time -  I was 
fairly well controlled - 1 was quite lucky and they were all fine -  lucky 
really’. (T1 4)
This woman felt that she would never have thought about asking for 
preconception advice or take in advice offered as it would not feel relevant until 
she was thinking of pregnancy.
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Another woman became pregnant in between the annual visits to the diabetes 
centre:
Well I saw them [health professionals] infrequently about once a year and 
when I saw them it wasn’t on the agenda - so it happened in the mean 
time and I wouldn’t have made a trip just to talk about that - actually I 
would now but not then -  you just go into it without thinking about it.’ (T1 
3)
Asked as to why she would now, she discussed her naivety of the situation:
‘I am older now and it scares me to death -  I am older and would worry 
about my health now -  I definitely would now -  I was naive and stupid!’
(T1 3)
When she was younger she felt that she did not worry about her health and that 
she had been naïve just getting pregnant without thinking about her DM.
There were different views on when health professionals should give information
about preconception care and pregnancy to women with DM. One woman felt
that earlier was the best option:
‘I think maybe its something you start talking to women in their 20s, 
nobody ever discussed having children with me in my 20s because they 
just assume you’re not going to, you don’t ask the question they assume 
you’re not going to and of course you don’t ask the question because 
mentally you’re not ready but its almost like you have to sow the seed...’ 
(T1 10)
The woman felt that although someone may not be ready to become pregnant 
and so may not ask questions about pregnancy, health professionals should give 
information to younger women with DM to put the idea that planning and care is 
needed before pregnancy. The woman felt that health professionals might
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assume that women in their 20’s were not ready to be pregnant. This may relate 
to the fact that women in the general population are tending to leave childbearing 
to later in life however in my questionnaire study of women with DM the average 
age of first child was 26 years.
One of the teenagers felt that she would have liked more information and agreed 
that information should be given before women are thinking about pregnancy.
‘it would be nice to know what happens when you’re pregnant and things 
like that because it is just interesting, so I think maybe if they did tell you 
more about [pregnancy] you would be more prepared for it rather than 
when you’re actually to have a baby and you kind of only start thinking 
about it then and then you’re a bit like ‘oh God!’, but then I understand why 
they don’t because obviously its not right for me at that point in time so 
they may see it as a waste of time but I would just find it interesting to 
know.’ (T1 14)
Although she thought that having more information was interesting and would 
make her more prepared for pregnancy, she also could see that the health 
professionals might not see it as relevant to her as a teenager and therefore it 
might be seen as a waste of time.
Another woman did not agree as she was not sure that she would have liked 
early information:
‘Until you think you are pregnant you don’t think about it -  I don’t think I 
would have taken kindly to anyone telling me or asking about pregnancy 
when I was at University -  it’s a tough one really.’ (T1 4)
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This woman acknowledged it was a difficult decision as to when to give 
information about pregnancy as it is not something that women think about until it 
becomes relevant. She did not think that she would have liked a health 
professional to discuss pregnancy with her when she was younger.
8.1.3 Summary
This section has presented the findings about knowledge of pregnancy issues for 
women with DM including preconception advice. Women had a range of 
expectations in relation to pregnancy with some experiencing concerns about 
complications and others not appearing to be aware that having DM could affect 
pregnancy. Health professionals felt that they gave all women preconception 
advice, particularly in relation to tight glycaemic control but it appeared that some 
women had no recollection of being given preconception advice. Women 
admitted that they were not always receptive to such information and that it 
needed to be relevant at the time. A majority of women had not asked for advice 
from health professionals prior to pregnancy, although some women said that 
they would have liked more information. The interpretation of these findings will 
be discussed further and integrated with data from Phase One and Two of the 
case study in Chapter Ten.
The next section will present findings from the perspective of the Health 
Professionals involved in the care of the women with DM.
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8.2. Knowledge and giving advice - The health professionals view
8.2.0 Introduction
During the interviews with the health professionals I asked about what 
information they gave to women in relation to preconception care and when and 
how this information was delivered. The following section presents the findings.
8.2.1 Information and Advice.
The health professionals talked about the messages that they tried to give 
women of childbearing age and most were focused on ensuring good glycaemic 
control:
The message that we’re trying to get across is that they need to have very 
good control of their diabetes before they get pregnant’ (HP 11).
‘I think that everybody ought to at least know that they need to have good 
control before they even entertain the idea of getting pregnant’. (HP 8)
The concept of achieving ‘good glycaemic control’ before pregnancy was the 
message that health professionals said that they regularly gave to women of 
childbearing age attending DM care. Indeed as data in Section 8.1 suggests, the 
women with DM who remembered being given preconception information had 
knowledge of this concept. However in Section 8.1, data also show that some 
women had no recollection of being given such advice, or admitted lack of 
receptiveness to such information. For some women being asked about 
pregnancy was a personal issue which they did not wish to discuss. This 
highlights the need to review how health promotion information is presented by
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health professionals as recent guidelines (DH 2001 a, CEMACH 2007) 
recommend that all women of childbearing age are given preconception 
information annually and health professionals may need to be sensitive to an 
individual woman’s receptiveness when delivering preconception advice. This 
issue is also raised later in this Chapter in Section 8.2.2 where the theme ‘timing 
of advice’ is considered.
Other professionals stressed the need to ensure that women were in good
general health before conceiving and that they were taking the recommended
dose of folic acid:
‘We need to make sure that they are in general good health and their 
kidney function is good, their blood pressures are good and that they’re 
taking 5mg of folic acid.’ (HP 11).
They need to have five milligrams of folic acid rather than the four 
hundred micrograms over the counter.’ (HP 8)
These professionals appeared to have a medicalised approach to women’s 
health in relation to DM care and this concept is discussed further in Chapter Ten 
Section 10.2.2. Kidney function can be damaged by DM and nephropathy is a 
complication which can worsen in pregnancy as shown in the literature in 
Chapter Three Section 3.2.4.1. The Health Professional’s recommendations 
regarding the higher dose of folic acid is presented later in this chapter in Section
8.3 and is described in the literature review Chapter Three.
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One professional mentioned she would also give the ‘standard advice’ given to
any women planning a pregnancy:
Well, I do the standard stuff. Plainly smoking. I tell them to get their 
rubella status checked. That’s about it really, isn’t it?’ (HP 8)
This Health Professional saw ‘standard advice’ on preconception as information 
about not smoking which has been shown to cause fetal morbidity and mortality 
(Delpisheh 2006, Dobson et al 1998) and ensuring that women had immunity to 
rubella, which can cause blindness, deafness, mental incapacity and cardiac 
anomalies in the fetus if contracted during pregnancy (Brundage 2002, Miller 
1990). However as shown in the literature in Chapter Three there are many 
more topics to be included in preconception care including dietary advice and 
folic acid supplementation, alcohol, infections, environmental and occupational 
hazards and medication review and that these issues may need to be discussed 
with women before conception.
Some of the health professionals gave information about why pregnancy care for
women with DM would be a bit different to that of the general population:
‘It’s just a sort of general chat about diabetes and pregnancy and why it is 
necessary to be a little bit different. Talk about delivery and the fact that 
you deliver around thirty eight weeks here, just so that they know what 
they’re letting themselves in for really.’ (HP 16)
The differences included that there would be more appointments and scans and 
that the baby was likely to be delivered by thirty eight weeks because of size and 
other complications occurring late in pregnancy. There are currently no national
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policies or guidelines recommending care during pregnancy as highlighted by 
CEMACH (2007) but the review by the National Institute for Clinical Excellence 
due for publication in 2008 is due to make such recommendations. (See Chapter 
Twelve Addendum).
The professionals highlighted that women who did attend for preconception care 
often had complications of DM which had been the trigger for them to seek 
advice.
‘I would suggest that most of our pre conceptual at the moment have 
other health problems as well, which probably were the triggers for them 
seeking advice, so for example we had somebody on ACE inhibitors, who 
since has had to come off metformin and seen me - quite a bit of work, so 
it is looking at the whole medication picture, looking at diet and weight, 
blood glucose control obviously. (HP16)
This professional talked about an important part of preconception care being to 
prevent fetal abnormalities from teratogenic medication such as changing Oral 
Hypoglycaemic agents and antihypertensive medication and this has been 
discussed in Chapter Three Section 3.3.4. It can be seen there are complex 
factors involved in preconception care and in order to promote healthy maternal 
and fetal outcomes, holistic assessment of women planning pregnancy by health 
professionals is vital.
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8.2.2 Timing of advice
The professionals discussed when preconception advice might be given to
women with DM and by whom and ideally health professionals wanted to discuss
preconception issues with women well before they were pregnant:
‘Well the first thing is that we need to see them pre pregnancy, what we try 
to do is to encourage them to come and talk to us if they are planning a 
pregnancy.’ (HP 11).
All of the diabetes centres offered pre pregnancy appointments where the
women were seen by a Consultant Obstetrician, Midwife or Diabetes Nurse
specialist depending on the centre. CEMACH (2007:7) recommend that all
women with DM are provided with specialist preconception services with access
to all members of a specialist multidisciplinary team’. In some of the centres the
initial ‘information’ appointment was then followed up by a series of consultations
‘I might then go on and see them the next three or four times before they 
conceive, possibly, particularly if they’ve got to work at their control. So it 
won’t necessarily be a one-off appointment. It may be that I see them two 
or three times. Sometimes you see them six to nine months before they 
actually get pregnant, you know. Rejoice with them and then you see 
them every two weeks.’ (HP 1)
Here the women worked with the Diabetes Nurse Specialist to obtain good 
glycaemic control and were seen regularly until a woman conceived. However 
the preconception services were not well attended and the diabetes 
professionals confessed to seeing mainly motivated women at these 
appointments.
There’s the young, sort of motivated-type ones who, yes, do sort of plan 
it. Some of our other younger, less-motivated, just get involved in a 
relationship or aren’t really thinking about pregnancy yet -  we get quite a 
few of those, and their control is really quite poor’ (HP 7)
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One of the doctors felt that the women were not always aware that preconception 
services were available:
‘I don’t think that we advertise our pre-conception services to the audience 
who need to know it. I mean, the GPs know that we do it and stuff, but 
you know -  I’m hoping that we’re going to start taking pictures of our 
babies, and putting them up on the noticeboard up here, saying ‘If you 
want one of these, then talk to us first.’ (HP 8)
The doctor had the idea of attracting attention to the topic of preconception care
by displaying photographs in the clinic of babies that had been born to women
with DM.
The timing for giving preconception advice could be difficult as the women may
only be seen for an annual review and then become pregnant in between times:
‘they’re probably only seen here once a year, so you need to remind 
people that planning a pregnancy is important and turning up and saying 
‘by the way I’m twelve weeks pregnant’, is not such a good idea.’ (HP 11)
This concurs with data in Section 8.1.2 from the woman who became pregnant in 
between annual visits to the diabetes centre and had not thought it necessary to 
contact the diabetes professionals. This highlights the need to examine ways to 
raise the importance of the concept of preconception care with women of DM and 
challenges whether current recommendations to give preconception advice 
annually to all women of childbearing age (DH 2001 a, CEMACH 2007) is the 
best way forward.
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Some professionals gave information to everyone in the hope that they would
remember to see the nurse when they wished to become pregnant:
I usually try to tell everybody, but then it’s very much in the forefront of my 
mind, and I usually say to them ‘Look, you know, it’s probably not relevant 
now, store it in the back of your brain somewhere, but if ever you’re 
thinking about getting pregnant, come and see us.’ (HP 1)
This health professional acknowledged that the information might not be relevant 
at the time but that it might be stored for later use. However another felt that 
unless it was relevant at the time the women would not take in the information:
‘if you’re thinking Tm not going to get pregnant anyway’, you don’t bother 
listening to that, I do it myself, I don’t listen to stuff that I know isn’t going 
to be appropriate for me, I think -  why would you remember in a couple of 
years time if you suddenly think Tve met this man and I’m going to have a 
baby’, ‘oh, I must get in touch with the nurse’ -  its not going to happen.’ 
(HP 5)
The decision of when to give information was seen as difficult if women were not 
currently planning pregnancy as they may not retain it and in addition there were 
some women who could be upset by being offered preconception advice at all:
‘And the difficulty is as well, you have some people who definitely don’t 
want to get pregnant or have had issues and problems with fertility and 
maybe you don’t know about it, I don’t think it happens to us as the nurses 
so much because we tend to know the people a bit more, but certainly the 
doctors have offended quite a few people, just because they don’t realise 
you know, they’re trying to do their best by asking and then they upset 
people and you can’t get it right all the time can you.’ (HP 16)
This health professional recognised that some women with DM who perhaps had 
fertility problems or who were not planning a pregnancy, were sensitive to being
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given information about preconception care. She felt that the nurses tended to 
have more of a relationship with and know the situation of the women but the 
doctors may not and had upset some women by asking about pregnancy. This 
concurs with narrative from some of the women with DM in Chapter Seven, 
Section 7.1.4 who felt they were often ‘being nagged’ about their glycaemic 
control or felt pregnancy was not relevant to them or that they would not want to 
discuss such a personal issue as pregnancy in an outpatient clinic. This again 
highlights the challenge of giving preconception advice to all women of 
childbearing age (DH 2001a, CEMACH 2007) and the need for individualised 
care.
8.2.3 Summary
The section has described the advice given by health professionals about 
preconception issues including the need for good glycaemic control prior to 
pregnancy, folic acid and dietary advice and review of medication. Variations in 
knowledge by health professionals are seen and the complexity of the factors 
involved and the need for holistic assessment is highlighted.
The findings have raised the need to review how health promotion information is 
presented by health professionals as recent guidelines (DH 2001 a, CEMACH 
2007) recommend that all women of childbearing age are given preconception 
information annually. It would appear that health professionals may need to be 
sensitive to an individual woman’s receptiveness when delivering preconception
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advice for it to be of benefit. The next section will consider narrative in relation to 
prescription of folic acid.
8.3. Folic Acid 
8.3.0 Introduction
The health professionals were asked about their knowledge and the advice they 
gave in relation to women with DM taking folic acid prior to and during 
pregnancy.
8.3.1 Advice given
The importance of preventing neural tube defects by taking folic acid prior to 
pregnancy and during the first twelve weeks of pregnancy was mentioned by 
most health professionals. One professional said that they did not mention the 
topic at all and two did not have knowledge of the recommended dose.
CEMACH (2007) recommends that a higher dose of 5mgs of folic acid is taken 
by all women with DM planning pregnancy and this must be prescribed, unlike 
the 400 microgram dose which can be bought over the counter. However 
amongst some of the health professionals there were differences in the dose that 
they advised.
‘Once they’ve got good control, then we will suggest they take the normal 
folic acid dose (400 micrograms). If they have poor control, then we 
usually prescribe 5mg of folic acid’ (HP 7)
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The policy in this particular diabetes centre was that if the HbA1c was under 7%
then the 400 micrograms dose was recommended and 5mgs if the HbA1c was
over 7%. Other centres reflected the policy of CEMACH (2007) and the NSF
(DH 2001 a) and recommended the 5mgs to all women with DM planning
pregnancy. These variations in clinical practice will be discussed in Chapter Ten.
The diabetes centres varied as to whether the women referred to them with DM
were taking folic acid already. Some professionals mentioned that many women
referred with type 2 DM from primary care were not taking the 5 mg dose:
‘Yes, I would say the majority don’t. Quite a number of them will take 400 
micrograms because they’ve decided themselves and they’ve been aware 
enough, but then we have to write to the GP and ask them to prescribe the 
5mg.’ (HP16).
The women had bought the over the counter dose and the diabetes professionals
had to advise the GP to prescribe the higher 5mg dose. However at another
centre the GPs appeared more aware and a higher percentage of women were
prescribed the recommended dose.
‘Our first contact would check for that and in my experience 99% of people 
have been prescribed that and are on it. So I think people are switched on 
to that, but again, it would be nice to implement that early and the co­
ordinator should make that happen; but there are a small number of 
people who clearly hadn’t been prescribed it. (HP3).
This diabetes professional thought that the GPs were well informed about the 
need for higher doses of folic acid. He hoped that by having a pregnancy co­
ordinator responsible for DM and pregnancy to liaise between the centre and the 
Primary Care Trust that awareness would increase.
239
Another professional thought that the women were aware of the need to take folic 
acid in general:
‘Yes, I think that the message has got through generally, yes. Whether 
women with diabetes know they need to have a prescribable amount is 
still debateable but yes, I think it is getting through. They always claim 
that Bianca from EastEnders did the best for us, NTD babies with her, so 
no matter how much money we throw at things perhaps certain things are 
a better way of getting it across (laughs).’ (HP 9)
It was suggested that TV soaps such as Eastenders had helped to promote
issues such as the need to take folic acid before and during pregnancy although
the professional was not convinced that women with DM knew that they required
a higher amount which could only be obtained on prescription.
This was borne out by the women interviewed who were asked if they had taken
folic acid and if so which dose. Although some of the women had not taken it at
all, many of the women knew about taking it but had bought the lower dose of
400 micrograms from the chemist:
‘I just took the normal dose of folic acid from the chemist.’ (T1 4)
‘I did take it, but I went out and bought it. I bought the Pregnacare.’ (T1 
13)
‘Yes I did take it, but not an increased dose’ (T1 10)
Some women had been told by health professionals to take the increased dose:
‘No I took the normal dose but when I went to the antenatal clinic they told 
me to take a higher dose’. (T1 6)
‘No I didn’t take folic acid but I went to see my GP and they prescribed 
folic acid but not before I was pregnant.’ (T1 3)
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In general the requirement for a higher dose of folic acid was not well known
amongst the women with DM although the health professionals appeared to have
good awareness and encouraged prescription once they were seen in
pregnancy. One woman mentioned how her diabetes nurse specialist was very
prescriptive about the need to take folic acid:
‘After I’d had the baby the diabetes nurse, was very much ‘Well, if you’re 
not taking the pill then you’re taking folic acid’ and that to her was a very 
clear thing.’ (T2 16)
The nurse felt that if there was any chance of pregnancy occurring because of 
women not using reliable methods of contraception, then folic acid should be 
taken.
8.3.2 Summary
CEMACH (2007) recommends that all women with DM take 5mg folic acid for 
three months prior to and for the first three months of pregnancy. One diabetes 
centre altered in their approach to this advice dependent on the woman’s HbA1C 
percentage. The data suggests that women appear to be aware of the need to 
take folic acid but are buying the 400microgrms dose over the counter and it was 
found that very few women with DM had taken the prescribed 5mg dose of folic 
acid in the preconception period. It appeared that greater awareness was 
necessary by GPs and primary care professionals caring for women with DM of 
the need to prescribe the higher 5mg dose of folic acid to women with DM 
planning pregnancy in order to prevent neural tube defects.
241
8.4 Getting the message across
8.4.0 Introduction
The health professionals were asked about their views pertaining to the delivery 
of preconception care advice and this section presents narrative in relation to the 
delivery of preconception information and the health professionals involved.
8.4.1 Delivery of preconception care information
Professionals were concerned that some women with DM were not always
receiving messages or information about preconception care.
‘I think the most important things are that people have the information they 
need to make their pregnancies as safe as they can be, both for them and 
for their babies. I don’t think that’s always the case - the type 2 diabetics 
are not getting the pre-conception care and information that they need.’ 
(HP 8).
This professional felt that as women with type 2 DM were often cared for in 
primary care that they were not always being given information on planning for 
pregnancy. This highlights the need for appropriate training and guidelines in 
preconception care for GPs and primary health care professionals caring for 
women with DM.
One health professional felt that if women were seen by doctors or other health
professionals in the diabetes clinic rather than a Diabetes Specialist Nurse then
again they might not receive advice:
I think a lot of it you see, is down to who sees them. If we’re [nurses] not 
actually seeing them and they’re just coming to the clinic, it may not be
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discussed; and unfortunately a thing like pregnancy is only relevant when 
it’s relevant, and some people find it hard to discuss it.’ (HP 1).
This professional noted that preconception advice may not always be seen as
relevant by all health professionals and that nurses were perhaps more likely to
deliver preconception messages during consultations.
Another professional thought that it did not matter who gave information as long 
as it was given when the patient was receptive:
‘I think the person who’s in front of the patient at the time when the patient 
wants to discuss it.’ (HP 8)
Receptiveness to information has been highlighted in Section 8.2 but this
approach does not take into account recommendations for annual preconception
advice to be given to all women (DH 2001 a, CEMACH 2007), and as has been
seen by data in Section 8.1.2, women may not raise issues about planning
pregnancy during consultations.
One nurse was clear that preconception messages were not getting through 
regardless of who the patient saw:
‘It would appear that we are providing education without anyone listening 
or else we’re not providing the education, because the message is just not 
getting through.’ (HP5).
This nurse had read a report (APPI 2006) relating to DM care which suggested
that patients were not getting or acting on messages to care for their condition.
The report suggests a more personalised approach to giving information and
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working in partnership with professionals and this was an approach favoured by 
one professional:
‘For me personally, I need to make sure that I know when which of my 
ladies are likely to get pregnant, who’s in relationships -  I know that 
sounds naughty but, the way that I always approach any consultation is on 
a very informal way anyway and I always try to make a note of any 
partners or any sorts of situations going on. So therefore, hopefully we’re 
a little bit more clued up to patients’ likely needs in the future’. (HP 14).
This health professional felt that it was important to have knowledge of the
situation regarding relationships of her patients and then more targeted advice
could be given. Another professional suggested targeting advice through use of a
tool to assess women of child bearing age with DM:
‘Presumably you could define better criteria which makes pregnancy 
unworkable to a large degree. I think renal function is one of the main 
determinants. I think that if you did that, then you could advise patients 
much better, if there was a tool to say, perhaps linked with the clinical 
information system, which flags up if a patient is of childbearing age with 
this set of problems.’ (HP3)
This health professional suggested devising a tool that could give parameters for
risk factors such as renal function and retinopathy in order to target and advise
those in danger of a high risk conception. This medicalised approach may
indeed highlight women at risk of complications in pregnancy and be a useful
adjunct when discussing pregnancy issues and Gupton et al (2000) discuss how
health care professionals should discuss perceptions of risk with women if they
are to work together to manage complicated pregnancies. However the factors
involved may be more complex as studies have shown that women given advice
not to become pregnant because of such risk factors were infact more likely to
have an unplanned pregnancy in the future (Holing et al 1998). This highlights
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the complexity of bio psychosocial factors that need to be considered in order to 
prevent unplanned pregnancy in women with DM.
In the primary care setting GP practice nurses were thought to be a good
professional to discuss preconception advice:
‘My perception would be that quite a lot of our diabetes ladies may find 
that the practice nurse who they know quite well and has done things with 
them, like cervical smears, so they have a more relaxed relationship with 
and they find it easier than doing it at the hospital, particularly if there is a 
male diabetes doctor.’ (HP 8)
The practice nurses are often female and women with DM may feel more
comfortable discussing pregnancy in the GP surgery environment rather than in
the hospital clinic with a male diabetes doctor. Similarly, two professionals felt
that family planning clinics could be a good option for some women to receive
advice:
‘I personally think the way to do it is to go in through family planning 
clinics, because if you’ve got people who are using contraception, then 
they appreciate that they might get pregnant and you can say “When you 
decide to stop using this, then you will need to...’ (HP 14)
The contraception clinic, which may either be in the GP surgery or a community
clinic, was seen as a good place to give information as women may be more
receptive to the advice as they are attending for sexual health matters.
One Primary Care Trust had tried having group ‘girly night’ sessions for women 
with DM to encourage young girls to chat about DM care including contraception
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and pregnancy but one of the health professionals talked about the low response
rate to these ‘parties’ and how preconception care was a real challenge:
‘..their turn-out for that [the parties] is 20%. So again, it just shows that no 
one is interested. It’s a start and up and down the country I’m sure other 
people do things, but you’re not going to persuade a 22 year old girl to get 
things sorted, and we have high HbM cs.’ (HP 4)
This professional felt very frustrated and challenged by preconception care for 
women with DM as women did not even take their insulin consistently never mind 
get their glycaemic control sorted out before they became pregnant. The 
concept of ‘girly parties’ was seen as a useful, but unfortunately the parties did 
not appear to be well attended. Such models of health promotion by health 
professionals could be explored further and are discussed later in Chapter Ten.
8.4.2. Summary
There was general concern by the diabetes health professionals that 
preconception care messages were not always being received by women with 
DM. The importance of having good relationships with patients when discussing 
preconception issues was highlighted and diabetes nurses and GPs and primary 
care professionals were suggested as key in delivery of such information due to 
their more personalised and relaxed relationship with women in their care. 
However the GPs and primary care staff were also seen as needing more 
training and education in the importance of preconception issues with particular 
reference to targeting and improving care for women with type 2 DM.
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8.5 Late referrals
8.5.0 Introduction
During the interviews the health professionals raised the issue of women with DM 
often being referred late for specialist antenatal care and this section describes 
their views.
8.5.1 Views of Health Professionals
If women were not seen in the preconception period then professionals were 
concerned that women often were not seen early in pregnancy and that women 
were often only seen at the specialist clinics when they were three or four months 
pregnant:
The idea is that they should be referred straight up and they should have 
scans ASAP, you know, seven weeks on. Sometimes that doesn’t happen 
and they don’t turn up until they’re twelve or fourteen weeks.’ (HP 17)
One health professional was frustrated that the GPs did not always send women
with DM straight away for specialist care in early pregnancy:
‘Occasionally they’ll go along to the GP and the GP will write a referral 
letter and that takes several weeks to get through the system, or the GP 
will say you don’t need to worry until you’re twelve weeks pregnant and 
things like this, and you think ‘no!’ (HP 16)
She remembered one such patient who had then been referred by a midwife:
This girl had been to her GP, who’d said ‘well wait till you’re twelve weeks’ 
and it was only the midwife who phoned me up, because we have close 
links with the midwives and she said Tve had this blood sugar come 
through of twenty something of somebody’s who booking in, what shall I 
do with it?’ [laughs]. ‘What !?!’ ( HP 16)
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The woman had been to her GP who had advised her to wait until twelve weeks 
gestation before she booked for care with the midwife, which is the normal 
referral pattern in some areas for women without DM, however the literature is 
clear that women with DM need pregnancy care ‘from the outset’ to 
ensure tight glycaemic control (CEMACH 2007:8). The midwife had discovered 
the woman with DM had a very high blood sugar reading of more than twenty, 
(target 3.5 - 6.5 mmol/l (Taylor & Davidson 2007)) and had had telephoned the 
health professional for advice. The health professional had been very concerned 
about the high glycaemic reading and contacted the woman immediately to 
attend for care.
Another professional was concerned about late referral of women with type 2 
DM:
The type 2s or those with type 2 that haven’t actually been diagnosed, 
who had previous gestational diabetes or PCOS or something, are often 
not pitching up until they’re fourteen or sixteen weeks, by which time 
they’ve missed the boat really.’ ( HP 8)
These women were often only being seen for specialist care in the second 
trimester of pregnancy when complications could already have occurred and had 
missed opportunities to prevent complications earlier in the pregnancy. The 
CEMACH report (2007) highlighted that women with type 2 DM were not referred 
for retinopathy assessment in the first trimester possibly because of later referral 
to specialist services.
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With the current NHS focus on delivery of services within primary care (DH 2007 
c) and the GMS contract (DH 2005 ) giving GP practices incentives to carry out 
DM care, women with DM are more likely to be receiving DM care at their GP 
Surgery. This raises issues of continuity of care and partnership working 
between primary and secondary care (Alazri et al 2007).
8.5.1 Summary
The professionals highlighted their concerns regarding late referral for specialist 
antenatal care from primary care services, which they felt could lead to poor 
outcomes in pregnancy. Women, who were referred late, missed opportunities to 
prevent complications earlier in the pregnancy and assessment for anomalies 
and retinopathy. The co ordination of care between primary and secondary care 
was seen as an important by the diabetes health professionals in promoting the 
best care for women with DM. This is of particular importance in the current NHS 
climate with the focus on delivery of services in primary care.
8.6 Planning for pregnancy
8.6.0 Introduction
In Phase Two of this case study, women were asked in the questionnaire 
whether they had planned their pregnancies and then this was expanded upon 
during the semi structured interviews and the findings are presented below. Of
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the sixteen women interviewed, five had planned their pregnancies, six had not 
planned and five had never contemplated pregnancy or ever been pregnant.
8.6.1 Becoming pregnant
The women were asked if they thought that having DM had had any effect on the 
ability to become pregnant.
Two of the women who had had difficulties becoming pregnant had attended 
fertility services and one thought that the DM had affected the chance of her 
becoming pregnant, through her having high glucose levels. She had become 
pregnant one month after being prescribed an oral hypoglycaemic agent 
Metformin.
Then I found out I was pregnant and another friend who has Polycystic 
Ovaries [PCOS] found out she was diabetic and was put on metformin and 
she got pregnant too. The thing about Metformin and then getting 
pregnant after all that time -  I am sure that there is a link that could be 
explored.’ (T1 6)
This woman who had been trying to become pregnant for four years was 
successful after being diagnosed with DM and having one month of oral 
hypoglycaemic treatment. She was sure that there was a link between the 
pregnancy and her treatment as her friend had had a similar experience. She 
may in fact have had Polycystic Ovary Syndrome herself which affects between 5 
and 20% of the general population (OKS 2008, RCOG 2003a) and commonly 
causes anovulatory infertility (Hellmuth et al 2000) with up to 75% of women
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having difficulties conceiving (Patel & Nestler 2005) and if they do become 
pregnant there is an increased risk of miscarriage in the first three months (Patel 
& Nestler 2005).
PCOS is associated with a five to ten fold increased risk of insulin resistance and
type 2 DM with resultant hyperinsulinemia (Legro 2006). Recently Metformin has
been used in the treatment of infertility secondary to PCOS (Haroush et al 2004)
with good effect as experienced by another woman in my study who had been
trying to conceive for eighteen years before being prescribed Metformin for type
2 DM. She did not agree that DM had affected her ability to conceive but that
the diabetes treatment had helped PCOS which was preventing her conceiving:
‘Infact if anything it probably helped because the tablets they gave me to 
start with helped the polycystic ovraries, so it probably helped rather than 
hindered if you like.’ (T2 12)
Metformin is used in the treatment of PCOS to decrease insulin resistance which 
can then counteract the underlying cause of PCOS and correct hormone 
imbalance leading to ovulation (RCOG 2003a).
It would therefore appear that women diagnosed with type 2 DM may have 
PCOS and women diagnosed with PCOS may be at risk of or have type 2 DM. 
These women could be at risk from poor maternal and fetal outcomes in 
pregnancy if glycaemic control is not optimal at conception. Promotion of 
preconception care to women with PCOS is therefore important and the links 
between fertility, DM and obstetric services may need strengthening in order for
251
women with PCOS and or type 2 DM to receive the best care. This is discussed 
further in Section 8.6.3 where concerns are raised by health professionals in 
relation to co-ordination of care.
Other women with DM thought that it was harder to conceive and also to keep a
pregnancy if blood glucose levels were uncontrolled:
‘I think it was also harder probably to get pregnant in the first place. My 
sugars were high and I took to miscarrying quite a lot [Three times]’. (T1 
13)
‘I think it is harder to get pregnant and stay pregnant if you have bad 
sugars.’(T1 15)
However several others did not think that having DM would affect the chances of
becoming pregnant or had not thought about it.
‘No - 1 had no trouble getting pregnant.’ (T1 3)
‘Oh can it - 1 hadn't thought about that?’ (T2 9)
‘No I had never got round to thinking about that as they were all 
unplanned.’ (T1 4)
The health professionals felt that conception for women with DM was no
difference than in the general population:.
‘I think some of them may think that it’s more difficult when they’ve got 
diabetes, but it isn’t and for me it’s important to let them know that it’s just 
as easy for them to get pregnant but also much more risky for the baby if 
they do and they’re not well controlled’. (HP 15)
This professional acknowledged that the women may think it would be harder 
because they had DM and in Chapter Seven narrative describes how this may 
relate to women with DM as seeing themselves as less fit’ than the general
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population and this will be discussed further in Chapter Ten. However the 
professional did not believe that DM affected the ability to conceive. Another 
health professional agreed that conceiving appeared all too easy:
‘I think they’re all too willing to get pregnant [laughs]; it’s all too easy for 
them isn’t it. I have seldom had that thought expressed to me, that I can’t 
get pregnant because I’ve got diabetes, I don’t -  no.’ (HP 11 )
This professional saw many women with unplanned pregnancies and so 
appeared to feel that conception was all too easy and she had never come 
across the notion that women with DM may think that they may have difficulty in 
conceiving.
8.6.2. Unplanned pregnancies
It can be seen from the literature that over 50% of pregnancies are unplanned
(CEMACH 2007) and this supports my questionnaire data which showed 51% of
the women who had had a previous pregnancy said that they had not planned
the pregnancy. Several of the health professional agreed that it was common for
women with DM also not to plan their pregnancies:
‘I think most women don’t necessarily plan their pregnancy, and a lot of 
ladies with diabetes join in with that.’ (HP 6)
This section will look at narrative from the theme unplanned pregnancy, starting 
with views of the women with DM on the reasons for not planning their 
pregnancy.
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8.6.2.1 Women with diabetes views on unplanned pregnancy.
8.6.2.1 .i Effects of Diabetes
One woman did not realise that she was pregnant until five months gestation:
‘I didn’t have periods anyway. I had them before my second baby was 
born but before that I was extremely thin, so even in my late teens, I think 
that I was about seventeen then and I didn’t get them and I remember my 
friends saying that people who were too thin didn’t have them.’
Q: Could that have been linked to your diabetes.
‘My thinness probably was yes, because I haven’t got it now.’ (T2 16)
This woman blamed her lack of menstruation due to her low weight as the reason 
as to why she did not realise she was pregnant as she would not have ‘missed’ a 
period signifying possible pregnancy. This could have been as a result of her 
DM as untreated or poorly managed DM can be linked with weight loss and 
ammenorrhoea can occur as a result.
Such unawareness of pregnancy may also be linked to the condition of 
‘diabulimia’ where women fail to self administer insulin in order to remain thin as 
discussed previously in Chapter Two, Section 2.1.5.2. This may result in 
amenorrhoea but despite this women may still become pregnant and are likely to 
have uncontrolled glycaemic levels with the high risk of complications.
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8.6.2.1 .ii ‘It just happened’
The women who said that they did not plan their pregnancies were asked if there 
was any reason for this. Several women talked about pregnancy ‘just 
happening’:
‘Well they kept saying at the outpatient clinic -  any plans, any plans and 
there was never any plan but it just kind of happened anyway’. (T1 3)
When asked by the diabetes health professionals, this lady said that she didn’t 
have any plans to become pregnant but as though out of her control ‘it just 
happened’. Data earlier in this section have shown that some women find being 
asked about their plans for pregnancy as too personal to discuss in the diabetes 
clinic and so do not disclose them and Holing et al (1998) found many 
psychological issues relating to unplanned pregnancies.
As seen in the literature review Chapter Three, Earle (2004) proposes categories 
of pregnancy intention and one woman talked about her unconscious decision to 
become pregnant:
The second and third, I wanted to get pregnant at some point but I did not 
plan as such. I think I thought if it happens then that's ok - sort of an 
unconscious thing really.’ (T1 1)
The woman was happy if she did become pregnant but did not count this as 
planning’ to be pregnant. Earle (2004) relates this to the ‘laissez-faire’ 
pregnancy where women stop using contraception but are relaxed about 
planning a pregnancy. This is discussed further in Chapter Ten in relation to 
preconception care.
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Similarly another woman stopped using contraception and was also happy if she
became pregnant although she admitted that her husband was not keen:
‘I didn't mind if I did get pregnant but my husband wasn't keen and we 
didn't really talk about it and then it just happened.’ (T1 13)
This woman was herself happy to become pregnant but may be she did not want 
to admit she was planning a pregnancy as her husband was not keen to have 
children. This strength of desire to have a child by women, but not by men, was a 
feature of several of the interviews as shown below:
One woman who said that she did not plan her pregnancy, thought her partner
‘would be fine’ if pregnancy happened but had not discussed this with him:
‘I don’t know why I didn’t plan them -  I was well controlled though but I 
didn’t really think about it - it just happens doesn’t it.’
Q:Did you discuss it with your partner?’
‘Oh not really - 1 was having trouble with the pill and I don't think he was 
really bothered - 1 thought if it happens it happens and I am sure he will be 
OK’. (T1 4)
This woman although saying that she did not plan her pregnancies, said that she 
had thought ‘if it happens it happens’, so in fact was aware that she might 
become pregnant. In addition she was happy that her blood glucose was well 
controlled, which is a factor in planning for a pregnancy for women with DM.
One young woman had no knowledge of DM and pregnancy and became worried 
when I asked about the topic:
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‘So is there a problem with diabetes and pregnancy? - should I be 
worried? - its not like I want to get pregnant now but - well you never 
know do you - Sometimes these things just happen...’ (T2 9)
She admitted that although she had no plans to become pregnant currently that it
could be a possibility as sometimes "accidents’ happened which she then
explained in more detail.
Q: ‘Can you tell me why you think that is?’
A: ‘Well I think some men don't always want children and women do - 1 
know [partner] is not sure and always says we can't afford them - well with 
the wedding and everything it hasn't been an issue but - well I think they 
might need persuading sometimes - 1 know my sister says that - sort of - 
that they don't know they want them until they have them, if you see what I 
mean?
Q: ‘Can you explain what you mean by ‘persuading” :
A: ‘Umm, yes, so you can not plan really, but not be too worried about 
contraception - he is the same as he doesn't like condoms so I don't know 
what he thinks when we don't use them - we don't talk about it really and 
then I just have my fingers crossed that my period will come ok. I know 
my sister said that her husband said he didn't want to have a baby when 
they got married last year but now he is mad about (baby). So I think that 
having an accident is one way. Also the family can be a pain asking all 
the time ' when are you having a baby' and it puts him off I think.’ (T2 9)
This woman thought that men were not always keen on the idea of having 
children but once they arrived they loved them, this was the experience of her 
sister. In addition the pressure from her extended family in asking when they 
were planning to have children made him more reticent. She felt that to take a 
risk of becoming pregnant by not using contraception all the time was not 
planning a pregnancy but having an ‘accident’ which was an easier way assert 
her wish to have a child.
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8 6.2.2 Failure of contraceptive method
Other reasons for not planning pregnancy included failure of contraception:
One woman used a condom which broke:
‘I have used condoms and with my first child one split’. (T1 4)
Condoms although shown as being 98% effective by the Family Planning 
Association (fpa 2007 a), can break or split (Guillebaud 2004) and some oil 
based medication can weaken latex condoms which may then split and break 
more easily (OKS 2007). This is discussed further in Chapter Ten in relation to 
vulvovaginal candidiasis and women with DM.
Another woman used the Contraceptive pill but it was not absorbed due to 
illness:
‘I was on the pill and had sickness and diarrhoea and didn’t know it 
wouldn’t work and I fell pregnant’. (T1 1)
If a woman vomits within two hours of taking the contraceptive pill this may mean
that the pill has not been absorbed and women will need to check that they are
protected from pregnancy. Severe diarrhoea can also mean protection is lost
through mal absorption and extra precautions may need to be taken (fpa 2007 a).
Misunderstanding of the natural method of contraception led to another 
unplanned pregnancy:
Then with the next one I was only in the first week of my cycle so I didn’t 
think I could get pregnant I was only day six of cycle and so I didn’t use 
anything.’ (T1 4)
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For this woman using ‘natural family planning methods, the misunderstanding of 
the risk of pregnancy occurring during her menstrual cycle resulted in a third 
unplanned pregnancy. This woman was using a calendar to predict the fertile 
period without using other important fertility indicators such as basal body 
temperature and cervical mucous and cervical position. Natural family planning 
methods can up to 98% effective, but require women to learn about fertility 
indicators and their personal menstrual cycle in order for this reliability to be 
assured.
Use of the Persona fertility monitor led to another unplanned pregnancy:
‘Yeah, and it’s my own fault entirely. I unfortunately, it had an amber light 
that day and I thought ‘oh these things always have an error margin’, 
they’re be at least a ten percent plus or minus each way. That wasn’t very 
clever was it? So you know, now I actually wonder whether I was ready, 
but didn’t want to have to admit it to myself ‘. (T1 10)
This woman admitted to having unprotected sexual intercourse on a day when 
the persona machine had measured her hormone in her urine and indicated that 
she may be fertile and should not have unprotected sexual intercourse. She had 
assumed that the machine would be calibrated with a margin of error and so 
risked not using contraception. She then went on to reflect that perhaps in using 
the natural method she subconsciously wished to be pregnant.
‘So you know, now I actually wonder whether I was ready, but didn’t want 
to have to admit it to myself and so this, I think Persona is a great tool 
actually if you’re not quite ready but it kind of, it puts enough uncertainty 
into it, which is a bit daft.’ (T1 10)
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By her ambivalent attitude to the use of this method of contraception, this woman 
speculated that she might have wanted to become pregnant but did not want to 
acknowledge this by stopping using contraception altogether. Persona as a 
method of contraception was seen by her as not always reliable and there was a 
chance that conception could occur. This links to previous narrative in Section
8.6.2.1 relating to the unconscious desire for pregnancy but this time with 
ambivalent use of contraception and this is also discussed in the literature by 
Furedi (1997) who sees this as a cause of accidental pregnancy in women who 
are uncertain if they want a child now but subconsciously may wish to discover if 
they can become pregnant. The haphazard use of contraception is discussed 
further in Chapter Ten in relation to prevention of unplanned pregnancy by use of 
long acting methods (LARC) for women with DM.
8.6.2.3 Not talking about it
Asked as to why they thought that women didn’t plan pregnancies, one of the
women interviewed and two of the questionnaire comments concerned the
concept that talking about trying for a baby would somehow prevent them getting
pregnant easily and so they had said that they were not planning pregnancy.
‘You don’t want to always admit that’s what you are going to be doing - it 
can put a curse on it -  it seems a bit of an imposition to talk about it at 
outpatients department.’ (T1 3)
‘It’s a private thing -  like if you talk about it, it won’t happen’ (T1 17)
These women felt that trying to become pregnant was a private and perhaps 
intimate issue, not to be readily discussed and especially not in a hospital
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outpatients department. They felt that by talking about pregnancy this would 
somehow put a ‘curse’ on the process and stop it happening. Another woman did 
not want to talk about it in case she did not become pregnant:
‘I didn’t want to mention it in case it didn’t happen’ (T1 18)
It appeared as if these women were actually planning pregnancy but stated that 
they were not as they felt that this may somehow prevent a pregnancy occurring. 
It may be that these women found planning for pregnancy was a stressful 
concept as is described by Moos et al (1997:385) who found for women did not 
state they were planning to be pregnant because of ‘potential disappointment. 
This raises challenges for health professionals promoting preconception care as 
these women would not be receptive to discussion or information within the clinic 
setting and other models of preconception promotion would be required.
8.6.2.4 Spoil the experience
Two of the women felt that ‘planning’ would spoil the experience of trying to 
become pregnant:
‘It takes the magic away.’ (T1 17)
‘We’d always said that we’d like to get pregnant without really trying, so 
luck was with us.’
Q: Why do you think that was that you wanted to become pregnant with 
out trying?
‘I think it can spoil things and if you are always thinking about it and worry 
that it won't happen - 1 don't know really - sort of pressure I suppose. 
Q:How do you mean spoil things?
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‘A different purpose - like I know a friend who became very - well she 
didn't talk about anything else - and she was always doing tests and was 
depressed when her period came - it was a nightmare for them.’ (T1 11)
These women had a romantic notion of becoming pregnant as described by 
Gregg (1995) and felt that ‘planning’ would take away the excitement and magic 
they associated with becoming pregnant. Barrettt & Wellings (2000:12) discuss 
how women can feel that ‘planning’ for pregnancy is ‘too clinical’ and prefer 
pregnancy to be a surprise and these psychosocial aspects of childbearing are 
discussed in Chapter Ten in relation to the prevention of unplanned pregnancy 
for women with DM.
One woman felt that by not planning she would not have the pressures and 
worries of not conceiving. This would therefore avoid her becoming despondent 
if pregnancy did not occur which had been a difficult experience for her friends. 
Planning for pregnancy was seen as a ‘pressure’ and so by not planning; the 
pressure and worry of not conceiving would be prevented and this concurs with 
findings in Section 8.6.2.3 where becoming pregnant was seen as a stressful 
concept as discussed in the literature by Moos et al (1997).
8.6.3 Planned pregnancies
For women who had planned their pregnancies I asked about any changes they 
had made to their lifestyle or DM care and whether they had sought any advice. 
One woman with type 1 DM had planned to become pregnant and had carefully 
monitored her blood glucose levels:
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‘When we decided that we’d like to have a baby I did purposely look at it 
extra special, all my blood tests. I didn’t jump into it straight away. I 
wanted to make sure that things were nice and calm because I know 
you’ve got to take that into consideration before becoming pregnant 
because it can cause problems with the pregnancy.’ (T1 15)
She took a measured approach, making sure that she had good glycaemic
control and then went on to find out information and make decisions about the
time to try for a pregnancy herself without contacting health care professionals:
‘You gain a lot of information, but I didn’t ask my GP or the doctors here, 
saying ‘I think I might want to have some children.’ Perhaps I should have 
done, but I didn’t because I felt I was well informed at the time. I would go 
on the internet as well and just look things up; and after about three or four 
months, checking on my results and things I thought perhaps it’s a good 
time.’ (T1 15)
One woman had had three miscarriages and had been trying to get pregnant for
eighteen months although she had poor glycaemic control:
‘Well, I took to miscarrying quite a lot and my sugars were still quite high’ 
(T1 13).
She had been given advice not to become pregnant until her ‘sugars were under 
control’. Asked if she had made any changes to her lifestyle, she had ‘bought the 
Pregnacare’, and had given up smoking3. So although being advised not to 
become pregnant this woman was making changes to her lifestyle in promotion 
of a healthy pregnancy.
Some of the women had planned and made lifestyle changes for their second 
pregnancy but not the first:
3 Pregnacare is a multivitamin formula marketed for pregnant women
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‘With the other two I planned and prepared myself more -  I worked really 
hard to get my sugars at an acceptable level - the first baby was 6lbs 4oz 
at thirty two weeks!’ (T1 5)
Having had one unplanned pregnancy with poor glycaemic control resulting in a
large baby she had decided to prevent this reoccurring and had planned
subsequent pregnancies.
Another woman had cut down on alcohol:
‘Well I didn’t talk to anyone about it I just knew that was what we were 
going to do and we did - but I didn’t discuss it with the diabetic nurse - 1 
cut down on alcohol’ (T1 3)
There is increasing evidence that alcohol consumption during pregnancy can
cause fetal damage (RCOG 2006) and, although the safest message to give
women is to avoid alcohol completely, the current guidelines are for no more than
one to two units of alcohol one to two times a week (DH 2007 d). No other
dietary changes appeared to have been made by this woman and as she had not
talked to anyone she may have been unaware of other preconception care
guidelines (BMA 2007, Food Standards Agency 2008)4.
Two of the women had been attending fertility services, one being diagnosed 
with DM during treatment for infertility. However no changes to their lifestyles 
were made before pregnancy. One of the women had stopped attending her 
diabetes centre appointments during this time:
4
In the UK one unit is defined as a drink containing 8 g of ethanol. This is equivalent to:
Half a pint o f average strength beer, lager, or cider (3-4%  alcohol by volume [ABV]).
Small pub measure (25 ml) o f spirits (40% ABV).
Standard pub measure (50 ml) of fortified wine, for Standard pub measure (50 ml) of fortified wine, for example sherry, port (20% ABV). 
A small glass (125 ml) o f average strength wine (12% ABV) contains 1.5 units of alcohol.
A standard pub measure (35 ml) o f spirits (40% ABV) contains 1.5 units of alcohol ( CKS 2008)
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‘I lost touch with diabetic service and started fertility treatment and then 
got back in touch with the diabetic centre’ [once pregnant] (T2 12)
This loss of specialist diabetes care could have resulted in poorly controlled
blood glucose levels putting any pregnancy resulting from the fertility treatment at
risk.
One of the health professionals was particularly concerned about lack of liaison 
with fertility services:
‘A lot of infertility people who are type 2s don’t get their diabetes sorted, 
go along and undergo a fertility programme and the next thing you’ve got 
a diabetic who’s got an HbA1c of 9. No one thought, of course, [whilst] 
they were stimulating eggs, to think about perhaps we shouldn’t be doing 
this until the Diabetes Nurse ... and then you suddenly find she’s happily 
pregnant. So the infertility people sometimes miss it -  the type 2s.’ (HP 4)
The professional was concerned that women with type 2 DM could become 
pregnant with treatment by fertility services without having their DM controlled 
first. There was concern that there was no established liaison between the 
diabetes and fertility services and this could result in women having suboptimal 
glycaemic control at conception and potential poor maternal and fetal outcomes. 
This lack of co-ordination has been raised previously in Section 8.6.1 where 
promotion of preconception care to women with PCOS was highlighted as 
important and links between fertility, DM and obstetric services needing review.
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8.6.4 Summary
This section has presented findings in relation to women with DM planning for 
pregnancy. The women’s views on their ability to become pregnant varied 
according to their experiences but the health professionals felt that conception for 
women with DM was no more difficult to that of the general population. Certain 
women had had difficulty conceiving or keeping a pregnancy and links were 
made between women diagnosed with PCOS and type 2 DM and the opportunity 
for promotion of preconception care to these women.
Views on reasons for unplanned pregnancies were presented and included 
differing psychosocial perspectives and beliefs and ambivalent use or failure of 
contraception. Finally the women’s experiences of planning for pregnancy was 
presented with women ensuring good glycaemic control and cutting down on 
alcohol but the women did not appear to have made changes to their diet and 
lifestyle as recommended by the BMA (2007), DH (2007d) and Food Standards 
Agency (2008) and this could have affected the outcome of their pregnancy.
The next section will present findings of the theme ‘Blood glucose control and 
pregnancy’.
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8.7 Blood Glucose Control and Pregnancy
8.7.0 Introduction
This section presents the findings in relation to glycaemic control for women 
planning pregnancy and during pregnancy. Narrative from the interviews on the 
motivation of pregnancy, hypoglycaemic episodes and treatment options for 
women with type 1 and type 2 DM will be described.
8.7.1 The Motivation of pregnancy
The women talked about how they would take more care and work harder at
controlling their glucose levels because they were pregnant:
‘It’s hard; because I think when you’re pregnant you’re so well-controlled 
because you’re more worried about the baby than you are yourself. So 
you make sure that they’re perfect, whereas when it’s just you, you think 
‘Oh, I’ll take it later.’ (T1 13)
‘I worked really hard to get my sugars at an acceptable level’ (T1 5)
The women were prepared to try to keep their blood glucose levels controlled as
they knew it affected the baby, whereas before pregnancy they were not so
concerned about their own health. The health professionals regularly saw this
motivation to ‘work hard’ and improve glycaemic control in pregnant patients:
‘We worked really hard, and her HbA1c is now six, so she’s done really 
really well, very impressed, Dr X just can’t believe it, that she’s managed 
it, because we’ve battled with her for years.’ (HP 16)
‘I can think certainly in the few occasion we’ve had youngsters getting 
pregnant and they’ve had terrible control normally and they’ve just got it 
together. It’s amazing what that baby’s done really.’ (HP 1)
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‘Even for the very badly controlled, who don’t test, will do seven tests a 
day, virtually every day of their pregnancy.’ (HP 7)
Becoming pregnant and knowing that uncontrolled blood glucose levels could 
adversely affect the baby, provided the motivation to work to gain good 
glycaemic control and the results often surprised health professionals. However 
as identified by Taylor & Davison (2007), congenital abnormalities related to 
poor glycaemic control with hyperglycaemia occur at or around the period of 
organogenesis, the first forty two days following conception and by the time 
pregnancy is confirmed for women this time may have passed and damage 
already occurred.
The women were asked about how often they would test their blood levels in 
pregnancy:
‘When I was pregnant I was doing them six or seven times’. (T1 11)
‘In the last one I tested my blood sugar six to seven times a day’. (T1 1)
‘Oh, pretty much five or, what I would do is I’ll do a whole day, so like 
morning, before lunch, two hours after lunch, before my evening meal, two 
hours after, before bed, so that I had a full set and then I could have a day 
off and then I’d do the full set again. (T1 10)
The women took regular blood glucose readings and many were testing between 
five and seven times a day. This meant that they could titrate the amount of 
insulin required depending on the result and as pregnancy progressed they said 
that they required more insulin:
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‘At one point my insulin demands were going up virtually every other day 
and I got lumps on my legs where I was injecting and stuff like that.' (T1 
10)
Towards the end I was doing it five maybe six times a day, but to start 
with it was two or three times a day and then obviously as you increase 
the insulin, the hormones demand a bit more don’t they when you’re 
pregnant.’ ( T2 3)
The women felt that the ‘hormones of pregnancy’ were seen to increase the
demand for insulin and this has been discussed in the literature review by
Buchanan & Dornhorst (1996 a) and some women found it very reassuring to
know the levels were remaining satisfactory:
‘I just, I really wanted to know what was going on with it so my fingers 
were like pin cushions, they were dreadful! But I loved the fact that you 
can keep an eye on it that much, I mean I don’t know what I would do 
without my glucometer.’ (T1 10)
This woman was keen to be in control of her glycaemic levels during pregnancy, 
even if it meant that her fingers became sore with testing.
Some patients were seen to take longer than others to be really well controlled:
They improve it, but most of them don’t get it...Probably about 10% of our 
patients get there at the beginning of pregnancy. They’ll get there by the 
end of pregnancy definitely.’ (HP 16)
The health professionals saw great improvements in gycaemic control by the end
of pregnancy and this was continued by some women so as to improve their
future control in general:
‘I learnt so much about diabetes with my first pregnancy -  before then I 
never varied my dose I just did what I was told and I didn’t do many sugar
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tests but during pregnancy I did at least four a day so I carried that on so 
getting pregnant helped me sort out my control.’ (T1 5)
For this woman, having a baby had helped her to learn how to titrate her insulin 
dose to gain good glycaemic control for the future. Before pregnancy she had 
just taken regular amounts of insulin as ’she was told’ and had not reviewed the 
glucose levels regularly. Regular tests during pregnancy, of at least four times a 
day, meant she could vary the amount of insulin to control blood glucose levels. 
This titration of insulin dose is a concept is now promoted by many health 
professionals in the Dose Adjustment Programme for Normal Eating (DAPNE) 
which is part of the national policy of structured education programmes to 
promote DM self care and good glycaemic control (DH 2003). This will be 
discussed in Chapter Ten in relation to glycaemic control and prevention of 
unplanned pregnancy.
One health professional confirmed that for some women becoming pregnant had 
changed their DM management for the future:
The motivation to improve control when they’re pregnant is great - I’ve 
had a few say to me ‘I think it’s saved my life, having this baby, because 
for the first time in my life I’ve got good blood sugars.’ (HP 6)
As well as regular blood glucose tests some women also made changes to their 
diet when they became pregnant:
‘I think that my entire diet changed because I knew that someone else was 
reliant on me’ (T1 6)
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‘Yeah, my diet changed completely. I mean whether it was because I was 
pregnant and you change your diet anyway but it changed completely and 
more healthy stuff and everything’. (12 12)
The change to eating more healthily because it was seen to be good for the baby 
was a common theme and for some women this continued after pregnancy:
‘After nine months on a low carb diet I have got used to it and am carrying 
on with it’ (T1 6)
‘I eat better now than I ever have’. (T1 5)
Pregnancy was therefore seen as a great motivator for many women in respect 
of gaining knowledge in the maintenance of glycaemic control by monitoring 
glucose levels and eating a healthy diet and for some women this continued after 
pregnancy leading to better glycaemic control for the future.
8.7.2 Hypoglycaemic episodes
As seen in the literature (Pearson 2008), the tight control of blood glucose and 
rise in demand for insulin during pregnancy caused many women to have severe 
hypo-glycaemic episodes:
‘I did manage to keep a very tight control of it [glycaemic contol], in fact so 
tight I mean I was having hypo’s all the time, it was just dreadful, and it got 
so bad that we actually had to come up here [hospital] was it to get the 
glucose.’ (T1 10)
‘I couldn’t get them [blood glucose levels] to come above four, they were 
sort of two and three and you know, which I think is worse than going high 
especially when you wake up in the middle of the night and you’re 
disorientated from sleep anyway but that makes it ten times worse, its like 
urghl’ (T2 12)
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These women were severely troubled by the hypoglycaemic episodes which 
could cause loss of consciousness. As seen in the literature review in Chapter 
Three, the recommended tight control of blood glucose levels can mean that 
asymptomatic hypoglycaemia can occur more frequently and lead to increased 
risk of unexpected severe hypoglycaemia (Pearson 2008). Taylor and Davison 
(2007) warn that women need counselling about such risks and the importance 
of ensuring blood glucose levels are satisfactory before driving. Women with DM 
should have an emergency glucogon kit that can be administered in an 
emergency (Pearson 2008).
Some women talked about how their partners also were concerned about the 
episodes and the need to give glucogon.
‘I had terrible hypos without any warnings - worse in pregnancy -  He was 
a bit on edge because of the hypos - 1 am on the pump now which is great 
for control’ (T1 1)
‘He got a bit concerned because obviously if I’m waking up in the middle 
of the night, getting up with me he didn’t really understand what was going 
on and it was just a case of explaining to him and making sure he was 
aware of what I was doing and why I was doing it really. I went shopping 
with my mum every week as well so I had to make her aware of you know, 
if this happens then this is what I need to do.’ (T2 12)
The partners were anxious about the hypoglcaemic episodes and required 
explanation of the need for glucagon which several of the women had to be given 
by partners during pregnancy. The need for such information for relatives and 
close friends was also seen important if they were spending time with the 
pregnant women.
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8.7.3 Dilemmas in treatment
8.7.3.1 Type 2 DM
There has been concern in the past about oral hypoglyaemic agents causing 
fetal abnormalities if taken during pregnancy and consequently it is currently 
common practice for women with type 2 DM who are planning a pregnancy to 
have their treatment changed to insulin injections (Diabetes UK 2007). One of 
the health professionals explained that this was preferably done some time 
before pregnancy:
if we have perhaps got ladies who say are type 2 ladies who are on oral 
medication and they have an inclination that they might get pregnant then 
we make a point of trying to get them swapped over onto the insulin a long 
time before conception takes place, so they can actually be stabilised on 
the insulin. Of course, the whole twelve plus years I've been doing this job, 
I've managed to catch about three unfortunately.’ (HP 14)
‘Catching’ women before they were pregnant so that they can achieve stable 
blood glucose levels prior to conception was not seen as easy. As can be seen 
in the literature over 50% of pregnancies are unplanned (CEMACH 2007) and 
also many women with type 2 DM are cared for in primary care where GPs are 
not always aware of the need for change. Other professionals felt that it was 
difficult to decide when to transfer from oral hypo glycaemic agents (OHAs) as it 
may take several months to conceive and having to inject insulin could be seen 
as an imposition:
‘It’s a really tall order though because if you have a person who is pretty 
well controlled on tablets and they say ‘I’m thinking of getting pregnant 
next year’, when should I come off the metformin and what do you do, you 
say ‘well, come off it and go on insulin now’ and they might not get
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pregnant for a year, that’s quite an imposition in somebody’s life isn’t it. 
(HP 5)
However others felt that to transfer to insulin just as pregnancy was confirmed 
could also be difficult:
‘I do think it’s slightly harsh, when you find out you’re pregnant, starting 
taking insulin the same week. It’s quite an emotional load for one person 
to take on. So a bit of getting used to things in advance, I think ... but 
maybe that’s just me, thinking how I’d react to that combination.’ (HP 6)
So it was felt that the timing of transfer was difficult, as women may prefer to get
used to injecting insulin before they conceived, rather than having pregnancy
diagnosed and immediately starting treatment with insulin. This may have been
helpful for one woman who saw injecting insulin as a frightening procedure.
‘I’m dreading having to take insulin anyway because I don’t like the idea of 
... I suppose you get used to it in the end, but when they talk, telling me in 
the hospital how to inject myself, I had to lie on the floor in the end to do it. 
(T2 16)
This woman, with type 2 DM was dreading having to change from OHAs to 
insulin because of having to self inject. There is however debate and controversy 
as to whether the transfer to insulin is necessary in the preconception period.
The literature shows that recent research has been reassuring with no 
differences in outcome for abnormalities noted between women on dietary 
control, insulin or OHAs during the first eight weeks of pregnancy (Langer 2002, 
Feig & Palda 2002) and there is increasing use of oral hypoglycemic agents to 
regulate blood glucose levels in pregnancy for women with type 2 DM and 
gestational DM (Tran et al 2004, Homko et al 2004, Langer 2002). Several of the 
health professionals were now of this view:
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‘It looks like metformin is safe in pregnancy and we convert everyone to 
insulin. But one hopes we might be able to use metformin or glycocide or 
something in pregnancy. I think metformin is deemed to be safe, I 
understand.’ (HP 4)
‘I think the general protocol now is that they keep on the metformin until 
pregnancy is confirmed and then they stop and that’s what they do in 
PCOS so that’s what we do in diabetes.’ (HP 16)
The view that metformin an OHA was now seen by some as not harmful in early
pregnancy meant that women could in future be transferred to insulin treatment
after conception. This was seen as particularly useful for women with type 2
diabetes who have diagnosed or undiagnosed polycystic ovarian syndrome
(PCOS) who are treated with metformin:
‘I don’t think the evidence for it being damaging is particularly high and it 
may actually be helping people to conceive. The pre-gestational type 2s 
are at higher risk of PCOS which hasn’t been formally diagnosed’. (HP 6)
As has been dicussed in Section 8.6, women with PCOS frequently have 
difficulty in conceiving and require treatment with metformin or a similar agent to 
control the condition. Metformin is used because it reduces testosterone levels 
and increase sensitivity to insulin therefore regulating the menstrual cycle and 
blood glucose levels. Therefore if a woman with type 2 DM has PCOS and was 
transferred from metformin to insulin treatment she may find difficulty conceiving.
8.7.S.2 Type 1 DM
Another dilemma seen in practice was with regard to women with type 1 DM 
taking the newer long acting analogue insulin which are not licensed for use in 
pregnancy. Several of the professionals mentioned that these women may need
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treatment changes to older style insulin which then upset the women’s blood 
glucose control. This was borne out by one woman who was very frustrated 
when she was told that the insulin she was using was not licensed for use in 
pregnancy:
‘When I approached Dr X and said W e’d like to have children’ he actually 
looked up the insulin I was on and my night time one, which wasn’t 
actually registered for use in pregnancy and he wanted me to change 
back to a different insulin. At which point I said ‘No I don’t believe my 
control is good enough on that insulin. I had great control and to think that 
everything was going well enough to conceive kids and then to find out 
that the insulin wasn’t suitable!’ (T1 11).
She had purposely ensured good glycaemic control in order to conceive and was 
then frustrated to be told that she would need to change to insulin that she felt 
was inferior in controlling her blood glucose levels at a time when this was of 
great importance. It would appear from current guidance (Diabetes UK 2007) on 
the use of insulin during pregnancy that most insulins are safe for use in 
pregnancy but that there is insufficient evidence in the use of insulin analogues 
and these are therefore currently avoided. It is hoped for further guidance in 
2008 from the NICE review (see Addendum and Appendix Eighteen).
8.7.4 Summary
The data presented demonstrates that becoming pregnant is a great motivation 
for women to control their blood glucose levels to ensure optimum outcomes of 
pregnancy. Many women worked hard and gained good glycaemic control for 
the first time and the knowledge gained could be used for future maintenance of 
DM care as women continued to titrate their DM treatment to their dietary
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requirements after pregnancy with continued benefits of good glycaemic control. 
Women in general had not gained control prior to conception and this may mean 
a poor outcome as identified by Taylor & Davison (2007). Congenital 
abnormalities related to poor glycaemic control with hyperglycaemia occur in the 
first forty two days following conception and by the time pregnancy is confirmed 
for women this time may have passed and damage already occurred.
The downside of gaining tight glycaemic control was the potential for more 
frequent hypoglycaemic episodes which both women and their partners found 
distressing and anxiety provoking. The importance of having a glucagon kit 
available for use in an emergency was highlighted and the need to train partners 
and others in the use of these auto injectors.
In regard to treatment of DM during the preconception period and during 
pregnancy for women with type 2 DM there was currently a dilemma for the 
health professionals as to the safe use of OHAs and the decision as to when to 
prescribe insulin although increasing evidence shows that Metformin appears 
safe to use in pregnancy. For women with type 1 DM the use of analogue insulin 
was of concern and this may mean that women may need to change insulin type.
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8.8 Complications in pregnancy and with birth for women with diabetes
8.8.0 Introduction
The CEMACH descriptive study (2005a) found that women with DM were of 
significantly higher risk of complications during pregnancy and of adverse 
outcomes compared to the general maternity population. My questionnaire study 
had shown that 56% of the women participating had had complications in 
pregnancy and during the interviews with the health professionals and women 
with DM these issues were explored and will be presented in this section.
8.8.1 Views of health professionals
The health professionals were asked if in their experience, women with DM who
were pregnant had had complications or poor pregnancy outcomes. Two of the
centres had undertaken audits of pregnancy outcomes for women with DM and
the response was varied with doctors at one centre feeling that there was no
difference in outcomes for women with DM than for the general population
whereas in another centre the comparison was currently unknown:
‘No. We've just finished an audit, which I haven’t seen the fullness of yet, 
but on eyeballing figures I think we’re doing quite well.’ (HP 3)
‘I don’t know. The obstetrics department has a designated consultant who 
looks after the people with diabetes. They do the outcomes and feed back, 
but I don’t know, from a diabetic point of view. We haven’t done them 
separately.’ (HP 8)
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It appeared that audits were being conducted within the DM and obstetric 
departments, but as yet the results were unknown. However the health 
professionals spoke about a range of complications that occurred in pregnancy 
for women they cared for and the women with DM also talked about their 
experiences which will be presented below.
The health professionals described a range of complications that patients had 
experienced whilst in their care:
‘We’ve had a selection of early miscarriages, seeing people at seven 
weeks with properly established pregnancies, but we haven’t had any 
major disasters.’ (HP 8)
‘We’ve had one major cardiac problem, and we haven’t had any other -  
we haven’t had any spina bifidas. We’ve had no other major, major 
problems, except macrosomia.’ (HP 4)
The feeling was that complications did occur but that these were not ‘major 
problems’ defined by one professional as ‘maternal death and a stillbirth’, which 
were thankfully rare. There appeared to be the view that an ‘early miscarriage’ 
was not seen as a major problem, but this perspective ignores the emotional 
feelings of the women concerned and the devastating psychological effect that 
miscarriage can have for women including depression and anxiety (Broquet 
1999, Maker & Ogden 2003, Gumming et al 2007).
One professional however acknowledged that major complications did occur:
W e’ve seen some still births and neonatal deaths as well [as pre 
eclampsia], which is a bit sad.’ (HP 14)
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The literature clearly shows that complications of pregnancy are common in 
women with DM and CEMACH (2005 a) found perinatal morbidity and mortality is 
increased up to five fold compared with the general population for women with 
type 1 and type 2 Dm. Other studies (Macintosh et al 2006, CEMACH 2005 a, 
Jensen 2004, Diabetes & Pregnancy Group 2003) have shown increases in 
miscarriage, preterm delivery, still birth, potential congenital malformations 
including neural tube defects and cardiac and bone abnormalities.
One issue that the health professionals discussed was the increasing the rate of 
complications linked to the later age at which women were tending to become 
pregnant:
‘In my own unit, the average age of first pregnancy is thirty four, so we’ve 
lots of forty year olds going through. If they’d had their babies in their 
twenties, these women, they would have been OK but now they’re in their 
late thirties, early forties, and we have a few cardiacs, well, a lot of cardiac 
problems here. In our unit we worry about heart attack.’ (HP 4)
The professional felt that cardiac disease was causing increasing complications
such as myocardial infarction for women in pregnancy due to the later age of
conception. Women with DM are at higher risk in general of cardiac disease and
may be at greater risk of cardiac complications in pregnancy and labour if they
conceive later in life. One professional was clear that women should be
encouraged to have babies earlier:
‘Well, I think one of my main issues is that they should try and have their 
pregnancies before they get too old, if you see what I mean. I certainly 
like them to have their first pregnancy by twenty five and ideally to have 
completed by thirty five.’ (HP 10)
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This professional felt that women with DM should complete their families before 
they may start to have complications from their DM, however this could be seen 
to be a medicalised view and may not concur with the social decisions from 
women who are often leaving child bearing until after the age of thirty years and 
this will be discussed further in Chapter Ten.
8.8.2 Views of the women with DM
There were few comments made in relation to about age and pregnancy during
the interviews, although in Chapter Six the findings of the questionnaires are
presented and show that nearly 25% (n =13) of participants who had been
pregnant, had their first pregnancy after the age of thirty years. One woman said
that she was glad to have had her children in her twenties:
‘A lot of women do wait. I'm very glad that I had children in my twenties. 
I’m twenty nine now. It was definitely beneficial, and also, from the long 
term complications, things like eye disease in diabetes, it’s probably better 
to do it younger when your eyes are healthier and that kind of thing, if 
there are going to be any complications there.’ (T1 11)
This woman was concerned about long term complications such as retinopathy if
women conceived when they were older and she felt she was less likely to have
complications as she had had her children in her twenties.
8.8.3 Miscarriage and abortion
For some women pregnancy had ended in a miscarriage or still birth thought to 
be due to poor glycaemic control in early pregnancy. The women told stories of
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their distress. One woman felt guilty that she had not controlled her blood sugar 
at the beginning of pregnancy and she had been told that this had led to her 
three miscarriages:
‘Make sure that your sugars are under control before you get pregnant, 
because the thoughts you have when you find out you are pregnant 
thinking what damage could I have already done, by having high sugars. 
You feel extremely guilty. So, my best advice would be that if you want to 
get pregnant, take care of yourself before you get pregnant, or you 
probably won’t get pregnant, or you’ll miscarry.’ (11 15)
This woman was giving advice to others as she blamed her self for her three 
miscarriages as she did not have good glyaemic control. Another woman also 
reiterated the same sentiment:
‘Your control has got to be spot on because otherwise there is problems 
and complications, so because when she was born she had problems with 
her heart, they’re linking that to the fact that my diabetic control wasn’t 
good the first twelve weeks.’ (T2 12)
This woman has a baby with a congenital cardiac condition and she had been
told that this was thought to be caused by poor glycaemic control in early
pregnancy. This woman also felt guilty that she had been responsible for her
daughter’s cardiac condition and now had to cope with regular journeys to a
specialist hospital in London for treatment and care of her child. The factor of
maternal guilt was also experienced by another woman who also had poor
glycaemic control had a late termination due to severe abnormality in the b a b y -
she talked of her anguish, of the way it was managed, and how she still worried
about it several years later.
They said ‘We can’t really see any kidneys.’ They didn’t feel that the baby 
had any kidneys and they did lots of tests and things and they thought she
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was suffering with Potters syndrome. I’d never been through a labour 
before and everything and I was in a little room on my own. Just outside 
was a toilet and I needed to go to the toilet and I went there and that’s 
where she was. It really traumatised me. My partner was hoping that I 
was so out of it that I wouldn’t remember what happened, but 
unfortunately I remembered every bit of it. The pain she must have gone 
through - 1 thought couldn’t they have given her something so she wouldn’t 
suffer, in a way -  I don’t like to use the words kill her, but why couldn’t 
they have given her something to knock her out so she’s asleep. It sounds 
horrible; I’m not explaining myself very well.
‘I would have liked to have had a photo. I didn’t think to ask. I didn’t think 
to bring the camera in, but I didn’t think to ask, and I never had the 
opportunity to hold her. I saw her and they put, you know these cardboard 
trays, she was put on one of those, and they brought her in, like a portion 
offish and chips.’ (T1 15)
The woman had vivid memories of this late termination of pregnancy and still felt 
traumatized by the whole event years later. She had delivered the baby in the 
toilet and was convinced that the baby would have been in pain and she wished 
that the baby could have been given medication to prevent such suffering. She 
was not given a photograph of the baby and her memory is of the baby on the 
cardboard tray.
These women had continued to carry guilt and blame for the outcome of their 
pregnancies for many years. As a woman, I found myself becoming quite 
emotional whilst talking to them and felt privileged to share their experiences. 
Having been a midwife I felt ashamed that the woman who had had the late 
termination was still experiencing anguish that her baby had been in pain and 
that she had not been given a photograph of the baby. It is common practice in 
late terminations of pregnancy to administer potassium chloride or other agents
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to stop the heart beat prior to labour (RCOG 2001), to reassure the parents and 
to always take photographs and let the parents hold the baby if they wish. As a 
researcher I felt helpless that I could not give this woman some reassurance 
about her baby and felt angry at the apparent lack of sensitivity of the staff 
presenting the baby on a cardboard tray ‘like fish and chips’.
The literature gives many illustrations of psychological effects of poor pregnancy 
outcomes on women, with feelings of guilt being common and causing future 
emotional problems (Freda et al 2003, Jackson & Mannix 2004). Baez et al 
(2004) present cases illustrating women who have had terminations of pregnancy 
who suffer long term grief and depression, and Hsu et al (2004) explored 
interpretations from women who had experienced a stillbirth and found that the 
women had a strong sense of personal failure and incompleteness and 
recommended that nurses listen to the perspectives of patients to help them 
come to terms with their loss. Nurses working with women with DM who may 
have complications of pregnancy, need to have awareness of the impact that 
such complications can have on women’s lives in order that women can be 
helped to work through their grief and feelings of guilt.
8.8.4 Pre-elampsia
The health professionals and women with DM also talked about other 
complications of pregnancy including Pre-elampsia. My questionnaire study had 
showed that 35.5% (n=22) of participants who had had a previous pregnancy had
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had pre eclampsia and this accounted for 65% of the total complications. Many 
of the health professionals confirmed that it was common for women with DM to 
have pre-eclampsia during pregnancy:
‘Certainly it’s quite normal to get pre-eclampsia.’ (HP 8)
‘Yes, some of them after all are hypertensive when they start the 
pregnancy, some of them have early hypertension with protein urine and 
so forth at the start of pregnancy, so yes, I think we expect a higher 
instance of pre eclampsia. I’m sure we see it. (HP 10)
‘Yes, that’s something that we’re monitoring them quite closely. We’ve had 
some quite serious cases of blood pressure, pre-eclampsia.’ (HP 14).
These health professionals were aware that they saw a high rate of pre
eclampsia and that blood pressure and protein urea were carefully monitored.
One doctor felt that this could be expected given that some of the women were
already hypertensive before pregnancy. However at one centre both obstetrician
and diabetologist did not agree:
‘I’ve not seen it, off the top of my head. There’s no particular reason why 
they would do ... I wouldn’t say pre-eclampsia was something ... I would 
say it was no different to the background population, in my opinion, but 
that’s anecdotally speaking. I’m unaware of any evidence in the literature 
that pre-eclampsia is higher.’ (HP 4)
‘I don’t think pre-eclampsia was part of that [the audit] -  I can’t be sure, 
but I didn’t think there was any increase. It was probably no better than 
the national average.’ (HP 3).
At this centre the medical leads did not agree that in their experience pre
eclampsia was of higher incidence than for the general population and they were
not aware of literature to support a difference. This is incongruent with studies in
285
the literature (Garner et al (1990), Girling & de Sweit (1997)) which cite higher 
risk of pre eclampsia for women with DM.
Several of the women with DM interviewed had experienced complications with 
pre eclampsia:
‘I suppose shortly after three months, maybe four months, I can’t 
remember what the week would be, it [blood pressure] started to raise a 
little bit and I think a little bit of protein was showing up and I thouqht ‘Oh 
dear’. (T1 15)
I kept thinking I’d got pre-eclampsia because I had high blood pressure 
and protein in my urine and everything.’ (T1 13)
The women were aware that they had increased blood pressure and protein in 
their urine which are signs of pre eclampsia. One woman talked of her concern 
because she had these signs:
It was more the fear you know, because everything’s so hard you know, 
like all the water retention and having to keep coming in for these tests ’ 
because there were signs of pre-eclampsia and that fear that you’re going 
to harm the baby you know’. (T1 10)
The woman was finding pregnancy hard because she had complications which 
meant that she had to go to the hospital for monitoring. The tests showed pre­
eclampsia and she was frightened that the baby would be harmed. Heightened 
anxiety in relation to the health of the baby in pregnancy is a commonly 
experienced phenomena for many pregnant women (Glover and O’Connor 2006) 
and it would appear that for women with DM there is additional anxiety in relation 
to possible medical complications from the DM. It may be important to 
encourage reduction of stress levels for these women as a study published by
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O'Connor et al (2002) suggests that high levels of cortisol produced when a 
woman is anxious may have harmful effects on the fetus and even increases the 
risk of behavioural problems in early childhood.
8.8.5 Complications in labour or with birth
8.8.5.1 Planned Early Delivery
When discussing the complications with pregnancy the health professionals
commonly talked about planned early delivery of babies for women with DM.
‘Nobody gets past thirty nine weeks. We deliver them all at thirty nine 
weeks and quite a lot of them are only going to thirty six or thirty seven, 
and we do have a question that they’re safer in the cot, but people don’t 
like to say really.’ (HP 8)
It appeared common policy across all Trusts to ensure women with DM delivered
their babies by thirty nine weeks although I could not find any clear national
policy giving guidelines to this effect. This policy meant induction of labour and
caesarian section for many women. The rationale appears to be the prevention
of excessive fetal growth but Kjos et al (1993) did not find any benefit in a
randomised control trial of women with DM either induced or randomised for
routine management. Yogev et al (2004) also found higher rates of caesarean
section in those women undergoing induction of labour and this agreed with
comments from one professional:
‘I mean, the caesarean section rate of diabetics is outrageously high. It’s 
because we induce them. I don’t allow mine to go over thirty nine weeks. 
By doing that, we’ve not had a still birth. That’s over-aggressive. I’ve 
allowed very few of them to go over term with diabetes, even in those with
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perfect control, because I know, even on perfect control, if we lost a baby, 
I would be criticised in hell, because we know the risk. (HP 4)
The professional was aware that by inducing women by thirty nine weeks this
increased the rate of caesarian sections that were performed. However they
were not prepared to take the risk of a poor birth outcome by delaying delivery
even in women who had well controlled blood glucose levels. This appears to
be a medicalised perspective with concerns of medical negligence and does not
appear to be backed up by evidence for those women will good glycaemic
control. If such women have worked hard throughout pregnancy to keep good
glycaemic control, then such birth management takes control away from women
who then are subjected to medical procedures because of the induction of
pregnancy rather than having the choice of a natural birth experience. The
professional was worried about being criticised or sued for leaving a woman to
give birth naturally in case there was a problem with the outcome.
One of the women with DM was aware that she may not have a ‘natural’ birth but 
thought that obstetricians were in general endeavoring to facilitate more natural 
births in women with DM:
‘I do admire that they’re trying to get the numbers of natural birth amongst 
diabetics higher but I think that sometimes they just have to admit its not 
going to happen with some particular people. So when we’d been shown 
around the hospital, you know like they have the tours don’t they of all the 
expectant mums, I actually did go into the theatre and I made [partner] go 
into the theatre, because I knew I’d end up in there. I know that sounds 
awful and it sounds terribly like I was giving up but it was more about, it 
had just been tough enough, that I felt like, is it 80% of diabetic births end 
up in a caesarean so I wasn’t that fit, that I was to be one of the ones that 
was going to break that mould, and I actually think given my choice again I
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would have insisted on having a caesarean straightaway, because I was 
induced for nearly two days before they did the caesarean' (T1 10).
This woman felt that a high percentage of women with DM delivered by a 
caesarian section and she was sure that because she was not very fit that this 
may well happen in her case. She made sure that she and her partner were 
prepared by going on a tour of the hospital delivery theatre. She felt that in 
admitting that she may have a caesarian she would be thought defeatist but she 
suggested that the pregnancy had been tough and any more problems would be 
too much to cope with. In the end wished she had asked for a planned caesarian 
as she was in labour for two days before eventually having a caesarian section.
8.8.5.2 Premature Delivery
Several of the women had premature births due to complications of DM causing 
premature labour:
‘My waters broke at twenty weeks and they left me until thirty four weeks 
and my blood pressure went sky high and it was just you know.’ (T2 13)
‘It may have been because the baby dropped down, but I’m quite pleased 
she was born like that, at thirty thee weeks. I was frightened at the time, 
but now I can see that it was the best thing that could have happened. It’s 
made no difference to her and she’s in a school year above, so it’s quite 
handy. She was August instead of September.’ (T2 16)
These women had gone into labour and delivered in the second trimester of
pregnancy which thankfully appeared to have a satisfactory outcome but could
have caused further complications for the baby as babies born early have a
greater risk of birth and neonatal complications such as intercranial
haemorrhage, respiratory difficulties and feeding difficulties (England 1996).
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Another woman had large babies which were delivered early:
‘I had them all early about thirty seven weeks - the first two were normal 
deliveries and the last an emergency Caesar - they were all big babies’
(T1 1)
This woman had had three pregnancies all of which were large babies. This can 
be due to macrosomia a complication of DM related to glycaemic control, which 
can lead to complications during labour such as shoulder dystocia and 
obstruction.
8.8.6 Summary
It can be seen from these findings that women with DM can have complications 
in pregnancy due to existing medical conditions and poor glycaemic control. The 
health professionals were concerned about cardiac events occurring in women 
who leave childbearing to later in life. One professional suggested that all 
women should have their children early to avoid complications, but this may not 
fit with the views of women who may follow demographic trends of later 
childbirth.
The health professionals interviewed spoke of caring for women who 
experienced complications during pregnancy and labour including pre eclampsia, 
premature labour and the devastating outcomes of stillbirth or neonatal death. It 
appears that pregnancy is a time of great anxiety for many of the women and 
some of the women talked about miscarriage or abortions that they had
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experienced. These had had long lasting psychological effects on the women 
who felt guilty that the occurrence was their fault for not controlling their blood 
glucose levels.
The women are more likely to have medical intervention and early induction of 
labour by thirty nine weeks which led to them often having a caesarian section. 
This appeared to be ‘normal practice’ despite lack of any national guidelines and 
little evidence from the literature to support this in women who had well controlled 
DM.
8.9 Training issues regarding preconception and pregnancy for women 
with diabetes.
8.9.0 Introduction
The health professionals were asked during the interviews about any training that 
they had had or were aware of in relation to preconception care and care in 
pregnancy for women with DM. Training received in this area appeared to fall 
into the three categories of ‘study days and updates’; ‘formal training’ and; 
‘learning on the job’ and the findings are presented below.
8.9.1 Study days and updates
The health care professionals were asked about any study days available with a 
specific focus on preconception or pregnancy and DM. Some professionals felt
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that DM and pregnancy were a specialist area and so study days would be aimed
only at the diabetes specialists specifically looking after women in pregnancy
‘I think probably there are study days that are around pregnancy for 
people, health care professionals, who have day to day contact with 
pregnancy and diabetes.’ (HP 12)
Other centres tried to generate interest by holding regular update sessions,
however one health professional felt that the GPs were not always interested in
the topic of DM and pregnancy:
‘its interesting as well when we hold sessions, educational sessions for 
GPs, we have an annual masterclass and that here, some of them are not 
very much, they’re not very interested in pregnancy, they always seem to 
think oh well, its a secondary care thing.’ (HP 16)
The health professional felt that GPs did not always have an interest in meetings
where pregnancy and DM were discussed as they felt that it was not relevant to
them in primary care. However as has been discussed in Chapter Three,
diabetes services are moving into primary care and GPs are more likely to be
caring for women with DM who are pregnant.
One NHS Trust held quarterly shared care meetings and recently had had 
speaker on pregnancy and DM:
‘Our GPs on the whole are cracking. We have these regular quarterly 
shared care meetings for the GPs, practice nurses, well community 
nurses, uncle Tom Cobbly and all that, the specialist team come as well, 
and the DNS has been and spoken on that (preconception & pregnancy) 
and said to them that we have this clinic (preconception) and if ever 
anybody expresses a desire (to become pregnant), we want them please.’ 
(HP 8)
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The health professional had been asked to talk at the multi professional shared 
care meeting about preconception and pregnancy care for women with DM. The 
health professionals were encouraged to refer any one who might be thinking of 
becoming pregnant to the Diabetes Centre.
In one PCT practice nurses were regularly updated at local meetings, again by 
Diabetes Specialist Nurses:
The Practice Nurses are regularly updated by the PCTs, Diabetes 
Specialist Nurses. They’ve recently had some pump training and they are 
looking after girls with pumps in pregnancy.’ (HP 8)
The practice nurses had been updated on use of insulin pumps in pregnancy as
they are being used to give better glycaemic control rather than regular insulin
injections. The women with DM can then be cared for in Primary Care by GP
practice nurses who have knowledge of pumps as modern methods of insulin
delivery.
One of the dieticians had been updated at a recent meeting:
‘I went on a DMEG which is a dietetic diabetes working group a couple of 
months ago and the afternoon was pregnancy. So they had a bit there 
about pre pregnancy as well, pre pregnancy clinics.’ (HP 13)
8.9.2 Formal training
A majority of the health professionals caring for women with DM had received no 
formal training in specifically caring for women in pregnancy and in fact were not 
aware of any courses with this focus:
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‘I’ve not seen any. There was a Warwick diabetes pregnancy day which 
actually was at end of the week of talks for the people doing a broad 
course. It was touched on. I don’t think there was a formal session ’ (HP 
6)
‘I don’t think so, not now, certainly not around here. All of our clinics have 
a GP and a practice nurse in them who are Warwick course trained and 
they’ve got a Warwick Postgraduate Certificate in Primary Care Diabetes, 
they’re all well trained.’ (HP 11)
The Warwick Diabetes programmes are well recognised courses for health
professionals specialising in DM in England. The health professionals were
aware that the curriculum at this and other diabetes post graduate courses briefly
included DM and pregnancy but not specifically preconception advice. Again
pregnancy issues were seen as a specialist area of work;
‘it is a bit of a specialist area, it’s not the same as talking about 
complications in type 2 or type 1 diabetes, its more specialised than that 
so it’s a small percentage of health care professionals that are specialists 
in pregnancy in diabetes. So I think therefore I don’t think there are so 
many courses around.’ (HP 12)
Another diabetes health professional felt that it was a specific job within diabetes 
care:
‘X [DNS] looks after the pregnant women, so I mean, if we want to do any 
training days or, things do come up but I haven’t actually gone forward to 
do any of those just because I think its more her job and less my job at the 
moment. (HP 15)
This professional had not attended any training as she felt it was a specific part
of DM care and another Diabetes Nurse Specialists role rather than part of her
job. This had caused problems for the Diabetes Team in one Centre:
‘Well, weekends, they can’t cope at a weekend or if I’m on holiday, 
because I’m the one that mainly deals with pregnancy, the others do it as 
well, but if I’m not here, the mid wives can be like can you come up here 
now’, - they don’t quite appreciate that they’ve got to take some 
ownership of this as well.’ (HP 16)
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This Diabetes Nurse Specialist felt that the midwives should be trained in care of 
women with DM so that they could take responsibility for caring for women with 
DM who were pregnant.
8.9.3 Learning on the job
Many of the health professionals said that they had ‘learnt on the job':
‘I mean, my colleague does the clinic [pregnancy], so I actually learn quite 
a lot from the pearls that fall from her mouth now really.’ (HP 2)
‘I learnt just from doing it for many many years.’ (HP 16)
‘As far as training goes I mean, I think most of it has been learning on the 
job if you like, so having been in diabetes for say ten years, over those ten 
years I’ve learnt an awful lot about pregnancy.’ (HP 11)
These professionals had gained experience whilst working in the field and from 
colleagues rather than from attending specific courses on DM and pregnancy. 
This ‘experiential’ learning (Kolb 1984) along with reflective practice has been 
shown to be a valuable way to learn nursing skills (Burnard 2002) but it could be 
argued that there is also a need for sound knowledge of the theory underpinning 
the skills and discussion of evidence to support such theory and these 
professionals may not have been offered this opportunity.
8.9.4 Summary
This section has highlighted that the health professionals feel that little training is 
available in relation to DM and pregnancy and many develop their knowledge by
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‘learning on the job’. For some professionals, care of women with DM in 
pregnancy was seen as specialist role and therefore some professionals were 
reluctant to do training in this field, this meant that some professionals did not 
attend organised updates or study days where the topic was DM and pregnancy.
8.10 Policy in relation to preconception care and pregnancy.
8.10.0 Introduction
The health professionals were asked about policies that they followed in relation 
to preconception care and care in pregnancy and the findings from the interviews 
are presented below.
8.10.1 Care Pathways for Preconception Care
None of the centres had a ‘formal’ care pathway developed specifically for
preconception care of women with DM:
Q:Do you have any local policies or care pathways, that you use for 
people that are planning pregnancy?
A: Yes, we have, well we have, I’m just trying to think if it’s written down, 
but we certainly have the informal pathway that we advise them to be well 
controlled, so they have a decent HbA1c under seven, certainly under 
7.5% for three months prior to pregnancy, that’s under the local 
guidelines if you like. You know, I don’t think it’s written down.’ (HP 14)
An informal pathway was followed by the diabetes health care professionals to
establish good glycaemic control for three months prior to conception but there
was no written guideline or audit of practice and this could mean inequity of care
for women. The NSF for diabetes (DH 2001a) recommends annual information
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be given to all women of childbearing age and without formal NHS Trust or 
Primary Care Trust guidelines this may not occur.
One centre used the patient’s notes to record conversation about preconception 
issues:
‘We like them to be aware of the increase risks of pregnancy and we do 
try and make a policy, we don’t have a formal care scheme that we do, we 
usually write in the notes if we’ve talked or printed in the letter that we talk 
to girls about pregnancy when they’re seen.’ (HP 10)
Another centre had a proforma for completion at the preconception clinic 
appointments:
W e don’t really have a local policy as such on pre conception, we have 
forms that we will fill in at the preconception clinic. What we give them in 
information is the diabetes UK, pregnancy and diabetes booklet because 
that’s so good -  very comprehensive; you can’t really better that one.’ (HP 
11)
The proforma was used to record care given during preconception care 
appointments and the women were given an information booklet on DM and 
pregnancy to back up advice given. Although these are useful guides for 
practice, without any formal guidelines women may not receive preconception 
care as is recommended (DH 2001a). This links to narrative in Section 8.1.2 
(Information and advice) and will be discussed in Chapter Ten and Eleven with 
recommendations for practice.
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8.10.2 Care Pathways in pregnancy
Health professionals at all but one of the centres were aware of care pathways 
used for women who were pregnant:
‘In pregnancy; yes. We have complete care pathways. We have 
complete obstetric pathways and we have complete obstetric guidelines 
for labour ward management, including the management of diabetic keto­
acidosis, should they come in ill.’ (HP 4)
‘Yes. We have - 1 don’t know if you’d call it a ‘care pack’ -  but we’ve made 
our own diabetes record sheets so that they get retinal screening in the 
first trimester and if they’ve been on it, then they get it again when they’re 
pregnant. Otherwise they only get one other. They’d all get their renal 
functions done every trimester. We don’t get excited about feet in 
pregnancy. I don’t know if anybody else does. They get scanned at -  
well, they’re supposed to get an early scan, sort of seven weeks -  they’re 
supposed to get a scan at twelve weeks for nuchal thickness and then we 
tend to scan them every four to six weeks. Then they get scanned at 
twenty eight, thirty two and thirty six for growth. Then they get an extra 
scan at Guys. At twenty weeks they normally scan here and they get an 
extra scan at Guys for cardiac stuff.’ (HP 8)
In most of the centres there were clear written pathways and documentation for
women with DM attending during pregnancy in terms of medical tests and scans.
Women were referred for extra scans and tests in comparison to the general
population confirming the concept that these women experienced a very
‘medically focused pregnancy’ as has been discussed earlier this chapter and will
be explored further in Chapter Ten.
Rather than having a care pathway one centre followed a jointly developed local 
policy ‘care of the women with DM during pregnancy.’
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‘We do follow, there were some guidelines drawn up about 3-4 years ago, 
perhaps a bit longer, from South West Thames as it was then, so it must 
be a bit longer, there was a conference of interested parties and 
guidelines were drawn up really in the absence of national guidelines - 
perhaps they’re a bit dated now.’ (HP 10)
There has been much controversy in relation to national guidelines for care of
women with DM during pregnancy as seen in the literature (NICE 2005a,
CEMACH 2007) and some individual units have therefore created their own local
guidelines and policies. NICE are due to report in 2008 recommending national
guidelines for care and these will be welcomed by many health professionals
(please see Chapter Twelve Addendum).
8.10.3 Summary
There is evidence of use of informal care pathways for preconception care in 
most of the diabetes centres and some had a notes template or form to 
complete. However there were no formal guidelines on preconception care and 
this may mean that women may not receive preconception care as is 
recommended (DH 2001 a) and there was no review or audit of practice in this 
area to evaluate care given.
For care during pregnancy there were clearer care pathways and local policies in 
use but as yet due to the lack of national guidelines no consistency in these was 
evident. It was hoped that a report from The National Institute for Clinical 
Excellence (NICE) would provide future guidance when published later this year.
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8.11 Conclusion to Chapter Eight
This chapter has presented the findings in relation to DM and pregnancy for 
women with DM and has included: knowledge and expectations of pregnancy 
and DM; glycaemic control in pregnancy; preconception care issues; care during 
pregnancy; training issues and; current guidelines and policy. It can be seen that 
for women with DM, pregnancy can bring specific challenges and issues which 
require consideration by the women and the health professionals caring for them.
One challenge is in relation to women receiving information about preconception 
care as recommended by current policy (DH 2001a, CEMACH 2007). Although 
there were no formal care pathways at the centres in relation to preconception 
care, the health professionals felt that they gave all women preconception 
advice. However, it appeared that some women had no recollection of being 
given such advice and were even not aware that having DM could affect 
pregnancy. Women who had become pregnant did not appear to have made 
changes to their diet and lifestyle as recommended by the BMA (2007), DH 
(2007d) and Food Standards Agency (2008) and many had not planned their 
pregnancies. Reasons for not planning pregnancy were presented and included 
differing psychosocial perspectives and beliefs and ambivalent use or failure of 
contraception, all of which appear to deserve further investigation in terms of the 
prevention of unplanned pregnancy.
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The findings have raised the need to review how health promotion information is 
presented by health professionals and there is evidence that it is important for 
health professionals to have a good relationship with women with DM in order to 
be sensitive to an individual woman’s receptiveness to preconception 
information. There also appeared to be a need for greater awareness by primary 
health care professionals to prescribe the higher 5mg dose of folic acid to women 
with DM planning pregnancy in order to prevent neural tube defects.
The co ordination of care between primary and secondary care was seen as 
important by the DM health professionals in promoting the best care for women 
with DM and diabetes professionals highlighted their concerns regarding late 
referral for specialist antenatal care from primary care services, which they felt 
could lead to poor outcomes in pregnancy.
The findings demonstrate that becoming pregnant is a great motivation for 
women to control their blood glucose levels to ensure optimum outcomes of 
pregnancy and women worked hard and gained good glycaemic control for the 
first time. However few women had gained good glycaemic control prior to 
conception and by the time pregnancy is confirmed damage to the fetus may 
have already occurred. There was concern over the safety of certain OHAs and 
insulins during the preconception period and during pregnancy and women 
should have a medication review to prevent teratogenic effects.
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Women with DM can have complications in pregnancy due to existing medical 
conditions and poor glycaemic control and some of the women talked about 
miscarriage or abortions that they had experienced. These had had long lasting 
psychological effects on the women who felt guilty that the occurrence was their 
fault for not controlling their blood glucose levels. The health professionals 
spoke of caring for women who had experienced complications during pregnancy 
and labour including cardiac events, pre eclampsia, premature labour and the 
devastating outcomes of stillbirth or neonatal death. In order to prevent 
complications and avoid concerns of medical negligence, it appeared that it was 
normal practice to induce labour by thirty nine weeks as was evident in the local 
formal care pathways for pregnancy and labour. Such intervention often resulted 
in women having a caesarian section and for women who have well controlled 
DM throughout pregnancy there appears to be no clear evidence to support this 
practice.
There was thought to be little formal training in DM and pregnancy available and 
many of the professionals had developed their knowledge by experiential 
‘learning on the job’. For some professionals, care of women with DM in 
pregnancy was seen as specialist area and some professionals were reluctant to 
do training in this field as they did not see it as part of their role. This may result 
in missed opportunities for highlighting preconception care issues when women 
attend for general DM care.
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The next chapter presents findings in relation to contraception for women with 
DM.
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CHAPTER NINE 
Findings: Contraception
9.0 Introduction
This chapter presents data relating to knowledge and use of contraception by 
women with DM, and knowledge and advice given by the health professionals 
involved in their care. My initial data base study found significant differences in 
the prescribing of hormonal contraception to women with DM compared to the 
general population within General Practice (see Chapter Five) and the 
questionnaire data presented in Chapter Six show that women with DM use a 
variety of methods of contraception. In this section the comments from the 
questionnaires and the narrative from the semi structured interviews will be 
presented, including reasons for choice of contraceptive methods and issues 
relating to knowledge and service delivery of contraception.
9.1 Advice and discussing contraception
Women were asked about advice that they had received regarding contraception. 
The questionnaire data showed 35.5% of the women completing the 
questionnaires said that they had not received advice in the past year from any 
health professional, 48% had had advice from their GP surgery and only 8% 
recalled having being given advice from diabetes health professionals. During
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the interviews the question was repeated: ‘Has anyone given you advice or 
mentioned anything about contraception or pregnancy at your appointments?’
Several of the women confirmed that they did not recall being given any 
information, either by any health professional or at their appointments for DM 
care.
‘No never.’ (T1 6)
‘No not with diabetes - 1 have been told at school and Uni and stuff about 
contraception.’ (T1 8)
One woman reflected her surprise at not being advised about contraception as 
she had had an unplanned pregnancy.
‘It’s funny that nobody really spoke to me about it, because contraception 
was a bit of a disaster.’ (T1 10)
On reflection, this woman thought it strange that no health care professionals had
spoken to her about her use of contraception as she had had an unplanned
pregnancy and had had difficulty finding a suitable method of contraception.
However I did not ask her if she had sought or asked for advice herself and as
will be discussed later it may be that the professional that she saw was not keen
to initiate such a conversation.
In the interviews the health professionals involved with the care of women with 
DM were asked about their knowledge of contraception for women with DM and 
their involvement in advice and prescribing for the women.
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Asked if they specifically talked about contraception at consultations, some of the 
Health Professionals stated that they regularly mentioned the topic.
‘I haven’t made any attempts to set it up as a contraceptive service, we 
haven’t got the skills. But I do talk to people about what they’re using for 
contraception.’ (HP 8)
This professional felt that a contraception clinic for women with DM attending the 
diabetes centre would not be feasible implying that the health professionals 
would not have the specialist knowledge and skills required in this area but that 
she did talk to the women with DM about contraception.
Other Health Professionals were very clear that reliable contraception must be 
used particularly in relation to poor glycaemic control:
‘I talk about, (contraception) especially when glycaemic control is not--------
optimal and there is clinical contraindication to it (pregnancy). I expressly 
state that and document that they do not get pregnant.’ (HP 3)
This doctor stated that if a woman had suboptimal blood glucose levels then she
would be advised not to become pregnant and that contraception was then
discussed. He felt it important to document this discussion presumably as good
practice to inform others of the consultation but also perhaps to prevent legal
comeback if the woman did become pregnant and have complications. In my
review of the literature such medial advice on waiting for optimal glucose control
was noted by Thomas (2003) to cause frustration for women planning to become
pregnant and indeed Holing et al (1998) found it to be linked to unplanned
pregnancies.
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One nurse felt that the diabetes professionals gave clear messages to women 
attending the diabetes service in regard to using contraception.
‘We do talk to our women about contraception and we certainly make sure 
they are using some form of contraception and it is an acceptable form of 
contraception, so that it’s a reliable form.’ (HP 11)
The approach used by this professional to discuss contraception with women 
with DM sounded didactic and proprietal and emphasises a medicalised and 
patriarchal approach to care which will be discussed later in Chapter Ten. The 
professional stated that they advised women with DM about contraception, and 
that specific methods of contraception were discussed to ensure that the women 
were using reliable methods. These were seen by this professional as hormonal 
methods which in some cases are not suitable or of choice for every woman 
(Guillebaud 2004).
Some professionals had found ways of bringing the topic of contraception into 
conversation:
There also is a way of dressing it up like ‘If you don’t want to get 
pregnant, take the pill dear.’ It’s a way of bringing that subject up, 
particularly if their parents are there, which can be difficult with 16 and 18 
year olds.’ (HP 6)
The topic of contraception was seen as a difficult subject to broach with 
teenagers who firstly may feel embarrassed discussing it, and secondly may 
have parents with them during the consultation who may not be aware of the 
teenagers sexual activity. This professional wanted to highlight the issue and so
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tried to bring up the subject in a more general way rather than asking specifically 
about contraception use, however by referring to the young person as ‘dear’, it 
could be said to be patronising.
Another professional also said that she highlighted awareness in a general way:
‘I just highlight their awareness that they need to be careful with family 
planning. So basically, all I’m doing is flagging it, rather than flogging it.’ 
(HP 2)
Specific advice or discussion about contraception therefore did not take place but 
rather the message was given that the teenager needed to use contraception 
carefully and not get pregnant unintentionally.
Other professionals reflected that they did not consider a conversation about 
contraception as part of a regular consultation:
‘I always ask them what medications they take so they would naturally tell 
me whatever brand of pill they were taking. But no, I don’t suppose, I 
wouldn’t really see that as something I’d be aware of.’ (HP 14)
‘I think that on a general basis we probably don’t [talk about 
contraception)], thinking about it.’ (HP 17)
However others said that they were reluctant to mention contraception at all
during consultations:
‘I don’t feel qualified to advise people on family planning issues’ (HP 16)
‘I don’t know, I used to, but I don’t know any longer the best one in terms 
of side effects and things.’ (HP 15)
‘No, because my contraceptive knowledge is very, very, very small. I’ve 
never done any, so I tend to leave that to ... I either suggest that they go
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and speak to their Practice Nurse or ask our doctors here if they’re under 
them ... and obviously the doctor she sees will obviously discuss, but I 
stay well out of that one.’ (HP 7)
These professionals feared that they did not have the knowledge or that their
knowledge was out of date and so did not discuss the topic with the women.
One stated that she referred women to a practice nurse at the GP surgery or that
the doctor was assumed to give advice. This highlights issues in relation to
policy which state that women with DM should be given contraceptive advice (DH
2001 a, CEMACH 2007) and for the training needs of staff involved especially as
the topic may be raised by patients with DM in the course of a routine
consultation as is seen below.
One health professional who did not specifically set out to discuss contraception 
found that the topic came up during consultations:
‘I think the great thing about being a Nurse and a Specialist Nurse is that 
they feel they can talk to you sometimes more than the doctor, so yes, it 
sort of comes into - It just sort of evolves when you’re talking to somebody 
in a clinic environment.’ (HP 17)
This nurse picked up on the fact that patients often feel that nurses are seen as
more approachable than doctors (Horrocks et al 2002) and women may develop
a relationship with a diabetes specialist nurse where they feel able to talk about
more intimate or embarrassing topics such as contraception. It is therefore
important that in order not to miss an opportunity to prevent unplanned
pregnancy that the diabetes specialists feel knowledgeable and able to discuss
contraception with women with DM.
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9.2 Provision of services
During the interviews the health professionals discussed the provision of 
contraceptive services for women with DM. For the majority of health 
professionals it was seen that provision of contraception and contraceptive 
services were very much the role of the GP and practice nurse rather than part of 
DM care.
‘Well, the most advice on contraception that I'm aware of is given again by 
general practice, because that’s where the contraceptive services sit, 
rather than here.’ (HP 11)
I don't tend to interfere with peoples family planning so maybe..That’s 
normally GPs. The GPs normally give that. Yes. GPs and Family 
Planning Clinics. (HP 6)
‘Basically, to me if they are sexually active they should speak to their GP 
about going on the pill....’ (HP 15)
This referral to General Practice for contraception services would concur with the
questionnaire data which showed 48% receiving advice via the GP surgery. The
current government policy (DH 2007c) rewards GPs for contraception care and
women are encouraged to attend the practice nurse or GP clinics. However two
Health Professionals recommended that women attended family planning clinics.
‘If someone asks I usually send them off to the family planning clinic for 
advice.’ (HP 16)
I always actually recommend they go to family planning service in a centre 
rather than GP. (HP 14)
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These diabetes nurses work at a centre which has a regular community family 
planning clinic on site with good access for all women and they suggested that 
the women with DM attend these clinics where more specialist advice may be 
available. Such services are not available in all areas as many community clinics 
are only providing a service to young people with other women expected to 
attend the GP surgery.
9.3 Choice of methods
9.3.0 Introduction
As can be seen from the questionnaire study, women with DM use a variety of 
methods of contraception (see Chapter Six). In order to explore reasons for their 
choices, one of the criteria used for selection of women for semi structured 
interview was that the women had used differing methods of contraception. In the 
questionnaire women were asked about methods of contraception they had used 
and were asked to comment on their choice of contraception i.e.(Q 8 Please can 
you explain why the method o f contraception you use is best for you? and Q 9. 
Has having diabetes affected your choice o f contraception?). During the 
interviews the women were asked about their contraceptive ‘history’. This 
included reasons why they had chosen to use methods at a particular time and 
any effects they considered that having DM had on their choice of contraception. 
The following sections will highlight narrative in relation to choice of methods by 
women with DM.
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9.3.1 Not using contraception
The questionnaire study showed that one third of the women were not currently
using any form of contraception. If reasons were given it included that they were
pregnant or trying to get pregnant or were not in relationships where
contraception was required. From the interviews it appears that some of the
women had put themselves at risk of unplanned pregnancy by not using
contraception and this included some of the women who had given birth within
the last four months. One woman had recently delivered following her third
unplanned pregnancy.
‘So, contraception after the two children, I did think of but never really got 
round to doing it’ (T1 4)
Contraception for this woman appeared to be a low priority in the scheme of 
juggling her daily life with the children and Furedi (1997) discusses how women 
can be at risk of an accidental pregnancy soon after the birth of a planned child 
as they are occupied with mothering and have not got into a contraceptive 
regime. For women with DM who have the extra work of checking blood glucose 
levels and attending appointments this may present an even greater risk of 
unplanned pregnancy.
Another woman with a six week old baby had decided not to use contraception
as she had had to have fertility treatment with her first pregnancy.
‘No I am not using anything -  it took me so long before, I would be happy 
to be pregnant again.’ (T1 6)
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She now understandably feels that it might take more treatment or a long time to 
become pregnant again so is not using contraception. However women who 
have previously had fertility treatment may often have a spontaneous pregnancy 
the second or subsequent times (Shimizu et al 1999, Craft 1999) and for a 
woman with DM this may mean that blood glucose levels are not well controlled 
at conception as in the postnatal period glycaemic control is often erratic 
(CEMACH 2007).
Another woman with a seven week old baby had yet to decide on a method of 
contraception.
‘I don't want anymore, I will be using something but I don’t know what yet’ 
(T2 12).
She then went on to say that she was told that she ‘couldn’t take anything for six 
weeks after having him’. As can be seen in the literature (JFPRHC 2004, 
Guillebaud 2004), women can start most hormonal methods of contraception 
within twenty one days of giving birth even if they are breast feeding and 
therefore prevent an unplanned pregnancy.
9.3.2 Natural Approach to Contraception
Some women took a ‘Natural approach’ to contraception by either choosing to 
use natural methods such as fertility awareness or a prediction device such as 
‘Persona’.
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Some women felt that they didn’t need to use contraception every time they had
sexual intercourse as they understood that a pregnancy could only occur at
certain stages of their menstrual cycle.
‘I was only in the first week of my cycle so I didn’t think I could get 
pregnant. I was only day six of my cycle and so I didn’t use anything.’
(T1 4)
For this woman using ‘natural family planning methods, the misunderstanding of 
the risk of pregnancy occurring during her menstrual cycle resulted in a third 
unplanned pregnancy.
Another woman also became pregnant by ‘accident’ by only using condoms at 
certain times during her menstrual cycle.
Q Were you using contraception?
A ‘Well not all the time - 1 took the natural approach and was worried 
about chemicals in my body so we used condoms (pause) at the right 
time.’ (T1 3)
The ‘right time’ was described as the periods of her menstrual cycle when she 
felt she could be fertile but this had not proved successful as a method of 
contraception. Despite only one of the interviewees stating in the questionnaire 
that she currently was using ‘natural methods of contraception’, a ‘natural 
approach’ was a common thread running through the interviews. Women with 
DM appeared to have particular concerns about ‘adding extra chemicals’ or 
‘hormones’ to their body on top of the insulin which they were already giving 
themselves for their DM and therefore they were choosing not to use hormonal 
methods of contraception.
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Tm not a great believer in all the hormones going down... I’m not 
particularly keen on the pill.’ ‘Even though I’m on insulin, it’s not like a 
non-diabetic - putting more hormones into your body, being on the pill’ 
(T111)
Q :Did you ever use hormonal methods like the pill?
‘No I didn’t like the idea of putting chemicals in my body. (T1 3)
The women who had used a natural approach were asked about their knowledge 
of natural family planning methods and how they had come to learn about the 
method.
‘I used to count the days and thought it was OK except for around days 14 
-  that’s when you ovulate - 1 read on the internet.’
Q: Did you do anything else?
No -  what like?
Q: Such as monitoring your temperature -  some people do that -  
‘No I didn’t.’ (T1 3)
Q ‘When you said you used natural methods, did you learn about fertility? 
‘Yes, I’d read about all the methods and avoiding pregnancy ... The 
calendar, I got a book - I sort of knew a bit anyway — I am not sure — 
maybe from magazines then I went on the internet and found a book.’ 
(T111)
None of the women interviewed had received training in natural family planning 
methods which would be available from health professionals trained in the 
method (fpa 2007 a). They were only using a calendar to predict the fertile 
period and it can be seen from the literature that other indicators of fertility such 
as basal body temperature, cervical mucous and position of the cervix are 
important factors which together with the calender give a more accurate 
indication of a women’s fertility within her cycle (Fertility UK 2007).
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One woman had used Persona a natural contraception device which monitors 
hormone levels by urine analysis, but had an unplanned pregnancy by using it 
incorrectly.
‘I thought it was great and I also have always said anybody who has an 
accident with pregnancy they’re just a bit daft (laughs), but then I 
proceeded to do exactly that. Its my own fault entirely as it had an amber 
light that day and I thought ‘oh these things always have an error margin’, 
they’re be at least a ten percent plus or minus each way! (T1 10)5
This woman admitted that she had made a mistake in having unprotected sexual 
intercourse on a day when the persona machine had measured her hormone in 
her urine and indicated that she may be fertile. She had assumed that the 
machine would be calibrated with a margin of error and so risked not using 
contraception
Despite the natural method of family contraception being a reliable method if 
used correctly by motivated women with established menstrual cycles (Fertility 
UK 2007), it is frequently seen by many health professionals as an unreliable 
method equivalent to playing ‘Russian Roulette’ with a possible pregnancy 
(Hammond 2003). None of the health professionals that were interviewed 
mentioned it as a method that they suggested or that was used by their patients.
9.3.3 Barrier methods
Barrier methods such as condoms or diaphragms were chosen by some women 
with DM. Some of the women who said that they did not want to use ‘hormones’
5 the machine gives green light when it is safe to have unprotected sexual intercourse and red for 
not safe
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also chose condoms as their regular method of contraception and the 
questionnaire findings showed condoms to be the second most popular method 
of contraception after the contraceptive pill.
Some of the health professionals felt that the women should not just rely on 
condoms as a contraceptive method on their own.
‘I just stress that condoms alone are not really adequate because the risks 
of an unwanted pregnancy are too great in diabetes that they have to be 
ultra cautious. It’s something that I speak to all my young women about.’ 
(HP 11)
‘Basically, to me if they are sexually active they should speak to their GP 
about going on the pill because I think condoms are very hit and miss and 
you’ve got to be prepared, whereas if you’re on the pill you’re, to me -  
you’re less likely to get pregnant than if you have to rely on going out and 
buying condoms.’ (HP 15)
These concerns by the health professionals about condoms being unreliable or 
of not having them to use when required were borne out by some of the women 
during interview. The women talked of their intermittent or occasional use of 
contraception, which particularly related to the use of barrier methods that require 
insertion or application before sexual intercourse such as the diaphragm/cap, 
and condoms. .
‘I used the cap with a gel ... and it was, not always, we didn’t always use 
it. Sometimes we did, sometimes we didn’t. It was just how things went’. 
(T1 15)
‘Condoms - 1 didn't think they were reliable - especially when we ‘forgot’ to 
use them! (laughs).’ (T1 13)
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These women admitted to sometimes not using the cap and the condom during 
sexual intercourse and this subsequently resulted in unplanned pregnancies for 
both of them. Condoms can be a reliable method of contraception if used 
consistently and if used correctly by for example being put on before genital 
contact occurs. They also provide protection from sexually transmitted infection 
which is currently an important factor with the rise of infections in the UK (HPA 
2008). There is however evidence in the literature (Guillebaud 2004), of poor 
compliance with condoms and use of other barriers such as the diaphragm.
Other women were given advice by health professionals to use condoms without 
being offered a choice of other contraceptive methods and this could have put 
them at risk of pregnancy through poor compliance.
Q: I notice that you put on the questionnaire that you were using the pill 
but had problems with your blood pressure and are now using condoms 
for contraception - did the doctor advise any other methods?
A: ‘No - he said I should stop taking the pill as my blood pressure went 
high and that I should use condoms - my partner hates them though.’
(T2 9)
The woman was diagnosed with hypertension by her GP who had consequently 
told her to stop taking oral contraception and recommended using condoms. As 
she said that her partner hated using condoms there was a risk that they would 
not be used reliably. The literature finds no contraindication to progestogen only 
methods of contraception for women with hypertension (fpa 2007a) and these 
could have been a suitable and more reliable option for this woman.
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Another woman said that she was only ever offered barrier methods by her GP.
‘I’ll be honest, they’ve never ever offered me any kind of alternative, it was 
always condom or that’s it pretty much, coil or the female one -  
diaphragm, oh god no! (laughs). Okay, so it was sort of a physical barrier 
basically.’ (T1 10)
This woman felt that barrier methods of contraception were the only choice 
offered to her by the GP and her disparaging remark (Oh God no!) about the 
diaphragm showed her possible reluctance to use such methods. It may have 
been possible that a progestogen only method could have been a suitable option 
for this woman who instead went on to use ‘natural methods and had an 
unplanned pregnancy.
Another issue for those using latex condoms or the latex diaphragm is that some
vulvo-vaginal medication can have the effect of weakening the latex and
therefore reducing the efficacy of the method. One such medication is anti fungal
treatment for Candida. This is often prescribed to women with DM as they
frequently suffer from this condition due to high glucose levels providing a
optimum medium for the growth of Candida as one woman decribed:
‘I’ve always had a supply of caniston, the cream and the pessaries, so as 
soon as I think something is not right, I will treat it. And if my blood sugars 
were a bit up for a period of time, thrush tends to be around then’. (T1 15)
During the interviews the women were asked if they had received any information 
regarding latex condom use and vulvo -vaginal medication and none of the 
women said that they had been given any information either by their GP, health 
professionals treating their DM or the pharmacist. For example :
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treatment for thrush?^ ^  ^  lnformatlon about condoms and using
A ■ XA/U^i. i - ! i j- . _A: What kind of information? 
Q: Explains
A: Umm - no I didn’t know about that. (T1 1)
This iack of awareness couid iead to an unplanned pregnancy if the women did 
not read the patient information leaflet carefully and either use non latex 
condoms or diaphragms or use a different method of contraception (CKS 2007).
9.3.4. Hormonal contraception
My database study has shown that there was a difference in prescribing of
hormonal contraception to women with DM compared with the general population
and from the questionnaire it can be seen that a,though many of the women were
us.ng hormonal contraception successfully, others stated in their comments that
they had had problems. The interviews thus aimed to explore reasons for
women’s choice of hormonal methods of contraception such as the combined
contraceptive pi,I, progestogen only pi„, imp,an, and depo provera injection and 
mirena intrauterine system.
9.3.4.1 Use of Hormonal methods
Th=,e to d lW n g  ^  ^  ^  ^  sife to ^  ^  ^  ^
*  . »  that sh. had been 
told that due to her DM she would not be allowed to use any hormonal methods 
of contraception.
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‘Diabetes means that you can’t take anything chemical or hormonal that’s 
how I’ve always understood. So there’s not really a lot of choice for you’. 
Q: Who told you that?
‘It was the GP who said I shouldn’t take it because of the added 
complications and in fact I’ve never been offered anything else, certainly 
even now.’ ( T1 10)
This woman understood from her GP that as she had DM she could not take the
contraceptive pill or any hormones as they may cause further medical
complications. She felt that this restricted her choice of contraception as she had
only been offered barrier methods. Several comments particularly in relation to
the use of ’the pill’ by women in the questionnaire data backed this view, but
could not be followed up by interviewing the participants:
‘In the past I was told that I could not take the pill’
‘Not allowed pill’
‘Would have liked the pill but told it was not suitable’
In interviewing the health professionals’, one was also of the view that some
women felt that they could not take hormones and that the GPs were reluctant to
prescribe hormonal contraception.
W e do periodically get ‘Oh, I’ve got diabetes and I’m not allowed to have 
pill’ which I think is a little old-fashioned. So if that does come up I try to 
say ‘Yes, you can, and I write to the GP - as long as your blood pressure 
is ok’. (HP 6)
This view that not using hormonal methods was seen as out of date advice for
women with DM, was also mentioned by other health professionals.
‘Years ago we always used to say they couldn’t sort of have oral 
combined pills and things like this... but I think with the advancement of 
both diabetes medications and of contraception medications its gone by 
the board now, they can have anything they want which is much better, 
much nicer’. (HP 14)
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‘In the olden days, when I was first a diabetes nurse there was issues 
about the contraceptive pill and diabetes, but I think that’s, I don’t think 
that’s a problem now’. (HP 16)
These professionals acknowledged that with advancements in medication for DM 
and hormonal contraceptives new guidelines meant that women with DM could 
now be prescribed hormonal contraception. The database study of prescribing in 
General Practice found less prescribing of hormonal contraception overall to 
women with DM for the year 2001. This would support the view of the women 
with DM that their GPs were less likely to offer them hormonal contraception. 
However the questionnaire data (Chapter Six) shows that the combined oral 
contraceptive pill was the most popular method of contraception overall for the 
women completing the questionnaires and the narrative relating to this method is 
considered next.
9.3.4.2 Combined oral contraceptive pill
The combined oral contraceptive pill is described in Chapter Three Section 
3.4.2.1, and is a popular method of contraception and in the questionnaire data 
seen as ‘convenient’, ‘reliable’ and ‘effective’.
Some women had taken it for many years with no problems or side effects:
‘I was on the pill for quite a few years.’ (T1 13)
‘Yes I was on the pill when I got diagnosed (with diabetes) and just 
continued afterwards.’ (T1 5 )
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I’m on the pill now, just microgynon. I’ve been on that since I was 16 
(26yrs in total). I think I had to switch it to a different one for a while when 
many years ago there was some sort of scare where somebody died. (T2
Other women had been prescribed the COC to regulate menstruation rather than 
for contraception:
They put me on a low dose thing, just to see if it would help my periods’
I had in the past used the pill, not so much for contraception, but my 
periods were playing up’. (T1 15)
These women had been prescribed COC which due to its mode of action of 
removing the ‘normal’ menstrual cycle by stopping ovulation and thinning the 
endometrium results in a lighter bleed (fpa 2007a).
Some women who had taken the COC, had had medical complications which 
had stopped them continuing with this method. In the questionnaire comments, 
there were several references to medical complications and these included 
raised Blood Pressure, Risk of thrombosis, Disruption of blood glucose control, 
Increase in weight and development of migraine, comments to support this 
include:
‘High BP on pill’
Taken off as Blood pressure raised’ 
‘Weight and blood pressure went up’. 
‘Put on two stone in weight’
‘Risk of thrombosis too high’
In 1995 there was a research report and subsequent media ‘pill scare’ suggesting that newer 
3rd generation pills gave an increased risk of venous thrombosis. This was subsequently 
rebuked with high court involvement in 2001 (Schering 2001)
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‘DVT on Pill’
‘Get Migraines on COC’
‘Affected control’
‘Caused depression and poor control’
The literature (fpa 2007a, Guillebaud 2004) advises that these events apart from
the weight gain and depression, could be side effects of the oestrogen
component of the combined pill and would be a reason to stop taking the COC.
Two women interviewed had been told that they should not take the combined
pill containing estrogen because of raised blood pressure.
0:1s there any particular reason that you thought that you shouldn’t be on 
the combined pill?
‘I don’t know - 1 think it was to do with blood pressure or something that 
makes it more risky to be on the combined pill?’ (T1 2 )
‘He (GP) said I should stop taking the pill as my blood pressure went high’. 
(T2 9)
The estrogen in the combined pill can cause a rise in blood pressure (Guillebaud
2004) and these women had been told that they should not take it for this reason. 
Another was changed from the COC to a progestogen only pill.
Q: So why do you think they stopped you from using the COC?
They thought that that would be a better thing to do because of, what is it
- estrogen in Yeah, they said the estrogen and it hasn’t got it in the
Cerazette.’ (T1 14)
This teenager had been prescribed Cerazette, a progestogen only pill as her GP 
felt that as she had DM it was a better option not to have a combined pill with 
estrogen. As this particular POP has a similar mode of action to the COC it has 
similar efficacy and can be seen as a suitable option (Guillibaud 2004). However
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the literature suggests that for women with DM without complications that the 
combined pill is a safe option (WHO 2007, Shawe & Lawrenson 2003, Girling & 
de Swiet 1997).
One woman had been taking the combined pill for several years and she suffered 
from focal migraines.
‘I get migraines about every couple of months and I need a whole day to 
recover’. (T1 5)
This woman should never have been prescribed the COO as it is contraindicated 
in women who have focal migraine (Guillebaud 2004). She could perhaps have 
been prescribed a POP as it is the estrogen component of the COO that 
increases risk of venous thrombosis in migraine sufferers.
Disruption of blood glucose control whilst taking the COO was mentioned by two
of the questionnaire respondents and one was followed up at interview.
Q: ‘You put on the questionnaire that hormonal methods of contraception 
disrupted your control -  can you tell me a bit about that?’
A: ‘I was on the pill for a number of the years whilst at university but I 
found the diabetes difficult to keep under control and I know during 
university years that you are not living a very healthy lifestyle but I found it 
very unpredictable. I did find it harder and was sure that the contraception 
disrupted it and I was sure that it was that as when I stopped it was ok so 
that’s why. ‘ (T1 2 )
This woman felt that taking the pill had affected her blood glucose control as 
when she stopped taking the pill it had become less unpredictable. However she 
was at university at the time and so her lifestyle and eating patterns may have 
also have disrupted her DM. The literature is equivocal about hormonal
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contraception and the effect on glycaemic control as although there are 
theoretical reasons for control to be altered in clinical practice this is rarely of 
concern (Shawe & Lawrenson 2003).
9 3.4.3 Progestogen Only Pill (POP)
The progestogen only pill is described in Chapter Three where literature is
discussed in relation to use of the POP in women with DM. As can be seen in
the literature the POP is seen as a good option for women with DM who have
complications or who smoke or who have other risk factors for the combined pill
(Guillebaud 2004, fpa 2007b). One woman felt that because of her DM she
should be prescribed the POP rather than the COC and was concerned that a
doctor had prescribed the COC.
‘I saw a junior Doctor a little while ago because I wanted to go back on the 
pill after a break and she prescribed Microgynon (COC) but I wasn’t sure I 
should be taking that with my diabetes so I made another appointment to 
see my normal Dr and he agreed with me that I should be on a mini pill 
and put me on Cerazette. I thought it was scary that if I hadn’t had that 
little bit of knowledge that I would be on the wrong pill. (T1 2 )
This woman was young and did not have complications of DM and could
therefore have been prescribed the COC as has been described before (WHO
2007, Shawe & Lawrenson 2003, Girling & de Swiet 1997). However Cerazette
is a relatively new progestogen only pill with clear benefits of anovulatory mode
of action and a 12 hour window in which to take it, making it a reliable choice.
Not all health professionals were up to date with this information and considered
POPs too unreliable for women with DM.
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'I'm instinctively wary of progesterone only pills, even though they’re 
handy from the metabolic point of view. I don’t think that most general 
women live organised enough life styles to take them by the clock. I think 
that’s a big risk factor.’ (HP 8)
This view relates to the old-style POPs which are not always anovulatory and
need to be taken within a three hour time window each day. However some
women with DM found that as they take Insulin at a regular time each day, it was
not difficult to remember their POP as well.
‘it is taken with my night time insulin so I would not forget’
In this respect, the old style POP if prescribed may be a suitable method for 
women with DM as they were less likely to forget to take it as they were already 
taking medication at this time.
The POP can have the side effect of changing bleeding patterns, making them 
irregular or causing amenorrhea (fpa 2007a) and for some women this is not 
acceptable. One teenager had found it hard to adjust to not having a regular 
period:
Tve now been put on Cerazette which is really good but I’m just coming to 
terms with not actually having a normal period which is quite difficult...’
(T1 14)
This woman had had irregular bleeding or no bleeding at all and found this 
difficult as she saw a regular period as reassuring and a confirmation that she 
was not pregnant.
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9.3A 4 Implant
The progestogen only Implant and literature relating to its use is discussed in 
Chapter Three. Only one of the women completing the questionnaire had an 
implant in situ and could not be followed up as she had not agreed to be 
interviewed. One of the women interviewed had used this method in the past 
and had found it very reliable.
‘After the second baby I had an implant put in which was great- it was a 
new thing and I didn’t have to remember anything -  It was reliable - 1 had 
it taken out to get pregnant with the third child. (T1 1)
The implant was seen as a reliable method of contraception and one that does
not need any action in terms of having to remember to take it. As seen in the
literature (fpa 2007a) it is licensed for three years continuous use and fertility
returns quickly following removal. However on asking the health professionals
about implants there appeared to be little knowledge about them and one health
professional was unclear in relation to suitability of use in certain age groups.
‘When I was working in East London they were using implants quite a lot. 
I think in an older population group you might say ‘You’ve got three 
children, you’re 30, you might be happy with implant, or if you’re having 
one, maybe having a second one in your late 30s. You may not want 
implants then.’ (HP 6)
The implant was seen by this health professional as suitable for women who had
completed their families rather than for younger women or women spacing their
families. The implant is suitable for most women with DM unless they have
complications and as a Long Acting Removable Contraceptive (LARC) it is
328
currently promoted in government policy to prevent unplanned pregnancy (NICE 
2005b).
9.3.4.S Intra Uterine Contraception (IUD)
The Intrauterine Contraceptive Device is discussed in relation to use in women
with DM in Chapter Three. From the questionnaire data four women (3.7%) had
an IUD in situ and three women (2.8%) an Intra Uterine System I US (Mirena)
containing progestogen. None of the women interviewed were using lUDs as a
method of contraception but one who had problems with menorrhagia was to be
fitted with an I US imminently.
‘Basically I've got a very heavy bleeding and I’ve been anemic because of 
it, so I think they wanted to just make sure and in fact the coil was actually 
offered to me more to try and prevent anemia than actually as a 
contraceptive device.' (T1 10)
The I US was offered to this woman as a method of stopping menorrhagia and
preventing her from further anemia. As can be seen in Appendix Seven the I US
works by releasing progestogen locally within the uterine cavity which thins the
endometrium therefore reducing blood loss. The IUS has revolutionised care of
women with menorrhagia and is also a very reliable contraceptive method. One
health professional regularly recommended it for her patients.
‘I am a fairly significant fan of Mirena for people with diabetes. 
They are as reliable as the combined pill and they reduce the risk of 
further infections which you get from an ordinary coil.’ (HP 8)
The professional recommended the IUS (Mirena) for women with DM as it is a 
reliable method. The IUS is another long acting reversible contraceptive (LARC)
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promoted by the government policy to prevent unplanned pregnancy (NICE 
2005b). One of the modes of action is to thicken the mucous in the cervix (fpa 
2007a). This then prevents potential infection entering the cavity which is of 
concern with insertion of the copper IUD.
The risk of infection with the IUD and the fact that women with DM are more 
likely to contract infections than the normal population meant that other health 
professionals felt it was a method that in the past had not been offered to women 
with DM:
‘Years ago we always used to say they couldn’t sort of have oral 
combined pills and things like this and they weren’t allowed to have 
Intrauterine devices and things because of infection.’ (HP 14)
However one of the health professionals now recommended it for some women
with DM:
The diabetic girls who are on insulin who are going off to College, we tend 
to go with the contraceptive pill, its easy its effective, slightly older ones 
we might recommend an IUD.’ (HP 10)
The health professional felt that older women with DM might be recommended to
use the IUD but not younger women. This may be as a result of the fact that the
IUD is not recommended to women without children due to potential infection
risks which can cause infertility. The IUS is therefore a better method for women
with DM who may be more susceptible to infection.
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9.3.4.6 Depo Provera Contraceptive Injection
Injectable methods of contraception and the use of Depo Provera is discussed in 
Chapter Three for women with DM. Data from the questionnaire study showed 
one woman (1%) was using Depo Provera as a method of contraception and she 
was not able to be followed up by interview. The GPRD study has shown a 
significant difference in use of Depo provera by women with DM with a more 
frequent use than in the general population.
A health professional noted use of the method in their practice.
‘Some of the younger girls are using progesterone injections, which 
obviously takes away the responsibility from them which is handy.’ (HP 8)
The health professional felt that by having the injection, the younger women did 
not need to be responsible for remembering to use contraception which was 
better for them. Progestogen injections are another LARC method (NICE 2005b) 
and increase compliance and therefore reliability of contraception.
Another health professional saw it as a method for a different group of women
‘Mothers who perhaps want to space out a family, we might suggest depo 
provera. (HP 10)
This health professional saw Depo provera as a good method for women in 
between children however as seen in the literature (fpa 2007a) there is a long 
term risk of subfertility with the injectable method, with fertility sometimes not
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returning for over a year following injection and so it should not be recommended 
for women wanting to become pregnant in this time.
9.3A 7 Female Sterilisation
The literature in Chapter Three discusses how sterilisation for women with DM
has been a popular option in the past once women had completed their families.
In my study four of women completing the questionnaires had been sterilised and
three of them were interviewed. Two of the women had severe complications
with their DM which meant another pregnancy could threaten their health. One
woman had complications with her eyes:
‘after the third child my eyes were damaged and it was suggested that I 
was sterilised.’ (T1 1)
This woman had retinopathy which worsens in pregnancy and may have caused 
blindness for this woman if she had gone on to have another pregnancy.
Another woman had had several miscarriages, a stillbirth and gave birth 
prematurely to a child who has cerebral palsy. She was advised that another 
pregnancy could be detrimental to herself and the baby.
‘Well, we were advised if we wanted to have any more pregnancies that it 
could affect me and my kidneys and everything, but we should think 
seriously about it because they couldn’t guarantee the next time that the 
baby would survive, or me.’ (T1 15)
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This woman had been advised that a further pregnancy could cause renal
damage and that the health professionals were concerned for both her own life
and that of the baby in any future pregnancy. She then rationalised the decision
making process that lead to her being sterilised:
We [self & partner] spoke about it and I said ‘Look. We've got x [child]. 
We’re lucky to have x.’ If we had another baby as early as x I would have 
to consider x as well as this baby. At least when I had x I didn’t have any 
children at home, I could keep my time with her as much as I wanted to 
and I thought well what happens if I go? Then he is left with two babies 
and no-one else.’ (T1 15)
This woman felt herself lucky to have one child and in deciding not to have
another pregnancy made reference to consideration for her child’s wellbeing, her
own mortality as she may not survive another pregnancy and her partner’s health
if she was to die and leave him with two children. Part of her decision also
revolved around the fact that she had DM so she felt that she should be sterilised
rather than her partner having a vasectomy.
‘So that’s what I decided. And I thought that because I had the problem it 
would be me that had it done, not him. Because at the time there was a 
lot of things about men who had vasectomies, there was a high risk of 
cancer or something. I thought ‘Oh dear, no, I’ll have it done. I have got 
the problem. I’ll have it done.’ (T1 15).
The woman had heard in the press about a study linking vasectomy and prostate
cancer which had added to her decision for her to be sterilised as opposed to her
partner7. She very much felt that she had the problem ‘ diabetes’ and so she
should be responsible for not getting pregnant and would be sterilised.
7 A meta-analysis examining the risk of vasectomy and prostate cancer (Dennis et al 2002) found 
no evidence of any association
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The third woman interviewed who had had a sterilisation following three 
unplanned pregnancies had originally asked about being sterilised at the time of 
the birth of her second child by planned caesarian section:
‘So as I had had a caesarean again I thought it was a good thing to have 
done but as I was under 30 my consultant was very reluctant to do 
anything -  which I understood. I had it done after the third caesarean.’
(T1 4)
The consultant was reluctant to sterilise this woman as she was under the age of 
thirty years. However for this woman this decision resulted in another unplanned 
pregnancy as she had had difficulties with finding a method of contraception to 
suit her.
‘I tried the combined pill and had side effects with my control - 1 tried a 
couple of different ones -  the mini pill was even worse I had terrible 
headaches’ (T1 4)
Various hormonal pills had affected her DM control and she had experienced 
side effects including headaches. Specialist contraceptive advice may have 
prevented her unplanned pregnancy.
The health professionals dealing with sterilisation of women are usually
gynecologists and obstetricians and on interview I asked whether they would give
advice on contraception?
‘As an Obstetrician, I have to be honest and say, probably not, unless 
we’re sterilising them. I would imagine, yes, sterilisation is the only 
contraception word I mention.’ (HP 4)
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The obstetrician did not talk about contraception with women unless they felt that 
sterilisation was appropriate. The opportunity to do a sterilization following a 
caesarian birth would appear a convenient option. However the efficacy is known 
to be less (Guillebaud 2004) than if the sterilisation is done at other times and so 
is often deferred, meaning that if the woman is not given other contraceptive 
options she may be at risk of unplanned pregnancy.
9.3.4.8 Vasectomy
Vasectomy for partners of women with DM is described in Appendix Seven and
some health professionals were keen to encourage vasectomy for the partners of
the woman with DM.
‘We do discuss, once they feel they’ve completed their family, and 
hopefully with the husband as well because its, we do discuss options for 
contraception, but nothing’s entirely ideal for people with diabetes, we 
tend to suggest that the husband might like to have a vasectomy’. (HP 10)
The health professional indicated that he did discuss contraception with women 
with DM and that after they had completed their families he encouraged 
vasectomy for the partner as he felt that no method of contraception was entirely 
suitable for women with DM. Vasectomy is a less invasive procedure with fewer 
risks than in sterilisation for a woman.
One partner who did not want another child was concerned about his wife’s DM,
and had to persuade her to agree to him having a vasectomy.
‘My other half has wanted to have a vasectomy for many, many years and 
I’ve always said ‘no’ because I didn’t want him to remove the choice - its
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really funny to be able to choose not to have a second child, it feels very 
different than being told you can’t, and so in fact actually this summer he 
went and had the vasectomy, actually it tied in at the same time as my 
scare.’ (T1 10)
Sterilisation must be seen as a permanent method of contraception and this
woman did not want to make a decision that meant they would only have one
child, taking their choices away. This changed when she had a pregnancy scare:
‘I had a day when I had a panic and I thought I may be pregnant, ... I just 
thought ‘oh my God, I can’t be pregnant now, it’s going to be disaster’, I 
wasn’t, but it was enough to scare the living daylights out of me’. (T1 10)
This woman had cardiac complications due to her DM and was then worried that 
she might be pregnant. She was concerned about her health and the effects of a 
pregnancy and this scared her enough to realise that she did not wish to be 
pregnant again and her husband then had a vasectomy.
9.4 Emergency Contraception
The two methods of emergency contraception currently available have been 
described in Appendix Seven. These are progestogen only pills and the insertion 
of an IUD. This section presents narrative in relation to use of emergency 
contraception for women with DM.
The questionnaire data showed that 37% of women had used emergency 
contraception and that they had obtained it in the main from their GP surgery.
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Most of the health professionals were not specifically asked about emergency 
contraception during interview as the topic arose out of interviews with the 
women with DM but those that were asked did not have knowledge of use in 
relation to women with DM and did not advise women routinely about emergency 
contraception.
Of the women interviewed, 25% had used emergency contraception and gave
reasons for use.
Q: You have used emergency contraception though?
A: ‘yes when the condom spilt -  I went to the GP. I didn't want to get 
pregnant but it did muck up my periods though.’ (T1 3)
The condom had broken and so this woman not wanting to get pregnant had
attended the GP for emergency contraception. This had had the effect of altering
her period which is a common feature with emergency contraception (fpa 2007a).
Another teenager had experienced diarrhoea which can make the pill less 
effective due to malabsorption:
‘I had to take it once when I was on Yasmin and had diarrhoea for three 
days.’
Q:‘Where did you go for it?’
‘My GP’
Q:‘Do you remember how you heard about it?’
‘At school I think.’
(T1 14)
She also had attended the GP surgery for a prescription having heard about 
emergency contraception when she was at school.
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One of the women had concerns about using emergency contraception because 
of complications
‘I would not bother I don't think - 1 would take a chance as it might upset 
my blood pressure - its hormones isn't it.’ (T2 9)
This woman was concerned that her emergency contraception would affect her 
blood pressure as it contained hormones. In fact it does not affect blood pressure 
and contains one hormone; progestogen. This worry about taking extra 
hormones was seen earlier in woman choosing to use natural methods of 
contraception.
Most women had gone to the GP for the prescription, although one had bought it 
from the chemist.
Q: You said you have used Emergency Contraception -when was that?
A: ‘In between the second and third pregnancy I bought it from the 
chemist -  it was less embarrassing than going to the Doctors.’ (T1 4)
This woman preferred to buy the emergency pill from the pharmacy as she was 
found that this was a less embarrassing option than going to her GP surgery.
Two women had knowledge that it was now available from the chemist.
Q:Do you know where you can get it?
A: The GP? I think that you could buy it now at chemists.’ (T1 2)
Q:‘l see from your questionnaire you have never taken emergency 
contraception
A:No I don’t think I have ever really thought about it -  I might now -  you 
can buy it now?’ (T2 16)
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The emergency pill is now on sale over the counter and is a good option for
women needing access when other sources are not available. However not
everyone was aware of this:
‘we had an accident after I had x and I went to the GP next day who gave 
it to me.'
‘Did you consider going to the chemist or family planning clinic?’
‘No I didn’t think about that’.
(T1 11)
Many of the women had no knowledge of its use at all.
Q: You said you have never used emergency contraception -  do you 
know when it can be used?
A: ‘No I wouldn’t know really -  what is that?’
Q: Explains...
A: ‘Oh that’s interesting -  no I don’t know.’
(T1 8)
Q:Do you know about emergency contraception?
A:‘No whats that?’
Q:Explains - were you given any information at school?
A:‘No I don't think so no - we were not told much at school’
(T1 7)
These women had not known about the emergency pill which may be a helpful 
strategy in preventing an unplanned pregnancy. Others were aware of it being 
called ‘the morning after pill’ rather than emergency contraception.
Q:Do you know about emergency contraception if you needed it?
A:‘No is that the morning after thing?’ (T2 12)
Q:You said you have never used emergency contraception -  do you know 
when it can be used?
A:Humm -  the morning after pill? I think it is up to 3 days? (T1 5)
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The morning after pill is an old term coined when the method was first available 
and which was dropped because of concern that women would perceive it could 
only be used the morning after unprotected sexual intercourse and not as it is 
licensed for up to 72 hours following unprotected sexual intercourse.
9.5 Conclusion to Chapter Nine
This chapter presents the findings of the semi structured interviews in relation to 
women with DM and issues of contraception. Narrative is presented highlighting 
the advice given by health professionals and the views of the women with DM 
and health professionals on choices of contraceptive methods available and 
those used by the women interviewed.
Although some of the health professionals were happy to give advice about 
contraception, a majority were concerned that they did not have the specialist 
knowledge required. Indeed my data did suggest that some of the health 
professionals had outdated knowledge particularly in relation to hormonal 
methods such as the combined and progestogen only pills and implants, but 
most were aware that these methods were suitable for women without 
complications of DM. Indeed the COC was the most popular method with the 
women because they found it to be ‘effective’, ‘reliable’ and ‘convenient’. The 
professionals felt that the GP practices were the most usual providers of 
contraceptive services and this concurred with the experiences of the women 
with DM.
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The interviews aimed to explore the reasons why women had chosen their 
method of contraception and this highlighted some incongruence between the 
views of health professionals and the women with DM. Health professionals in 
general felt that women with DM should be using a ‘reliable’ method of 
contraception such as hormonal or intrauterine methods, however several 
women with DM had chosen to use ‘natural’ methods of contraception because 
they did not want to put extra hormones in their body but were putting 
themselves at risk of unplanned pregnancy by not using this method correctly.
Condoms were a popular method of contraception but were not always used 
consistently. In addition women did not appear aware that vaginal medication 
used to treat Candida Albicans can weaken latex and cause condoms to break 
and split leading to unplanned pregnancy.
Use of other methods was described and the IUS was seen as particularly 
reliable and useful for women with menorrhagia. Permanent contraception by 
sterilisation or vasectomy were methods recommended by health professionals 
and chosen by women with diabetic medical complications for whom a 
pregnancy would endanger their own or the life of the baby.
Emergency contraception had been used by a quarter of the women interviewed 
but many of the women were unaware of its use or safety for women with DM
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and the knowledge that it is a safe option for most women may have prevented 
unplanned pregnancies.
This chapter concludes the presentation of the findings of the study and the next 
chapter will pull together all five chapters of findings and discuss the implications 
in relation to the research questions and the case: The prevention of unplanned 
pregnancy for women with type 1 or type 2 DM.
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CHAPTER TEN 
Discussion
10.00 Introduction
This research study examines the issue of prevention of unplanned pregnancy in 
women with DM in order to gain understanding of the factors that promote or 
discourage effective preconception care for women with type 1 or type 2 DM.
The current evidence base on this topic is limited and this case study has aimed 
to address this gap and make recommendations for clinical practice.
As stated in Chapter One, the major research questions arising from the 
literature review were as follows:
• What are the experiences, attitudes & knowledge in relation to planning for 
pregnancy for women with type 1 or type 2 DM?
• What factors promote or discourage effective preconception care in women 
with DM?
• What health care and advice is currently provided by health professionals in 
order to encourage positive pregnancy outcomes for women with DM?
• To what extent is there congruence between the women's & professional's 
perspectives in relation to reproductive health issues?
• How can health professionals encourage positive pregnancy outcomes for 
women with DM.
• What recommendations for practice can be generated?
These questions will be considered throughout the discussion and within the Key 
Findings and conclusions of the study in Chapter Eleven.
343
The findings from the three phases of my research study are presented in five 
Chapters with Chapter Five giving results of statistical analysis of the database 
study; Chapter Six the statistical results of the questionnaire study and Chapters 
Seven to Nine the findings of the semi structured interviews in three themes; 
Living with Diabetes, Diabetes and Pregnancy and Contraception. This chapter 
now focuses on integrating and interpreting these findings and placing them in 
context of wider issues of policy and practices within the case study: ‘Prevention 
of Unplanned Pregnancy in Women with Type 1 or Type 2 DM.’
The discussion relates to the structuration and reconstruction phases of 
Burawoy’s model (1998) (Chapter Four, Section 4.1.4, Figure Two) where the 
effects of external forces such as service delivery, national and local policy and 
the concept of médicalisation is examined and cases compared and connected. 
Theory is then generated leading to recommendations for clinical practice.
The discussion is divided into three main sections of Living with Diabetes 
Mellitus; Planning for pregnancy; and Contraception. In addition the topics of co­
ordination of care, training issues and relevant policy are also highlighted 
throughout the chapter.
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10.1 Living with Diabetes Mellitus
The chapter firstly discusses issues arising in relation to pregnancy in context of 
the epidemiology of DM for women with pre-gestational diabetes and the health 
professionals involved in their care.
Epidemiological data chart a rise in cases of type 1 and type 2 DM both in the UK 
and Worldwide (IDF 2007, NHS IC 2007). There is an acknowledged rise in 
cases of type 2 DM linked to risk factors such as obesity (Williams and Farrar 
2008) and the health professionals in my study had noticed an increase of 
younger women with type 2 DM attending their services, one commenting that 
the numbers were ‘quite scary’. The estimate that over one million people may 
be yet undiagnosed (MREC 2004) is of concern as type 2 DM has seen a 
particular increase of incidence in women of childbearing age (Clausen et al
2005). This is both due to levels of obesity causing type 2 DM in a younger 
population (Feig & Palda 2002) and also later childbearing practices meaning 
those who have developed type 2 DM in their thirties or early forties may become 
pregnant at this age, in line with national trends (Bewley et al 2005). If these 
women have undiagnosed DM they may have high glycaemic levels at 
conception which has been found to cause an increased risk of stillbirth, perinatal 
mortality and fetal congenital anomaly (Macintosh et al 2006).
In my database study the findings about pregnancy showed no differences in 
pregnancy rates between women with type 1 DM and the comparison group for
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the year 2001, although women with type 2 DM were less likely to have a 
pregnancy than the comparison group. Data from my questionnaire study 
showed no difference in mean age of first pregnancy for women with type 1 or 
type 2 DM which was 27 years; slightly younger than the average age of first 
birth in England and Wales which has increased to 29 years (ONS 2006). As 
seen in my interview study women with DM are encouraged by health 
professionals to have their children ‘earlier rather than later’ which may account 
for the slightly younger age of first pregnancy. However in contrast to an earlier 
study using the General Practice Research Database (Lawrenson et al 1999) 
which found lower incidence of pregnancy in women with type 1 DM over the age 
of 25 years, my database study showed that in 2001, there was no difference in 
the numbers of women with type 1 DM over thirty years of age becoming 
pregnant compared to a comparison group of women without DM matched for 
age (see Chapter 5, Section 5.1.2). There was also no difference in pregnancy 
rates between women with type 1 DM compared to those with type 2 DM when 
data were adjusted for age. This correlation with the national trend for later 
childbearing was also seen in the results of the questionnaire study which 
showed that nearly 25% (n =13) of participants had their first pregnancy after the 
age of thirty years.
Health professionals found the late childbearing practices of women with DM of 
concern because of the potential for complications both from the perspective of 
the mother and the fetus (Temmerman et al 2004, Haung et al 2008). One
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doctor was very concerned about the number of women over forty years and
particularly those with DM attending the ante natal clinic, with the potential for
cardiac conditions and myocardial infarction (Chapter Eight, Section 8.8.1) and
another professional was clear that women with diabetes should be encouraged
to have babies earlier:
‘Well, I think one of my main issues is that they should try and have their 
pregnancies before they get too old, if you see what I mean. I certainly 
like them to have their first pregnancy by 25 and ideally to have completed 
by 35.’ (HP 10)
Microvascular complications of DM positively correlate with the duration of the 
condition and women with established DM may infer additional risk on a 
pregnancy and the pregnancy may cause further deterioration of retinopathy and 
nephropathy in the mother (Pearson 2005). This could be of particular concern 
as my questionnaire data found that over 44% of the women had at least one 
other medical problem in addition to their DM. Women with DM who become 
pregnant later in life and fail to establish good glycaemic control prior to 
conception can therefore be at an even greater risk of poor pregnancy outcomes.
In a society where women appear to be deferring childbearing this leaves a 
dichotomy of choice for women with DM. Bewley et al (2005) state that reasons 
for the rising maternal age remain unclear and discuss a host of theories 
including women wanting careers, being unable to find a suitable partner, good 
access to contraception and financial reasons. Women may see the availability 
of fertility treatments as an option for late childbearing and the recent ruling for
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changes in the Human Fertilisation and Embryology Bill (DH 2008) which give 
single women and lesbian women the right to fertility treatments may encourage 
this view. Gamble (2005) suggests that late childbearing in some ethnic groups 
is a cultural issue with those of Asian origin often having a large number of 
children born over a woman’s reproductive life, rather than career choice. South 
Asian women also have a higher propensity to type 2 DM (CEMACH 2007) and 
may be doubly at risk in late childbearing with the additional risk of complications 
that DM purveys.
At the other end of the age spectrum, the UK has a high teenage pregnancy rate 
(TPU 2008) and teenagers with DM have been identified as being a group at high 
risk of unintended pregnancy (Charron-Prochownik et al 2001). In Chapter Two, 
Section 2.1.6.2.iii, I have discussed how young people may find difficulty in 
general in coping with their DM during adolescence (Snoek 2000), therefore if 
they do become pregnant they are likely to have poor glycaemic control with the 
high risk of poor fetal outcome. In my questionnaire study 13% (n=7) of the 
women had become pregnant before the age of twenty years and all these 
pregnancies were unplanned with the potential for poor outcomes. The issue of 
teenagers with DM will be discussed later in Section 10.5 in relation to 
contraception and health promotion.
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10.1.2 Summary
In summary, DM and pregnancy is becoming an important topic as rates of type 
1 and type 2 DM are increasing in all age groups. Women with DM appear to 
have similar rates of pregnancy to the general population but there is clear 
evidence that women with DM are at greater risk of complications in pregnancy 
(CEMACH 2007, Macintosh et al 2006). Whilst teenagers may be at risk from 
having higher rates of unintended pregnancy with poor potential outcome due to 
unreliable management of their DM, the later childbirth practices in women with 
DM may also infer additional risk from progression of complications from DM 
impacting on the health of the mother and fetus.
10.2 Planning for pregnancy
The next section of the discussion considers issues arising from the data in 
relation to the topic of planning for pregnancy. Firstly the notion of a ‘planned 
pregnancy’ is debated and médicalisation of care discussed. Then experiences, 
attitudes and knowledge of preconception care issues including glycaemic 
control and folic acid are explored in relation to women with DM and the health 
professionals involved in their care.
10.2.1 ‘Planned’ or ‘Unplanned’ pregnancy
The concept of ‘unplanned’ versus ‘planned’ pregnancy has been explored in the 
general population by Earle (2004) as discussed in the literature review (Chapter
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Three). My research seeks to gain understanding of the factors that promote or 
discourage effective preconception care for women with type 1 or type 2 DM and 
the questionnaire study included a question that asked women if they had 
planned their pregnancies (Appendix Thirteen). Data were in agreement with the 
literature (CEMACH 2007, Dex & Joshi 2004, Holing et al 1998) with 51% of 
pregnancies to women completing my questionnaire being deemed ‘unplanned’. 
These data were then used to compare factors that may be important in 
understanding why women do or do not plan their pregnancies. On analysis of 
the interview data of the women with DM it became apparent that there was 
potential diversity in the meaning of ‘planned pregnancy’ for some women.
In my study several of the women who said that their pregnancy was ‘unplanned’
had a ‘laissez-faire’ attitude to pregnancy as discussed by Earle (2004) and did
not appear to mind if they did become pregnant but did not count this as
‘planning’. They talked about pregnancy ‘just happening’.
‘I think I thought if it happens then that’s OK -  sort of an unconscious thing 
really’ (T11)
‘If it happens, it happens’ (T1 4)
Others reflected that failure or ambivalent use of contraception given as a reason
for the ‘unplanned’ pregnancy, may have been subconsciously intended:
‘So you know, now I actually wonder whether I was ready, but didn’t want 
to have to admit it to myself.’ (T1 10)
This unconscious intention is considered by Raphael-Leff (1994:16) who
discusses the range of decisions that couples make in deciding on parenthood
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and points out that even ‘having the choice does not necessarily mean that 
choice has been exercised’ in that accidents can still happen and unconscious 
motivation and misconceptions can still be determinants of conception. A recent 
study by the Guttmacher Institute USA (Wind 2008) found that nearly one in four 
women who stated that they were not trying to become pregnant conversely said 
that they would be happy if they found out that they were pregnant and another 
study of 110 women undergoing antenatal care found that although 35% of the 
women stated that the pregnancies were “planned”, 91% of them said that they 
were “wanted” (Rosenfield & Everett 1996). This demonstrates the complex 
psychological issues involved for women in relation to decisions about 
childbearing and the strength of maternal desire that can lead women to have a 
child which has been explored by de Marneffe (2004) in her text ‘On children, 
Love, And The Inner Life’. Furedi (1997) suggests that women who have an 
unintended pregnancy may be sub-consciously testing their fertility due to anxiety 
raised by the media about infertility, causing women to doubt their capability to 
have a child. Women may therefore take risks in order to see if they are fertile.
My interview data suggest that there is a continuum of planning for pregnancy as 
discussed by Holing (2000) and Bachrach and Newcomber (1999) where an 
‘unplanned’ pregnancy may not have been altogether unexpected. It could also 
be argued that the women were stating that pregnancy ‘just happened’ as a way 
of making sense of the conception retrospectively as described by Bartlett (1932) 
with the concept of ‘effort after meaning’.
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On researching the literature, the term ‘unplanned pregnancy’ is used regularly 
throughout medical studies and journal articles (Holing et al 1998, Holing 2000, 
CEMACH 2005a, 2007, Taylor & Davidson 2007) and in relation to women with 
DM has been defined as ‘one which is desired prior to conception, contraception 
was stopped for the purpose of becoming pregnant and the woman said that she 
attempted to improve her DM control prior to becoming pregnant’ (Holing 
2000:11).
However Barrett and Wellings (2002) interviewed 47 women to study the 
meaning of ‘planned pregnancy’ and explore understanding of terms used in 
terminology of pregnancy. They found that the term ‘planned’ was only applied 
by women if four key criteria were met: ‘Intending to become pregnant, stopping 
contraception, partner agreement and the right time in terms of lifestyle/ stage’ 
(Barrett & Wellings 2002:1).
In terms of partner agreement, this would equate with findings from my data of 
women stating an ‘unplanned’ pregnancy that had not discussed the issue of 
pregnancy with their partners and had become pregnant ‘accidentally on 
purpose’.
‘I didn’t mind if I did get pregnant but my husband wasn’t keen and we
didn’t really talk about it and then it just happened’. (T1 13)
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Furedi (1997:1) discusses situations where a woman may frequently ‘forget’ to 
take her contraceptive pill if she is ready to ‘assert her maternal ambitions’ and in 
my study women admitted to often not using contraception reliably.
Using the terms ‘planned’ or ‘unplanned’ in my questionnaire study may therefore 
have imposed categories that could have been a limitation in discovering the true 
circumstances of women’s’ intention to become pregnant at conception.
Although the terms ‘planned’, ‘unplanned’,( Barrett & Wellings 2002), ‘intended’, 
‘unintended’ (Rosenfield & Everett), ‘wanted’ and ‘unwanted’ (Fischer et al 1999) 
are widely assumed to be clear to professionals and in health research, Barrett & 
Wellings (2000) found that they were in fact interpreted very differently by 
women. In my study, no definition was given to women completing the 
questionnaires and it would be constructive to revisit this question in future 
research.
Data from my questionnaires and the interviews revealed that some women were 
‘resistant to planning’ pregnancy per se. Planning for pregnancy was seen as a 
‘pressure’ and so by not planning the pressure and worry of not conceiving would 
be prevented. This was also described by Moos et al (1997:385) who found 
planning for pregnancy was a stressful concept for women because of ‘potential 
disappointment’. Two women whom I interviewed who had attended fertility 
services spoke of the frustration and disappointment of not becoming pregnant 
and another wanted to ‘get pregnant without trying’ to avoid the experiences of
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friends who had become very despondent when they had not conceived easily.
There is a large literature on psychological issues in relation to infertility
(Raphael-Leff 1994, Griel 1997) which is not explored here but health
professionals need to be aware that such factors may affect women's attitudes to
planning pregnancy. This was highlighted by one health professional interviewed
in my study who recognised that women who may have had problems conceiving
or have experienced miscarriages may be sensitive to information about
preconception care:
‘And the difficulty is as well, you have some people who definitely don’t 
want to get pregnant or have had issues and problems with fertility and 
maybe you don’t know about it..’ (HP 16)
Health professionals therefore needed to be aware of the situation of women
attending their services in order to give appropriate advice and support.
Another concept talked about by women who had not ‘planned’ their pregnancies 
was that they did not want to mention they were planning to become pregnant as 
they felt that by referring to pregnancy this would somehow put ‘a curse’ on the 
process and stop it happening. Others felt that pregnancy was a private issue 
not to be openly discussed and two women felt that ‘planning’ would spoil the 
experience of trying to become pregnant. There appears to be little in the 
literature in respect of this topic although Barrettt & Wellings (2002:12) describe 
one woman who felt that ‘planning’ for pregnancy was ‘too clinical’ and another 
who wanted pregnancy to be a surprise. These concepts link to literature on 
psychosocial aspects of childbearing where cultural and folk beliefs include
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practices reflecting unconscious ideas (Raphael-Leff 2004) and romantic notions 
of becoming pregnant (Gregg 1995). It could be argued that such attitudes also 
relate to the current promotion by some women and mid wives to ‘normalise’ 
childbearing in opposition to the médicalisation of pregnancy. For women with 
DM planning pregnancy and health professionals involved in their care this has 
particular relevance which will be discussed below.
10.2.2 Médicalisation
The questionnaire study and interviews found women with DM experienced a 
medically ‘disease or illness’ focused pregnancy with many women commenting 
on the large number of hospital appointments and tests they had undergone. In 
the UK routine maternity care is very medically defined, despite attempts by 
midwives to ‘normalise’ childbirth (RCM 2000) and for women with DM who are 
planning pregnancy or who are pregnant this is amplified by care pathways which 
expect attendance at frequent medical appointments and anomaly scans.
The médicalisation of pregnancy is discussed by many sociologists and feminists 
(Oakley 1981, Kent 2000, Ehrenreich & English 2005) who argue that it is a 
paternalistic model of social control with over emphasis on disease and the 
physiological aspects of pregnancy. They maintain that the medical and often 
male obstetric domination of childbirth has denied women the right to make their 
own decisions and be in control of their bodies. The examination of national 
policy for this case study shows that current guidelines for DM care (DH 2001a)
355
mean that women with DM will be offered regular medical assessment and 
review of their DM as discussed in the literature review. Thomas (2003: 404) 
describes how women with pre-existing chronic illness such as DM can be said 
to ‘have acquired the status of patienthood before the status of pregnant woman’ 
and this may lead to a whole host of medical advice and decision making during 
pregnancy. Indeed health professionals described the advice and care they 
would give women with DM. This included seeking advice from the medical 
profession if they were planning pregnancy and an intensive schedule of medical 
care throughout pregnancy.
Although I could find no national guidelines, there was a standard practice across 
all Trusts of medical intervention to induce labour by 39 weeks. This meant that 
women were likely to have a caesarian section as discussed by one health 
professional:
‘I mean, the caesarean section rate of diabetics is outrageously high. It’s 
because we induce them...’ (HP 4).
This was seen nationally by The Confidential Enquiry into Maternal and Child
health (CEMACH 2007) who found a 67% caesarian section rate for women with
DM in comparison to 22% in the general maternity population. The rationale for
early delivery relates to concerns about excessive fetal growth due to poor
glycaemic control but this management could be challenged in women who have
very well controlled blood glucose levels throughout pregnancy and Kjos et al
(1993) did not find any benefits of intervention in a randomized control trial of
women with DM either induced or randomised for routine management.
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Obstetricians on the other hand appeared to be wary of such management when
they could be at risk of negligence if there was a poor birth outcome :
‘I know, even on perfect control, if we lost a baby, I would be criticised in 
hell, because we know the risk’ (HP 4).
It appears therefore that even if women have worked hard throughout pregnancy
to keep good glycaemic control, that the choice of a natural birth may be denied
due to medical influences. Nevertheless, one of the women with DM thought that
obstetricians were in general endeavoring to facilitate more natural births for
women with DM:
‘I do admire that they’re trying to get the numbers of natural birth amongst 
diabetics h i g h e r ( T 1  10)
This may be as result of policy involving patients in partnership with their health
care provider (DH 2005b) as discussed below.
Recent national policy and guidelines have an emphasis on self management 
within DM care, aiming towards a more holistic approach including psychological 
wellbeing (DH 2001a, DH 2003), and this could be particularly important for 
health professionals working with women with DM with the aim to promote 
preconception care. Such joint working depends on good patient professional 
relationships (DH 2005b), and working in partnership with patients (Mead &
— Bower 2000, DH 2005b) which may be prevented by a medicalised approach. 
Berg (2005) discusses the construct of duality in ‘mastery or enslavement’ in 
relation to women with DM in pregnancy and how health carers can either act in
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a supporting role, sharing care or as a controlling factor taking control away from
women. Some health professionals in my study referred to the women with DM in
a proprietal and patriarchal way implying ownership and control, for example:
‘I need to make sure that I know which of my ladies are likely to get 
pregnant..’ (HP14)
‘We do talk to our women about contraception.’ (HP 11)
These attitudes infer positions of power and may prevent mutual working (Mead 
& Bower 2000).
On occasions health professionals said that they may advise women not to 
become pregnant because the pregnancy may cause further complications of the 
DM and they may even recommend sterilisation as a permanent method of 
contraception to facilitate this. Holing et al (1998) found that women given such 
messages by their health care providers were in fact more likely to go on to have 
an unplanned pregnancy and reasons given included that the women felt the 
advice was negative and judgmental and consequently they had a poorer 
relationship with their health care provider and were reluctant to discuss any 
pregnancy plans.
Women also mentioned that they resented ‘nagging’ about glycaemic control and
as one woman commented
‘If you have diabetes - it can get annoying people telling you all the time -  
you just want to be left alone.’ ( T1 4)
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This tension between ‘therapeutic nannying’ (Fitzpatrick 2004) and an individual’s 
right to behavioural choice was seen in the narrative from the health 
professionals, who were aware that women with DM ‘just want to be normal’, but 
also that women need to be aware of the importance of preconception care in 
order to promote a healthy pregnancy and prevent deterioration of their DM.
The importance of psychological theory such as Self Efficacy theory (Bandura 
1977) and Locus of Control (Rotter 1966) in relation to chronic illness 
management has been discussed in Chapter Two. The beliefs, cognitions and 
attitudes of those with DM can affect predictions of patients’ concordance or 
adherence with treatment and motivation for self care (Snoek & Skinner 2000). 
Indeed Berg (2005) suggests that the self understanding learnt by women in 
taking control of their blood glucose management is part of the concept of 
mastery leading to a woman’s general wellbeing. It is therefore important that 
women are actively encouraged to keep their sense of control and self 
management of their DM throughout pregnancy and promotion of such strategies 
in relation to diet and glycaemic control are discussed later in this chapter.
10.2.3 Summary
In summary my data is in agreement with national statistics (CEMACH 2007) 
showing that over half of all pregnancies to women with DM are ‘unplanned’. 
However the terms ‘planned’ or ‘unplanned’ pregnancy although regularly used 
by health professionals can be seen to be open to different interpretation by
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women with DM and may need further exploration when used in research. There 
appear to be many complex psychosocial perspectives and beliefs involved in 
why women do not plan their pregnancies including unconscious intention, 
ambivalent use of contraception and laissez-faire attitude which make for a 
continuum of pregnancy planning.
The concept and influence of médicalisation was discussed in the light of the 
current government policy for a ‘patient centred’ and a ‘self managed’ approach 
to care. The impact of the importance of good patient/professional relationships 
and partnership working was considered in relation to decision making by women 
with respect to preconception and DM care. The next section of the discussion 
will go on to look at specific issues relating to preconception care for women with 
DM.
10.3 Preconception care
The importance for preconception care for women with DM is highlighted by the 
significant improvements in outcome of pregnancy seen in studies comparing 
women who have undergone preconception care with those who did not (Temple 
et al 2006, Diabetes & Pregnancy Group France 2003, McEIvy et al 2000, 
DCCTRG 1996). However in my study, even women who said that they had 
‘planned’ their pregnancy were not always aware of concerns relating to DM and
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pregnancy and had not sought advice or made any changes to their lifestyle 
before becoming pregnant.
10.3.1.Information and Knowledge of Preconception Care
In the questionnaire study I found that 48% (n=28) had been given information
about planning for pregnancy or preconception care, and 52% (n=30) said they 
had not had information. This was incongruent with views of the health 
professionals who when interviewed stressed how they regularly gave women of 
childbearing age information about preconception care including the importance 
of good glycaemic control; taking folic acid; not smoking; retinopathy checks and; 
changes to medication. However the only information remembered by women 
who said they had been given information appeared to be in relation to tight 
glycaemic control.
The literature also finds low levels of knowledge amongst women with DM 
(Diabetes & Pregnancy group in France 2005, Charron-Prochownik et al 2006b) 
and it appears that despite health professionals regularly giving preconception 
care information, the message is not getting through to women with DM. This 
concern is highlighted in respect of general DM care in the Diabetes Information 
Jigsaw Report (APPI 2006) where patients have been found not to act on DM 
care messages and similarly my research shows that even if women had been 
given preconception information this did not mean that they were more likely to 
plan their pregnancies. Statistical analysis of the questionnaire data showed no
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significant difference in those women who had or had not been given 
preconception care information versus those who said that they planned or did 
not plan pregnancy (see Chapter Six,Table Twenty Five).
Many women interviewed had only contacted the health professionals when they 
were actually pregnant rather than in the preconception period and were asked 
why they had not asked health care professionals for preconception advice. 
Some of the women said that they had not asked as they were only seen yearly 
at their annual DM review and had become pregnant in between times. Others 
said that until pregnancy was relevant they would not ask questions or absorb 
information and that they did not know the questions to ask so they did not ask 
them. One woman had carefully planned her pregnancy; reading books on pre 
pregnancy care; stopping the contraceptive pill and using condoms for three 
months; taking folic acid and eating healthily but she had not considered her 
glycaemic control or her DM to be a problem. These women all had established 
DM and it could be argued that for some women, the self care routine of living 
with DM with relatively few complications had become ‘normalised’ as part of life 
as discussed in the literature by Bury (2001), and Robinson (1993). Pregnancy 
may also have been seen as a natural process, as many of the women 
interviewed in my study did not feel that DM would have any effect on them being 
able to become pregnant and they did not perceive there to be any risk to 
pregnancy either.
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The literature discusses how perception of risk in pregnancy affects women’s 
behaviour but Corbin (1987) found that patients and health professionals do not 
always perceive the same risks. Gupton et al (2000) discuss how health care 
professionals should discuss perceptions of risk with women if they are to work 
together to manage complicated pregnancies. A number of the women 
interviewed felt that health professionals had not made them aware of just how 
DM could affect pregnancy and they had been shocked by this knowledge when 
told once pregnancy was diagnosed.
The National Service Framework (DH 2001a) Standard 9 states that a woman 
should be given information annually about the risks associated with pregnancy, 
and perhaps health professionals need to be more explicit about communicating 
the concerns for women with DM in respect of pregnancy. As one woman 
commented:
‘All of this stuff that is more likely to happen to you because you have
diabetes -  it should be outlined more so that you are aware of it.’ (T1 3)
However if planning pregnancy is not currently relevant then women may not be 
receptive to such information and several women wrote comments to this effect 
on the questionnaires and it was discussed during interviews (see Chapter Eight 
Section 8.1.2). Health professionals therefore have a challenge in promoting 
preconception care and strategies to facilitate this will be discussed later in this 
chapter.
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10.3.2 Primary Care Services
Many women with type 1 and type 2 DM are now cared for within Primary Care 
(Williams & Farrer 2008) or in joint care with the secondary care service. The GP 
contract rewards DM care (DH 2005b) but the health professionals felt that DM 
and pregnancy were still seen as a specialist secondary care matter. 
Consequently some of the health professionals interviewed felt that not all GPs 
were focused on the issues relating to DM and pregnancy and they were 
concerned that women were not getting messages about preconception care. 
Indeed narrative from both health professionals and women with DM showed that 
some GPs were not aware of need for preconception or specialist care in 
pregnancy for women with DM.
The health professionals were concerned that GPs had not always reviewed the 
medication that women with DM may be prescribed which may be teratogenic in 
pregnancy. GPs had not always changed prescriptions or advised women to 
stop Oral Hypoglycaemic Agents (OHAs) in exchange for insulin or change anti­
hypertensive medication such as angiotensin converting enzyme inhibitors (ACE) 
and lipid regulating drugs such as statins. There is currently a dilemma as to 
when to stop Oral Hypoglycaemic Agents and change women with type 2 DM to 
insulin (for the duration of the pregnancy). This is because although there has 
been concern in the past about such agents being teratogenic, recent research is 
reassuring (Tran et al 2004, Horn ko 2004, Langer 2002). It may take several 
months for a woman to conceive, and injecting insulin may not be an attractive 
option but some health professionals felt that the transfer to insulin just as
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pregnancy is confirmed may also be a difficult change. In addition women with 
Polycystic Ovarian syndrome (PCOS) who are taking OHAs to control the 
condition (RCOG 2003a) would have difficulty in conceiving if changed to insulin. 
It appears that further research is required to establish clear guidelines for health 
professionals on this matter and it may be that the National Institute for Clinical 
Excellence will offer some guidance as part of the review of DM and Pregnancy 
due for report this year (See Addendum Chapter Twelve).
Another concern of the health professionals were the many examples of late 
referrals for antenatal booking for women with type 2 DM. Feig & Palda (2002) 
found that type 2 DM was often thought of as 'mild' DM by clinicians and it could 
be argued that this misconception caused a relaxed approach to referral. In fact 
perinatal mortality can be even higher for women with type 2 DM than for women 
with type 1 DM (Macfarlane & Tuffnell 2006, Cundy et al 2000, Clausen et al 
2005, Feig & Palda 2002) due to the risk factors of obesity and cardiac vascular 
disease associated with type 2 DM. Some of the late referrals included women 
who had been undergoing treatment by infertility services and women with 
PCOS. There was concern by the health professionals that there was no 
established liaison between the DM and fertility services and this could result in 
women having suboptimal glycaemic control at conception with potential poor 
maternal and fetal outcomes. There appears to be an opportunity for education 
of staff in these areas and for strengthening liaison between fertility, DM and
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obstetric services in order for women to receive the best care with good 
glycaemic control before conception.
CEMACH (2007) have made recommendations for multidisciplinary 
preconception services to be available to all women with DM planning 
pregnancy. The literature demonstrates that pre pregnancy programmes are 
worthwhile for the women who attend them. However there has been little 
difference in overall outcomes for centres which run such programmes as many 
women do not attend (Tattershall 1992). Health professionals interviewed in my 
study expressed concern that women do not know about such services and that 
they were not well advertised. One doctor wanted to attract attention to the 
service by using a photo board of babies born to women with DM with a slogan ‘if 
you want one of these talk to us first’.
With DM care moving into Primary Care there is an opportunity for more localised 
services and perhaps more individualised continuity of care. This is 
recommended as a strategy for improving DM self care in the Diabetes 
Information Jigsaw report (APPI 2006) and may relate to preconception care as 
the relationship with health professionals was seen as important by women 
interviewed in my study. One woman, who commented on her good relationship 
with her DM consultant, welcomed his advice that it would be a good time for her 
to conceive as her glycaemic control was stable. Other women mentioned that 
pregnancy was not something they would like to discuss with a male doctor in the
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outpatients department and health professionals said that it was often easier for 
the nurses to discuss such issues with women under their care as they had a 
‘more relaxed relationship’.
Perhaps with local diabetes services and GP care, women will have greater 
continuity of care and develop relationships with health professionals where they 
feel able to discuss intimate topics such as pregnancy. Stewart et al (2000) and 
Brooks (2005) found primary care consultations to develop positive patient 
outcomes although Mead & Bower (2002) found such associations were not 
definitive. Such discussion with patient’s may however highlight some 
requirement for training in preconception care as few of the health professionals 
in my study had any formal training in preconception or pregnancy issues and 
DM. There appeared to be a lack of formal provision nationally in this area with 
many professionals learning experientially ‘on the job’. It was commented upon 
by one health professional that the diabetes services provided study sessions to 
update GPs and Practice Nurses in DM care during pregnancy but interest and 
attendance varied. Even amongst the diabetes health professionals some saw 
‘pregnancy’ as a specialist role and had chosen not to attend training in this topic.
10.3.3 Folic acid
The importance of folic acid in the prevention of neural tube defects is discussed 
in Chapter Three. Although all women planning pregnancy are advised for 
twelve weeks prior to conception and for twelve weeks afterwards to take 400
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microgrammes of folic acid daily (DH 1992b), women with DM are advised a 
higher dose of 5 miligrammes (Diabetes UK 2008,CEMACH 2007, BMA 
2004,RCOG 2003b) which is only available on prescription unlike the 400 
microgrammes which can be bought over the counter.
My research showed that for the health professionals there were variations in 
knowledge about folic acid and in the promotion of the higher dose. Some 
professionals were not aware of the dose or did not discuss supplementation with 
women. One diabetes health professionals strongly recommended that women 
who were not using a ‘reliable’ method of contraception such as ‘the pill’ should 
be taking folic acid as a precaution in case they became pregnant accidentally. 
Three of the four centres recommended the 5 milligram dose and there was 
some concern that GPs had not prescribed the higher dose to women in their 
care. One centre advised a regular 400 microgram dose to those women who 
had good glycaemic control and 5 milligrammes otherwise. This practice may be 
based on concern that the evidence of folate requirement is not clear (Capel and 
Corcoy 2007) and there have been recent studies showing potential deleterious 
effects including promotion of neoplasia, and in pregnancy, an increased risk of 
insulin resistance and obesity in future for offspring (Smith et al 2008). It appears 
that further research is therefore required specifically for women with DM as to 
the risk benefit ratio of the higher dose supplement.
Narrative from interviews with the women with DM who had planned their 
pregnancies showed that there appeared to be awareness of the need to take
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folic acid in pregnancy but most had bought 400 microgram supplements from 
the chemist rather than being prescribed the higher 5 miligram dose by a health 
professional.
10.3.4 Summary
In summary it appears that health professionals giving information about 
preconception care to women with DM does not equate with women 
remembering such information or in planning their pregnancies. It may be that 
information given needs to be more explicit as women with DM are often shocked 
when learning of the risks on becoming pregnant. The importance of the 
relationship between health professionals and women with DM is demonstrated 
in relation to seeking knowledge and discussion, particularly as to the relevance 
of preconception information as this has been shown to affect receptiveness.
The move of DM services into primary care may facilitate this however GPs and 
other services may need updating on specific guidelines for women with DM in 
order to prevent complications from teratogenic medication. In relation to folic 
acid supplementation, women with DM are not aware of the current guidelines 
recommending a 5 milligram dose and further research appears necessary to 
review local practice policies. The next section of the discussion goes on to 
consider glycaemic control which is also a major factor in preconception care but 
also has an effect throughout pregnancy.
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10.3.4 Glycaemic Control and Blood Glucose Monitoring
Discussion in relation to this section highlights a mix of both physiological and 
social issues with women’s behaviour, in relation to blood glucose testing and 
dietary regime, affecting the physiological outcome of achieving optimal 
glycaemic control with implications for fetal and maternal health. Relationships to 
current policy and guidelines are discussed in the light of examining macro 
influences for this case study.
In the literature review Chapter Three, studies showed the importance of optimal 
glycaemic control in the preconception period and throughout pregnancy in order 
to minimise the risk of complications (Taylor & Davison (2007), Jensen et al 
2004, Evers et al 2004, Damm & Molsted-Pedersen 1989, Mills et al 1988). My 
study identified that health professionals said that they gave information to 
women about the importance of such control and advised attending for 
preconception care, but few women attend ‘preconception’ DM services in an 
attempt to gain stable control before they conceive. Reasons for this were 
unclear in that women who said that they had been given information about 
pregnancy and DM identified good glycaemic control as being important but did 
not attend services until they were actually pregnant.
Once pregnant however, it appeared that women were extremely motivated to 
gain good control and health professionals described how women would change 
their behaviour towards controlling blood glucose levels when pregnant:
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‘Even for the badly controlled, who don't test, will do seven tests a day, 
virtually every day of their pregnancy.’ (HP 7)
This concurred with narrative from the women who despite seeing blood glucose 
monitoring as a ‘chore’ and ‘hard work’, on becoming pregnant worked hard to 
gain good glycaemic control. The knowledge that uncontrolled glucose levels 
could affect the baby provided motivation to test and review diet and treatment as 
necessary. For some women this practice led to ongoing improvements in 
diabetes control:
‘I learnt so much about diabetes with my first pregnancy -  before then I 
never varied my dose I just did what I was told and I didn’t do many sugar 
tests but during pregnancy I did at least four a day so I carried that on so 
getting pregnant helped me sort out my control.’ (T1 5)
This process of making changes to their diet and varying their insulin doses to 
match dietary requirements in pregnancy allowed the women to gain control over 
their chronic illness and their bodies and experience self understanding. This 
concept has been mentioned earlier in the chapter, (Section 10.2.2), as 
discussed by Berg (2005) in relation to the construct of ‘mastery versus 
enslavement’. It has been shown that women who feel in control and have 
mastered their DM management have better general wellbeing.
The Dose Adjustment Programme for Normal Eating (DAPNE) which is part of 
the national policy of structured education programmes to promote DM self care 
and good glycaemic control promotes such an approach. The programme has 
undergone several European trials (DAPNE Group 2002) and shown substantial
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improvements in outcome of glycaemic control. If women using insulin for 
glycaemic control had undertaken this programme prior to pregnancy they might 
have better control in the preconception period. In addition it could be argued 
that pregnancy issues should perhaps be included in such programmes to 
highlight the importance of preconception control. For women with type 2 DM, 
the Diabetes Education and Self-Management for Ongoing and Newly Diagnosed 
(DESMOND (2008)) programmes could similarly be used to highlight pregnancy 
issues.
The importance of gaining good glycaemic control prior to conception was 
demonstrated by some women who unfortunately had experienced complications 
in pregnancy such as miscarriage, still birth and congential cardiac disorders. 
They blamed themselves for poor glycaemic control causing these events and 
talked about the guilt they still felt. One woman wanted to give advice to other 
women:
‘Make sure that your sugars are under control before you get pregnant, 
because the thoughts you have when you find out you are pregnant 
thinking what damage could I have already done by having high sugars. 
You feel extremely guilty.' (T1 15)
One of the health professionals had suggested that women with DM who are
planning pregnancy or who are pregnant should be ‘buddied up’ with other
women who had successfully gained good glycaemic control to share
experiences. This would be in line with national policy such as the Expert Patient
Initiative (DH 2001b) where patients are seen as ‘experts’ in their condition and a
user led focus for promoting self management of chronic disease is encouraged.
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This mechanism of support could also be used for partners who were often 
anxious about the pregnancy and hypoglycaemic episodes that occur. Women 
with DM saw the importance of information for partners and relatives about giving 
them glucogon in the event of a severe hypoglycaemic episode but only one 
health care professional specifically mentioned giving information about glucagon 
as a factor in preconception care.
10.4.5 Summary
In summary, few women with DM attend preconception care services and so 
often women begin pregnancy with less than optimal glycaemic control.
However once pregnancy is diagnosed there is motivation to gain good control 
and most women achieve this by the end of pregnancy. Some women 
experience excellent control by learning to titrate doses of insulin in line with their 
dietary requirements and this is continued after the birth. In general DM care the 
structured educational programmes DAPNE and DESMOND can help to 
establish good self management and these could be recommended prior to 
pregnancy and could incorporate issues relating to pregnancy and DM. In line 
with the Expert Patient initiative (DH 2001b) women could ‘buddy up' with women 
with DM trained in support and advice during pregnancy.
The next section of the discussion focuses on the issue of contraception for 
women with DM and will explore findings from the database study, 
questionnaires and semi structured interviews.
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10.4 Contraception for women with diabetes melllitus
Contraception is important for women with DM in order to prevent the risks that 
can occur with unplanned pregnancy. Women are advised to use a reliable 
method of contraception until their HbA1c is stable at recommended levels 
(CEMACH 2007). This section will bring together data from the General Practice 
Research Database (GPRD), Questionnaires and Semi structured interviews and 
highlights key issues in relation to use of contraception by women with type 1 
and type 2 DM.
A review of the literature relating to contraception and women with DM can be 
seen in Chapter Three. Women with DM have the same choice of 
contraceptives as the general population but the potential metabolic effects of 
hormonal methods need to be considered in relation to an individual’s DM profile 
and their need for effective contraception. Currently there appear to be wide 
variations in the way that professionals evaluate the risk benefit equation and 
significant differences in prescribing practice have been identified (Shawe & 
Lawrenson 2003).
There is limited information on the use of contraception by women with DM and 
almost all the studies have been in women with typel DM (Shawe & Lawrenson 
2003). There have been some studies on patterns of contraceptive practice in 
women with DM from a number of other countries particularly Europe (Kjaer et al 
1992, Kimmerle et al 1994, Fontbounne et al 1987, Kim et al 2002, Lawrenson et
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al 1999) and New Zealand (Gibb et al 1994) but these are mainly descriptive of 
women attending DM services. The strength of the GPRD study is that a 
population based sample of women with type 1 and type 2 DM was selected and 
compared with an aged matched comparison group from the same population 
with no DM. Using computerised records from the GPRD allowed the study of a 
substantial number of women of childbearing age with DM from a database that 
has good prescribing data.
Although hormonal methods of contraception appear well recorded on the 
GPRD, there is however, an apparent low recording on the database of non- 
hormonal methods. My questionnaire study and interviews showed that women 
with DM use a wide range of non hormonal methods and these will discussed 
later in this section. The low recording on the GPRD may be related to the fact 
that women in the general population often attend community contraception 
clinics rather than the GP for non hormonal methods. My questionnaire study 
shows that women with DM accessing regular care from their GP surgery are 
likely to use the GP for their contraception as well. Only 4.7% (n=5) of women 
with DM accessed the community contraception clinics whilst 48% (n=51) went to 
the GP for contraception advice. The current government policy (DH 2007) 
rewards GPs for contraception care and women are encouraged to attend the 
practice nurse or GP clinics. In many areas the community contraception clinics 
have had funding withdrawn and will now only see women under the age of 25 
years with all other clients being advised to attend GP services.
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The health professionals very much saw the GP surgery with the GP or practice 
nurses as providers of contraception services and said that they would refer 
women if they asked about contraception. The health professionals appeared 
reluctant to give advice themselves and this could be a factor in the prevention of 
unplanned pregnancy as my study data showed very haphazard use of 
contraception by some women with DM. Narrative from the interviews with 
health professionals showed that some said they mentioned contraception 
especially if a woman had poor glycaemic control but others found the topic 
difficult to broach or were reluctant to mention it because of their lack of 
knowledge. This concept is raised in the literature (Haboubi & Lincoln 2003, 
Stokes & Mears 2000, Guthrie 1999) which acknowledges that health 
professionals have difficulties in discussing sexual health issues with clients and 
are reluctant to raise the topic for fear of not being able to address concerns or 
from lack of time, or worries about the complexity that is involved. Indeed 35.5% 
of women with DM completing the questionnaires said they had not received any 
contraceptive advice in the past year from any health professional and many of 
the women interviewed did not recall being given any advice at any time.
Although for some of these women contraceptive advice may not have been 
relevant, one woman who had had an unplanned pregnancy reflected that
‘It’s funny that nobody really spoke to me about it, because contraception 
was a bit of a disaster.’ (T1 10).
The NSF for diabetes (DH 2001a) recommends that women with DM should
receive regular contraceptive advice and for some women the only contact with
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health professionals will be at DM consultations or annual review. This highlights 
the need for specific training in ‘talking about contraception with clients’ which 
may give health professionals the confidence to encourage discussion during 
consultations.
10.4.1 Choice of Contraceptive Methods
My study data found haphazard use of contraception by some of the women with 
DM and this section discusses their chosen methods and explores specific 
issues in relation to contraceptive methods for women with DM.
The questionnaire study showed that one third of the women were not currently 
using any form of contraception and although some were pregnant or not in 
relationships where contraception was required others had put themselves at risk 
of unplanned pregnancy. This was particularly apparent with women who had 
given birth within the last four months and post natal contraception is discussed 
later in this section.
10.4.1.1 The ‘Natural Approach’ - Barrier and Natural Methods
My data showed a surprising number of women taking a ‘natural approach’ to
contraception by using barrier or natural methods of contraception. 24% of 
women completing the questionnaire were using condoms as their main method 
of contraception and 8.5% were using ‘natural methods’ such as the safe period/ 
rhythm method. This compares to rates in the general population of 22% for
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condom use and only 3% for natural methods identified by the Office for National 
Statistics (2008) as use of the safe period/ rhythm method and Persona (Lader 
2006, fpa 2007a). The review of the literature found little reference to use of non 
hormonal methods of contraception by women with DM but St James et al (1992) 
also found that women with DM and their partners tended to use condoms more 
frequently.
Condoms can be a reliable method of contraception if used consistently and if 
used correctly by for example being put on before genital contact occurs. They 
also provide protection from sexually transmitted infection which is currently an 
important factor with the rise of infections in the UK (HPA 2008). There is 
however evidence from my interview data and in the literature (Guillebaud 2004), 
of poor compliance with condoms and use of other barriers such as the 
diaphragm and in my study women had experienced unplanned pregnancies 
through failure to use these methods or use them correctly during sexual 
intercourse.
Condoms can sometimes break or split (Guillebaud 2004) and some oil based 
medication can weaken latex condoms which may then split and break more 
easily (CKS 2007). Medication used to treat Candida is often topical and oil 
based and can affect latex condoms and similarly diaphragms may wear out 
more quickly. Women with DM have a greater propensity to vulvovaginal 
candidiasis (Bohannon 1998). Increased levels of glucose in the vulvovaginal
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tissue promote growth and adhesion of yeast cells as epithelial cells in the vagina 
bind to Candida albicans more easily in women with DM (Singh 2003).
Women using oil based topical medication should be advised to wait three days 
after the last treatment before using condoms or diaphragms for contraception 
(Singh 2003). My study found that none of the women interviewed had received 
this information or the advice to use non latex condoms, or a different method of 
contraception during treatment. Such information needs emphasizing to women 
with DM in order to prevent unplanned pregnancy as they may be more likely to 
use condoms to prevent transmission to a partner when they have an episode of 
Candida.
The health professionals were adamant that condoms alone were not a reliable 
method to prevent unplanned pregnancy for women with DM, however some of 
the women with DM had been advised by other health professionals to use 
condoms because of medical concerns with hypertension and other women had 
only ever been offered barrier methods by their GP. I discuss later how it may be 
possible that other methods such as progestogen only methods may have been 
a more reliable alternative if the women had no other complications. Poor 
compliance may put women at risk from unplanned pregnancy if no choice of 
method is discussed or if partners are not in agreement with the method as 
highlighted by Luthra (2008).
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In Chapter Three and in Appendix Seven, Natural methods of contraception are 
outlined. It can be seen that for motivated women with regular menstrual cycles 
who receive training, it can be a reliable method (Fertility UK 2007), however 
data from my interviews showed worryingly low levels of knowledge and 
misunderstanding in the use of the ‘natural’ method and for many of the women 
this had resulted in unplanned pregnancies.
The women were often using a calendar to predict the fertile period without using 
other important fertility indicators such as basal body temperature and cervical 
mucous and position. None of the women interviewed had received instruction in 
use of the ‘natural’ method which is available from specialist family planning 
health professionals and they had either read about the method in books or on 
the internet. With the increasing use of the internet as an information source it 
may be appropriate to put more comprehensive guidelines for contraception on 
websites such as Diabetes UK. However it must be ensured that information is 
evidence based and up to date as recently I personally have contacted Diabetes 
UK to correct information displayed about contraception for young people.
The increased use of natural methods and approach to contraception by women 
with DM may be explained by narrative from the interviews showing their 
apparent concern about adding extra ‘chemicals’ or ‘hormones’ to their body on 
top of insulin or other medication for treatment of their DM; One woman 
explained:
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'I'm not a great believer in all the hormones going down... I’m not 
particularly keen on the pill.’ ‘Even though I’m on insulin, it’s not like a non­
diabetic - putting more hormones into your body, being on the pill’ (T1 11).
The concern about ‘hormones’ is also seen in the general population and often 
given as the reason for ‘having a break’ from the contraceptive pill as discussed 
by Guillebaud (2004). Perhaps the belief that hormones are harmful is more 
poignant for women with DM treating themselves with insulin but this was 
incongruent with views of the health professionals who were strongly of the 
opinion that women with DM required ‘reliable’ methods of contraception 
equating to the IUD or hormonal methods such as ‘the pill’ or IUS.
The belief that use of hormonal methods was not appropriate at all with DM was 
held by some women and there were several comments relating to ‘not being 
allowed’ to take the pill. This concept may have come from the past when the 
higher dose pills were deemed unsuitable for women with DM (Vessey et al 
1977) and this is still the case with combined contraceptive pills if a woman has 
DM complications (WHO 2007). The health professionals were up to date with 
their knowledge that women with DM without complications could take the 
combined pill and the discussion will now look at issues relating to hormonal 
contraception for women with DM.
10.4.1.2 Hormonal Contraception
The GPRD study demonstrates that prescribing patterns for women with type 1 
and type 2 DM are significantly different to the general population. Women with
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DM were significantly less likely to be prescribed hormonal contraception overall. 
The prescribing rates for women with type 1 DM in 2001 were unchanged from 
those found in the UK in 1994 (Lawrenson et al 1999).
10.4.1.2.1 Combined Oral Contraceptive Pill (COC)
It is possible that women and prescribers may avoid the COC because of
concerns about potential metabolic and cardiovascular side effects (Gibb et al 
1994), although studies involving lower dose COCs have shown no evidence of 
metabolic disturbance of DM (Girling & de Swiet 1997, Swerlow & Jones 1996).
It is now recognised that low dose COCs are a safe and effective option for women 
with uncomplicated well-controlled DM (WHO 2007). I did not have comprehensive 
information about the metabolic control of the patients with DM on the GPRD and it 
maybe that clinicians are appropriately avoiding COCs for those women with poorly 
controlled DM, or those who are obese or have additional cardiovascular risk 
factors. Due to the increased risk of cardiac and cerebrovascular disease, the 
COC is not a suitable choice for those with any existing macrovascular change.
The risk of such changes rise with age and for smokers (RCOG 2000). Women 
with DM who smoke or who are over the age of thirty five would not be 
recommended to take the COC (WHO 2007). In addition COC pills may slightly 
raise diastolic and systolic blood pressure (Girling & de Swiet 1997) and for women 
with DM who are hypertensive the risk is increased and the COC is not 
recommended (WHO 2007). Alternatively clinicians could give consideration to the
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known beneficial effects of the COC, for example reduced iron deficiency anaemia, 
dysmenorrhoea and some gynaecological malignancies.
Compared with a population of women matched for age, the GPRD study found 
that women with type 2 DM were significantly less likely to be prescribed a third 
generation COC. No difference between prescribing rates for women with type 1 
DM and an age matched population was found. The third generation COCs offer 
theoretical advantages for women with diabetes in that they increase the levels of 
High Density Lipoprotein (HDL) and reduce levels of Low Density Lipoprotein (LDL) 
(Shawe & Lawrenson 2003). In the mid 1990’s there were some studies which 
suggested that 3rd generation COCs were associated with an increased risk of 
venous thromboembolism (WHO 1995, Jick et al 1995, Spitzer et al 1996) and 
many prescribers abandoned their use. Later analyses of these data suggested 
the risks had been overestimated, (Lewis et al 1999, Lawrenson et al 2000) and an 
independent assessment of the evidence by the High Court in the UK upheld this 
view and indeed determined that 3rd generation COCs do not cause an increase in 
venous thromboembolism (Mackay et al 2002). These beneficial effects mean that 
third generation COCs should be preferred to 2nd generation products for women 
with DM.
Some of the women interviewed had been taking the COC for many years but 
others had developed medical complications such as hypertension, thrombosis 
and migraines which had prevented them continuing with the method, as
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recommended by WHO (2007). Two women had discontinued with the COC 
because of disruption to their glycaemic control, but although there are 
theoretical reasons for control to be altered (Shawe & Lawrenson 2003), there is 
no substantial evidence of this in the literature and it may be that lifestyle factors 
were involved.
If women with DM have complications to the COC or they smoke then the 
progestogen only pill is seen as a good option for women and is discussed next.
10.4.1.2.ii The Progestogen Only Pill (POP)
This database study supports previous findings that progestogen only methods 
including the injectable contraceptive Depo Provera and progestogen only pills 
are often preferentially prescribed for women with DM due to lower risks 
associated with cardio vascular disease (Mestman & Schmidt Sarcosi 1993,
Steel 1985, RCOG 1977). Women with complications such as severe arterial 
disease may however need special consideration as a deterioration in lipid 
profiles has been demonstrated in some POP users (Girling & de Swiet 1997) 
and non hormonal methods of contraception would be recommended for these 
patients. In addition women with type 2 DM are more likely to have a higher BMI 
or be obese (DH 2003) and if women have a body mass index (BMI) of over 
thirty, then this is a relative contraindication to the COC and they may be 
prescribed the POP instead.
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POPs in general have a lower efficacy and need be taken at the same time each 
day, which may be of concern as prevention of unplanned pregnancy is crucial 
for women with DM (CEMACH 2007). However those with type 1 DM are likely 
to have good compliance if they take the pill with a regular insulin dose and this 
was evident from the narrative of women with DM. Cerazette a newer POP 
containing desogestrel a third generation progestogen with the benefit of a 
twelve hour window period and enhanced efficacy with an anovulatory mode of 
action (BMA RPSGB 2007) is more reliable alternative to the older POPs and 
some women had been prescribed this pill. Some of the health professionals 
considered POPs too unreliable for women with DM and they needed updating 
about the benefits and suitability of Cerazette.
Although contraceptive pills are very popular and easy for women to take, they all 
depend on good compliance and adherence for efficacy to be assured. In order 
to prevent unplanned pregnancy and provide more choice for women, the 
National Institute for Clinical Excellence (NICE 2005b) has recently developed a 
clinical guideline promoting discussion of a wider range of long-acting reversible 
contraceptive methods (LARC) which include the injections, implants and 
intrauterine device and system. Some of these methods require training in fitting 
and insertion and are not offered by all GPs, who may refer women to community 
contraceptive clinics where they are available. LARC methods for women with 
diabetes arel now discussed beginning with Depo Provera injectable 
contraception.
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10.4.1.2.iii. Depo Provera
The GPRD database study found that women with type 1 and type 2 DM were 
significantly more likely to be prescribed the injectable contraceptive Depo 
Provera as a method of contraception. The questionnaire study found just one 
woman using the method and she could not be followed up by interview, so no 
experiential data is available. The injection can easily be given in the GP surgery 
and has the benefit of being a very reliable method of contraception, in fact 
women should be counselled that there is a risk of subfertility, with fertility not 
always returning for over a year following injection (fpa 2007a).
The literature raises some concerns over use of the method by women with DM 
and research (Diab & Zaki 2000) has shown an unfavorable lipid profile and 
impaired glucose control in some users and Sorenson et al (2002) has further 
concern that hypooestrogenism associated with Depo Provera may adversely 
affect cardiovascular status. I would therefore suggest that injectable 
contraception should only be used for those patients in a low risk category (WHO 
2007) and assessment of a baseline lipid profile should be performed before 
using this method.
Although the health professionals talked about use of this method with young 
people, recent guidelines have suggested that Depo Provera is not 
recommended as a first line method for under 19 year olds due to concern with
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loss of bone mineral density and an increased risk of osteoporosis (NICE 2005b). 
In addition the doctor interviewed, who saw Depo Provera as a good method for 
women spacing their children may have been better recommending another 
more reversible method such as the implant.
10.4.1.2. iv. Implants
The GPRD study did not include any data in relation to the implant which as a 
single rod was new at this time with very few GPs fitting the device. Although the 
implant (Implanon) has been available in the UK for over seven years few of the 
health professionals had any knowledge of the method and surprisingly only one 
woman completing the questionnaires had one in situ. The implant, a 
progestogen only method, licensed for three years continuous use, appears an 
eminently suitable method of contraception for most women with DM as it 
provides steady blood levels of progestogen which reduces potential metabolic 
change and does not appear to alter blood lipid ratios or glycaemic control 
(Dorflinger 2002). It has good efficacy as it requires no action once fitted and 
when it is removed, fertility returns quickly therefore it could help prevent 
unplanned pregnancy amongst women with DM willing to try a hormonal method 
of contraception . There appears to be little information from clinical studies of 
the safety of Implants in women with DM and I believe further research is 
needed.
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10.4.1.2 v Intrauterine Devices IUD I Intrauterine System IUS
The GPRD study found no significant difference between women with DM and
the comparison groups in relation to use of an IUD. There have been concerns in 
the past about the risk of infection at IUD insertion and the fact that women with 
DM are more likely to contract infections than the normal population. This often 
meant that as a method the IUD was not routinely offered to women with DM 
(Clark 2004). However with newer insertion techniques which minimize infection 
risk and with screening for infection and antibiotic cover available the method is 
used more regularly by women with DM.
The levenorgestrel releasing IUS is perhaps more suitable for women with 
diabetes as one of the modes of action is to thicken the mucous in the cervix (fpa 
2007a) which prevents potential infection entering the cavity. The IUS is also 
extremely reliable and is licensed for up to five years and many women have 
accordingly opted for an IUS instead of sterilisation.
10.4.1.2.vi. Sterilisation
A previous GPRD study (Lawrenson et al 1999) had found that women with type 
1 DM were more likely to have been sterilised than a comparison group however 
my database study found no significant difference in sterilisation rates for the 
year 2001 between those with or without DM, although in women with type 1 DM 
the prevalence of prior sterilisation was greater than found in the 1994 study.
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Once they have completed their family, women with DM may be recommended 
sterilisation as a permanent method of contraception. In my study, this was 
evident from the interviews with women who had been sterilised, mostly as 
recommended by health professionals, because of complications of their DM.
One woman interviewed was not happy with the idea of sterilisation as it took 
away her choice to have another child. Even though she had a cardiac condition 
she felt that it was very different to be told that she could not have another child 
rather than choosing not to. In the study by Holing et al (1998) women who were 
advised not to become pregnant were found to be more likely to have an 
unplanned pregnancy. It could be argued that in such situations in order to 
prevent unplanned pregnancy, health professionals should look at suitability of 
the option of the IUS which Guillebaud (2004) states is a viable alternative to 
sterilisation but will still provide the sentiment of choice to women.
Gynecologists and Obstetricians are reluctant to sterilise women under thirty 
years of age due to the higher rate of failure with the method in this age group 
and the potential that they may change their mind later in childbearing years 
(Guillebaud 2004). One woman under thirty years, interviewed for my study had 
had her request for sterilisation refused and had then gone on to have an 
unplanned pregnancy. The importance of offering specialist contraceptive advice 
and reliable methods of contraception that are acceptable to individual women
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can therefore be seen to be important in preventing unplanned pregnancy in 
women with DM.
Female sterilisation is a surgical procedure and carries the risks associated with 
any surgery and if used, general anesthesia. These risks may possibly be 
greater for women with DM (Glasier & Winikoff 2005) and one of the health 
professionals recommended male sterilisation which potentially has less risk, to 
couples who had completed their families. This was not acceptable to one of the 
women interviewed in my study who felt strongly that DM was ‘her problem’ and 
she should therefore take responsibility for being sterilised rather than her 
partner. The doctor’s recommendation could also be said to take a very 
medicalised and stereotypical view of the situation and the relationship which in 
the present climate can be varied and unlike sterilisation not always permanent. 
Wellings & Hart (2002) discuss how social and interpersonal dynamics can be 
ignored in a medical approach to sexual behaviour and in this respect it would be 
useful to research the views of the partners of women with DM in relation to 
acceptability of contraceptive methods.
My research highlighted other groups that require special consideration in 
relation to contraception including teenagers and women in the postpartum 
period and these findings are now briefly discussed.
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10.5 Teenagers
In Chapters Two and Three, I indicate how young people may have difficulty in 
coping with their DM (Diabetes UK 2007) and how this can lead to them taking 
risks in relation to their DM management as described by Hanna & Guthrie 
(2000). This may result in poor blood glucose control, and in addition they may 
be starting sexual relationships which can leave them vulnerable to unplanned 
pregnancy with an increased risk of complications and congenital abnormality.
In my questionnaire study all women who had had a first pregnancy between 16 
and 19 years of age had not planned the pregnancy.
Health professionals were concerned that the topic of contraception was difficult 
to broach with teenagers who firstly may feel embarrassed discussing it, and 
secondly may have parents with them during the consultation who may not be 
aware of the teenager’s sexual activity. Teenagers said that they had not 
received contraceptive or preconception advice from the health professionals.
My research showed that although specific advice or discussion about 
contraception did not take place during consultations, sometimes messages were 
given that the teenager should not get pregnant unintentionally. However 
teenagers may not have the knowledge or skills to transfer this message to use 
of contraception during sexual activity as the literature has highlighted that they 
often have poor knowledge of contraception and sexual health issues (Janz et al 
1995, Kjaer 1992, Charron-Prochownik & Michel 2006). Adolescents with DM
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should therefore be targeted through reproductive health education and 
preconception counseling prior to sexual activity in order to empower them to 
prevent unplanned pregnancy (Charron-Prochownik & Michel 2006). 
Contraceptive methods that are popular with young people include the 
progestogen releasing implant which may be a good option as it is suitable for 
women with DM and does not require any action for three years once fitted, the 
combined pill and the newer progestogen only pill Cerazette. In addition the use 
of condoms is recommended to prevent sexually transmitted infections which are 
increasing in the 16 -25 year old age group (HPA 2008).
10.6 Women in the postpartum period
The interviews with the women with DM revealed that a surprising number of 
women with DM who had given birth within the last four months had put 
themselves at risk of an unplanned pregnancy.
In the postpartum period women are often exhausted and totally consumed by 
the demands of a new baby, however despite potentially having low levels of 
sexual interest studies have suggested that up to 50% of women resume sexual 
intercourse by six weeks after the birth (Glazener 1997, Guillebaud 2004). Furedi 
(1997) discusses how women can be at risk of an unintended pregnancy at this 
time as they are occupied with mothering and have not got into a contraceptive 
regime. Fertility can return from day twenty one following birth if a woman is not
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fully breast feeding (fpa 2007d), and so in order to prevent unplanned pregnancy, 
contraception should be used from this time.
The women interviewed in my study had several different reasons for not using 
contraception. Just ‘not getting round to it’ was an understandable reason given, 
however one woman had been given wrong advice that she could not take 
anything for six weeks after the birth. As stated above most methods can be 
started by three weeks with the exception of the injection at five to six weeks due 
to the association of prolonged bleeding and the diaphragm at six weeks to allow 
for return of muscle tone (Guillebaud 2004).
Another woman with a six week old baby had decided not to use contraception 
as she had had fertility treatment with her first pregnancy and understandably felt 
that it might take more treatment or a long time to become pregnant again. This 
concurs with findings in the literature by St James et al (1992) who found that 
women with DM believed that they may have difficulty in conceiving. However 
from my clinical experience and as seen in the literature (Shimizu et al 1999,
Craft 1999) women who have previously had fertility treatment may often have a 
spontaneous pregnancy the second or subsequent times and for a woman with 
DM this may mean that blood glucose levels are not well controlled at conception 
as in the postnatal period glycaemic control is often erratic (CEMACH 2007). 
Thomas (2003) discusses how following delivery, women with chronic illness felt 
that the focus of health care was on the baby rather than their own health and
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that there was little postnatal support. Women with DM in the postnatal period 
have been found to have suboptimal care following delivery and CEMACH (2007) 
have made recommendations for practice in that there should be a care plan 
which includes management of glycaemic control and contraceptive advice for 
the mother.
Human error is inherent in use of contraception and no contraceptive method is 
100% effective hence another strategy in the prevention of unplanned pregnancy 
is emergency contraception is now discussed.
10.7 Emergency Contraception
The database study found that women with type 1 DM were significantly more 
likely than the comparison group to use emergency contraception pills (OR 1.50 
95% Cl 1.02-2.14). Although women with type 1 DM may be more concerned 
about unplanned pregnancy, it is possible that they attend their general 
practitioner for all medication whereas the general population may prefer the 
anonymity of the community contraception clinic or buy it over the counter at a 
pharmacy. There was no significant difference between women with type 2 DM 
and their comparison group for prescriptions of emergency contraception.
My questionnaire data also showed that a third of the women had used 
emergency contraception at some point, mainly receiving it from the GP surgery.
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A quarter of the women interviewed had used emergency contraception in the 
past but many other women were unaware of its use at all. Raising awareness of 
emergency contraception may be an opportunity for promoting prevention of 
unplanned pregnancy. The post coital method is safe for women with DM to use 
and although only post coital pills were mentioned by the women the other 
method of IUD insertion up to 5 days post coitally may also be an option for some 
women.
10.8 Summary of discussion on contraception
There appeared to be a lack of congruence between the views of health 
professionals and women with DM in relation to contraception. In the desire to 
prevent unplanned pregnancy it is important that professionals advising women 
with DM are aware of the range of contraceptive choices available and that the 
choice of contraceptive method is made by the woman with DM and that she is 
happy using the method. The GP surgery was seen as the most usual provider 
of contraceptive services but perhaps with training, diabetes health professionals 
may feel more confident to give contraceptive advice as part of holistic care 
especially if they are caring for women in primary care settings where they may 
develop a closer relationship with their patients.
My study has highlighted significant variation in prescribing of hormonal 
contraception to women with type 1 and type 2 DM in comparison to those 
without DM. Hormonal contraception is seen as a safe option for women with
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DM without complications (WHO 2007), however I found a high number of 
women with DM taking a natural approach to contraception by using barrier or 
natural methods in their wish to avoid taking hormones or chemicals. It was 
apparent that this behaviour was putting them at risk of unplanned pregnancy 
and that women need more information about such methods.
For women that were using hormonal methods such as the contraceptive pill it 
would be important to establish adherence to use of the method and where 
appropriate discussion of the long-acting methods such as the Implant and 
Intrauterine system (IUS). For women to whom pregnancy would cause 
deterioration of their health; danger to a fetus or was no longer desirable then the 
IUS may be an alternative to sterilisation for some women. For some women 
with DM such as teenagers and women in the postpartum period, contraception 
is an important challenge and the importance of discussion with health care 
providers was highlighted.
10.9 Conclusion to Chapter Ten : Discussion
This chapter has focused on integrating and interpreting the findings of my study 
in relation to preconception care; planning for pregnancy and contraception for 
women with DM and placing these findings in context of wider issues of policy 
and practices within the case study: The Prevention of Unplanned Pregnancy in
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Women with Type 1 or Type 2 Diabetes Mellitus.’ The case study considers 
both epidemiological and bio-psychosocial evidence from my data in relation to 
women with DM and the health professionals caring for them and this and the 
following Chapter Eleven, represent the ‘structuration’ and ‘reconstruction’ phase 
of the extended case method (Burawoy 1998) which aims to generate theory and 
make recommendations for practice.
From an epidemiological perspective, diabetes and pregnancy is becoming an 
important topic as rates of type 1 and type 2 DM are increasing in all age groups 
and there is clear evidence that women with DM are at greater risk of 
complications in pregnancy (CEMACH 2007, Macintosh et al 2006). There are 
more women of childbearing age who have DM and my data found no difference 
in pregnancy rates for women with type 1 DM in comparison to a group matched 
for age. Women in general appear to be leaving childbearing to later in life and 
my data again showed no difference to the general population in this respect with 
a quarter of women answering the questionnaire, giving birth over the age of 
thirty years. The health professionals found the tendency for late childbearing by 
women with DM of great concern due to the propensity for complications of 
diabetes to increase with age which may then complicate pregnancy and 
maternal health. These findings thus form a tension for women with DM between 
psychosocial issues such as readiness to have a baby, financial stability, partner 
choice and availability of good contraception versus the maternal and fetal health 
benefits of early childbirth.
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It was seen as important by the health professionals that women with DM plan 
their pregnancies however preconception services were poorly attended. My 
data show that in line with national policy (DH 2001a), health professionals said 
that they regularly gave information about preconception issues to women with 
DM of childbearing age. However there was incongruence in this aspect in that 
many women did not agree they had received such information and in analysis of 
the questionnaire study there was no difference in those women receiving 
preconception information in respect to planning pregnancy. Narrative from the 
women showed that receptiveness to preconception information appeared to be 
affected by the relevance at the time and the strength of the relationship between 
the health professional and women with DM. Women with DM were not aware of 
the current guidelines recommending a 5 milligram dose of folic acid 
supplementation prior to and during the first trimester of pregnancy and such 
knowledge may have prevented fetal neural tube defects.
In agreement with national statistics (CEMACH 2007) my data showed that over 
half of all the pregnancies to the women with diabetes were ‘unplanned’ and the 
interview data were then analysed to seek meaning from examination of 
psychosocial factors. It appeared that the terms ‘planned and ‘unplanned’ 
pregnancy were open to different interpretation of meaning which may need 
clarification in future research. The concept of ‘planning pregnancy’ evolved as a 
continuum with many complex psychosocial perspectives and beliefs as to why
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women do not plan their pregnancies. These included unconscious intention, 
ambivalent use of contraception and laissez-faire attitude. The notion of 
‘resistance to planning’ emerged highlighting the belief systems of the women 
against the ‘pressure’ of planning and of cultural and romantic beliefs about 
pregnancy. Such attitudes may relate to the current promotion by some women 
and midwives to ‘normalise’ childbearing in opposition to the médicalisation of 
pregnancy which was another emergent theme of my data.
It was evident from my data and from current local policies that women with DM 
experienced a medically focused pregnancy. Obstetricians were reluctant to 
avoid medical intervention and allow ‘natural’ childbirth incase of poor outcome 
with the potential for negligence and women with diabetes who were pregnant 
experienced frequent hospital appointments and scans and were expected to 
keep very tight control of their blood glucose levels. This intensive medical 
management is in contrast to the climate of current government policy (DH 
2005b) where a ‘patient centred’ and ‘self managed’ approach to care is more 
common. However analysis of my data would suggest that by using the 
principles of the self managed ‘structured education programme’ DAP NE and 
DESMOND, that women could be encouraged to have better glycaemic control 
before conception, so preventing fetal complications. This was evident because 
my data showed women who often began pregnancy with less than optimal 
control having the motivation once pregnant to undertake glucose testing up to 
seven times a day. Several women gaining excellent glycaemic control through
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titration of insulin to dietary requirements learnt during pregnancy which they 
then continued for life.
Self management gives women control over their DM and could avoid concerns 
raised in my data by the women, of resentment over ‘nagging’ from health 
professionals about glycaemic levels. Findings showed tension for health 
professionals trying to promote the importance of preconception care between 
‘therapeutic nannying’ (Fitzpatrick 2004) and allowing women the right to 
behavioural choice. It appeared that good patient/professional relationships were 
important in relation to decision making by women with respect to preconception 
and DM care. With the move of diabetes services into primary care this may be 
facilitated by more local and personal care. However my data indicate that GPs 
and other services may need updating on specific guidelines for women with DM 
and pregnancy such as medication review and referral guidelines.
In order to prevent unplanned pregnancy, effective contraception is important for 
women with DM and women are advised to use a reliable method of 
contraception until their HbA1c is stable at recommended levels (CEMACH 
2007). Hormonal contraception is seen as a safe and reliable option for women 
with DM without complications (WHO 2007), but my data highlighted significant 
variation with less prescribing of hormonal contraception to women with type 1 
and type 2 DM in comparison to the general population. In addition there was a 
lack of congruence between the views of health professionals and women with
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DM in relation to contraception. Health professionals were in the main keen that 
reliable hormonal methods were used to prevent pregnancy but I found a high 
number of women with DM wanting to take a ‘natural approach’ to contraception 
by using barrier or ‘natural methods’ in their wish to avoid taking hormones or 
chemicals. The health professionals were not keen to give contraceptive advice 
despite policy in the NSF for Diabetes (DH 2001a) recommending that women 
with DM should receive regular contraceptive advice and for some women the 
only contact with health professionals will be at DM consultations or annual 
review. My data showed that women were using a range of contraceptive 
methods but there was greater use of methods such as condoms which have a 
higher user failure rate and little evidence of use of long acting methods of 
contraception (LARC) that are in general suitable for women with DM and have 
better efficacy.
Teenagers with DM have been identified as being a group at high risk of 
unintended pregnancy (Charron-Prochownik et al 2001) and indeed all of the 
teenage pregnancies in my study were unplanned. They are more likely to have 
poor glycaemic control due to the difficulties that young people have in coping 
with their diabetes and therefore may also be at higher risk of poor pregnancy 
outcomes. Discussion about contraception is therefore an importance part of 
general care for teenagers.
401
In the next and final chapter, I look at the key findings of my study in relation to 
the original research questions and there is a final discussion of the conclusions 
of the study and implications for practice.
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CHAPTER ELEVEN
Key Findings and Final Conclusions
11.0 Introduction
This thesis explores the case of prevention of unplanned pregnancy for women 
with type 1 and type 2 DM. The importance of preconception care and planning 
for pregnancy by women with DM is clearly demonstrated in the literature review 
in Chapter Three, which established that unplanned pregnancy can present 
major health risks to both a woman with DM and her fetus (CEMACH 2007, 
Taylor & Davison 2007, Macintosh et al 2006, CEMACH 2005a, Jensen et al 
2004, Evers et al 2004, Damm &, Molsted-Pedersen 1989, Mills et al 1988).
Poor glycaemic control at conception and throughout pregnancy can accelerate 
the complications of DM and lead to severe obstetric complications as Macintosh 
et al (2006) found, with a fivefold increased risk of stillbirth, a threefold increased 
risk of perinatal mortality and a twofold increased risk of fetal congenital anomaly. 
In spite of these risks my study concurs with others which have found that less 
than half of women with DM plan their pregnancies (Holing et al 1998, CEMACH 
2007).
My study was planned with the aim of understanding the factors that promote or 
discourage effective preconception care in women with DM. The extended case
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method, after Burawoy (1998), was used to embrace the macro and micro 
perspectives on the case and the study comprised of three phases; a database 
study; a questionnaire study and; thirty two semi structured interviews. The 
phases were sequential with each phase informing development of the next, as 
presented diagrammatically in Chapter Four.
The findings are presented in Chapters Five to Nine and interpretation and 
discussion of the results occurs in Chapter Ten. This chapter returns to the 
research questions and summarises the key conclusions in respect of 
information gained throughout the study. Recommendations for practice and 
further research are then made. My findings from the reconstruction phase of 
this case study would suggest that the approach to prevention of unplanned 
pregnancy and preconception care for women with DM requires 
reconceptualisation with a shift away from a medicalised model of care to a more 
holistic woman-centred, bio- psychosocial approach. In Section 11.6,1 suggest a 
tri-partite model for promotion of preconception care, with the holistic care of 
women with DM being the central focus of three overlapping spheres 
representing the domains of Professional care'; ‘Glycaemic control' and; 
‘Contraception’. The ‘macro’ external influences seen within my study such as 
delivery of services, national policy and guidelines are also identified within this 
model.
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11.1 Research Question 1
‘What are the experiences, attitudes & knowledge in relation to planning for 
pregnancy for women with type 1 or type 2 DM?’
In the past women with DM may have been deterred from childbearing altogether 
or would have experienced potentially life threatening outcomes for mother and 
baby (Potter & Kicklighter 2007) and my data show that many women had 
negative experiences in relation to pregnancy which could have had profound 
psychological affects as discussed in the literature by Snoek (2005). Recent 
advances in research and DM treatments mean that for women without major 
complications of DM, with careful planning, pregnancy can now be considered a 
safe choice and an expectation of women with DM (Bewley 2002, Taylor & 
Davison 2007).
My database study shows no differences in pregnancy rates for women with type 
1 DM in comparison to the general population, although those with type 2 DM 
were less likely to have a pregnancy than a comparison group matched for age in 
the year 2001. It would be useful to repeat this comparison as recent 
epidemiological data (CEMACH 2007) show a rise in the number of women with 
DM of childbearing age and my study highlighted an increasing number of those 
with type 2 DM becoming pregnant.
In line with national trends, some women with DM delayed childbearing and 25% 
of the women studied had their first pregnancy after the age of thirty years. This
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caused concern to the health professionals involved in their care in relation to the 
DM and obstetric complications that this might present, particularly as many of 
the women had at least one other medical condition in addition to their DM. It 
was suggested by some health professionals that women with DM should be 
encouraged to have their children at a younger age. This however represents a 
narrow perspective on the issue as for women with DM, such advice may present 
a tension in their life between psychosocial influences such as their readiness to 
have a baby, financial stability, partner availability and career plans versus the 
physiological maternal and fetal health benefits of early childbirth.
My study found that there is potential diversity in the meaning of a ‘planned 
pregnancy’ which could cause disparity of understanding and purpose between 
health professionals promoting preconception care and women with DM. In 
agreement with statistics from CEMACH (2007), more than half of women who 
completed my questionnaire study said that they had not planned their 
pregnancy. However on analysis of interview data, it became clear that there 
was a continuum of planning in agreement with studies by Holings (2000) and 
Bachrach & Newcomber (1999) where an ‘unplanned’ pregnancy is not 
altogether unexpected and where possibly by unconscious intention (Raphael- 
Leff 1994) pregnancy sometimes ‘just happens’. This was a frequent phrase 
emerging from my data. There appeared to be complex psychological factors 
involved in women who experienced accidental pregnancy and Furedi (1997) has 
suggested that women may be testing their fertility and de Marneffe (2004)
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discusses the strength and influence of maternal desire to bear children. Women 
gave a wide range of reasons for ‘not planning’ including contraceptive failure 
and cultural and psychosocial belief systems around becoming pregnant.
Some women were ‘resistant to planning’ per say, either because they found it 
stressful to have potential disappointment, as is discussed by Moos et al (1997), 
or that they had beliefs which romanticised becoming pregnant such as wanting 
pregnancy to ‘be a surprise’. It could be argued that for women with DM, who on 
a day to day basis live with a medical condition, that such attitudes oppose more 
intervention and médicalisation and may relate to current promotion by some 
women and midwives to ‘normalise’ childbearing and this will be elaborated upon 
below.
From the health professionals’ point of view, planning a pregnancy equated with 
preconception care and involved women gaining good glycaemic control prior to 
conception, having a review of medication; a prescription for folic acid and; 
making lifestyle changes such as stopping smoking and eating a healthy diet. 
However this was incongruent with the views and behaviour of the women as 
even women who said they had ‘planned’ their pregnancy still varied in their 
approach and several women had not sought any advice or made any lifestyle 
changes before becoming pregnant. A majority of women interviewed for my 
study did not appear to know about, or be concerned about, risks of pregnancy 
with DM before they became pregnant and many had been shocked by the
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reaction of health professionals and the information regarding risk when they 
presented at the antenatal clinic. The women then experienced anxiety and guilt 
in the fear that they had harmed their baby and indeed some had experienced 
poor obstetric outcomes. Several of the women carried such ‘maternal guilt' for 
years and in the literature Freda et al (2003) and Jackson & Mannix (2004) 
describe how this may cause future emotional problems for women.
This case study by application of the extended case method, has highlighted how 
‘macro’ influences, such as national policy including the NSF for diabetes (DH 
2003) and CEMACH (2007), guide health professionals to provide women with 
DM with regular preconception advice and information, but there appeared to be 
incongruence in views as to whether women received such information. In 
general women did not ask for advice before they were pregnant and although 
the centres all provided preconception services these were poorly attended. The 
health professionals stated that they regularly gave preconception advice to all 
women of childbearing age but over half the women in my study said that they 
had not received information about planning for pregnancy or preconception care 
and others only remembered information in relation to tight glycaemic control.
Even more surprising was that receipt of information about preconception issues 
was found to have no influence on whether a woman planned her pregnancy as 
there was no statistical correlation of those receiving information to those 
planning pregnancy. It appeared that national policy to provide preconception 
information to women with DM may have been delivered by the health
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professionals but it was having little effect and it would appear that the whole
approach to preconception care requires reconceptualisation with a more holistic 
focus.
I previously discussed the current promotion by midwives and women to 
‘normalise’ pregnancy in opposition to the medical and often male obstetric 
domination of childbirth in recent years. Many sociologists and feminists such as 
Oakley (1981), Kent (2000) and Ehrenreich & English (2005) state that this has 
denied women the right to make their own decisions and be in control of their 
bodies. Women in my study were found to experience a very medically focused 
pregnancy with health professionals providing an intensive schedule of 
appointments and medical assessment leading to medical advice and decision 
making, seemingly out of the women’s control. Women with DM may even be 
denied the chance of a ‘natural birth’ because the common practice of planned 
early medical induction for women with DM infers a greater incidence of delivery 
by caesarian section.
Berg (2005) raises the concept of duality experienced by women with DM with 
respect to ‘mastery or enslavement’, with mastery refuting ‘médicalisation’ and 
giving control to women over their DM. In this model, health professionals play a 
supporting coaching role in DM care rather than having a controlling approach 
which encourages ‘enslavement’. The concept of mastery was seen in my study 
in relation to glycaemic control. My data shows that most women begin
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pregnancy with less than optimum glycaemic control which can then impact on 
fetal and maternal wellbeing. However once pregnant, the potentially negative 
effects on the fetus provide excellent motivation for women to gain good control. 
Although blood glucose monitoring was seen as ‘hard work’ and a ‘chore’, 
women tested several times a day and titrated insulin in line with dietary 
requirements, with most achieving optimal levels during pregnancy. Some 
women said that this DM management during pregnancy had taught them how to 
achieve stable glycaemic levels for the future with one woman stating that 
‘pregnancy saved my life’. It was as if gaining control of their DM meant that the 
women could also feel in control of their bodies and Berg (2005) found that such 
self understanding led to general wellbeing and reconciliation with having a 
chronic disease. Self-management programmes are a part of national policy to 
encourage patient led services (DH 2005b) and a holistic approach (Coulter 
1999). The structured education programmes ‘Dose Adjustment For Normal 
Eating’ (DAFNE 2002) and ‘Diabetes Education and Self-Management for 
Ongoing and Newly Diagnosed’ (DESMOND 2008) for those with type 1 or type 2 
DM are available and nationwide women are being encouraged to attend group 
meetings to enhance management of their DM. The Expert Patient initative (DH 
2001b) has been successfully used in several types of chronic disease to 
improve patient self management and in relation to DM. Deakin (2006) 
discusses how health indicators are improved by patients undertaking the 
programme. If women were offered these programmes prior to pregnancy they
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may have better glycaemic control at conception thus preventing poor pregnancy 
outcomes.
My data showed that women with DM planning pregnancy did not always receive 
optimum preconception and early pregnancy care from primary care 
practitioners. Many women with type 1 and type 2 DM are now cared for in 
primary care settings and my study highlighted concerns regarding awareness of 
general practice staff in relation to preconception care for women with DM. The 
interviews showed evidence that women did not have potentially teratogenic 
medication reviewed or folic acid prescribed and that there was late referral for 
antenatal care. This emphasises the need for further education and training in 
preconception and pregnancy issues for professionals involved in DM care.
11.2 Research Question 2
‘What factors promote or discourage effective preconception care in women with
Diabetes Mellitus?’
The importance for preconception care for women with DM has been highlighted 
in my study in the review of the literature (Temple et al 2006, Diabetes & 
Pregnancy Group France 2003, McEIvy et al 2000, DCCTRG 1996), and in 
outcomes for women who have undergone preconception care. In Section 11.1,
I discuss the multitude of factors apparent in the concept of ‘planning’ pregnancy
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and with regard to preconception care, the factors involved appear equally 
complex.
Women who said that they had ‘planned’ their pregnancy were not always aware 
of concerns relating to DM and pregnancy and had not sought advice or made 
any changes to their lifestyle before becoming pregnant. This lack of awareness 
of risk therefore appeared to be one factor involved in women not accessing 
preconception care and Gupton et al (2000) discuss how health care 
professionals should discuss perceptions of risk with women if they are to work 
together to manage complicated pregnancies. A number of the women 
interviewed felt that health professionals had not made them aware of just how 
DM could affect pregnancy and they had been shocked by this knowledge when 
told once pregnancy was diagnosed. On the other hand health professionals 
said that they were regularly delivering preconception information to women with 
DM as per national guidelines (DH 2003). This provision of health promotion 
information appears to have little effect on promoting preconception care in 
women with DM as women who said they had been given preconception 
information were no more likely to plan their pregnancies. In addition, despite 
multidisciplinary preconception clinics being available for women with DM as 
recommended by CEMACH (2007), my study found that the services that already 
exist are poorly attended with women generally only seeking advice once they 
are actually pregnant.
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Another factor involved may be receptiveness by women to information about 
preconception care and pregnancy. In my study some women said they 
resented information being given as it was not relevant to them at the time and 
some women felt it was insensitive to discuss such issues if they had been 
having fertility treatment or had recently experienced pregnancy loss. In addition 
those women with romanticised beliefs about pregnancy, or who had ‘resistance 
to planning’ as discussed in Section 11.1 may also be un receptive to receiving 
information. This then presents a dilemma for health professionals who are 
guided by national policy which states that all women with DM should be given 
information on preconception care at least on an annual basis and sensitivity to 
the position of the women is required. The way information is presented to 
women with DM appears to be very important and consideration needs to be 
given to the timing and delivery of preconception information given by health 
professionals. My study found that unless women were thinking of becoming 
pregnant they appeared to ignore preconception messages and the relevance of 
information to a woman at the time it is given may be an important factor as to 
whether it is acted upon.
One key finding that could be of influence in promoting effective preconception 
care is that women with DM could use more reliable methods of contraception or 
use methods more reliably. My study has highlighted variations in knowledge, 
choice and use of contraception by women with DM with some wishing to take a 
‘natural’ approach which had put them at risk of unplanned pregnancy. My
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database study found differences in prescribing of contraception to women with 
DM by General Practitioners and in addition diabetes health professionals had 
variations in their knowledge of contraception. Women with DM were 
consequently often using less reliable or less suitable methods of contraception 
or methods that they were not entirely happy with. These issues are discussed 
further in Section 11.5.
11.3 Research Question 3
‘What health care and advice is currently provided by health professionals in 
order to encourage positive pregnancy outcomes for women with diabetes?’
As discussed above in Section 11.2, my study found that specific services for 
preconception care and clinics have not in general been well attended; however 
the health professionals said that preconception advice and information was 
regularly given to women during routine appointments. The health professionals 
were clear in their advice to women to ensure good glycaemic control of under 
7.0mmol/litre before conception and throughout pregnancy. The provision of 
contraceptive information was not routine, but, to prevent unplanned pregnancy, 
some health professionals spoke to women about the importance of using a 
reliable method of contraception until good glycaemic control was achieved.
Women were recommended to have a review of their medication particularly 
Angiotensin-converting enzyme inhibitors, Angiotensin-!i receptor antagonists
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and Statins which may be teratogenic. Women using OHAs may be transferred 
to insulin, however the use of Metformin in pregnancy is currently under review 
with many health professionals advising women to continue the drug until 
pregnancy is confirmed. Women on long-acting insulin analogues may also 
require switching to another type of insulin as there is little evidence of their 
safety during pregnancy.
In order to prevent neural tube defects, it is currently recommended by CEMACH 
(2007), BMA (2004) and RCOG (2003) that women should be prescribed 5 
miligrammes of folic acid for twelve weeks before and for the first twelve weeks 
of pregnancy. Some of the health professionals felt that on more recent 
evidence (Smith et al 2008, Capel & Corcoy 2007) that the higher dose should 
only be prescribed to women who had an HbA1c of over 7% and for women who 
were well controlled, the 400 microgramme dose was advised.
Women were recommended to have a retinopathy review prior to pregnancy and 
some health professionals mentioned general preconception care issues such as 
rubella status and lifestyle factors such as; giving up smoking; eating a healthy 
diet and; restriction of alcohol. There was no mention of current preconception 
dietary recommendations such as, not consuming liver due to the high vitamin A 
content or unpasteurised soft cheeses to prevent risk of infection.
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As part of preconception care some of the health professionals had a discussion 
with women and made them aware of the usual medical care that was offered to 
women with DM during pregnancy. This was to enable them to have a better 
understanding of how their care during pregnancy may differ from that of the 
general population, for example in the number of appointments, possible extra 
scans and interventions and planned early delivery required.
A number of the health professionals were aware that they required training in 
preconception and pregnancy issues and some were reluctant to give information 
to women, seeing it as a specialist area of colleagues responsible for pregnant 
women with DM.
11.4 Research Question 4
To what extent is there congruence between the women's & professional's 
perspectives in relation to reproductive health issues?’
It was found that both congruence and incongruence existed in relation to 
reproductive health issues. Women with DM were divided in their knowledge and 
request for information about pregnancy issues, with some claiming that they did 
not know the risks involved in having poor glycaemic control at conception and 
wanting clearer more specific information. Others did not wish to be given 
information seeing it as an intrusion or as being ‘nagged’.
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As discussed in Section 11.1, once women became pregnant there was 
congruence with the health professionals in relation to the importance of gaining 
and maintaining good glycaemic control. For the women, the knowledge that the 
physiological effects that their maternal glucose levels could exert on the 
wellbeing of the baby, had psychological influences on the women to work hard 
to achieve good glycaemic control. This was not the case before pregnancy, 
however and many women had less than optimal control at conception. The 
health professionals found that working with pregnant teenagers was sometimes 
a challenge due to the fact that they were more likely to have erratic DM 
management, but that even they usually managed to achieve good glycaemic 
control by the end of pregnancy.
In relation to suitable methods of contraception the health professionals and 
women were often of differing opinions. Some health professionals 
recommended ‘reliable’ hormonal methods and some women with DM did not 
want to use such methods, seeing them as ‘putting extra hormones or chemicals’ 
into their body. Alternatively some women had been advised by health 
professionals that they could not use hormonal methods when in fact they may 
have been suitable.
The extended case method used in this study, considered the effect of national 
policy and guidelines within the findings and the data suggest that the focus of 
some policies appear to be incongruent with observed clinical practice. On a
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macro level government health policy emphases self management within DM 
care, aiming towards a holistic approach and partnership with health care 
providers (DH 2003). In contrast, at a micro level, the experience of many of the 
women in relation to preconception and pregnancy was a medicalised approach 
with an intensive schedule of medical care. The effect of this on the women with 
DM in relation to their control of their bodies is discussed already in Section 11.1. 
Similarly, as discussed in Section 11.1, on a macro level health professionals said 
that they followed guidelines and policy in providing preconception information 
but then it was seen that, at a micro level, women with DM did not appear to 
have always received or be aware of such information.
Another incongruence that has also been highlighted previously is the advice by 
health professionals to women to have children ‘earlier rather than later' as they 
were concerned about complications of DM affecting pregnancy and pregnancy 
affecting the women’s DM. Although some women with DM had their first 
pregnancy earlier than the general population, in my study, 25% waited until after 
the age of thirty years of age.
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11.5 Research Question 5
‘How can health professionals encourage positive pregnancy outcomes for
women with DM?’
My study found that in order to encourage positive pregnancy outcomes, women 
with DM need to be informed and there needs to be discussion of the risks of 
unplanned pregnancy to enable them to make choices to gain good glycaemic 
control before conception. This appears to be a challenge for health 
professionals as women do not always seem to be receptive to information, yet 
national guidelines (DH 2001a) recommend annual provision of information about 
pregnancy issues.
My study demonstrates the importance of a good working relationship and 
partnership in care between health professionals and women with DM and here it 
can be seen how the wider influence of policy can have an effect on the micro 
level of care in two respects. Firstly in using a sharing and empowering 
approach to care as promoted by patient led services (DH 2007), women are 
allowed to be in control of their DM and professionals who play a supporting 
coaching role in DM care encourage self management and wellbeing in women 
rather than encouraging ‘enslavement’ by being controlling (Berg 2005).
Secondly the effects of recent service reorganisation with the move to provide 
care for women with DM in primary care settings may provide more individualised
419
continuity of care and improved patient outcomes as discussed by Stewart et al 
(2000) and Brooks (2005). This means that health professionals may build 
relationships with patients and have knowledge of the beliefs and the situation of 
the women, enabling sensitive information and advice about contraception and 
preconception to be tailored to the women’s needs and for women to perhaps 
feel more comfortable about discussing intimate topics.
My study indicates that use of contraception is a factor in the prevention of 
unplanned pregnancy and that health professionals could ensure up to date 
information is available to women, to enable them to choose a method with which 
they are happy to use and that is reliable. My research shows significant 
differences in prescribing practice to women with DM possibly because of 
variations in the way that professionals evaluate the risk benefit equation (Shawe 
& Lawrenson 2003). It is therefore important that health professionals 
prescribing contraception ensure that their knowledge is current with regards to 
methods that are available and suitable for women with DM.
Hormonal contraception is a safe option for women with DM, without 
complications (WHO 2007), and thought should be given to long-acting reversible 
methods such as the Implant or Intrauterine system which give three and five 
years protection respectively. My study highlighted that several women did not 
wish to use hormonal methods of contraception and were putting themselves at 
risk of unplanned pregnancy by misunderstanding use of ‘natural’ methods.
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Women can access information and training in Natural Family Planning from 
trained nurses in Community Contraception Clinics and women identified as 
wishing to use ‘natural methods’ should be referred for specialist advice.
My research also draws attention to the special consideration that is needed 
regarding contraception for some groups such as teenagers and post natal 
women in order to prevent unplanned pregnancy. Young people may have 
difficulty coping with their DM and may have poor glycaemic control. In addition 
they may be starting sexual relationships which may leave them vulnerable to 
unplanned pregnancy. The high rate of teenage pregnancy in the UK has led to 
policy aimed specifically at young people (DH 1999). Research has shown that 
young people prefer to attend services that are confidential and specific to their 
age group (Brook 1998, Gleeson et al 2002, FFPHRC 2004) and specialist 
contraceptive services are now available in Primary Care aimed at young people 
and in settings where they feel more comfortable to attend (Dennison 2004). 
Health professionals can therefore refer young people to such services in their 
local area. Post natal women were also found to be putting themselves at risk of 
unplanned pregnancy both through incorrect knowledge and difficulty in 
accessing services. Health professionals, including midwives, could ensure up to 
date information is discussed with women, regarding suitable contraception and 
access to services which may prevent unplanned pregnancy.
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Women with DM need to be aware of emergency contraceptive methods 
available including the pill and the intrauterine device (IUD) in case they have 
unprotected sexual intercourse. The pill is licensed for use up to seventy two 
hours following unprotected sexual intercourse and the IUD for five days after the 
calculated earliest day of ovulation. Both are safe for women with DM and may 
help to prevent unplanned pregnancy.
The diabetes health professionals interviewed, appeared reluctant to raise sexual 
health issues with women with DM. This is discussed in Chapter Ten and is seen 
in the literature (Haboubi & Lincoln 2003, Stokes & Mears 2000, Guthrie 1999) 
which highlights that health professionals may be concerned about not being 
able to address concerns or have lack of time, or worries about the complexity 
that is involved. If diabetes health professionals, midwives and general practice 
staff could be updated to be able to have basic knowledge of contraception, 
preconception and pregnancy issues then they may be happier to raise the topic 
with women and to suggest appropriate referral.
Health professionals could encourage positive pregnancy outcomes by using 
evidence based practice to develop care pathways and local guidelines for 
preconception care. My study identified various models of care used in the four 
diabetes centres in the preconception period including single appointments; a 
series of appointments and group sessions either by single health professionals 
or a multidisciplinary team including a dietician, nurse and doctor. My findings
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show that these current medicalised models of promotion of preconception care 
are having little effect in achieving the aim of women with DM planning their 
pregnancies and, in the Section 11.6, I propose a tri-partite model which has a 
holistic approach and could be used in development of care pathways for 
preconception care.
11.6 Research Question 6
What recommendations for practice can be generated?
11.6.0 Introduction
This section discusses recommendations for practice that have been generated 
from the findings of the case study. Firstly a holistic model of care is developed 
and secondly recommendations for potential future research are made.
11.6.1 Proposed Holistic Model of Care
In the reconstruction phase of the extended case method, I have generated a 
holistic model for promotion of preconception care using key findings that 
emerged from the case study: The prevention of unplanned pregnancy in women 
with type 1 or type 2 DM.’
I developed the tri-partite model using a framework based on the notion of 
overlapping spheres that Andrew Tannahill used for his classic model of health
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promotion in 1985. It is the diagrammatic framework of the model rather than the 
theoretical content that I have adapted and it is the concept of the dynamic 
interaction between the seven domains that is of particular interest. TannahiH's 
model is therefore only used as a template for the spheres, but his original work 
can be seen in Appendix Seventeen. Within my model I have identified the 
macro influences from my study such as service delivery, national policy and 
clinical guidelines which may cause an external effect on the domains.
The model is holistic and dynamic in that there is interaction between the 
domains. In accordance with the feminist focus of my study it is woman centred, 
in that it has a bio-psychosocial approach with partnership between women and 
professionals to promote preconception care and the prevention of unplanned 
pregnancy. The model comprises of three main domains i.e: ‘Professional care'; 
‘Glycaemic control’; and; ‘Contraception’. These overlap to give seven domains 
in total, each with the focus of the woman with DM being central and domain 
seven of the model where all three spheres overlap providing holistic 
preconception care.
Figure Eleven below shows a diagrammatic representation of the model with 
each domain numerically identified and I now go on to explain the content of 
each domain with reference to findings from my study.
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Figure Eleven Proposed Holistic Model of Care -  Prevention of 
Unplanned Pregnancy and Promotion of 
Preconception Care fo r Women w ith Type 1 or Type 2 DM
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Domain One. Professional Care
This domain concerns the professionals involved in the care of women with DM 
and focuses on three key areas; The relationship between the health 
professionals and women with DM; partnership working and; preconception care 
provision.
My study found that the strength of the relationship between women with DM and 
the health professionals involved in their care was an important factor in the 
promotion of preconception care. The first key area in this domain therefore 
promotes strong positive relationships between health professionals and the 
women with DM.
In my study, women with DM experienced a medicalised approach to their DM 
care in general and, in relation to the prevention of unplanned pregnancy, this 
was not seen to be promoting preconception care. From a feminist point of view, 
some of this approach could be seen to be due to national policy such as the 
NSF for Diabetes (DH 2001a) which recommends a medical schedule of care 
and advice for women with DM planning pregnancy rather than focussing on the 
individual needs of the woman. Médicalisation as a concept is discussed in 
Chapter Ten, Section 10.2.2 and is seen by many sociologists to be a form of 
paternalistic social control (Oakley 1981). For some of the women interviewed in 
my study, this approach led to lack of receptiveness to advice or care, as health 
professionals were seen as ‘nagging’ rather than as supportive. In the literature,
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Holing et al (1998) found women who had a poor relationship with their health 
care provider were less likely to discuss pregnancy plans and Bower & Mead 
(2000) found that partnership working (as discussed below), may be prevented if 
professionals have attitudes that infer a position of power.
The second key area in this domain is ‘partnership working’ and this includes 
health professionals working in collaboration with both women with DM and with 
other health professionals such a diabetes specialists, dieticians, doctors, nurses 
and midwives to ensure mutual decision making to create an individual approach 
to care which is acceptable and tailored for each woman.
Recent policy (DH 2000, 2005b, 2007a) has promoted a move away from the 
medical model of care with a focus of patient and in this case, ‘women’ centred 
care and working in partnership with patients. The aim within DM care is to 
promote an emphasis on self management of DM by women, and for health 
professionals to have a supporting role, sharing care and thus promoting 
‘mastery’ as discussed by Berg (2005) in Chapter Ten.
My study found that there is currently incongruence in views of the professionals 
and women with DM in relation to preconception care issues which could inhibit 
promotion of preconception care. These included; the awareness of risk in 
pregnancy; belief about planning for pregnancy and; in information given about 
preconception care. By professionals focusing on the individual needs of the
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women and working in partnership, with sensitivity in communication and 
discussion of a woman's beliefs, then this may promote greater understanding to 
allow such differences to be resolved.
My study found that current NHS service reorganisation is seeing a move to the 
provision of general DM care into primary care under the care of the GP and 
practice nurses and this has implications for partnership working. In order to 
provide the best care for women with DM, the GP service may need to work 
jointly with diabetes specialists and other local health professionals. Depending 
on local policies this may involve early referral from primary care to secondary 
specialist care DM services or primary and secondary care services may 
alternatively join together to provide joint care within the primary care setting.
The third key area in this domain is preconception care provision. In order to 
promote preconception care and to provide equity of care to women with DM, 
preconception care services need to be readily available and accessible and 
advertised to women with DM.
My study found that although all the diabetes centres provided some form of 
preconception care service, they were not well attended and not all women 
received equity of care, particularly if they attended primary care services. A 
local model of care for preconception care services and a care pathway could be
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agreed between primary and secondary care services and discussed with 
women as appropriate.
A range of services are recommended for women attending for preconception 
care and these include: The higher 5mg dose of folic acid in order to prevent 
neural tube defects (Diabetes UK 2008, CEMACH 2007, BMA 2004, RCOG 
2003b); a referral for baseline retinopathy screening (CEMACH 2007) and; a 
review of medication, particularly of anti-hypertensive drugs and treatment with 
statins (Diabetes UK 2007). In addition access to dietary and lifestyle advice 
including occupational and environmental hazards (BMA 2007 and RCOG 2006) 
could be made available. Training needs for professionals in relation to this 
provision may need to be identified and training provided as required.
Domain Two. Glycaemic Control
This domain stems from the knowledge that poor outcomes of pregnancy can be
prevented by a woman having optimal glycaemic control at conception (Taylor
and Davidson 2007, Jensen et al 2004, Evers et al 2004, Damm &, Molsted-
Pedersen 1989, Mills et al 1988). Women can be encouraged to ensure optimal
control in the preconception period and the key areas in this domain are the
promotion of establishing good glycaemic levels by regular testing and the
promotion of self management of DM by attendance at structured education 
programmes.
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The recommended levels for optimal glycaemic control before women become 
pregnant are near normal pre- and postprandial capillary plasma glucose levels 
of: pre prandial 4.4 -  6.1 mmol/l, postprandial less than 8.6 mmol/l.control (DH 
2001a, Diabetes UK 2005). This will involve a woman testing her blood samples 
between four and seven times a day to establish glycaemic levels. Women in my 
study found such testing to be a ‘chore’ and ‘hard work’, but pregnancy was 
found to be a great motivator and health professionals who have a strong 
relationship with women with DM may be able to encourage women to carry out 
such testing in the preconception period rather than only when once pregnant, 
which is currently more common. Such tight glycaemic control may predispose 
to hypoglycaemic episodes and women may require support from partners, 
friends and family who may need training in delivering glucagon treatment for 
such episodes.
With the concept of self management and structured education programmes, 
women could be supported to establish good control as a routine. In this case if 
pregnancy occurred glycaemic levels would be already be at an optimum level. 
My study found that by titrating insulin to dietary requirements, women were able 
to gain good glycaemic control and this allowed them to take control of their DM 
which in turn promoted wellbeing and led to them feeling in control of their 
bodies. This concept forms part of the DM structured education programmes i.e. 
The Dose Adjustment Programme for Normal Eating (DAPNE) for type 1 DM and 
for those with type 2 DM, The Diabetes Education and Self-Management for
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Ongoing and Newly Diagnosed (DESMOND 2008). The promotion of these 
programmes prior to pregnancy may help women to achieve better control.
In addition the laity led self management programme of the ‘Expert Patient’ (DH 
2001 b) may encourage women to support each other with the complexities of DM 
and pregnancy and encourage healthy eating and exercise routines (Coulter 
1999).
Domain S.Contraception
Contraception is an important part of preconception care as a strategy to prevent 
unplanned pregnancy. The NSF for diabetes (DH 2001a) recommends that 
women with DM should receive regular contraceptive advice but my study has 
highlighted that perhaps a greater focus needs to be placed on working with 
women with DM to ensure they are happy with their chosen method and that it is 
reliable. This domain contains three main areas; Choice; Long Acting Reversible 
Contraception and; Emergency Contraception.
In the first key area of ‘choice’, women with DM have the same choice of 
contraceptives as the general population but the potential metabolic effects of 
hormonal methods need to be considered in relation to an individual’s DM profile 
and their need for effective contraception (Shawe & Lawrenson 2003). For 
women without complications of DM or other risk factors, hormonal methods are 
entirely suitable. The World Health Organisation (2000) have established
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medical eligibility criteria for contraceptive use (Chapter Three, Section 3A 5.4  
Table Two) which gives guidance on suitability of methods for women with DM.
In my study, a higher proportion of women with DM than in the general 
population had chosen to use ‘natural methods’ of contraception and were 
putting themselves at risk of unplanned pregnancy by using the method 
erroneously. If women with DM wish to use this method of contraception then 
they can ask for a referral for specialist advice and training by nurses or doctors 
trained in teaching the method (Fertility UK 2007).
The second key area of this domain relates to promotion of Long Acting 
Reversible Contraception (LARC). My study found little use of LARC methods 
amongst women with DM and when discussing contraception with women with 
DM, thought could be given to offering use of LARC methods such as Implant, 
Injectables and Intauterine device or systems. These methods have greater 
efficacy than other methods such as contraceptive pills, in that the dimension of 
human error is reduced (Guillebaud 2004). These methods would also require 
removal prior to pregnancy which would allow for discussion of preconception 
care and glycaemic control before conception.
The third area in the domain concerns raising awareness of emergency 
contraception with women with DM as this may be an opportunity for promoting 
prevention of unplanned pregnancy. Both post coital methods are safe for
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women with DM with the post coital pill being available for use up to seventy two 
hours following unprotected intercourse and the Intrauterine device being able to 
be inserted up to five days post coitally (fpa 2007a).
Domain Four. Contraception in relation to Glycaemic Control
In this domain there is interaction between the domain ‘contraception’ and the 
domain ‘glycaemic control’. It is important that women are happy with their 
choice of contraceptive method as they are then more likely to plan pregnancy 
(Snoek 2000) and for good pregnancy outcomes to be achieved, women need 
encouragment to continue with a reliable method of contraception until they have 
achieved optimal glycaemic control at levels suggested in Domain Two.
Domain Five. Professional Care and Contraception
This domain involves professionals working with women with DM to ensure 
effective contraception if it is required. Women may want the opportunity to 
discuss their individual requirements for contraception to ensure satisfaction and 
acceptability with the chosen method. Professionals may like to suggest or use 
promotional materials such as leaflets to add to their discussion in relation to 
available methods including LARC and emergency contraception.
The training requirements of professionals in relation to contraception for women 
with DM may need to be addressed to ensure that professionals feel confident
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and are competent to give basic contraceptive advice or that there is an easy and 
speedy referral process for women to access advice.
Domain Six. Professional Care and Glycaemic Control
This domain involves professionals working with women with DM to encourage 
good glycaemic control. Women planning pregnancy may need a review of their 
medication that they use to regulate glycaemic levels as certain medications may 
need to be changed to ensure they are non teratogenic (Diabetes UK 2007). If 
this involves a change to use of insulin then particular support from professionals 
may be beneficial for women who are adjusting to self injection.
Some women in my study said that they were not aware of the risks associated 
with high glycaemic levels at conception and during pregnancy and that they 
would have liked more information. Health professionals are able to discuss 
these risks with women and give information and make referrals to dieticians to 
help with dietary changes and advice if appropriate.
Domain Seven: Partnership and Holistic Care, Incorporating Domains One 
to Six
This final central domain holds pivotal women with diabetes and brings together 
the culmination of partnership working and complexities involved within the three 
domains; Professional Care; Glycaemic Control and Contraception to ensure 
holistic negotiated care for women with diabetes. This domain will be dynamic in
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that the focus of provision will be different for individual women and health 
professionals at different times.
In this domain health professionals can provide best practice in holistic 
preconception care by developing strong relationships and working in partnership 
with women prior to conception. The content of domains one to six are 
incorporated within this domain and as discussed earlier, this may include a 
complexity of factors including promoting the concept of ‘mastery’ in relation to 
glycaemic control (Berg 2005). Structured education programmes give women 
the opportunity to participate and learn how to adjust their medication to their 
chosen diet and lifestyle with the outcome of consistently good glycaemic levels 
leaving them in control rather than ‘enslaved’ to their diabetes (Berg 2005).
My research has acknowledged that there are many psychosocial factors 
involved in the process of planning for pregnancy and that women may not state 
that they wish to become pregnant even if they are not actively preventing such 
an event. Women who have a strong relationships with their health professionals 
may feel more able to also discuss reproductive matters with them. Health 
professionals may also feel able to discuss contraception to ensure women feel 
happy with their chosen contraceptive method and that they are encouraged to 
continue with a reliable method until good glycaemic control levels can be 
achieved.
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Other specific factors for best practice in relation to preconception care for 
women with diabetes include review of lifestyle and diet and offering information 
in relation to risks involved in pregnancy for women with diabetes. In addition 
health professionals should propose a review of medication that may be 
teratogenic such as statins, ACE inhibitors and OHA's and discussion about 
taking a prescribed 5mg dose of folic acid. Prior to pregnancy a retinal 
assessment and renal screening should be offered as relevant to provide 
baseline levels to enable review and comparison during pregnancy.
The holistic negotiated approach of this domain with close relationships of health 
professionals working in partnership with women with diabetes will hopefully lead 
to individual tailoring of care in the preconception period leading to healthy 
outcomes of pregnancy for women with diabetes mellitus.
External ‘Macro’ Effects
Use of the extended case method within my study shows that the wider ‘macro’ 
issues such as government and local policies and initiatives may exert an effect 
on the issues relating to the prevention of unplanned pregnancy in women with 
type 1or type 2 DM. Consequently they have been identified within the proposed 
holistic model of preconception care as shown diagrammatically in Figure 
Eleven.
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Domains One and Two, Four and Seven are influenced by the move towards 
patient centred services and related policy includes reports from the Department 
of Health (DH 2000, 2005b and 2007a) and the Expert Patient Initiative (DH 
2001b). A woman’s glycaemic control may be influenced by attending a 
structured education programme as recommended by policy from the 
Department of Health (DH 2005b) and in the report Diabetes Education and Self 
Management for Ongoing and Newly Diagnosed (DESMOND 2008).
The reorganisation of service delivery to provide general DM services more 
locally in primary rather than in secondary care is another ‘macro’ effect that may 
affect the care that women experience.
The National Service Framework for Diabetes (DH 2001a) includes 
recommendations in relation to pregnancy and provision of preconception care 
information and may affect all seven domains by influencing the work of health 
professionals and the care that women with DM receive.
In relation to Domains Three, Five, Six and Seven, the policy on Long Acting 
Reversible Contraception (LARC) (NICE 2005b) encourages use of contraceptive 
implants, injections and intrauterine devices and systems to reduce human error 
associated with other methods. These methods may be offered by health 
professionals as suitable for many women with DM in order to prevent an 
unplanned pregnancy.
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New technology may also affect the way services are delivered and on the way 
information is gained by women with DM. Women access information in a variety 
of ways and as such information should be available in appropriate formats and 
languages to suit their needs. Advantage may be taken of the internet as a 
media tool and information could be incorporated on web sites as appropriate. 
Several studies highlight the benefit of using computer mediated or interactive 
health communication (Fotheringham et al 2000, Pandey et al 2003, Blake 2008) 
and Pandey et al demonstrate that women have a greater tendency to use the 
internet for health information due to time restraints, care obligations or personal 
health concerns. In other formats, pod casts could be used for download on MP3 
or IPOD players. A leaflet for women incorporating contraception, preconception 
and pregnancy issues is planned along with a poster for use in primary care and 
in the diabetes centres and such information could also be included in digital 
form such as a digital video disc (DVD) to use on a computer. Diabetes UK 
magazine ‘Balance’ is widely read by women with DM and articles could be 
incorporated to highlight preconception and pregnancy issues. Text or electronic 
messaging is another strategy that could be explored as it is already being used 
successfully by health professionals to keep in touch and support women trying 
to achieve good glycaemic control. Such initiatives such as ‘sweet talk’ delivers 
automated motivating text messages to the eighteen to twenty five year olds 
(Franklin et al 2003) and ‘Nurse short message’ which uses the internet to review 
and assess glycaemic levels and give health promoting advice (CDA 2008).
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Following on from this model, the study also generated other recommendations 
for practice which are outlined in Section 11.6.2.
11.6.2 Other recommendations are in relation to potential future research.
11.6.2.1. Further research is required to explore in more depth the concept 
of ‘planning’ a pregnancy for women with DM.
My study showed potential diversity in the meaning of a ‘planned’ pregnancy for 
women with DM as discussed in Chapters Eight and Ten. The term ‘planned’ 
pregnancy although unambiguous to health professionals with clear implications 
for promotion of preconception strategies and care was incongruent with the 
views of many women who often made no changes to their lifestyle. There 
appear to be complex psychosocial factors involved which need further 
exploration in order to understand why women have accidental pregnancies. 
Further research is therefore required to explore the concept of ‘planning 
pregnancy’ in more depth and to identify the wider factors affecting ‘planning’ for 
women with DM to establish congruence in meaning for women with DM, health 
professionals and researchers. Research in my own and most of the previous 
studies reviewed, have investigated women once they had given birth which may 
have affected their views and it would be interesting to explore intentions for 
preconception care and perspectives on planning pregnancy with women who 
had not yet had children.
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11.6.2.2 Further research is needed to explore the use of contraceptive 
methods by women with DM.
Previous research has in general studied the use of hormonal methods of 
contraception by women with DM (Kjaer et al 1992, Kimmerle et al 1994, 
Fontbounne et al 1987, Kim et al 2002, Lawrenson et al 1999, Gibb et al 1994), 
but there is little evidence of use of non-hormonal methods or of the newer 
hormonal methods such as the implant, the IUS and the POP, Cerazette.
Further investigation of use of these methods by women with DM would enable 
the suitability of such methods to be assessed and best practice to be 
recommended.
11.6.2.3 Further research is needed to examine the evidence for prescribing 
5 milligrammes of folic acid to all women with DM, in the light of recent 
research.
In 1992 an Expert Advisory Group (DH 1992), made recommendations for 
women with DM to be prescribed 5 milligrammes of folic acid for twelve weeks 
prior to conception and for the first trimester of pregnancy in order to prevent 
neural tube defects (CEMACH 2007, BMA 2004, RCOG 2003b). Within my 
study I found that one diabetes centre did not follow this practice for women who 
had well controlled DM. This practice was based on evidence from recent 
studies showing that the levels of folate requirement are not clear (Capel and 
Corcoy 2007) and that there may be potential deleterious effects including 
promotion of neoplasia, and in pregnancy, an increased risk of insulin resistance 
and obesity in future for offspring (Smith et al 2008). It therefore appears that
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further research is required specifically for women with diabetes as to the risk 
benefit ratio of the higher dose supplement.
11.6.2.4. Further research is needed into the role of partners of women with 
diabetes in relation to pregnancy.
My study showed that partners of the women with DM had anxieties about 
pregnancy, both for the health of their partner and the health of baby. They were 
also concerned about dealing with hypoglycaemic episodes which were more 
common in pregnancy for women with DM and involved the partner giving an 
injection of glucagon to aid normalisation of blood glucose levels. Their concerns 
may have affected decisions relating to pregnancy as shown by one partner who 
did not want another child as he was concerned about his wife’s DM and her 
going through another pregnancy but he had to persuade her to agree to him 
having a vasectomy.
I could not find any research studies exploring these issues which may be 
important for women planning pregnancy as it has been found that women who 
are happy with their partner relationship are more likely to plan their pregnancies 
(Snoek 2000).
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11.7 Conclusion
This thesis examines the issue of unplanned pregnancy in women with diabetes 
mellitus (DM) with the aim of understanding what factors promote or discourage 
effective preconception care. The findings indicate that important factors appear 
to include; the strength of relationships and congruence of views between health 
professionals and women with DM; the belief systems of the women with 
diabetes in relation to planning for pregnancy; receptiveness to preconception 
information and; care and the use of contraception.
The extended case method following Burawoy (1998) was used to explore the 
macro and micro perspectives on the case: The prevention of unplanned 
pregnancy in women with type 1 or type 2 DM. The study used ethnographic 
principles and a feminist focus and included both positivist and interpretative 
methodology with the use of mixed methods being inherent in the study design. 
There were three sequential phases; a database study providing baseline 
evidence of reproductive health care issues amongst women with DM and the 
comparison group; a questionnaire study asking questions about reproductive 
health and planning for pregnancy; and thirty two semi structured interviews 
examining the experiences, attitudes and knowledge of women with DM and 
health care professionals providing their diabetes care. Thus qualitative 
methodology was used to establish meaning from the epidemiological data 
generated by the quantitative phase. The first two phases were analysed using 
SPSS and the qualitative data by NVIVO 7.
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The study findings show that there is incongruence in the meaning or views 
between the health professionals and women with DM which could cause 
disparity of understanding and purpose in the promotion of preconception care. 
Health professionals were clear in the meaning of a planned pregnancy but for 
women with DM of whom over 50% had not planned pregnancy, it appeared that 
there was a continuum o f ‘planning’ which involved unconscious intention, beliefs 
that made them resistant to planning and a complexity of psychological factors 
which deserve further study.
The extended case method, applied to the case study, examines the effect of 
wider ‘macro’ influences such as policy on the case. In respect of national policy 
to provide preconception information to women with DM (DH 2001a), the women 
did not appear well informed despite health professionals saying they gave 
regular preconception information to all women of childbearing age. Women 
were not always receptive to preconception advice and it would therefore seem 
that the information may have been delivered by the professionals but it was 
having little effect. Few women attended preconception services or asked for 
advice before they became pregnant and consequently many women had less 
than optimum glycaemic control at conception, leading to increased risk of poor 
pregnancy outcomes.
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Women in the study in general experienced a medicalised approach to their DM 
care and this was in conflict to national policy promoting a patient (woman) - 
centred approach (DH 2005b). Recent emphasis on self management within DM 
care (DH 2005) has meant a move away from medical dominance to a 
partnership approach and attendance at structured education programmes which 
can help women to gain good glycaemic control and be empowered to regain 
control of their bodies. This along with diabetes services being provided locally 
in primary care may mean that women will feel more comfortable to ask the GP 
or practice nurse about pregnancy issues and contraception.
The use of contraception was found to be an important factor in the prevention of 
unplanned pregnancy but not all health professionals felt they had knowledge or 
were keen to discuss methods of contraception during consultations. Although 
women used a variety of methods, differences were seen in the prescribing of 
contraception to women with DM and there was less use of more reliable 
hormonal methods and LARC. Some women did not want extra hormones in 
their body and preferred to use ‘natural methods’ of contraception and, this was 
incongruent with health professionals who felt that natural methods were 
unreliable. Women in the postnatal period and teenagers were found to use 
contraception erratically and were therefore at high risk of unplanned pregnancy, 
with the added risk of poor outcomes as they also tend to have unstable 
glycaemic control.
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My study identifies areas for further research and exploration. These include
examining the concept of ‘planning pregnancy’ to identify the wider factors
affecting ‘planning’ and to establish the meaning for women with DM, health
professionals and researchers; exploring further the use of contraceptive
methods by women with diabetes; examining the evidence for prescribing 5
milligrammes of folic acid to all women with DM, in the light of recent research
and; investigating the role of the partners of women with DM, as in my study,
they had anxieties about pregnancy both for the health of their partner and the
health of baby and their views and attitudes may have affected decisions relating 
to pregnancy.
The findings of my case study would suggest that that the current medicalised
model of promotion of preconception care is having little effect in achieving the
aim of promoting preconception care and encouraging women with DM to plan
their pregnancies. I would therefore suggest that the whole approach to
preconception care requires reconceptualisation with a shift away from a
medicalised model of care to a more holistic, woman-centred, bio psychosocial 
approach.
I have proposed a tripartite model of care generated using evidence from the 
findings of my study and which addresses the factors that emerged as important 
in the prevention of unplanned pregnancy and promotion of preconception care 
for women with DM. The model is holistic and dynamic and, in accordance with
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the feminist focus of my study, it holds pivotal the woman with DM as its central 
focus. Within the model there is dynamic interaction between the three main 
domains ‘Professional care’; ‘Glycaemic control’ and; ‘Contraception’ influenced 
by external factors such as policy and service provision. This interaction gives 
rise to seven domains which create a framework which has women with diabetes 
at the centre, for health professionals to promote a holistic approach to the 
prevention of unplanned pregnancy and preconception care for women with DM.
The strategy for implementation of my findings and the proposed model will 
include dissemination through peer reviewed publication and conference 
presentations to professionals and by raising awareness in publications, leaflets 
and posters for women with DM. As such my work will form part of the body of 
knowledge of health professionals including nurses, midwives, medical staff and 
dieticians and recommendation can be made to policy makers and legislators to 
influence development of future policy such as NICE guidelines and guidance for 
service provision.
My study has combined epidemiological, bio-psychosocial and feminist theory, 
cumulating in a framework for the holistic prevention of unplanned pregnancy 
and preconception care for women with DM. As such I believe it provides a 
unique contribution to knowledge and to the literature which can influence future 
policy and practice leading to healthy outcomes of pregnancy for women with 
diabetes mellitus.
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CHAPTER TWELVE 
Addendum To The Thesis
In the time that I have carried out my research study there has been increasing 
activity and interest in the topic of ‘diabetes and pregnancy’ due to poor maternal 
and fetal outcomes identified for women with DM. In 2004 The Confidential 
Enquiry into Maternal and Child Health (CEMACH) published a report from its 
diabetes programme which surveyed maternity services for women with type 1 
and type 2 DM in England, Wales and Northern Ireland. This highlighted 
concerns in service delivery and was followed by another report in 2005 of a 
descriptive study of women with pre-gestational diabetes. In 2007, the final 
CEMACH report of a Confidential Enquiry using multidisciplinary panel case 
reviews, studied the impact of clinical care on pregnancy outcome and an audit 
of care during and after pregnancy, for women with pre-gestational diabetes.
This found a ‘worrying lack of emphasis on care prior to pregnancy’ (CEMACH 
2007:xii).
In 2003 The National Institute for Clinical Excellence received a remit from the 
Department of Health to: "To prepare a clinical guideline for the NHS in England 
and Wales for the management of diabetes in pregnancy (specifically excluding 
the identification of gestational diabetes." (NICE 2003:1) which after consultation 
was initially published in March 2008 and then reissued with amendments in July 
2008.
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The guidance: Diabetes and Pregnancy; Management of Diabetes and its 
complications from preconception to the postnatal period; Clinical guideline 
number sixty three, is a comprehensive review of literature incorporating the 
CEMACH studies (2004’2005,2007) to give clinical recommendations for practice 
and research.
The guidance states that it is ‘women and baby centred’ in that the women’s 
needs and preferences should be taken into account and ‘women should have 
the opportunity to make informed decisions about their care and treatment, in 
partnership with their healthcare professionals’ (NICE 2008:3). However the tone 
of the guidance has a medical focus and states for example that ‘Women with 
diabetes who are planning to become pregnant should be informed ...’, (page 4), 
should be offered information’ (page 5) and I would suggest that working in a 
holistic manner is not always evident within the guidance.
The guidance for preconception care can be seen in Appendix Eighteen and 
covers the following key outcomes (NICE 2008:3)
1. Outcomes and risks for the woman and baby
Women with diabetes who are planning to become pregnant should be informed 
that establishing good glycaemic control before conception and continuing this 
throughout pregnancy will reduce the risk of miscarriage, congenital 
malformation, stillbirth and neonatal death. It is important to
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explain that risks can be reduced but not eliminated.
2. Importance of planning pregnancy and the role of contraception
The importance of avoiding unplanned pregnancy should be an essential 
component of diabetes education from adolescence for women with diabetes.
3. Self-management programmes
Women with diabetes who are planning to become pregnant should be offered 
preconception care and advice before discontinuing contraception and should be 
offered structured education programmes where possible before pregnancy.
These outcomes are in agreement with my study findings and it is interesting to 
note the emphasis on self management and participation at structure education 
programmes which concurs with my recommendations. The guidance makes 
specific recommendations and I will discuss four of these which follow up from 
the findings in my study; The issue of use of Metformin in pregnancy; The issue 
of safety of certain insulins; The issue of prescribing the higher dose of folic acid 
and The issue of use of contraception.
Metformin
In respect of use of metformin, NICE is reassuring in that it appears safe to use 
during pregnancy which will help many women with type 2 diabetes to keep good 
glycaemic control and help those with Polycystic Ovary syndrome to become
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pregnant. The guidance suggests all other oral hypoglycaemic agents should be 
discontinued before pregnancy and insulin substituted.
Insulin
The guidance on use of insulin has been updated following the first publication in 
March 2008 and is now reassuring stating that: The recommendation on the use 
of the rapid-acting insulin analogues aspart and lispro in pregnant women with 
diabetes is now as follows: Healthcare professionals should be aware that data 
from clinical trials and other sources do not suggest that the rapid-acting insulin 
analogues (aspart and lispro) adversely affect the pregnancy or the health o f the 
fetus or newborn baby. ’ (NICE 2008:49)
This will mean that many women who had gained good glycaemic control on with 
these products will be able to remain on them during pregnancy.
Folic acid
The guidance confirms that Women with diabetes who are planning to become 
pregnant should be advised to take folic acid (5 mg/day) until 12 weeks of 
gestation to reduce the risk of having a baby with a neural tube defect. In my 
study one centre was advising women who had glycaemic control under 7mmo/l 
to take a 400 microgramme dose as is recommended to the general population.
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This practice may be based on concern that the evidence of folate requirement is 
not clear (Capel and Corcoy 2007) and there have been recent studies showing 
potential deleterious effects including promotion of neoplasia, and in pregnancy, 
an increased risk of insulin resistance and obesity in future for offspring (Smith et 
al 2008). NICE (2008) do not discuss these concerns or recommend further 
research is specifically required for women with diabetes as to the risk benefit 
ratio of the higher dose supplement.
Use of Contraception
The original scope for the guideline in 2003 stated in the search strategies for 
evidence for the guideline The importance of planning pregnancy and the role of 
contraception’ that ‘No specific searches were conducted for this section of the 
guideline’. Contraception was not considered within the evidence of the 
guideline and I consider this to be a missed opportunity.
With reference to contraception and avoiding unplanned pregnancy, the guideline 
offers the following recommendations:
• The importance of avoiding unplanned pregnancy should be an essential 
component of diabetes education from adolescence for women with 
diabetes. (1.1.1.1)
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• Women with diabetes who are planning to become pregnant should be 
advised: to use contraception until good glycaemic control (assessed by 
HbAic8) has been established (1.1.1.2)
• Women with diabetes whose HbA1c is above 10% should be strongly 
advised to avoid pregnancy. (1.2.4.3)
• The intentions of women with diabetes regarding pregnancy and 
contraceptive use should be documented at each contact with their 
diabetes care team from adolescence. (1.2.8.2)
The guidance therefore suggests that use of contraception is important but 
fails to give any specific guidance on contraception for women with DM. As 
my study has shown, there are many complexities involved in ensuring 
women with DM choose effective contraception and that health professionals 
need to be aware of these issues in order to encourage women to plan 
pregnancies and promote preconception care.
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N ationa l Sei v io t  Prnmesvnrk Is jr D ia ltc ies: Sianda id.-:
Aim
To achieve a good outcom e and experience o f pregnancy and ch ild b irth  fo r w om en w ith  
pre-existing diabetes and fo r those w ho develop diabetes in  pregnancy.
Standard 9
The NHS w ill develop, im plem ent and m onitor policies that seek to  em power and support 
w om en w ith  pre-existing diabetes and those w ho develop diabetes during pregnancy to  
optim ise the outcomes o f the ir pregnancy.
Rationale
1. The aim  o f m aternity care is to  ensure that a ll pregnant wom en have a positive 
experience o f pregnancy and ch ildb irth  and receive care that prom otes the ir physical 
health and psychological w e ll-be ing and optim ises the health o f th e ir baby. A lthough 
some w om en’s experience o f a ‘m edicalised’ and h igh-in te rven tion  labour and 
delivery can be a negative or frighten ing one, this need no t be the case i f  they and 
the ir partner are invo lved in  decision-m aking and kep t fu lly  inform ed.
2. Diabetes is the most com m on pre-existing m edical d isorder com plicating pregnancy 
in  the UK. A pproxim ately one pregnant w om en in  250 has pre-existing diabetes.
This is associated w ith  increased risks fo r both m other and baby.
3. Women w ith  pre-existing diabetes are much more lik e ly  to  lose th e ir baby than 
w om en w ho  do no t have diabetes, either during pregnancy as a result o f a 
m iscarriage o r an intrauterine death, o r after b irth . In  the UK, perinata l m orta lity  
rates13 amongst the babies o f diabetic mothers are up to five  tim es h igher than in  
the general popula tion. Congenital m alform ations are the m ain cause o f this h igh 
perinata l m orta lity. These result from  abnorm al feta l developm ent during the six 
weeks fo llo w in g  conception. Later in  pregnancy, the m ain risks to  the baby are 
excessive feta l g row th (macrosomia), w h ich  can result in  damage to both  the baby 
and the m other during delivery. The m ain risk to  the baby after de live ry is 
hypoglycaem ia. These risks can be reduced if  near-norm al b lood  glucose levels are 
achieved before and around the tim e o f conception, th roughout pregnancy and 
during  labour.
13 Perinatal mortality rate is defined as the number of stillbirths plus the number of deaths during the first week of life per 
1000 live births.
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4. Pregnancy results in  increasing insu lin  resistance and, i f  this is no t m atched by more 
insu lin , hyperglycaem ia ensues. However, in tensified glucose con tro l can also 
increase the risk o f hypoglycaem ia. Pregnancy can also result in  the progression,
i f  present, o f d iabetic retinopathy and diabetic nephropathy. W omen w ith  pre-existing 
diabetic nephropathy also have an increased risk o f pre-eclam psia, hypertensive 
disease o f pregnancy and placental insufficiency. M aternal deaths in  w om en w ith  
diabetes are now  thankfu lly  rare, bu t do s till occur occasionally.
5. Outcomes can be im proved if  w om en w ith  pre-existing diabetes are supported to 
plan the ir pregnancies and to  optim ise the ir b lood  glucose con tro l before and 
throughout the ir pregnancies. They should receive close m on ito ring  and specialist 
care throughout pregnancy and ch ildb irth .
6. Between 2 and 12 percent o f w om en develop gestational diabetes14, w h ich  is more 
common in  wom en from  m inority  ethnic groups. These w om en are m ore lik e ly  to 
have large-for-dates babies, a risk that can be reduced by reducing m aternal 
hyperglycaem ia. Women whose b lood  glucose levels revert to  norm al after de livery 
have an increased risk o f developing Type 2 diabetes later in  life . They can reduce 
this risk by increasing the ir physical activ ity levels, eating a balanced d ie t and 
avoiding excessive w eight gain.
7. The C hildren’s N ational Service Fram ework w ill set standards fo r m atern ity services 
and w ill com plem ent the N ational Service Fram ework fo r Diabetes.
Key interventions „ _ ___
o T ight b lood  glucose contro l before and during pregnancy in  w om en w ith  pre-
existing diabetes leads to a reduction in  congenital m alform ation rates and perinata l 
m orta lity rates. (L e ve l 1)
c T ight b lood  glucose contro l during the th ird  trim ester can reduce the risk o f fe ta l 
macrosomia and its associated consequences. (L e ve l 3 )
0  T ight b lood  glucose contro l during labour reduces the risk  o f neonatal 
hypoglycaem ia. (L e ve l 3 ) :
14 Gestational diabetes is defined as any degree of impaired glucose regulation, resulting in raised blood glucose levels of 
variable severity, which is first recognised during pregnancy. This includes Type 1 diabetes presenting for the first time 
during pregnancy; Type 2 diabetes identified during pregnancy, which in many cases was probably present, but 
undiagnosed, before the pregnancy; and lesser degrees of impaired glucose regulation, which in most cases reverts to 
normal after the pregnancy.
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Implications for Service Planning
8. The NHS w ill need to  agree, im plem ent and audit loca l protocols fo r the management 
o f pregnant w om en w ith  diabetes. These should cover:
© the p rovision  o f advice to  a ll wom en o f child-bearing age w ith  diabetes about 
the im portance o f good b lood glucose contro l before and during  pregnancy
@ the provis ion  o f pre-conception care
e the p rovis ion o f antenatal care, includ ing  the detection and management o f
m icrovascular com plications o f diabetes and the detection and management o f 
obstetric com plications
© the p rovis ion o f intrapartum  and postpartum  care
@ the detection and management o f neonatal hypoglycaem ia and other neonatal
com plications in  babies born to  wom en w ith  diabetes.
9. The NHS w ill also need to  review  local policies fo r the detection and management o f 
gestational diabetes to  ensure that they are in  line  w ith  the latest guidance from  the 
N ational Screening Committee.
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DEFINITION AND DIAGNOSIS 
OF DIABETES MELLITUS 
AND INTERMEDIATE 
HYPERGLYCEMIA
REPORT OF A WHO/IDF CONSULTATION
World Health 
^  Organization International Diabetes Federation
Blood glucose levels
Biochemical criteria (venous plasma) for the diagnosis of diabetes, 
impaired glucose tolerance and impaired fasting glucose or 
impaired fasting glucose*
Glucose concentration, mmol 1-1 (mg dl-1)
(Venous plasma)
=>7.0 (=>126)
Diabetes mellitus:
Fasting and/or
2-h post glucose load => 11.1 (=> 200)
< 7.0 (< 126)
Impaired glucose tolerance (IGT)
Fasting (if measured)
and  2-h post glucose load =>7.8 (=>140 ) and <11.1 (< 200)
=> 6.1 (=> 110) and <7.0 (<126)
Impaired fasting glycaemia or impaired fasting glucose (IFG)
Fasting
and  (if measured)
2-h post glucose load < 7.8 (< 140)
*adapted from "Definition, Diagnosis and Classification of Diabetes Mellitus and 
its Complications, WHO Geneva, and the International Diabetes Federation 
IGT/IFG 2003 Consensus Statement 1,2. WHO
SUMMARY OF 
TECHNICAL REPORT 
AND RECOMMENDATIONS
Since 1965 the World Health Organization (WHO) has published guide­
lines for the diagnosis and classification of diabetes. These were 
last reviewed in 1998 and were published as the guidelines for the 
Definition, Diagnosis and Classification of Diabetes Mellitus and its 
Complications. Since then more information relevant to the diagnosis 
of diabetes has become available. In November 2005 a joint WHO and 
International Diabetes Federation (IDF) Technical Advisory Group met 
in Geneva to review and update the current WHO guidelines.
After consideration of available data and recent recommendations made 
by other organisations, the Group made the following recommendations:
Recommendation 1 The current WHO diagnostic criteria for diabetes should be maintained 
-fasting plasma glucose 1 7.0mmol/l (126mg/dl) or 2-h plasma glucose 
^ 11.1mmol/l (200mg/dl).
Despite the limitations with the data from which the diagnostic criteria for 
diabetes are derived, the current criteria distinguish a group with signifi­
cantly increased premature mortality and increased risk of microvascular 
and cardiovascular complications.
Recommendation 2 Since there are insufficient data to accurately define normal glucose lev­
els, the term ‘normoglycaemia’ should be used for glucose levels associ­
ated with low risk of developing diabetes or cardiovascular disease, that 
is levels below those used to define intermediate hyperglycaemia.
Recommendation 3 The current WHO definition for Impaired Glucose Tolerance (IGT) should 
be maintained for the present.
Consideration should be given to replacing this category of intermediate 
hyperglycaemia by an overall risk assessment for diabetes, cardiovascular 
disease, or both, which includes a measure of glucose as a continuous 
variable.
1
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Recommendation 4 The fasting plasma glucose cut-point for Impaired Fasting Glucose (IFG) 
should remain at 6.1mmol/l.
This decision was based on concerns about the significant increase in IFG 
prevalence which would occur with lowering the cut-point and the impact 
on individuals and health systems. There is a lack of evidence of any 
benefit in terms of reducing adverse outcomes or progression to diabetes 
and people identified by a lower cut-point eg 5.6mmol/l (100mg/dl) have 
a more favourable cardiovascular risk profile and only half the risk of 
developing diabetes compared with those above the current WHO cut- 
point. Lowering the cut-point would increase the proportion of people 
with IGT who also have IFG but decreases the proportion of people with 
IFG who also have IGT.
Consideration should be given to replacing this category of intermediate 
hyperglycaemia by an overall risk assessment for diabetes, cardiovascular 
disease, or both, which includes a measure of glucose as a continuous 
variable.
Recommendation 5 1. Venous plasma glucose should be the standard method for measuring 
and reporting glucose concentrations in blood. However in recognition 
of the widespread use of capillary sampling, especially in under-re­
sourced countries, conversion values for capillary plasma glucose are 
provided for post-load glucose values. Fasting values for venous and 
capillary plasma glucose are identical.
2. Glucose should be measured immediately after collection by near-pa­
tient testing, or if a blood sample is collected, plasma should be im­
mediately separated, or the sample should be collected into a container 
with glycolytic inhibitors and placed in ice-water until separated prior 
to analysis.
Recommendation 6 The oral glucose tolerance test (OGTT) should be retained as a diagnostic 
test for the following reasons:
E fasting plasma glucose alone fails to diagnose approximately 30% of 
cases of previously undiagnosed diabetes,
B fan OGTT is the only means of identifying people with IGT,
B fan OGTT is frequently needed to confirm or exclude an abnormality 
of glucose tolerance in asymptomatic people.
An OGTT should be used in individuals with fasting plasma glucose 6.1- 
6.9mmol/l (110-125mg/dl) to determine glucose tolerance status.
2
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SUMMARY OFTECHNICAL REPORT AND RECOMMENDATIONS
Recommendation 7 Currently HbA1c is not considered a suitable diagnostic test for diabetes 
or intermediate hyperglycaemia.
The following Table summarises the 2006 WHO recommendations for the 
diagnostic criteria for diabetes and intermediate hyperglycaemia.
Diabetes ___________________________________ _____
Fasting plasma glucose sZOmmoI/l (126mg/dl)
2-h plasma glucose* or
>11.1mmol/l (200mg/dl)
Impaired Glucose Tolerance (IGT) _________________
Fasting plasma glucose <7.0mmol/l (126mg/dl)
2-h plasma glucose* and
>7.8 and <11.1mmol/l 
(140mg/dl and 200mg/dl)
Impaired Fasting Glucose (IFG)________________________
Fasting plasma glucose 6.1 to 6.9mmol/l
2-h plasma glucose* (110mg/dl to 125mg/dl)
and (if measured)
<7.8mmol/l (140mg/dl)
* Venous plasma glucose 2-h after ingestion of 75g oral glucose load
* If 2-h plasma glucose is not measured, status is uncertain as diabetes 
or IGT cannot be excluded
3
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3. Summary of recommendations
This chapter includes the recommendations that have been made arising from the findings of this report. 
Details of the process followed to derive the recommendations can be found in Chapter 5.
The recommendations below apply to all women with type 1 and type 2 diabetes.
Social and lifestyle issues
1. Preconception and maternity services related to pregnancy should be easily accessible and 
responsive to all women with diabetes, and provide appropriate care and information.
2. There should be mechanisms in place to identify vulnerable communities and individuals, 
so that additional services can be provided as appropriate to women of childbearing age 
with diabetes, thereby ensuring optimal preconception care.
3. Providers of diabetes care should develop educational strategies that will enable all women 
of childbearing age with diabetes to prepare adequately for pregnancy.
Audit and research
4. Research should be carried out to:
,  identify the barriers to accessing preconception care
• identify possible strategies to support self-care and pregnancy planning by women with diabetes. 
Clinical issues: preconception
1. Commissioners of services must ensure that all women with diabetes are provided with specialist 
preconception services, with access to all members of the specialist multidisciplinary team.
As a minimum, these services should include:
* Clear signposting to different aspects of care
* Diet and lifestyle advice
e Provision of appropriate contraception
* Higher dose folic acid supplementation
* Smoking cessation support , 1 ■ '
* Assessment and management of diabetes complications * /  •
.  Setting of glycaemic control targets and regular discussion of results of self-rnonitojfng, % • ‘ /
to enable the woman to achieve control that is as near to normal as possible.before conception*-
* Discussion of diabetes pregnancy risks and expected management strategies
* Clear documentation of care and counselling, ideally using a standard template.
Clinical
Clinical
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Audit and research
2. Preconception services should be audited to ensure that minimum standards are being met. 
Clinical issues: pregnancy
Clinical
1. An individualised care plan covering the pregnancy and postnatal period up to 6 weeks should be 
clearly documented in the notes, ideally using a standard template. The plan may require changes to 
be made depending on the clinical circumstances through pregnancy. As a minimum, the care plan 
should include:
• Targets for glycaemic control
* Retinal Screening schedule 
« Renal screening schedule 
e Fetal surveillance
• Plan for delivery
• Diabetes care after delivery.
2. The care plan should be implemented from the outset of pregnancy by a multidisciplinary team 
present at the same time in the same clinic. As a minimum, the multidisciplinary team should include 
an obstetrician, diabetes physician, diabetes specialist nurse, diabetes midwife and dietitian.
3. Pregnancies with ultrasound evidence of macrosomia should have a clear management plan put in 
place by a consultant obstetrician. This should include timing of follow-up scans, fetal surveillance 
and mode and timing of delivery.
4. A care plan for postnatal management should be clearly documented in the notes for all women.
As a minimum, this should include:
• Plan for management of glycaemic control 
e Neonatal care
« Contraception
* Follow-up care after discharge from hospital.
Audit and research
5. Research should be carried out to investigate:
* the most appropriate management strategy following antenatal evidence of macrosomia 
in babies of women with diabetes
# how best to achieve optimal blood glucose control during pregnancy, labour and delivery.
C linical governance
Clinical
1. Commissioners should recognise the complexity of diabetes management immediately before 
and during pregnancy, and ensure that the available service provision includes all members of the 
multidisciplinary team.
2. Patient pathways of care including preconception counselling, pregnancy care and post-pregnancy 
management should be incorporated into the clinical record.
3. Services should review their local guidelines. The NICE Diabetes in Pregnancy guideline,
due to be published in November 2007, is anticipated to provide current evidence for best practice.
4. In order to raise awareness, specialist multidisciplinary teams should provide regular educational 
days for all primary and secondary care professionals likely to be involved in the care of women with 
diabetes in the local population, to cover all aspects of preconception, pregnancy and postnatal care.
Audit and research
5. Diabetes networks should carry out regular audits of preconception and pregnancy services.
Type 1 and type 2 diabetes
Clinical
1. During pregnancy, retinal and renal screening schedules should be provided for both women 
with type 1 and women with type 2 diabetes.
2. Advice about hypoglycaemia during pregnancy, including prevention and management strategies, 
should be provided to both women with type 1 diabetes and women with type 2 diabetes.
Audit and research
3. Diabetes networks should audit standards of preconception and pregnancy care for both women 
with type 1 and women with type 2 diabetes.
Neonatal care o f term babies o f women with diabetes
1. All units delivering women with diabetes should have a written policy for the management
of the baby. The policy should assume that babies will remain with their mothers in the absence 
of complications.
2. Mothers with diabetes should be informed antenatally of the beneficial effects of breastfeeding 
on metabolic control for both themselves, and their babies.
3. Mothers with diabetes should be offered an opportunity for skin-to-skin contact with their babies 
immediately after delivery. Breastfeeding within one hour of birth should be encouraged.
4. Blood glucose testing performed too early should be avoided in well babies, without signs of ' 
hypoglycaemia. Testing should be performed before a feed, using a reliable method ^ward-based 
glucose electrode or laboratory analysis). For all blood glucose tests, the time it is-performedr .. 
method used, result, and action taken should be clearly documented in the notes. Further research 
is needed to define the optimal timing of first blood glucose test in babies of diabetic mothers.
5. Junior paediatric staff should be trained in the management of babies of mothers with diabetes...
This should include appreciation of the importance of supporting early breastfeeding, avoidance of 
early blood glucose testing in the well baby, and formulation of a written plan agreed with the mother.
6. Midwives should recognise the importance of supporting early breastfeeding for women with 
diabetes, and the need to document this aspect of care. - ^
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Food Standards Agency - Eat well, be well - Trying for a baby Page 1 o f3
FOOD1 STANDARDS AGENCY Eat well., be well Helping you make healthier choices
Print this Page
Trying fo r a baby
A healthy diet is im portant at any 
time, but particularly when you're 
planning a pregnancy.
What to  eat
When you're trying for a baby, as at other times, you 
should try  to eat a healthy and varied diet.
This means trying to eat a variety o f foods including:
e plenty of fru it and vegetables (fresh, frozen, tinned, dried or a 
glass o f ju ice). Aim for at least five portions a day
•  plenty of starchy foods such as bread, pasta, rice and potatoes - 
try  to choose wholegrain options
•  protein such as lean meat and chicken, fish, eggs and pulses 
(beans and lentils). These foods will also supply you with iron (see 
below)
•  try  to eat fish at least twice a week including some oily fish. But 
don't have more than two portions of oily fish a week. This 
includes fresh tuna (not canned tuna, which does not count as oily 
fish), mackerel, sardines and trou t
•  dairy foods such as m ilk, cheese and yoghurt, which contain 
calcium
You should cut down on foods containing fa t and sugar such as cakes 
and biscuits. This will help you to keep your weight under control.
Healthier snacks you m ight want to choose include sandwiches or 
pitta bread filled with chicken, cottage cheese or lean ham; low-fat 
yoghurts; vegetable and bean soups or fru it including fresh, canned 
in ju ice or dried fru it such as raisins or apricots.
Pregnant women can become deficient in iron so make sure you 
have plenty of iron-rich foods to build up your iron stores. Have 
some food or drink containing vitam in C, such as fru it or vegetables, 
or a glass of fru it juice, with any iron-rich meals to help your body 
absorb the iron.
On this page
What to eat 
What to avoid 
Vitamins 
Alcohol
More information
Good sources of iron:
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•  red meat
•  pulses
•  dried fru it
•  bread
•  green vegetables
•  fortified breakfast cereals
back to top
What to avoid
Make sure you don't have too much vitam in A. This rneans you 
should avoid eating liver and liver products such as pâté and avoid 
taking supplements containing vitamin A or fish liver oils (which 
contain high levels of vitam in A).
You need some vitamin A, but if you have too much during 
pregnancy, this could harm your unborn baby. Ask your GP or 
midwife if  you would like more information.
You should also avoid eating shark, swordfish and marlin and lim it 
the amount of tuna you eat.
Don't eat more than two tuna steaks a week (weighing about 140g 
cooked or 170g raw) or four medium-size cans of tuna a week (w ith 
a drained weight o f about 140g per can).
This is because of the levels o f mercury in these fish. At high levels, 
mercury can harm an unborn baby's developing nervous system.
Should I avoid peanuts?
Your baby could be at higher risk o f developing a 
peanut allergy if you, the baby's father, brothers or 
sisters have a food allergy or other allergic conditions 
such as hayfever, asthma and/or eczema.
I f  you th ink that your baby may be in this higher-risk 
group, you may wish to avoid eating peanuts and 
peanut products when you're trying to get pregnant and during
back to top
When you're trying to get pregnant you should take 
a daily 400 microgram (meg) folic acid supplement. 
You should take these from the tim e you stop using 
contraception until the 12th week of pregnancy.
This vitam in helps prevent neural tube defects such 
as spina bifida. I f  you would like to take your folic 
acid in a supplement tha t contains other vitam ins, make sure it 
contains 400mcg folic acid and doesn't contain vitamin A or fish liver 
oils.
You should also eat foods containing folate - the natural form of folic 
acid - such as green vegetables and brown rice as well as fortified 
bread and breakfast cereals.
When you are trying to get pregnant, and during pregnancy, 
remember to avoid taking supplements containing vitamin A or fish 
liver oils (which also contain high levels of vitam in A).
pregnancy.
Vitamins
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back to top
Alcohol
When you're trying to get pregnant, it's best to stop 
drinking alcohol altogether. But if you do drink, have 
no more than 1 or 2 units o f alcohol, once or twice a 
week and don't get drunk.
A unit is half a pint of standard strength beer, lager 
or cider, or a pub measure of spirit. A glass of wine is 
and alcopops are about 1.5 units.
More information
I f  you would like more information on planning a pregnancy, speak 
to your GP or health visitor, or contact your local health promotion 
unit.
back to  top
URL: http://www.eatwell.gov.uk/agesandstages/pregnancy/trybaby/
about 2 units
©  Crown copyright
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Department 
of Health
Summary of Results:
1. The Baseline Review of Contraceptive Services was a voluntary collection and 246 PCTs submitted 
a completed return, representing an 82% response rate.
2. 164 PCTs had performed some form of needs assessment in relation to contraception provision. Of 
these, 124 PCTs were identified as having performed a full needs assessment.
3. Over half of respondents (138) reported consortium-working arrangements
4. 72% of responding PCTs reported the use of informal networks including telephone help lines for 
professionals With limited care pathways in place and informal arrangements between community 
contraceptive services and other service providers. Only 7% of responding PCTs reported that formal 
networks were in place to facilitate community contraceptive service provision.
5. Only 5% of responding PCTs had undertaken a comprehensive audit of Long Acting Reversible 
Contraception (LARC) methods.
6. The average spend on community contraceptive services (including primary care prescriptions and 
emergency contraception) for PCTs who responded; regardless of consortia arrangements, was 
£11.67 per female aged 15-49.
7. 80% of (responding) PCTs reported having undertaken a review of abortion services. However, 53% 
of (responding) PCTs who undertook a review reported no subsequent review of the uptake of
terminations (by residence/postcode) in relation to local access.
8. 57% of (responding) PCTs reported no formal strategy in place to address rising STI rates utilising 
specialist community contraceptive and primary care services. PCTs reporting formal strategies in 
place included:
o Expansion of community based services to integrate contraceptive services.
o Expansion of GUM and sexual health services into Contraceptive and Sexual Health 
services.
o Development of contraceptive services in pharmacies.
o Expanding free condom provision.
o Skilling -up contraceptive services staff by attendance at Sexually Transmitted Infection
Foundation (STIF) training in order for level one services to be provided.
9. Responses to this questionnaire were returned before the re-configuration of PCTs which took place 
from 1 October 2006. The results are therefore shown using the old PCT configurations (see 
paragraph 16 for more information).
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Methods of Contraception 
Non hormonal methods of contraception
Barrier Methods
Barrier methods provide a physical barrier by stopping sperm coming into contact 
with an ovum and therefore preventing fertilisation.
Condoms
a) Male condom 98% effective (fpa 2007)
A condom is a thin sheath rolled onto an erect penis before sexual contact. It is 
made out of latex or polyurethane. Latex condoms must only be used with water- 
based lubricants as oil-based lubricants can cause the latex to weaken.
Condoms can also protect against sexually transmitted infections such as 
Chlamydia, Gonorrhoea and HIV. (fpa 2007)
b) Female condom 95% effective (fpa 2007)
A female condom (Femidom) fits inside the vagina and is made of soft 
polyurethane shaped in a pouch. It has an inner ring that goes into the upper 
part of the vagina, and an outer one which sits over the vulva, (fpa 2007)
Diaphragms 92 to 96% effective and Caps 74-91 % effective (Cook et al 
2003)
The diaphragm and cap are devices made of soft latex that are inserted into the 
upper vagina to cover the cervix before sexual intercourse and left in place for at 
least six hours afterwards. They need to be fitted for size by a doctor or family 
planning nurse and spermacide used with them (fpa 2007)
Spermicides 79 -  94% effective (Glasier & Winikoff 2005)
Spermacide, usually the chemical nonoxynol-9 works by causing a hostile 
environment for sperm by altering pH levels and by changing the cell membrane 
of the sperm to render them inactive. It does not provide reliable contraception 
when used alone but can increase the effectiveness of barrier methods of 
contraception such as diaphragms and caps. Pessaries, vaginal tablets, films, 
creams and gels are available and a sponge impregnated with spermicidal gel is 
soon to be available in the UK. It is no longer recommended that they are used 
with condoms as no benefit has been found (fpa 2007)
Hormonal Methods of Contraception
Several methods of contraception rely on manipulation of endocrine response 
within the body. Methods include pills, sub dermal implants, injection, intrauterine 
system and transdermal patches all containing progestogen and estrogen or 
progestogen only.
Combined oral contraceptive pill. Over 99% effective (fpa 2007)
The most frequently chosen method of hormonal contraception for young women 
with diabetes is a combined oral contraceptive (COC) containing estrogen and a 
progestogen (Lawrenson et al 2001). COCs work by inhibition of ovulation, 
thickening of cervical mucus to prevent sperm entering and thinning the 
endometrium to discourage implantation (fpa 2007)
Most combined products contain 30-35mcg ethinylestradiol although some of the 
older preparations still contain 50mcg ethinylestradiol or 50 meg mestranol.
Some products use 30-40mcg depending on the time of the cycle in the so called 
biphasic or triphasic preparations and recently preparations containing as low as 
15mcg ethinylestradiol have been introduced (IPPF 2007).
Most of the original formulations used principally norethisterone or levonorgestrel 
as the progestogen. These combined products with low doses of ethinylestradiol 
were called the second generation products to differentiate them from the early 
first generation products which contained between 50-150 meg of estrogen. 
COCs containing the progestogens desogestrel, gestodene, and norgestimate 
became available in the 1980’s and have become known as the third generation 
products. The newest COC contains 30mcg of ethinylestradiol and 3 mg of 
drospirenone (bnf 2007).
COCs come in a variety of regimes the most common being 21 days of daily pill 
taking followed by 7 days break when women will experience a withdrawl bleed. 
New regimes to enhance compliance include continuous daily pill taking for a 
year followed by 7 days break i.e. one bleed per year (fpa 2007).
Side effects are mainly minor and can improve or disappear within 3-6 months, 
these include mood change, fluid retention, nausea, headache, mastalgia and 
greasy skin. Serious side effects are rare but involve venous thromboembolism 
and can lead to myocardial Infarction and stroke.
Cyprdterone acetate and ethinylestradiol is a product that combines the 
antiandrogen cyproterone acetate with 35mcg of ethinylestradiol and is used to 
treat women with acne who also require contraception.
Progestogen only oral preparations 99% effective (fpa 2007)
The progestogen only pills (POPs) contain either norethisterone, norgestrel, 
etynodiol diacetate, levonorgestrel or desogestrel. The POP works by, 
thickening of cervical mucus to prevent sperm entering and thinning the 
endometrium to discourage implantation in addition some POPs will also inhibit 
ovulation (fpa 2007). Most POPs need to be taken at very regular intervals daily 
with out a break. Side effects include erratic bleeding patterns, mood changes 
and breast tenderness.
Sub dermal Implants 99% effective (fpa 2007)
Implants contain the progestogen etonogestrel and work in a similar way to the 
combined contractive pill. The implant as a single rod is inserted into the sub 
dermal layer of the inner upper arm which slowly releases progestogen and is 
licensed to be effective for 3 years (fpa 2007). Side effects are as the 
Progestogen only pill.
Transdermal Patch. Over 99% effective fpa 2007)
The Transdermal patch is a small square sticky patch which is attached to skin 
(usually on the buttocks) and releases 20 pg/day of ethinyl estradiol and 150 
pg/day of norelgestromin. Each patch is changed weekly and after 3 patches 
women have a break of one week when they will have a withdrawal bleed (fpa 
2007). Side effects are as for the Combined Oral Contraception.
Injectable contraception. Over 99% effective (fpa 2007)
The injectable contraceptive Depo Provera contains a progestogen, 
medroyprogesterone acetate licenced for 12 weeks or norethisterone enantate 
given every 8 weeks. It works in a similar way to the COC by primarily stopping 
ovulation. There is some concern regarding loss of bone mineral density in young 
people using this method and for those with a history of osteoporosis (NICE 
2005). Side effects include weight gain, erratic bleeding and ammenorrhoea.
Intrauterine Contraceptive Device 99% effective (fpa 2007)
The intra-uteri ne contraceptive device is a small plastic and copper device, which 
is inserted into the uterus. It works by releasing copper which causes an 
inflammatory reaction and an increase in white blood cells in the cervix interfering 
with sperm transport. It may also work by stopping a fertilised egg from 
implanting in the womb.
The IUD is licensed for between 3 and 10 years depending on the type fitted.
Side effects include heavy bleeding and menstrual disturbances, risk of 
perforation, potential infection, ectopic pregnancy and expulsion.
Intrauterine system (Over 99% effective fpa 2007)
The intrauterine system (IDS) is a small T-shaped plastic device which slowly 
releases levonorgestrel over a 5 year period locally within the uterine cavity. It 
works by thickening the cervical mucus to prevent sperm entering and thinning 
the endometrium to discourage implantation and in some women it also inhibits 
ovulation (fpa 2007). Side effects include erratic bleeding, ammenorrheoa, risk 
of perforation, ectopic pregnancy and expulsion.
Natural Methods 80 to 98% effective (fpa 2007)
Natural methods make use of natural indicators (temperature, cervical mucus 
and cervical position) within the body to pinpoint ovulation and therefore when a 
woman is fertile during her the menstrual cycle. It is recommended that women
using this method receive specialist instruction from a family planning nurse 
trained in natural methods of contraception (fpa 2007).
Persona, is an electronic device bought over the counter which measures 
hormone levels in the urine and the manufacturer claims it is 94% effective.
Sterilisation
Sterilisation is a surgical procedure to permanently prevent fertilization in a male 
(vasectomy) or female.
a) Male Sterilisation - Vasectomy - failure rate o f 1 in 2,000 (fpa 2007)
Vasectomy is a minor operation usually performed under local anaesthetic and 
recently using a ‘non scape! technique. It involves cutting or tying the vas 
deferens.
b) Female Sterilisation -  failure rate of 1 in 200 (fpa 2007)
This operation is usually performed under general anaesthetic. The Fallopian 
tubes are cut, tied or blocked, often through laproscopic keyhole surgery.
Emergency Contraception
There are two forms of emergency contraception licenced in the UK.
a) Emergency pill - Levonelle 15001 Levonelle onestep
This pill containing 1500 ug of levonestrel is licensed for use if taken within 72
hours of unprotected sex. Current evidence indicates that it will prevent 95% of
expected pregnancies if taken within 24 hours of unprotected sex, 85% between 
24-48 hours and 58% if used within 48-72 hours (FFPRHC 2006)
It is thought to work in different ways depending on the stage of the cycle it is 
taken either by stopping ovulation, thickening the mucus to prevent sperm from 
reaching the ova, or preventing a fertilised ova from implanting in the uterus.
b) Emergency Intra uterine device (98%-99% effective fpa 2007).
A copper device can be fitted up to 5 days after unprotected sex. It works by 
stopping the ova from being fertilised or implanted. It can be removed after the 
next period or can be left in for use as regular contraception.
Services
Contraception and Emergency contraception is available free on the NHS and 
can be obtained from General Practitioners, Community Contraception or Sexual 
Health clinics and Young people’s services. Emergency contraception is also 
available from most NHS Walk in Centres, some Accident & Emergency 
departments and is sold over the counter in most pharmacies.
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University of Surrey
INFORMATION SHEET (as01 July 2005 Version 3)
Project T itle: Diabetes and Reproductive Health 
Investigator: Jill Shawe Clinical Lecturer
Tel: 01483 684541 E mail:J.shawe@surrey.ac.uk
Dear
My name is Jill Shawe and I work both as a nurse and a Lecturer. I am currently 
undertaking a research project as part of a PhD degree which is looking at women with 
diabetes and health care needs in relation to contraception & pregnancy.
Please take time to read the following information carefully and discuss it with others if 
you wish. Ask if here is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part.
The purpose o f the study ,
The research aims to increase understanding of women with diabetes and their healtn
care needs in relation to contraception & planning for pregnancy 
W hy have I been chosen?
All women aged 1 6 - 4 4  years of age attending the diabetes clinic are being asked it 
they will participate in the study. It is up to you to decide whether or not to take part. If 
you do decide to take part you will be given this information sheet to keep. If you decide 
to take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive.
W hat w ill happen to me if  I take part?
You will be asked to complete one short questionnaire. The questionnaire should take 
no more than 10 minutes to complete and please be assured that the information you 
give will be absolutely confidential and anonymous. No names will be used and you will 
not be able to be identified from the information given.
Four women from the clinic will then be asked if they would participate in one interview 
lasting for approximately 60 minutes. If selected for interview this will be arranged by 
telephone at your convenience and will take place at (one of the four sites). The 
interview will allow you to express ideas and opinions in order to influence future 
services for women with diabetes.
W hat are the possib le disadvantages and risks o f tak ing part?
No risks are anticipated to taking part in the study. One of the interview questions will 
ask about past obstetric history including miscarriages & abortion which could possibly 
stir emotional feeling.
What are the possible benefits of taking part?
Benefits include being able to have the opportunity to express ideas and opinions in 
order to influence future services and care of women with diabetes.
Will mv taking part in this study be kept confidential?
Yes, please be assured that the information you give will be absolutely confidential and 
anonymous. No names will be used and you will not be able to be identified from the 
information given.
What will happen to the results of the research study?
The results will be written up as part of a PhD thesis and for publication. The results will 
be presented and discussed with colleagues in Diabetes clinics. Participants will receive 
a summary of the results and findings and recommendations.
Who is organising and funding the research?
The research is part of an educational degree funded by the researcher and the 
University of Surrey.
Who has reviewed the study?
The study is supervised by Professors at University of Surrey and has been reviewed 
by Diabetes Specialist Nurses in the local NHS Trusts.
Contact for Further Information
Jill A Shawe 
Clinical lecturer 
Duke of Kent Building 
University of Surrey 
Stag Hill 
Guildford 
Surrey 
GU27TE
Tel :  01483 684541 
i.shawe@surrev.ac.uk
Thank you for reading this and for your help.
Jill Shawe Clinical Lecturer
I
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University of Surrey
INFORMATION SHEET FOR STAFF (28lh July 2005 version 3)
Project Title: Diabetes and Reproductive Health 
Investigator: Jill Shawe Clinical Lecturer
Tel: 01483 684541 E mail:J.shawe@surrey.ac.uk
Dear Colleague,
My name is Jill Shawe and I work both as a nurse and a Lecturer. I am currently 
undertaking a research project as part of a PhD degree which is looking at women with 
diabetes and health care needs in relation to contraception & pregnancy.
I would be grateful if you would be able to take part in the study. Before you decide it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with others if 
you wish. Ask if here is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part.
The purpose of the study ,
The research aims to increase understanding of women with diabetes and their healtn
care needs in relation to contraception & planning for pregnancy
Who will be asked to participate? , , _
All women aged 1 6 - 4 9  years of age attending the diabetes clinic are being asked it 
they will participate in the study. An information sheet and questionnaire would need to 
be given out to these women. It should take no more than 10 minutes to complete and 
could be completed in the waiting room. I will provide a box for the completed 
questionnaires. Please be assured that the information given will be absolutely 
confidential and anonymous. No names will be used and no person will be able to be 
identified from the information given.
Following the questionnaires four women will be selected and asked if they would 
participate in one interview lasting for approximately 60 minutes. If selected for 
interview this will be arranged by telephone at their convenience and will take place at 
(one of the four sites). The interview will allow the women to express ideas and opinions 
in order to influence future services for women with diabetes.
Four members of staff who provide direct care to women with diabetes in the clinic will 
also be asked to participate in an interview
What will happen to me if I take part?
You will be asked to participate in an interview lasting up to 60 minutes. Please be 
assured that the information you give will be absolutely confidential and anonymous.
No names will be used and you will not be able to be identified from the information
given.
What are the possible disadvantages and risks of taking part?
No risks are anticipated to taking part in the study.
What are the possible benefits of taking part?
Benefits include being able to have the opportunity to express ideas and opinions in 
order to influence future services and care of women with diabetes.
Will mv taking part in this study be kept confidential?
Yes, please be assured that the information you give will be absolutely confidential and 
anonymous. No names will be used and you will not be able to be identified from the 
information given.
What will happen to the results of the research study?
The results will be written up as part of a PhD thesis and for publication. The results will 
be presented and discussed with colleagues in Diabetes clinics. Participants will receive 
a summary of the results and findings and recommendations.
Who is organising and funding the research?
The research is part of an educational degree funded by the researcher and the 
University of Surrey.
Who has reviewed the study?
The study is supervised by Professors at University of Surrey and has been reviewed 
by Diabetes Specialist Nurses in the local NHS Trusts.
Contact for Further Information
Jill A Shawe 
Clinical lecturer 
Duke of Kent Building 
University of Surrey 
Stag Hill 
Guildford 
Surrey 
GU27TE
Tel : 01483 684541 
i.shawe@surrev.ac.uk
Thank you for reading this and for your help.
Jill Shawe Clinical Lecturer
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University of Surrey
CONSENT FORM
(27th June 2005 Version 2) 
Centre Number:
Study Number:
Patient Identification Number:
Title of Project: Diabetes and Reproductive Health
Name of Researcher: Jill Shawe Clinical Lecturer Tel: 01483 684541 E mail:J.shawe@surrey.ac.uk
Please initial box
1. I confirm that I have read and understand the information sheet dated Ju ly  2005 
(version .3) for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be looked at by responsible
individuals from [University of Surrey] or from regulatory authorities where it is relevant to my 
taking part in research. I give permission for these individuals to have access to my 
records.
4. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent 
(if different from researcher)
Date Signature
Researcher Date Signature
1 for patient; 1 for researcher; 1 to be kept with hospital notes
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RESTRICTED-COMMERCIAL
Excellence in Public Health Research Scientific & Ethical Advisory Group
SEÀG EVALUATION OF PROTOCOLS 
FEED-BACK TO APPLICANTS
CONFIDENTIAL by e-mail
PROTOCOL NO: 514R
PROTOCOL TITLE: A study of the contraceptive choices and associated risks of
cardiovascular disease in women with diabetes
APPLICANT: Prof Ross Lawrenson
APPROVED [X] APPROVED WITH COMMENTS/
RECOMMENDATIONS □
REJECTED/NEEDS REVIEW Q
COMMENTS:
DATE:
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Brighton and Mid Sussex Research Ethics Committee
East Sussex Research Ethics Committee
Brighton and Hove City Teaching PCT
03 August 2005 6th Floor
Vantage Point
Mrs Jill Alison Shawe New W a n d  Road
Clinical Lecturer Br,g^ J
EIHMS University of Surrey
Stag Hill Tel: 01273 296437
Guilford or 01273 296588
Surrey Fax: 01273 296578
GU2 7TE Email: kerry.longhurst@bhcpct.nhs.uk
or: michelle.roman@bhcpct.nhs.uk
Dear Mrs Shawe
Full title of study: A Study of the Reproductive Health Choices of Women
with Type 1 or Type 2 Diabetes 
REC reference number: 05/Q1907/43
Thank you for your letter of 29 July 2005, responding to the Committee’s request for further 
information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting
'ddCUïfià^iürrasT^se^-- ^  .....
The Committee has designated this study as having “no local investigators". There is no 
requirement for other Local Research Ethics Committees to be informed or for site-specific 
assessment to be carried out at each site.
Conditions of approval
The favourable opinion is given provided that you complywith the conditions setout in the 
attached document. You are advised to study the conditions carefully.
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
ÿVêrttiôri&itâ
Application 26 February 2005
InvÀstinatnr CV 1 (None Specified)
Prnfnml 1 17 February 2005
Covering Letter (None Specified)
Interview Schedules/Topic Guides 17 February 2005
Copy of Questionnaire 2 27 June 2005
Participant Information Sheet - For Staff 3 28 July 2005
Participant 1 nform'ation Sheet 3 28 Juiv 2005
Participant Consent Form 2 27 June 2005
Response to Request for Further Information 29 Julv 2005
05/Q1907/43 Page 2
Response to Request for Further Information 1 06 Julv 2005
Supervisor's CV 1 (None Specified)
Information Sheet (for questionnaire) 1 17 February 2005
Consent Form (for questionnaire) 1 17 February 2005
Information Sheet (for interview) 1 17 February 2005
Consent Form (for interview) 1 17 February 2005
Management approval
You should arrange for all relevant-NHS care organisations to be notified that the research 
will be taking place, and provide a copy of the REC application, the protocol and this letter.
All researchers and research collaborators who will be participating in the research must 
obtain management approval from the relevant care organisation before commencing any 
research procedures. Where a substantive contract is not held with the care organisation, it 
may be necessary for an honorary contract to be issued before approval for the research can 
be given.
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The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet.
Notification of other bodies
The Committee Administrator will notify the research sponsor that the study has a favourable 
ethical opinion.
Statement of compliance
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Ethics Committee
10 November 2005
Ms Jill Shawe 
Clinical Lecturer 
E I H M S
Dear Ms Shawe
A study of the reproductive health choices of women with Type 1 or Type 2 diabetes 
(EC/2005/119/E1HMS1 -  FAST TRACK
On behalf of the Ethics Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the submitted protocol and supporting 
documentation-
Date of confirmation of ethical opinion: 10 November 2005
The list of documents reviewed and approved by the Committee under its Fast Track 
procedure is as follows:-
Document Type: Application:
Dated: 21/10/05 
Received: 01/11/05
Document Type: Approval Letter from the Brighton and Mid Sussex REC 
Dated: 03/08/05 
Received: 01/11/05
Document Type: Research Proposal 
Dated: 17/02/05 
Received: 01/11/05
Document Type: Information Sheet for Participants 
Version: 3 
Dated: 28/07/05 
Received: 01/11/05
Document Type: Information Sheet for Staff 
Version: 3 
Dated: 28/07/05 
Received: 01/11/05
Document Type: Consent Form 
Version: 2 
Dated: 27/06/05 
Received: 01/11/05
2Document Type:: Questionnaire 
Received: 01/11/05
Document Type: Risk Assessment 
Received: 01/11/05
This opinion is given on the understanding that you will comply with the University's Ethical 
Guidelines for Teaching and Research.
The Committee should be notified of any amendments to the protocol, any adverse 
reactions suffered by research participants, and if the study is terminated earlier than 
expected with reasons.
You are asked to note that a further submission to the Ethics Committee will be required in 
the event that the study is not completed within five years of the above date.
Please inform me when the research has been completed.
Yours sincerely
Catherine Ashbee (Mrs)
Secretary, University Ethics Committee 
Registry
cc: Professor T Desombre, Chairman, Ethics Committee 
Professor P Smith, EIHMS 
Professor I Robbins, EIHMS
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(Version 2 22.11.05) 
Questionnaire Number :
Questionnaire for Women with Diabetes
First please tell us about yourself
1. Marital status Please circle
1a. Married Yes No
1b. Divorced Yes No
1c. Single Yes No
1d. Partner Yes No
2. Pregnancies
2a. Have you ever been pregnant? Yes No
If no please go 
to question 2i
2b. I am currently pregnant Yes No
2c. How many children do you have?
2d. How old were you when you had your first child?
2e. Did you have diabetes before your first pregnancy? Yes No
2f Did you plan your pregnancies? Yes No
1
2g. Were you given information about your diabetes and planning for 
pregnancy / pre conception care? Yes No
2h. If Yes who gave you information? 
Please state below:
2i. Were there any complications with your pregnancies? Yes No 
If yes please can you explain below.
2j. Are you seeking to become pregnant in the future? Yes
3. About vour diabetes
3a. Please can you tell me in what year you were
diagnosed as having diabetes? ---------------
3b. What is your age now?----------------------------------- ---------------
2
4. How is your diabetes managed?
4a. Are you treated by insulin? Yes No
4b Are you taking tablets for your diabetes? Yes No
4c Are you controlled by diet only? Yes No
5. Controlling vour blood pressure
5a. Do you have any problems with your blood pressure?
Yes No Don’t know
5b. Do you take any tablets for high blood pressure? Yes No
6. Other Medical History
6a. Do you smoke
6b. Do you suffer from migraines
6c. Please can you tell me your weight
6d. Please can you tell me you height
Yes No
Yes No
6e. Do you have any other medical conditions? Please state below
3
Family Planning
7. What methods of contraception I family planning have you used in the 
last year? Please tick
7a. Oral contraceptive pill
7b. Progestogen only pill (mini pill)
7c. IUD (Coil)
7d. IUS Mirena coil
7e. Depo provera injection
7f. Implant
7g. Patches
7h. Condoms
7i. Natural methods
7j. None
7k. I have had a tube tie (sterilisation)
71. My partner has had a vasectomy
7m. I have had a hysterectomy
8. Please can you explain whv the method of contraception you use at 
the moment is best for you?
4
9. Has having diabetes affected vour choice o f contraception?
9a. Yes No
9b. If yes please explain in what way?
10. Have you ever used Emergency Contraception? (Morn ing after p ill)
10a. Yes No
10b. If Yes where did you obtain it from (please circle)
GP Chemist Family Planning Clinic Walk in Centre
Other please state:...................................................................................
11. Are vou concerned about Sexually Transm itted Infections_
11a. Yes No
11b. If Yes what are your concerns?
5
12. Who has given vou family planning advice or a contraception 
prescription in the last year?
Please tick
12a. My General practitioner 
12b. My Nurse at the GP surgery 
12c. My Hospital Consultant 
12d. The Hospital Diabetes nurse 
12e. The Family Planning clinic
12f. Other -  please specify........
12g. None of the above
Finally
Have you any other comments you would like to make?
6
Thank you very much for completing this questionnaire. As part of this 
research project I also wish to speak to women with diabetes to find out 
more about their health care needs in relation to contraception and 
planning for pregnancy. The information would again be confidential 
and anonymous. I would be very grateful if you would be able to help 
with this and I would initially contact you by telephone. Please give 
your name and telephone number below if this would be possible.
Name
Contact Telephone number 
E-màil address:
13. Please can vou tell us vour e thn ic group 
Please tick
W hite
Black
Asian
Other -  please state
14. W hat is vou r occupation?
Thank you again fo r your help 
J ill Shawe 01483 684541
7
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TOPIC GUIDE 
Semi Structured Interviews - Outline questions
1. Parous Women with Diabetes
Can you tell me what you heard about diabetes and pregnancy before you 
became pregnant?
Recall being given any advice?
What do you think are the issues around glucose control 
(H bA lc<7). (Knowledge of risks)
Do you think having diabetes makes any difference to 
trying to get pregnant?
Can you tell me about your own experiences of pregnancy? -  link to
questionnaire. .
Did you seek any advice prior to becoming pregnant/
Were you offered any advice?
If so who gave you advice?
Any concerns about getting pregnant?
How much of your approach to pregnancy was planned?
Can you tell me about any changes you made to your lifestyle 
before getting pregnant. (Folic acid, Smoking, Alcohol, Medication,
Dietary control).
If not planned -  how did you feel? Once you knew of pregnancy 
did you make any changes to your lifestyle?
How did your partner feel about pregnancy and your diabetes?
Can you tell me why you chose the contraceptive methods you have used? -
(Link to questionnaire)
What methods might you recommend to other women with
diabetes?
Who are the main health professionals looking after your diabetes?
How do you feel about asking them for advice?
Can you discuss contraception and pregnancy with them?
What makes it easier/harder?
How do you respond to their advice?
Is there anything else I have not asked that you think would be important to
mention?
Is there anything you would recommend to other women with diabetes who 
were thinking about getting pregnant?
2. Nulliparous women
Can you tell me what you have heard about diabetes and pregnancy?
Recall being given any advice?
What do you think are the issues around glucose control 
(HbA1c<7).
Do you think having diabetes makes any difference to 
trying to get pregnant?
Have you ever been offered any advice about diabetes and pregnancy?
If so who gave you advice? (Link to questionnaire)
Can you tell me about any changes women with diabetes should 
make to their lifestyle before getting pregnant? (Folic acid, Smoking,
Alcohol, Medication, Dietary control)
Can you tell me why you chose the contraceptive methods you have used? -
(Link to questionnaire)
What methods might you recommend to other women with 
diabetes?
Who are the main health professionals looking after your diabetes?
How do you feel about asking them for advice?
Can you discuss contraception and pregnancy with them?
What makes it easier/harder?
How do you respond to their advice?
Is there anything else I have not asked that you think would be important to 
mention?
S.Health Professionals
What do you think are the most important issues for women with diabetes in 
relation to pregnancy?
Advice to specific groups -  teenagers, older women
Who do you think are the most salient health professionals to give advice 
about reproductive health? How do you see your role?
What contraceptive methods do you recommend to women with diabetes? 
Advice to specific groups -  teenagers/ older women
When and how do you tend to deliver advice on preconception care?
Folic acid 400 meg or 5mg?
Can you tell me about any policies about advising women with diabetes about 
reproductive health?
Have you ever received training in delivering preconception advice to women 
with diabetes?
Is there anything else I have not asked that you think would be important to 
include about this topic?
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Project: PHD DIABETES AND REPRODUCTIVE HEALTH 
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D ocum ent
Total References 81
Node Coding Cases\JS- HP 16 References 1 Coverage 100.00 %
Reference 1 C haracter Range 0 -  15,612
So, thank you for taking part today. First of all, can you tell me about your role here in the diabetes clinic.
Tm lead nurse in diabetes, so my role is as a diabetes specialist nurse, education and listening to patients, but I also 
have a managerial side to that role and educating carers and other staff, so quite a broad role. Anything to do with 
diabetes we do it really.
For you, what are the most important issues for women with diabetes in relation to pregnancy.
Well my big thing, having sat on the CEMACH committee is trying to get women engaged with pre pregnancy care. 
The problem is really now because so much is now done in primary care is actually trying to get the message across 
to everybody, because I think people still think 'oh yes, type 1 diabetes, young people that's secondary care', 
forgetting more and more people getting into primary care, so my, what was the question.
The most important issues for you.
So that's it, and getting them referred in because the way we have the system here is that if they're known, if they 
are diabetic already then they usually phone us and let us know as soon as they've got their pregnancy confirmed, 
and its making sure that they're getting into the system very very early, because occasionally they'll go along to the 
GP and the GP will write a referral letter and that takes several weeks to get through the system, or the GP will say 
you don't need to worry until you're 12 weeks pregnant and things like this, and you think 'no!', so that's my big 
thing, a -  trying to get them pre conceptionally, but failing that to get them fast tracked through into the service as 
soon as possible, so that we can sort things out.
What particular things would you want for that particularly?
For them to have fantastic blood glucose control and knowledge of what to expect throughout the pregnancy.
Do you have a separate clinic here?
Yes, we do and we see our pre conceptual in that same clinic because its a small clinic and its myself and Dr x 
unless either one of us is on holiday, so there's tha t continuity.
So with that as your aim, who do you think are the most important health professionals in trying to give that. 
Midwives and GPs really.
And when you say they're seen more in primary care, is that for the whole of their care, or is that shared cared with 
you?
No, some of them, the GPs surgeries are looking after type 1, people with type 1 diabetes and certainly doing their
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Thinking about planning for pregnancy and contraception, do you recommend any particular contraceptive method? 
No, I don't I  don't get involved to be honest.
What do you do if someone asks?  ^ , .  . . , ,
I f  someone asks I usually send them off to the family planning clinic for advice. In the olden days, when I was first a 
diabetes nurse there was issues about the contraceptive pill and diabetes, but I  think that's, I  don t  think that s a 
problem now -  she says (laughs), but I don't feel qualified to advise people on family planning issues.
Do you have many people that come in who are not taking 5mgs of FOLIC ACID. . , . . .  .
Yes, I would say the majority don't. Quite a number of them will take 400 micrograms because they ve decided 
themselves and they've been aware enough, but then we have to write to the GP and ask them to prescribe the 5mg. 
Really I  think because the women and self referring before they've seen their GP.
So they've gone and bought 400 micrograms ...
Yeah, and because they haven't come to see us pre conceptually, it's jus t -  got pregnant.
So for them to be advised about the 5mg you'd have to be actually seen them before.
Yes, so if they come to us pre conceptually, I have a little handful of women who I'm  seeing pre conceptually, tney 
are all on the 5mg, but, the majority as I say self refer once they're pregnant.
And what happens if they're being looked after by the GP? I f  they're unknown to us then, those are few and very far
between at the moment, if they're unkn
Node Coding Tree Nodes\CONTRACEPTION References. 2 Coverage 3.41 %
Reference 1_______________ ___ __________________________________________Character Range 2,493 - 2,651
Thinking about planning for pregnancy and contraception, do you recommend any particular contraceptive method? 
No, I don't I  don't get involved to be honest.
Reference 2__________________________________________ ______________ Cheracter Range----- 2,655 - 3r030_
What do you do if someone asks? , ^  „  , ie,_c firC|. -,
I f  someone asks I usually send them off to the family planning clinic for advice. In the olden days, when I was first a 
diabetes nurse there was issues about the contraceptive pill and diabetes, but I think that s, I  don t  think that 
problem now -  she says (laughs), but I  don't feel qualified to advise people on family planning issues.
Node Coding Tree Nodes\CONTRACEPTION\KNOWLEDGE References 1 Coverage 2 .4 0 %
Reference 1 ____________________________________________________  C haracter Range___2,655 - 3,030
What do you do if someone asks? , ^  , .  . . „  T f=rcr a
I f  someone asks I  usually send them off to the family planning clinic for advice. In the olden days, when I  was first a
diabetes nurse there was issues about the contraceptive pill and diabetes, but I think that s, I  don t
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Node Coding Tree Nodes\HARD WORK\BLOOD SUGAR References. 1 Coverage 1 .9 7 %
TESTING
Reference 1_______________   ;___________________ Character Range 12,202 - 12,510
In general, they work really hard and we see them regularly in the clinics, but they're expected to contact us once a 
week as well just to keep in touch, and I  think because we're a smallish friendly unit and there aren't big numbers, 
then we build up good relationships, so we don't tend to have problems.
Node Coding Tree Nodes\HEALTH PROFESSIONAL References 1 Coverage 2.43 %
Reference 1 __________________________________________________  Character Range-------------- ÇL----- 222.
So, thank you for taking part today. First of all, can you tell me about your role here in the diabetes clinic.
I'm  lead nurse in diabetes, so my role is as a diabetes specialist nurse, education and listening to patients, but I also 
have a managerial side to that role and educating carers and other staff, so quite a broad role. Anything to do with 
diabetes we do it really.
Node Coding Tree Nodes\HEALTH PROFESSIONAL References 1 Coverage 2 .4 3 %
\BACKGROUND QUALIFICATIONS
Reference 1______________________________________________________  Character Range--------------0 ^ ------3S0
So, thank you for taking part today. First of all, can you tell me about your role here in the diabetes dime.
I'm  lead nurse in diabetes, so my role is as a diabetes specialist nurse, education and listening to P ^e n ts , b u t l  al 
have a managerial side to that role and educating carers and other staff, so quite a broad role. Anything to do with 
diabetes we do it really.
Node Coding Tree Nodes\HEALTH PROFESSIONAL \ROLE References 1 Coverage 2.43 %
Reference 1 Character Range 0 - 380
So, thank you for taking part today. First of all, can you tell me about your role here in the diabetes clinic, 
^ m ^  do with
diabetes we do it really.
Node Coding Tree Nodes\MEDICALISATION References 1 Coverage 1 .6 7 %
Reference 1_____________________________________________________ Character Range------------ 7,901 - 8,162_
How does that work with the GP primary care bit? . . . . , „  „ #or
We jus t tell them what we're doing basically and they allow, they're quite happy for us to jus t take over, they 
appreciate that its an area about which they don't know very much so that's not the problem at all.
Node Coding Tree Nodes\POLICY AND GUIDANCE References 2 Coverage 8 .41 %
Reference 1_________________ ____________________________________  Character Range------5,975 - 6,559
When it comes to your pregnancy clinics, do you have care pathways or policies?
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Reference 1      C haracter Range 8 ,392  - 9,139
DoTou see that as any problem if they're coming in late at 12 weeks or whatever and they've been on medication
do in diabetes.
Node Coding Tree Nodes\GLYCAEMIC References 1 Coverage 3 .8 8 %
CONTROL\MOTIVATION FOR GOOD CONTROL
. C haracter Range 1 1 ,597  - 12,202
Reference 1 ----------- — — ------------------------------------K r ± ____________ _____________ _____________________ ____ ___________ _____________________
to me, now I  know I can do it. So they get their control.
lode Coding Tree Nodes\GLYCAEMIC CONTROL\SWAP TO 
IN S U LIN
References 1 Coverage 0.29 %
C haracter Range 7 ,748  -  7,794
Reference 1______________ _________ _ _______ ________________________ _—
I f  they're type 2 we switch them to insulin.
Node Coding Tree Nodes\HARD WORK References 2 Coverage 6.48 /
1    C haracter Range 12,202 - 12,510^
then we build up good relationships, so we don't tend to have problems.
2    C haracter Range 13,660 - 14,36±wmmmMsmf
) pregnancy.
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th in k  th a t's  a p ro b lem  now  -  she says ( la u g h s ), b u t I  d o n 't fee l qua lified  to  a d v ise  peo p le  on fa m ily  p lanning  issues.
Node Coding Tree Nodes\CONTRACEPTION\REFERRAL
Reference 1
References 1 Coverage 2.40 %
Character Range 2,655 - 3,030
What do you do if someone asks? . .  . T ««-t- „
I f  someone asks I usually send them off to the family planning clinic for advice. In the olden days, when I was first a 
diabetes nurse there was issues about the contraceptive pill and diabetes, but I think that's, I  don't think that s a 
problem now -  she says (laughs), but I don't feel qualified to advise people on family planning issues.
Node Coding Tree Nodes\GLYCAEMIC CONTROL
Reference 1
References 3 Coverage 11.21 %
Character Range 11,597 - 12,202
Going on from that, people who do get pregnant, how do you find the outcomes.
In general the outcomes are fine, its always very interesting, you get some people when your heart sinks when tney 
tell you they're pregnant, but, that's why I enjoy doing it and that's why I  specialise in it, because its very rewarding, 
you can have some teenager that you've spent years battling with (laughs) and then all of a sudden during their 
pregnancy they get it right because they're very motivated. Its satisfying for them, I remember once somebody said 
to me, now I know I can do it. So they get their control.
Reference 2 Character Range 13,195 - 13,635
The main thing is getting the message across that it's an important thing to be focusing on in the GP surgeiy rather 
than just ticking the boxes on the template, ensuring that these women are making sure they're taking their folic 
acid and their HbAlc is good. Although the risks are small, you know, its a horrible feeling when you have somebody 
referred to you with HbAlc of 11% which we had earlier this year, and you th ink 'oh, no!'.
Reference 3 Character Range 13,660 - 14,364
Well she was and the midwife, this girl had been to her GP, who'd said well wait till you're 12 weeks and it was only 
the midwife phoned me up, because we have close links with the midwives and she said I've had this blood sugar 
come through of 20 something of somebody's who booking in, what shall I  do with it? (laughs). What !? !, (laughs) 
mentioned the person's name and I thought well I  know her, so I phoned the woman and got her in and we worked 
really hard, and her HbAlc is now 6, so she's done really really well, very impressed. Dr x just can t  believe it, that 
she's managed it, because we've battled with her for years, but that's you know, 12 weeks at a crucial time in me 
pregnancy.
Node Coding Tree Nodes\GLYCAEMIC CONTROL\diet
Reference 1
References 1 Coverage 0.50 %
Character Range 5,238 - 5,316
Do they see the dietician as well?
They can do yes, they don't routinely.
Wode Coding Tree Nodes\GLYCAEMIC
CONTROL\MEDICATION\METFORMIN
References 1 Coverage 4 .78 °/o
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T h e re  is a p reg n a n c y , ca re  o f th e  w o m e n  w ith  d ia b e te s  during  p re g n a n c y  policy h ere .
Where did that, did it come particularly from x (Local Trust ) or is it Diabetes UK?
I don't think its an x (Local Trust) one but its based on, you know I can't remember what its based on, but its from 
the Diabetes UK report, who was is it, it was published in diabetic medicine quite a number of years ago now, hmm 
..but its a jo in t policy that was written with, between ourselves and the obstetric department.
Reference 2____________________________________________ ;____________ Character Range 14,775- 15,504
Anything else you think I  should know?
I don't think so, no. Well, actually I was going to say that we're quite proud of the fact we ve got a small unit and 
there's good communication but it falls down if we're not here, the midwives don't seem to be able to think on their 
own, despite all the protocols and policies being in place, so in a way we're bit of our own worse enemies.
Well, weekends or, they can't cope at a weekend or if I'm  on holiday, because I'm  the one that mainly deals with 
pregnancy, the others do it as well, but if I'm  not here, the midwives can be like 'can you come up here now , and 
they'll be going 'well no', they don't quite appreciate that they've got to take some ownership of this as well.
Node Coding Tree Nodes\PO LICY AND GUIDANCE\CARE References 3 Coverage 9 .1 5 %
PATHWAYS
Reference 1 ______________________ _________________________________ Character Range 5 ,318- 5,434
And do you have any sort of care pathways for women that come along?
You mean a formal care pathway.
Yes.
No.
Reference 2___________________ _____________________________________ Character Range 5,975 - 6,559
When it comes to your pregnancy clinics, do you have care pathways or policies?
There is a pregnancy, care of the women with diabetes during pregnancy policy here.
Where did that, did it come particularly from x (Local Trust ) or is it Diabetes UK? . . . . .  m
I  don’t  think its an x (Local Trust) one but its based on, you know I can't remember what its based on, but its rrom 
the Diabetes UK report, who was is it, it was published in diabetic medicine quite a number of years ago now, hmm 
..but its a jo in t policy that was written with, between ourselves and the obstetric department.
Reference 3___________________ _____________________________________Character Range 14,775- 15,504
Anything else you think I  should know? n -,nri
I don't think so, no. Well, actually I  was going to say that we're quite proud of the fact we ve got a small unit and 
there's good communication but it falls down if we're not here, the midwives don't seem to be able to think on their 
own, despite all the protocols and policies being in place, so in a way we're bit of our own worse enemies.
Well, weekends or, they can't cope at a weekend or if I'm  on holiday, because I'm  the one that mainly deals
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Node Coding Tree Nodes\PREGNANCY References 5
Coverage 14.60  %
  Character Range______ 479 - 905
  Character Range 945 - 1,697
m m m m m
soon as possible, so that we can sort things out.
Character Range 1,701 - 1,874
Reference 3_______ __________ ______________
what to expect throughout the pregnancy.
_____________Character Range 10,662 - 11,385
s T s o T o f going on from that then, when you, where does the information actually come up, when people come, ao
people and you can't get it right all the time can you, but - very difficult.
___________   Character Range 11,389 - 11,593
So^how^ obviously they're coming once a year if everything's fine or whatever, is that common here as well?
Yes.
Do you think it would be mentioned at most review visits? 
I would think orobablv. ves.
Node Coding Tree Nodes\PREGNANCY\ADVICE References 2
Coverage 5.94 %
 ________  Character Range 10,662 - 11,385
sT so rt”  going on from that then, when you, where does the information actually come up, when people come, ao 
you regularly ask them or do you have a set time when you ask them or.
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No, its very ad hoc. And the difficulty is as well, you have some people who definitely don't want to get pregnant or 
have had issues and problems with fertility and maybe you don't know about it, I  don't think it happens to us as the 
nurses so much because we tend to know the people a bit more, but certainly the doctors have offended quite a few 
people, just because they don't realise you know, they're trying to do their best by asking and then they upset 
people and you can't get it right all the time can you, but - very difficult.
Reference 2___________________________________________   C haracter Range 11,389  -  11,593
So how, obviously they're coming once a year if everything's fine or whatever, is that common here as well?
Yes.
Do you think it would be mentioned at most review visits?
I would think orobablv. ves.
Node Coding Tree Nodes\PREGNANCY\APPOINTMENTS References 2 Coverage 6 .7 9 %
Reference 1____________________________________    Character Range 945 - 1,697
So that's it, and getting them referred in because the way we have the system here is that if they're known, if they 
are diabetic already then they usually phone us and let us know as soon as they've got their pregnancy confirmea, 
and its making sure that they're getting into the system very very early, because occasionally they'll go along to me 
GP and the GP will write a referral letter and that takes several weeks to get through the system, or the GP will say 
you don't need to worry until you're 12 weeks pregnant and things like this, and you th ink 'no !', so tha ts  my big 
thing, a -  trying to get them pre conceptionally, but failing that to get them fast tracked through into the service as 
soon as possible, so that we can sort things out.
Reference 2____________________________________     Character Range 12,202 - 12,510
In general, they work really hard and we see them regularly in the clinics, but they're expected to contact us once a 
week as well just to keep in touch, and I  think because we're a smallish friendly unit and there aren t  big numbers, 
then we build up good relationships, so we don't tend to have problems.
Node Coding Tree References 1 Coverage 3 .3 9 %
Nodes\PREGNANCY\COMPLICATIONS\PRE  
ECLAMPSIA
Reference 1______________________________________    Character Range 12,512 - 13,041_
What about, outcomes at the end are one thing but do people tend to have more complications ...pregnancy?
No, no, they're very few and far between. We've had, in the last year we did have one still birth. But other than mac, 
we get the polyhydramneous and slightly big baby but not major major, we haven't had any major congenital 
abnormalities I can think of.
And., my questionnaires showed pre-eclampsia led to having babies early.
That's the main thing, but you know, it all seems to work it's self out in the end.
Node Coding Tree Nodes\PREGNANCY\FOUC ACID References 2 Coverage 5.16 °/o
Reference 1________________________________________   Character Range_3,034 - 3,418_
Do you have many people that come in who are not taking 5mgs of FOLIC ACID.
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Yes, I  would say the majority don't. Quite a number of them will take 400 micrograms because they've decided 
themselves and they've been aware enough, but then we have to write to the GP and ask them to prescribe the 5mg. 
Really I think because the women and self referring before they've seen their GP.
Reference 2_____________________________________________________ Character Range 3,420 - 3,841
z So they've gone and bought 400 micrograms ...
Yeah, and because they haven't come to see us pre conceptually, it's jus t -  got pregnant.
So for them to be advised about the 5mg you'd have to be actually seen them before.
Yes, so if they come to us pre conceptually, I  have a little handful of women who I'm  seeing pre conceptually, they 
are all on the 5mq, but, the majority as I say self refer once they're pregnant.
Node Coding Tree Nodes\PREGNANCY\KNOWLEDGE AND References 2 Coverage 4 .5 8 %
EXPECTATIONS OF PREGNANCY
Reference 1____________________________ ____________________________ Character Range 1,701 - 1,874
What particular things would you want for that particularly?
For them to have fantastic blood glucose control and knowledge of what to expect throughout the pregnancy. 
Reference 2_________________________________________________________Character Range 5,434 - 5,975
Do you think there are any other issues particularly pre conceptually that you talk to the women about, or with any 
particular different age groups?
I  don't think so, there's a lot of focus on obviously getting their HbAlc under 7 is our goal. Other than that, no, its 
jus t a sort of general chat about diabetes and pregnancy and why it is necessary to be a little bit different. Talk 
about delivery and the fact that you deliver around 38 weeks here, jus t so that they know what they're letting 
themselves in for really (laughs).
Node Coding Tree Nodes\PREGNANCY\LABOUR AND References 1 Coverage 3.47 %
DELIVERY
Reference 1_____________________________________________________ Character Range 5,434 - 5,975
Do you think there are any other issues particularly pre conceptually that you talk to the women about, or with any 
particular different age groups?
I  don't think so, there's a lot of focus on obviously getting their HbAlc under 7 is our goal. Other than that, no, its 
just a sort of general chat about diabetes and pregnancy and why it is necessary to be a little bit different. Talk 
about delivery and the fact that you deliver around 38 weeks here, jus t so that they know what they're letting 
themselves in for really (laughs).
Lode Coding Tree Nodes\PREGNANCY\LABOUR AND References 1 Coverage 3.39 %
DELIVERY\BABY OUTCOMES
Reference 1_______________________ •______________________________  Character Range 12,512 - 13,041
What about, outcomes at the end are one thing but do people tend to have more complications ...pregnancy?
No, no, they're very few and far between. We've had, in the last year we did have one still birth. But other
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than that, we get the polyhydramneous and slightly big baby but not major major, we haven't had any major 
congenital abnormalities I can think of.
And., my questionnaires showed pre-eclampsia led to having babies early. 
That's the main thinci, but vou know, it all seems to work it's self out in the end.
Node Coding Tree Nodes\PREGNANCY\PLANNING
Reference 1
References 5 Coverage 12.49 %
Character Range 479 - 905
Well my big thing, having sat on the CEMACH committee is trying to get women engaged with pre pregnancy care. 
The problem is really now because so much is now done in primary care is actually trying to get the message across 
to everybody, because I think people still th ink 'oh yes, type 1 diabetes, young people that's secondary care, 
forgetting more and more people getting into primary care, so my, what was the question.
Reference 2 Character Range 4,715 - 5,234
So when you do your pre conceptual clinics what other advice are you mentioning. , *.u +
Its looking at their other medication, because in fact I  would suggest that most of our pre conceptual at the moment 
have other health problems as well, which probably were the triggers for them seeking advice, so for example we 
had somebody on mexitrexiate, since has had to come off, and has seen me - quite a bit of work, so it is looking at 
the whole medication picture, looking at diet and weight, blood glucose control obviously.
Reference 3 Character Range 5f238 - 5,316
Do they see the dietician as well? 
They can do yes, they don't routinely.
Reference 4 Character Range 10,662 - 11,385
So sort of going on from that then, when you, where does the information actually come up, when people come, do 
you regularly ask them or do you have a set time when you ask them or? .
No, its very ad hoc. And the difficulty is as well, you have some people who definitely don t  want to get pregnant or 
have had issues and problems with fertility and maybe you don't know about it, I don't think it happens to us as the 
nurses so much because we tend to know the people a bit more, but certainly the doctors have offended quite a few 
people, just because they don't realise you know, they're trying to do their best by asking and then they upset 
people and you can't get it right all the time can you, but - very difficult.
Reference 5 Character Range 11 f389 - 11,593
So how, obviously they're coming once a year if everything's fine or whatever, is that common here as well? 
Yes.
Do you think it would be mentioned at most review visits? 
I  would think orobablv. ves.
Node Coding Tree Nodes\PREGNANCY\SCANS
Reference 1 ______________
References 1 Coverage 2.62 °/o
Character Range 14,366 - 14,775
Do they have any different scans or care or anything? 0 . M iir arlH
I think they have more scans, I don't know what the standard is, I think they have 2 or 3 ,1 don t  know, and
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they're sent for retinal screening.
Good quest^n tL^?  I'll ask Dr x that one. And the fact they're seen in the specialist clinic and the obstetrician, they 
see the obstetrician, the consultant obstetrician as well.
Node Coding Tree Nodes\PREGNANCY\SUPPORT References 1 Coverage 1 .9 7 %
R ^ 1 ________________________________________ ___________C haracter Range 12,202 - 12,510
then we build up good relationships, so we don't tend to have problems.
Node Coding Tree Nodes\PREGNANCY\SUPPORT\HEALTH References 1 .Coverage  1 .9 7 %
PROFESSIONAL
1 ___________________________ ____________  C haracter Range 12,202 - 12,510
then we build up good relationships, so we don't tend to have problems.
Node Coding Tree Nodes\STRUCTURE OF SERVICES References 1 C oyeage 4 .42 o/o
1 ____ _________________________ ______________ C haracter Range 14,816 - 15,506
Node Coding Tree Nodes\STRUCTURE OF SERVICES\ACUTE  
CARE
References 2 Coverage 7.51 %
479 -Character Range
We,, my big thing, having - t o n  the CEMACH c— eels tr^n g  to get women e ^ e a  with pre pregnancy care.
now done in primary care is actually trying to get the message across 
: 'oh yes, type 1 diabetes, young people that's secondary care,The problem is really now because so much is
forgettmg°moVeaCnd m oreTeop primary care, so my, what was the question.
Character Range 8,392 - 9,139
Reference 2________________________________
Do you see that as any problem if they're coming in late at 12 weeks or whatever and they've been on
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do in diabetes.
Node Coding Tree Nodes\STRUCTURE OF References 6 Coverage 2 0 .0 9 %
SERVICES\DOCTORS\GP SERVICE
1  Character Range_____ 945 - i/6 9 7msmmmsm
soon as possible, so that we can sort things out.
  Character Range 2,234 - 2,489
And" when you say they're seen more in primary care, is that for the whole of their care, or is that shared careo w.rn
Noisome of them, the GPs surgeries are looking after type 1, people with type 1 diabetes and certainly doing their 
annual reviews.
Character Range 3,845 - 4,569
Reference 3------------------------------------------------------------------ ---------- -------------------------------------------------------- -
the women most of the time know us and so will refer themselves.
Character Range 7,901 - 8,162
Reference 4------------- ------------ ----------- - ---------- ------------------------------------------------------------------------------ - ------ -
______   Character Range 13,195 - 13,635
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have somebody referred to you with HbAlc of 11% which we had earlier this year, and you think 'oh, no!'.
____________________________C haracter Range 13,660 - 14,364
pregnancy.
Node Coding Tree Nodes\STRUCTURE OF 
SERVICES\MIDWIVES
Reference 1
References 3 Coverage 14.62 %
Character Range 6,634 - 7,522
w s m m m m .
protocols for delivery suite and paperwork and that sort of thing, so.
2    Character Range 13,660 - 14,36±mmsmsam'
pregnancy.
^ 3 ______________________________ Character Range 14,816 - 15,506
Dding Sum m ary Report
Page 13 of 18
Node Coding Tree Nodes\STRUCTURE OF References 1 Coverage 5 .6 9 %
SERVICES\MULTIDISAPLINARY WORKING
Reference 1 _______________ ____________________________________  Character Range 6,634 - 7,522
well, after the sort of report, they decided they were going to have a diabetes specialist midwife, so called, and so 
they employed somebody but she's not actually doing the diabetes at all,(laughs) and doesn't really know anything 
about diabetes. So when they advertised the post, the person who actually eventually got the job came to me and 
said 'how would I feel with her taking over my job', and I  said 'you won't actually be taking over my j ob ^  the 
diabetes', but really what she does is facilitate the pathway through, so she doesn't get involved, other diabetes 
specialist midwives I've meant have had an active role in controlling blood glucose and that sort of thing, she doesn 
sit in on the clinics but she organises the clinic and ensures they get a smooth journey and we re working together on 
protocols for delivery suite and paperwork and that sort of thing, so.
Node Coding Tree Nodes\STRUCTURE OF References 1 Coverage 4 .6 4 %
SERVICES\NURSES
Reference 1_________________________   ;_______________ Character Range 3,845 - 4f569_
And what happens if they're being looked after by the GP? , n . IIC h_vinn
I f  they're unknown to us then, those are few and very far between at the moment, if they re unknown to us, haying 
said that its going to be something that's going to be a problem, particularly in the local area where ther? model o 
care is that they look after all the diabetes so the women won't necessarily know how to contact us, but in the x area 
the women most of the time know us and so will refer themselves.
Z f a t atbheUmomenVweWhïven 't got anybody. All we can do. I've, I've just talked at the practice nurse meetings to 
make them aware of the issues, but other than that all we can do is wait for their referral through.
Node Coding Tree Nodes\STRUCTURE OF References 1 Coverage 4 .4 2 %
SERVICES\NURSES\PARTNERSHIP
Reference 1_______ ________________________________________ ________ Character Range 14,816 - 15,506
don't think so, no. Well, actually I was going to say that we're quite proud of the fact we've got a smaM umt and 
there's good communication but it falls down if we're not here, the midwives don t  seem to be able to think on their 
own, despite all the protocols and policies being in place, so in a way we're bit of our own worse enemies.
Well, weekends or, they can't cope at a weekend or if I'm on holiday, because I'm  the one that mainly deals with 
pregnancy, the others do it as well, but if I'm  not here, the midwives can be like 'can you ^ m e  up here now , and 
they'll be going 'well no', they don't quite appreciate that they've got to take some ownership of this as well.
Node Coding Tree Nodes\STRUCTURE OF References 4 Coverage 1 2 .9 9 %
SERVICES\PRECONCEPTION CLINICS
Reference 1 _________________________________ Character Range 9 45 - 1,697
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So that's it, and getting them referred in because the way we have the system here is that if they're known, if they 
are diabetic already then they usually phone us and let us know as soon as they've got their pregnancy confirmed, 
and its making sure that they're getting into the system very very early, because occasionally they'll go along to the 
GP and the GP will write a referral letter and that takes several weeks to get through the system, or the GP will say 
you don't need to worry until you're 12 weeks pregnant and things like this, and you think 'no!', so that's my big 
thing, a -  trying to get them pre conceptionally, but failing that to get them fast tracked through into the service as 
soon as possible, so that we can sort things out.
Reference 2_________________________________________   Character Range 1,874 - 2,090
Do you have a separate clinic here?
Yes, we do and we see our pre conceptual in that same clinic because its a small clinic and its myself and Dr x 
unless either one of us is on holiday, so there's that continuity.
Reference 3    Character Range 4,715 - 5,234
So when you do your pre conceptual clinics what other advice are you mentioning.
Its looking at their other medication, because in fact I would suggest that most of our pre conceptual at the moment 
have other health problems as well, which probably were the triggers for them seeking advice, so for example we 
had somebody on mexitrexiate, since has had to come off, and has seen me - quite a bit of work, so it is looking at 
the whole medication picture, looking at diet and weight, blood glucose control obviously.
Reference 4_______________________________________   Character Range 5,434 - 5,975
Do you think there are any other issues particularly pre conceptually that you talk to the women about, or with any 
particular different age groups?
I don't think so, there's a lot of focus on obviously getting their HbAlc under 7 is our goal. Other than that, no, its 
1 just a sort of general chat about diabetes and pregnancy and why it is necessary to be a little bit different. Talk 
about delivery and the fact that you deliver around 38 weeks here, just so that they know what they're letting 
themselves in for really (laughs).
Node Coding Tree Nodes\STRUCTURE OF References 6 Coverage 2 1 .4 3 %
SERVICES\PRIMARY CARE
Reference 1____________________________________     Character Range 479 - -905
Well my big thing, having sat on the CEMACH committee is trying to get women engaged with pre pregnancy care. 
The problem is really now because so much is now done in primary care is actually trying to get the message across 
to everybody, because I think people still think 'oh yes, type 1 diabetes, young people that's secondary care, 
forgetting more and more people getting into primary care, so my, what was the question.
Reference 2   Character Range 945 - J ,697
So that's it, and getting them referred in because the way we have the system here Is that if they're known, if  they 
are diabetic already then they usually phone us and let us know as soon as they've got their pregnancy confirmed, 
and its making sure that they're getting into the system very very early, because occasionally they'll go along to me 
GP and the GP will write a referral letter and that takes several weeks to get through the system, or the GP will say 
you don't need to worry until you're 12 weeks pregnant and things like this, and you th ink 'no !', so that's my big 
thing, a -  trying to get them pre conceptionally, but failing that to get them fast tracked through into the service as 
soon as possible, so that we can sort things out.
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Reference 3   Character Range 2,234 - 2,489
And when you say they're seen more in primary care, is that for the whole of their care, or is that shared cared with 
you?
No, some of them, the GPs surgeries are looking after type 1, people with type 1 diabetes and certainly doing their 
annual reviews.
Reference 4   Character Range 3,845 - 4,571
And what happens if they're being looked after by the GP?
I f  they're unknown to us then, those are few and very far between at the moment, if they're unknown to us, having 
said that its going to be something that's going to be a problem, particularly in the local area where there model of 
care is that they look after all the diabetes so the women won't necessarily know how to contact us, but in the x area 
the women most of the time know us and so will refer themselves.
What about if they're type 2?
No, at the moment we haven't got anybody. All we can do, I've, I've just talked at the practice nurse meetings to 
make them aware of the issues, but other than that all we can do is wait for their referral through.
Reference 5  Character Range 8,392 - 9,139
Do you see that as any problem if they're coming in late at 12 weeks or whatever and they've been on medication 
that people are still on or shouldn't be...
Yes, I  can't remember when it happened, we have had letters from GPs saying, 'this woman is pregnant and on these 
drugs, please look after her during pregnancy', so they don't think to stop them, but we stop them. I don't think its 
ever caused a problem and increasingly women are using METFORMIN for PCOS anyway, so they're getting pregnant 
on metformin. I t  doesn't seem to cause a problem. We stopped, I think the general protocol now is that they keep 
on the metformin until pregnancy is confirmed and then they stop and that's what they do in PCOS so that's what we 
do in diabetes.
Reference 6 ______________________________________________________Character Range 13,195 - 13,635
The main thing is getting the message across that it's an important thing to be focusing on in the GP surgery rather 
than just ticking the boxes on the template, ensuring that these women are making sure they're taking their folic 
acid and their HbAlc is good. Although the risks are small, you know, its a horrible feeling when you have somebody 
referred to you with HbAlc of 11% which we had earlier this year, and you think 'oh, no!'.
Node Coding Tree Nodes\TEENAGERS AND YOUNG PEOPLE References 1 Coverage 3 .8 6 %
Reference 1   Character Range 10,056 - 10,658
Well, they tend to transfer from the paediatric clinic at 16 and so we do an introductory hello, this is the adult clinic 
and by the way, how's your sex life? (laughs). Only becuase at the paediatric clinic, the thought of their little 
children having sex is, they just can't, you mention it to them and they can't possibly do it so we make sure that we 
do it as soon as we meet them. Because it hasn't happened yet, but you know. I'm  sure there's some areas where 
they've had pregnancies in the paediatric clinic. But being middle classed Surrey, our problem is more the other end 
of the age scale.
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Node Coding Tree Nodes\TEENAGERS AND YOUNG References 1 Coverage 3 .8 6 %
PEOPLE\SEX EDUCATION
Reference 1    Character Range 10,056 - 10,658
w m m m s m m is k
of the age scale.
Node Coding Tree Nodes\TRAINING References 2 Coverage 4 .24
Reference 1 __________________________________________________Character Range 9,141- 9 ^ 9
So thinking about training issues and things, have you yourself had particular training in diabetes in pregnancy and
pre pregnancy.
No (laughs).
as well when we hold sessions, e d u c a ^ l ^ n s  for GPs,
it for many many many years, so.
n ,  -, Character Range 15,506 - 15,590Reference 2____________        —-------------------- -------------- ----------—
So you think there's an opportunity for education for the midwives as well.
Oh yes.
Node Coding Tree N odes\TR A IN IN G \H EA LTH  References 2 Coverag e  4 .2 4 » /.
PROFESSIONALS
Reference 1    Character Range 9,141 - 9,719
So thinking about training issues and things, have you yourself had particular training in diabetes in pregnancy and
pre pregnancy.
No (laughs).
it for many many many years, so.
_ ,  -  Character Range 15,506 - 15,590Reference 2------------- -------------- ------------------------ --------------- ------ - ------------------------------------ - ------------- ------------------
So you think there's an opportunity for education for the midwives as well.
Oh yes.
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Node Coding Tree Nodes\TYPE 2 DIABETES
Reference 1
References 1 Coverage 1.59 %
Character Range 4,323 - 4,571
What about if they're type 2?
No, at the moment we haven't got anybody. All we can do. I've, I've just talked at the practice nurse meetings to 
make them aware of the issues, but other than that all we can do is wait for their referral through.
Node Coding Tree Nodes\WOMEN W ITH References 1 Coverage 1.11 %
DIABETES\KNOWLEDGE
Reference 1_________________________________________________________ Character Range 1,701 - 1,874
What particular things would you want for that particularly?
For them to have fantastic blood glucose control and knowledge of what to expect throughout the pregnancy.
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Reference 1
References 1 Coverage 100.00 °/o
Character Range 0 ~ 13,515
Can you tell me what you heard about diabetes and pregnancy before you became pregnant? 
Nothing - no not before the first time.
So when was that?
That was a couple of years ago.
Did that affect you in pregnancy at all, particularly, getting pregnant in the first place?
Yes, I  think so.
W en jl todc to misœrndre q u ite  a lot and my sugars were still quite high. I think it was also harder probably to get 
pregnant in the first place.
So how long were you trying? Obviously you had a miscarriage and that's distressing anyway isn't it, but how long 
were you trying before you got pregnant?
About a year and a half, and I got pregnant a few times and miscarried again.
Do you know how many times?
About three times
And when you got pregnant were you seen by your doctor or were you seen by the diabetes clinic- when you were 
first diagnosed as being pregnant?
I t  was my doctor. They saw me and then I  had to go to diabetes clinic. They arranged a scan for me.
Is it a long way to travel to the diabetes centre?
Not ages away, but it's a drive, so it's a bit of hassle.
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The advice I had was not to get pregnant until my sugars were under control.
Who told you that?
Everybody I  think.
So was that your GP as well, or just at the diabetes centre?
Both, I  think.
So that was one lot of advice, what else were you told?
Nothing, really.
OK. Did they put you on any tablets or anything?
I  got put on Metformin
And did they put you on folic acid?
No. I  did take it, but I  went out and bought it.
Was it  jus t the one from the chemist that you bought?
I  bought the Pregnacare.
Yes, it's got vitamins as well, hasn't it?
So you were aware then that there might be problems with your blood sugar being high. Did they say anything else
No^My sugars went as high as 27 and I  think when the last time I  miscarried before I  had her they were about 
17/18.
Did they say what might happen to the baby if you had high blood sugars?
They mentioned it might have heart problems.
Like what?
Diet or any changes to eating. Do you smoke at all?
I do smoke, but I didn't then.
So you stopped?
I was more healthy when I  was pregnant than I ve ever been.
I  dW ev^rytWrlg^ight'while I  was pregnant. I  jus t don’t  do it when I am not pregnant.
So when you say your diabetes was controlled, how many times a day were you having to test your sugar levels?
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That's brilliant, isn't it?
And they were in between about three and six.
Ye l^haT theTsaW  was°that Iw as going a little b it too, sort of over about it, taking too much, then not enough, 
becaus
Node Coding Tree Nodes\CONTRACEPTION References 2 Coverage 10.40 /o
Reference 1 ___ ____________________ __ __________ Character Range 6,274 - 6,816
Obviously before you were trying to get pregnant it  was a while so you weren't using contraception, can you tell me if 
you used contraception in the past at all?
Yes, I  was on the pill.
were you on the combined pill, the one that you take for three weeks and then have a week off?
Yes.
And was that from the GP?
Yes.
Have you used any other methods at all, before?
I was on the pill for quite a few years, but other than that, obviously, condoms - but I  didn't think they were relaible
Character Range 6,820 - 7,684
Reference 2
And now that you've delivered, are you using contraception again?
I haven't really thought about it
r Z d o i  until we want to try  again as we want
another baby, not like really soon, but you know.
the baby, have you gone back to your GP again for your diabetes care or the Centre?
No where yet.
You mentioned condoms -  did any one give you any information about condoms and using treatment for thrush? 
What kind of information?
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Explains.......
Umm -  nn T riirin't know ahniif that 
Node Coding Tree Nodes\CONTRACEPTION\ADVICE References 1 Coverage 6 .3 9 %
Character Range 6,820 - 7,684
Reference 1 _______ ______________
And now that you've delivered, are you using contraception again?
I haven't really thought about it.
T h ^ h a v e g ^e ^m e ^ le a fle ^a b o u tlt^u t^ w e 'v e  decided to " d o ' m s  unti, we want to «nr again as we want 
another baby, not like really soon, but you know.
the baby, have you gone back to your GP again for your diabetes care or the Centre?
No where yet.
You mentioned condoms -  did any one give you any 
What kind of information?
information about condoms and using treatment for thrush?
Explains........
Umm -  no I  didn't know about that
Node Coding Tree Nodes\CONTRACEPTION\EMERGENCY  
CONTRACEPTION
Reference 1______________________
Did any one mention about using emergency contraception? 
umm no what is that?
References 1 Coverage 0 .8 5 %
Character Range 7,686 - 7,801
The morning after pill 
No
Node Coding Tree Nodes\CONTRACEPTION\METHODS
Reference 1
References 2 Coverage 10.40 %
________ ________ Character Range 6,274 - 6,816
Obviously before you were trying to get pregnant it  was a while so you weren't using contraception, can you tell me if 
you used contraception in the past at all?
Yes, I was on the pill.
Were you on 
Yes.
the combined pill, the one that you take for three weeks and then have a week off?
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And was that from the GP? 
Yes.
Have you used any other methods at all, before?
I was on the pill for quite a few years, but other than that, obviously, condoms - but I  didn't think they were relaible
C haracter Range 6 ,820 -  7 ,684
_ r \ o r - » /*» /*! , 1 1 . ,  >*>/"> F / x t - r x  ■ ■ « ' ' '  f - l x ^ r x - .  I
Reference 2_________ __ _____________________
And now that you've delivered, are you using contraception again?
I haven't really thought about it.
r —  un«, we want to try  again as we want
another baby, not like really soon, but you know.
the baby, have you gone back to your GP again for your diabetes care or the Centre?
No where yet.
You mentioned condoms -  did any one give you any Information about condoms and using treatment for thrush? 
What kind of information?
Explains.......
Umm -  no I didn't know about that 
Node Coding Tree Nodes\GLYCAEMIC CONTROL References 6 Coverage 16.42 %
C haracter Range 192  -  428
C haracter Range 9 ,125  -  9 ,655
gooVfor^ou to h^ve^îgh'sugare^I really don't kn(w?9As soon as I d had herfhey w'ere not v e ^  we,, controlled
again, and they were perfect while I was pregnant with her.
Pause:
_______C haracter Range 9 ,657  -  9,961
It'sTeally hard to say because you know you should be doing it anyway, you don't need anybody to tell you to
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take your insulin and to make sure your sugars are OK and you eat the right things. You know exactly what to do.
So I don't know if there's anything anyone can say because you already know it.
^  f  4  _________ _________________________________ C haracter Range 10,019  - 10,749
W m M m ë m m S z .
thought then obviously.
R f  5  ______________________________________ C haracter Range 10,821 - 11,074_
working harder at it.
Reference 6  __ ___________________________ ________C haracter Range 11,122 - 11 ,288
To Te honest I'd  rather sleep than eat or worry about taking insulin, so I have to think 'Shall I  go and eat and have 
insulin or sleep?'
Because vou're so tired.
Jode Coding Tree Nodes\GLYCAEMIC References 1 Coverage 1 .8 3 %
CONTROL\HYPOGLYCAEMIA
_ ,  ,  C haracter Range 3 ,843  -  4,091
Reference 1________ _______ _ ______________________________________________________ ___________ — ~
Node Coding Tree Nodes\GLYCAEMIC References 1 Coverage 3 .92 o/o
CONTROL\MOTIVATION FOR GOOD CONTROL
R f  j ________________________ ________________________________________ C haracter Range 9 ,125  -  9 ,655
again, and they were perfect while I was pregnant with her.
Pause:
Node Coding Tree Nodes\GLYCAEMIC References 1 Coverage 1.75  o/o
CONTROL\MEDICATION
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Reference 1 ________________________ ______________ ________ Character Range 192 - 428
wen^to^eTa œnsulta^t and^e was^ite^angr/and saW '^You're no^dietcolitrolled^You^ecftobe^o^l'nsulin-'^
M nrif Coding Tree Nodes\HARD WORK References 1 Coverage 1.87 %
Reference 1 _______________________________ _________ Character Range 10,821 - 11,074
working harder at it.
Node Coding Tree Nodes\HEALTH PROFESSIONAL References 1 Coverage 1 .4 1 %
Reference 1 _________________________________________ Character Range 11,8 6 7 - 12,058
you are looked after really well; and at first it's a bit 'Oh, leave me alone.' But afterwards you think T m  really happy 
that they were there and they did all that and they were worried.
Nod» rnriinn Tree Nodes\HEALTH PROFESSIONAL \ROLE References 1 Coverage 1.41 »/o
Reference 1 ____________________________________________ Character Range 11,867 - 12,058
you are looked after really well; and at first it's a bit 'Oh, leave me alone/ But afterwards you think 'I'm  really happy 
that they were there and they did all that and they were worried.
Node Coding Tree Nodes\PREGNANCY References 5 Coverage 21.48 %
Reference 1 _______________________________________________  Character Range-486 - 1,069_
Did that affect you in pregnancy at all, particularly, getting pregnant in the first place?
Yes, I think so.
W e^ljl to ^k  to miscarrying quite a lot and my sugars were still quite high. I  think it was also harder probably to get 
pregnant in the first place.
So how long were you trying? Obviously you had a miscarriage and that's distressing anyway isn't it, but how long 
were you trying before you got pregnant?
About a year and a half, and I  got pregnant a few times and miscarried again.
Do you know how many times?
A  U  ■ i t -  4-1^ ^
Reference 2_______________________________________________   Character Range-1,437 - 1,798
So when you were trying to get pregnant did anybody give you any advice at all?
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The advice I  had was not to get pregnant until my sugars were under control.
Who told you that?
Everybody I think.
So was that your GP as well, or jus t at the diabetes centre? 
Both, I think.
So that was one lot of advice, what else were you told?
Reference 3   Character Range 9 1 2 5 -  9 655
again, and they were perfect while I was pregnant with her.
Pause:
Reference 4 __________   Character Range 11.554 - 12,340
S IS S E S tïF S fïbut it's good advice for someone who wants to make themselves get their insulin under control and look after 
themselves properly, is to get pregnant. I  don't think it makes that much of a difference.
Reference 5 __________________________________   Character Range 12,821 - 13,46±iS=lESf§BBBiE
you get pregnant, or you probably won t  get pregnant, or you II miscarry.
Norte Coding Tree Nodes\PREG NANCY\ADVICE References 1 Coverage 2 .6 7 %
Reference 1______________________________________       Character Range----------- 1,437- 1,798
So when you were trying to get pregnant did anybody give you any advice at all?
The advice I  had was not to get pregnant until my sugars were under control.
Who told you that?
Evervbodv I  think.
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So was that your GP as well, or just at the diabetes centre? 
Both, I think.
So that was one lot of advice, what else were you told? 
Node Coding Tree Nodes\PREGNANCY\CHOICE References 1 Coverage 5.82 °/o
Reference 1______________ ____________ ______________________________Character Range 11,554 - 12,340
I have to say that I think I'd have probably got pregnant quicker and probably not miscarried f s
diabetes. I think it's actually better for women who are diabetic to be pregnant because they '° ° k
but it's good advice for someone who wants to make themselves get their insulin under control and look after 
themselves properly, is to get pregnant. I don't think it makes that much of a difference.
Node Coding Tree Nodes\PREGNANCY\COMPLICATIONS References 1 Coverage 2 .6 9 %
Reference 1 ___________ _______________________________________ Character Range 2,097 - 2,46±
So you were aware then that there might be problems with your blood sugar being high. Did they say anything else
No?'My sugars went as high as 27 and I  think when the last time I  miscarried before I  had her they were about 
17/18.
Did they say what might happen to the baby if you had high blood sugars? 
They mentioned it might have heart problems.
Node Coding Tree References 1 Coverage
2 .7 4  %
Nodes\PREGNANCY\COM PLICATIONS\PRE
ECLAMPSIA
Reference 1 Character Range 4,260 - 4,630
sickness or anything.
Node Coding Tree Nodes\PREGNANCY\FOLIC ACID
Reference 1
References 1 Coverage 1.61 %
Character Range 1,879 - 2,097
And did they put you on folic acid?
No. I did take it, but I  went out and bought it.
Dding Summary Report
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Was it jus t the one from the chemist that you bought? 
I bought the Pregnacare.
Yes. it's oot vitamins as well, hasn't it?
NnH* ending Tree Nodes\PREGNANCY\KNOWLEDGE AND References 2 Coverage 1 0 .1 3 %
EXPECTATIONS OF PREGNANCY
D ,  m  1 Characte r  Range 486 -  1 ,069
Reference 1 ________________________ _ _______________ _______ ______________ ________________________
Did that affect you in pregnancy at all, particularly, getting pregnant in the first place?
Yes, I think so.
W en jl Itook to m lscar^in^quite  a lot and my sugars were still quite high. I think it was also harder probably to get 
pregnant in the first place.
So how long were you trying? Obviously you had a miscarriage and that's distressing anyway isn’t  it, but how long 
were you trying before you got pregnant?
About a year and a half, and I got pregnant a few times and miscarried again.
Do you know how many times?
A  I *  A  • â-L» M  4«! MM M  M
f  2     C haracter Range 11 ,554  -  12,340
m Ê Ê Ê Ë Ê B m s m
themselves properly, is to get pregnant. I don't think it makes that much of a difference.
Node Coding Tree Nodes\PREGNANCY\PARTNERS References 1 Coverage 4 .2 1 %
,  C haracter Range 5,703 - 6,272
Reference 1 -------------- ------------------------------- --- -------------------------------------------- ------------------------- ------------------------------------------------
pregnant.
But he was more worried about it?
Yes.
Did they have to show him how to use glucagon and things in case you had hypos?
No. He nrettv much knew what to do anvwav.
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Node Coding Tree Nodes\PREGNANCY\PLANNING References 4 Coverage. 13.44 “/o
Reference 1____________________________ ____________________________Character Range_____ 486 - 1,069
Did that affect you in pregnancy at all, particularly, getting pregnant in the first place?
Yes, I  think so.
W e lljl to^k to miscarrying quite a lot and my sugars were still quite high. I  think it was also harder probably to get 
pregnant in the first place.
So how long were you trying? Obviously you had a miscarriage and that's distressing anyway isn't it, but how long 
were you trying before you got pregnant?
About a year and a half, and I got pregnant a few times and miscarried again.
Do you know how many times?
A  I *  ^  4-«
Reference 2___________________________________     Character Range-1,437 - 1,798_
So when you were trying to get pregnant did anybody give you any advice at all?
The advice I had was not to get pregnant until my sugars were under control.
Who told you that?
Everybody I  think.
So was that your GP as well, or just at the diabetes centre?
Both, I think.
So that was one lot of advice, what else were you told?
Reference 3_____________________________________   Character-Range-2,097 - 2,461_
So you were aware then that there might be problems with your blood sugar being high. Did they say anything else
No^My sugars went as high as 27 and I  think when the last time I miscarried before I  had her they were about 
17/18.
Did they say what might happen to the baby if you had high blood sugars?
They mentioned it might have heart problems.
Reference 4 __________________________________________________   Character Range-2,463 - 2,972_
So obviously you were planning to be pregnant, so did you make any changes to your lifestyle, apart from you went 
out and bought a Pregnacare which is great, did you do anything else at all particularly?
Like what?
Diet or anv chanaes to eatina. Do vou smoke at all?
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I do smoke, but I didn't then.
So you stopped?
I was more healthy when I was pregnant than I've ever been.
That's what a lot of people say.
Node Coding Tree Nodes\PREGNANCY\POST NATAL References. 1 Coverage 1 .2 3 %
Reference 1___________________________ ____________________________ Character Range 11,122 - 11,288
To be honest I'd rather sleep than eat or worry about taking insulin, so I  have to think 'Shall I go and eat and have 
insulin or sleep?'
Because vou Ye so tired.
Node Coding Tree Nodes\PREGNANCY\POST  
NATAL\BREAST FEEDING
References 1 Coverage 0.90 %
Reference 1      Character Range____5,491 - 5,612
And how about feeding? What did you do with feeding her?
I  tried breast feeding but my milk didn't come through at all.
lode Coding Tree Nodes\STRUCTURE OF SERVICES
Reference 1
References 2 Coverage 4.49 %
Character Range 1,071 - 1,432
And when you got pregnant were you seen by your doctor or were you seen by the diabetes clinic- when you were
first diagnosed as being pregnant? ,
I t  was my doctor. They saw me and then I had to go to diabetes clinic. They arranged a scan for me.
Is it a long way to travel to the diabetes centre?
Not ages away, but it's a drive, so it's a bit of hassle.
Reference 2________________________ ________________________________ Character Range 8,206 - 8^452_
So you haven't had an appointment. Do your GPs normally deal with all the diabetes, when you're not pregnant?
No. I  normally go to the Diabetes Centre.
So they're the main health professionals who are looking after your diabetes.
Yes.
Node Coding Tree Nodes\STRUCTURE OF SERVICES\ACUTE References 1 Coverage 2 .6 7 %
CARE
Reference 1____________________ ____________________________________ Character Range___ 1,071 - 1,432_
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And when you got pregnant were you seen by your doctor or were you seen by the diabetes clinic- when you were 
first diagnosed as being pregnant?
It  was my doctor. They saw me and then I  had to go to diabetes clinic. They arranged a scan for me.
Is it a long way to travel to the diabetes centre?
Not ages away, but it's a drive, so it's a bit of hassle.
Node Coding Tree Nodes\STRUCTURE OF References 1 Coverage 2 .6 7 %
SERVICESXDOCTORS
Reference 1 __________________________ _ ________________  Character Range 1,071 - 1A32
And when you got pregnant were you seen by your doctor or were you seen by the diabetes clinic- when you were 
first diagnosed as being pregnant?
It  was my doctor. They saw me and then I  had to go to diabetes clinic. They arranged a scan for me.
Is it a long way to travel to the diabetes centre?
Not ages away, but it's a drive, so it's a bit of hassle.
Node Coding Tree Nodes\GLYCAEMIC References 1 Coverage 1.75 %
Reference 1_______________________    Character Range_____ 192^-------428
The first time in 2000 was just diet controlled, then I kept getting ill quite a lot still and they did blood tests and I 
went to see a consultant and he was quite angry and said 'You're not diet controlled. You need to be on insulin.
Node Coding Tree Nodes\ GLYCAEMIC CONTROL\WOMEN References 1 Coverage 5.40 /o
Reference 1 ___________________________________________ ;___________ Character Range 10,019- 10,749
In a way worse. I mean, I  get it from the family every day. 'How are you feeling? Are your sugars OK?' Most of 
the family nag me quite a lot. I get that quite a lot. I don't think there's anything anyone can say. I t  s up to 
someone to want to take care of themselves, and I've found I've got a lot of people who use scare tactics with me, 
saying 'Oh, this will happen. You'll go blind. You'll die at like 50. You'll get all these different diseases . Trying to 
scare me into taking it, but it was more just upsetting me than making me want to take it. I t  was m° r® t ™ " , 9 T 
'Well, what's the point of taking it because I'm  going to die at 50 anyway.' I  may as well enjoy myself. That s wnat i  
thought then obviously.
Dding Sum m ary Report
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APPENDIX EIGHTEEN
Diabetes & Pregnancy NICE Guidelines (NICE 2008)
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Diabetes in pregnancy Pre-conception care
Pre-conception care
Information and advice
® Offer information, care and advice to  women w ith  diabetes w ho are planning to  become pregnant 
before they discontinue contraception.
o Give pre-conception care in a supportive environment. Encourage the woman's partner or a family 
member to  attend.
© This should build on previous care given in routine appointments w ith  healthcare professionals, 
including the diabetes care team (see box 1).
Box 1 Encouraging w om en w ith  diabetes.to seek pre-cpncephon care ,3., -v J ^
Starting from adolescence:
© healthcare professionals should give information about the benefits o f pre-conception glycaemic 
control at each contact 
© the diabetes care team should record the woman's intentions regarding pregnancy and 
contraceptive use at each contact 
© the importance o f avoiding unplanned pregnancy should be an essential component of 
diabetes education.
Give advice and information on:
o the risks o f diabetes in pregnancy (see box 2) and how to  reduce them w ith  good glycaemic control 
© diet, body weight and exercise, including weight loss fo r women w ith  a body mass index (BMI) 
over 27 kg/m2 
© hypoglycaemia and hypoglycaemia unawareness 
© pregnancy-related nausea/vomiting and glycaemic control 
o retinal and renal assessment 
© when to  stop contraception
© taking folic acid supplements (5 mg/day) from pre-conception until 12 weeks o f gestation 
0  review of, and possible changes to, medication, glycaemic targets and self-monitoring routine 
® frequency o f appointments and local support, including emergency telephone numbers.
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Box 2 Risks o f diabetes in pregnancy
Risks to  women and babies include: 
e fetal macrosomia 
o birth trauma (to mother and baby)
9  induction o f labour or caesarean section 
9  miscarriage 
© congenital malformation 
© stillbirth
© transient neonatal morbidity 
9 neonatal death
© obesity and/or diabetes developing later in the baby's life.
Care, assessment and review
Offer:
© folic acid supplements (5 mg/day)
© blood glucose meter fo r self-monitoring
o ketone testing strips to  women w ith type 1 diabetes and advise on use if hyperglycaemic or unwell 
© diabetes structured education programme 
© monthly HbA1c
© retinal assessment by digital imaging w ith mydriasis using tropicamide* (unless carried out in previous 
6 months)
o renal assessment (including microalbuminuria) before stopping contraception.
Consider:
© referral to a nephrologist if serum creatinine is 120 micromol/litre or more or the estimated glomerular 
filtration rate (eGFR) is less than 45 m l/m inute/1.73 m2.
Review:
© current medications fo r diabetes and complications o f diabetes (see box 3)
© glycaemic targets and glucose monitoring (see box 4).
* Drug names are marked w ith  an asterisk if they do not have UK marketing authorisation specifically fo r pregnant and 
breastfeeding women at the time of publication (March 2008). Informed consent should be obtained and documented.
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© M etform in* may be used before and during pregnancy, as well as or instead o f insulin.
© Rapid-acting insulin analogues (aspart and lispro*) are safe to use in pregnancy and have 
advantages over soluble human insulin* during pregnancy.
© Evidence about the use o f long-acting insulin analogues during pregnancy is limited. Isophane 
(NPH) insulin* is the first-choice long-acting insulin during pregnancy.
Before o r as soon as pregnancy is con firm ed:
© stop oral hypoglycaemic agents, apart from m etform in*, and commence insulin if required 
© stop angiotensin-converting enzyme inhibitors and angiotensin-!! receptor antagonists and 
consider alternative antihypertensives
© stop statins.
© Agree individualised blood glucose targets fo r self-monitoring.
© Advise women who need intensification o f hypoglycaemic therapy to  increase the frequency o f 
self-monitoring to  include fasting and a mixture o f pre- and postprandial levels.
© Offer monthly HbA1c.
© Advise women to  aim fo r an HbA1c below 6.1 %, if safe.
© Inform women that any reduction in HbA1c may reduce risks.
© Advise women w ith  HbA1c above 10% to avoid pregnancy.
© Do not offer rapid optimisation o f glycaemic control until after retinal assessment and treatm ent 
are completed.
* Drug names are marked with an asterisk if they do not have UK marketing authorisation specifically for pregnant and 
breastfeeding women at the time of publication (March 2008). Informed consent should be obtained and documented.
NICE clinical guideline 63 Quick reference guide
